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ABSTRACT 
Background 
There is good evidence that therapist delivered interventions have modest beneficial 
effects for people with low back pain (LBP). Identification of subgroups of people with 
LBP who may benefit from these different treatment approaches is an important 
research priority.  
Aim and objectives 
Overall aim was to improve the clinical and cost-effectiveness of LBP treatment by 
providing patients, their clinical advisors, and health service purchasers with better 
information about which participants are most likely to benefit from which treatment 
choices. Our objectives were to:  
 synthesise what is already known about the validity, reliability and predictive 
value of possible treatment moderators (patient factors that predict response to 
treatment) for therapist-delivered interventions 
 develop a repository of individual participant data from randomised controlled 
trials testing therapist-delivered interventions for LBP 
 determine which participant characteristics, if any, predict clinical response to 
different treatments for LBP 
 determine which participant characteristics, if any, predict the most cost-
effective treatments for LBP. 
To achieve these objectives required substantial methodological work including the 
development and evaluation of some novel statistical approaches. This programme of 
work was not designed to analyse main effect of interventions and no such 
interpretations should be made. 
  
  iii 
Methods 
Firstly, we reviewed the literature on treatment moderators and subgroups. We initially 
invited investigators of trials of therapist-delivered interventions for LBP with >179 
participants to share their data with us; some further smaller trials offered to us were 
also included. Using these trials we developed a repository of individual participant 
data of therapist delivered interventions for LBP. Using this dataset we sought to 
identify which participant characteristics, if any, predict response to different 
treatments (moderators) for clinical and cost effectiveness outcomes. 
We did an ANCOVA to identify potential moderators to apply in our main analyses. 
Subsequently we developed and applied three methods of subgroup identification; 
recursive partitioning (interaction trees and subgroup identification based on a 
differential effect search), adaptive risk group refinement, and an individual participant 
data indirect network meta-analysis to identify sub-groups defined by multiple 
parameters.  
Results 
We included data from 19 randomised controlled trials with 9,328 participants (mean 
age 49 years, 57% females). Our prespecified analyses using recursive partitioning and 
adaptive risk group refinement performed well and allowed us to identify some 
subgroups. The differences in the effect size in the different subgroups were typically 
small, and unlikely to be clinically meaningful. Increasing baseline severity on the 
outcome of interest was the strongest driver of sub-group identification that we 
identified. Additionally we explored the application of Bayesian indirect network meta-
analysis. This method produced varying probabilities that a particular treatment choice 
would be most likely to be effective for a specific patient profile.  
Conclusion 
These data lack clinical or cost-effectiveness justification for the use of baseline 
characteristics in the development of subgroups for back pain. The methodological 
developments from this work have the potential to be applied in other clinical areas. 
  iv 
The pooled repository database will serve as a valuable resource to the LBP research 
community.  
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GLOSSARY 
 
Adaptive refinement – a method to identify subgroups of participants, defined by cut-
offs for the selected covariates resulting in box-shaped subgroups. 
Cross walking – this is a method of mapping multiple participant-reported outcome 
measures that measure the same domain, to a common scale. 
Moderator – These are factors measured prior to randomisation and subsequently 
influence the effect of the treatment. 
Recursive partitioning – a technique that searches all possible binary splits of 
covariates to identify subgroups of participants. 
Standardised mean difference – this is the score divided by the standard deviation of 
the baseline score of all participants.  
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SCIENTIFIC SUMMARY 
Background: Identifying subgroups of people living with low back pain who may do 
better, or worse, with different treatment choices is a high research priority 
internationally. Many RCTs could be designed to address individual components of this 
problem. High quality trials in this area are very costly and time consuming (typically 
requiring a minimum of 700 participants, at a cost of one to two million pounds, and 
taking at least six years from design to implementation); each will only address one 
small part of this complex problem.  
Alternative methods can provide complementary information that could add value to 
our knowledge. Approaches, which make the best possible use of existing data might 
produce timely answers to a range of important research questions and provide 
substantial added-value to the money already invested in this area.  
We present a programme of work, using systematic reviews, methodological 
development, and secondary analyses of existing datasets to identify strategies to 
improve outcomes for people seeking treatment for back pain, by improving how 
participants, clinicians, and purchasers choose treatments. Our programme of work 
ensures that the maximum information is gleaned from existing substantial trial 
datasets. The analysis plan for these data and modelling of clinical and cost-
effectiveness are informed by our literature reviews.  
Aims and objectives: The overall aim of this programme grant was to improve the 
clinical and cost-effectiveness of therapist delivered treatments for low back pain 
treatment by providing participants, their clinical advisors, and health service 
purchasers with better information about which participants are most likely to benefit 
from which treatment choices. Our objectives were: 
1. To synthesise what is already known about the validity, reliability and 
predictive value of possible treatment moderators (participant factors that 
predict response to treatment).  
2. To develop a repository of individual participant data from RCTs testing 
therapist-delivered interventions for LBP. 
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3. To determine which participant characteristics, if any, predict clinical response 
to different treatments for LBP 
4. To determine which participant characteristics, if any, predict the most cost-
effective treatments for LBP. 
Seeking to achieve these objectives required substantial methodological work including 
the development and evaluation of some novel statistical approaches. This programme 
of work was not designed to analyse main effect of interventions and no such 
interpretations should be made.  
Method and Results:   
To synthesise what is already known about the validity, reliability and predictive value 
of possible treatment moderators.  
We carried out two systematic reviews, one to identify potential moderators of 
treatment effect from studies of therapist delivered interventions to inform our analyses, 
and the second, a review of the quality of subgroup analyses in low back pain trials.  
As the purpose of moderator identification was for future application in our analyses 
we identified potential moderators with strong evidence (P<0.05) and potential 
moderators with weaker evidence in one or more studies (0.05<P≤0.20). Data from four 
trials were included in the review. Potential moderators with strong evidence included 
age, employment status and type, back pain status, narcotic medication use, treatment 
expectations and education. Potential moderators with weaker evidence included 
gender, psychological distress, pain/disability and quality of life. Although the overall 
data were weak and lacking in rigour to inform clinical practice it provided a starting 
point for application in our analyses.  
The second review looked at the quality and reporting of subgroup analyses in low back 
pain. Thirty-nine papers were included in the final review. The majority of papers 
provided only exploratory or insufficient findings. Only three trials provided 
confirmatory findings i.e. sub-group analyses were hypothesis driven and grounded in 
existing theory or empirical data. The overall quality of reporting was poor and 
generally the subgroup analyses have been severely underpowered. We concluded the 
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need to develop new approaches to subgroup identification to identify multiple 
participant characteristics or clusters of moderators that would identify who is most or 
least likely to benefit. 
To develop a repository of individual participant data from RCTs testing therapist-
delivered interventions for LBP. 
To allow the identification of subgroups in appropriately powered datasets we 
developed a repository of data from completed trials. We used a systematic approach 
in identifying trials and approaching chief investigators for their data. Our pool of 
potential trials came from the search results generated in our review of moderators. As 
a starting point we were only interested in randomised control trials of therapist 
delivered interventions with a sample size of >179. We were offered data from three 
smaller trials which we also included.  
The final repository comprises of 19 trials, with 9,328 participants. No two trials had 
identical interventions or controls. Despite the large initial sample, we had to broadly 
pool interventions into groups for our analyses in order to draw any meaningful 
comparisons. As a first step we identified the control interventions and classified these 
as either usual care or as a sham control, furthermore we have specified the type of 
sham as there may be qualitative differences between sham treatments. To cluster the 
interventions we firstly classified them into core groups (individual physiotherapy, 
exercise, manipulation, advice/education, psychological therapy, graded activity, 
acupuncture, combination therapy, mock transcutaneous electrical nerve stimulation, 
sham acupuncture and control). We later looked at the data to explore the scope for 
direct and indirect comparisons and the data available for these comparisons. This 
indicated without grouping these interventions it would be difficult to make any 
meaningful comparisons therefore the collaborative team decided on broader 
categories; active physical (exercise and graded activity), passive physical (individual 
physiotherapy, manipulation and acupuncture) and psychological (advice/education 
and psychological therapy). In this programme of work we are not seeking to estimate 
the true effect size of any individual intervention. Rather, we are seeking to identify 
predictors of treatment response making it reasonable to pool in this manner.  
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In addition to the challenges of pooling multiple datasets using multiple interventions, 
there was careful consideration of how to most accurately map multiple participant-
reported outcome measures that measure the same domain, to a common scale. We 
concluded that due to the lack of correlation and responsiveness in outcomes from two 
measures in the same individual, it would not appropriate to map any physical disability 
outcome measures to another. 
To determine which participant characteristics, if any, predict clinical response to 
different treatments for LBP 
We did ANCOVA analyses comparing all intervention groups with all controls to 
identify potential moderators to take forward for our main analyses. We were able to 
take forward the Hannover Functional Ability score, Roland and Morris Disability 
questionnaire, SF12/36 physical and mental component scores, age, gender, pain, fear 
avoidance and coping as variable with a possible signal in one or more analysis. 
In this programme grant we have explored in considerable details new and novel 
methods for subgroup identification. We have presented three core methods in this 
report; recursive partitioning (interaction trees and subgroup identification based on a 
differential effect search), adaptive risk group refinement and individual participant 
data indirect network meta-analysis.  
Our pre-specified analytical approaches; recursive partitioning and adaptive risk group 
refinement produced identifiable subgroups whose parameter definitions were 
grounded in the data. The differences in effect sizes, between groups, were however 
small and unlikely to be clinically meaningful. The effect sizes in the groups who did 
less well would still justify the use of these interventions. The overall results point to 
larger treatment responses in those with higher levels of the outcome of interest at 
baseline. The results also suggest those with greater psychological distress as measured 
by the SF-12/36 mental component score do not have a greater treatment effect, on 
physical outcomes, from any of the therapist deliver interventions tested. Targeting low 
intensity interventions at those higher levels of psychological distress for treatment 
might not be justified.  
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We did a post hoc exploratory individual participant data indirect network meta-
analysis to identify sub-groups. This does not identify subgroups in the traditional 
manner but rather uses the available data to work out the probability that a particular 
treatment choice is most likely to be effective. The outputs from this method have the 
potential to inform clinical decision making but requires further testing and application.  
To determine which participant characteristics, if any, predict the most cost-effective 
treatments for LBP. 
We applied the directed peeling algorithm to the economic and resource use data. When 
exploring interventions vs control subgroups were identified. These subgroups 
comprised patients who were older with relatively worse physical functioning at 
baseline. The gain in treatment effect for the subgroup was small; therefore, given the 
relatively low cost of the intervention treatment it is likely to be cost effective for the 
whole patient group. No convincing subgroups were found for active and passive 
physical treatment. This may be due to lack of power, or simply that there is no 
subgroup to be found. 
Age, SF12/36 physical component score and Roland and Morris Disability score were 
the three potential moderators identified from the economic analysis. However the 
relationship of the Quality Adjusted Life Years (QALY) with the moderators differed 
in some cases to that of the clinical outcome measures. Subgroups were only identified 
in the comparison of treatment vs. control. Our interpretation is that those who are older, 
with worse RMDQ and SF12/36 physical component score are likely to gain a greater 
benefit on QALY outcomes from treatment. Doing this will not, however, improve 
overall QALY gain and is very unlikely to be seen as a cost-effective choice if the NICE 
threshold of £20,000 - £30,000 per QALY is used to inform treatment choices. 
  
Conclusions and Recommendations: In this programme of work we have developed 
advances in methodological developments for subgroup analyses. We have developed 
different approaches to the identification of differential subgroup effects that provide 
considerable added value compared to conventional analyses that simply test for 
interactions between single baseline parameters and treatment allocation. In addition 
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we have developed advanced systems for pooling and storing large datasets, highlighted 
the it is not possible to map different outcome measures for a meta-analyses, and finally 
we have developed an important resource for back pain researchers wishing to do 
further analyses on data from multiple trials. 
Clinically, the application of the different frequentist methods (recursive partitioning 
and adaptive design) has not allowed us to identify subgroups of patients that might 
benefit from different back pain treatments. Some of the core outputs and 
recommendations from this work include: 
 Application of these methods for the identification of subgroups in other clinical 
areas 
 Re-analysis of existing meta-analyses of back pain treatments to separate out 
results from trials with different outcome measures 
 Further development of methods and application to the data we already have 
 Making the dataset available to other researchers 
 Adding additional trial datasets to the repository 
 Developing and testing a web portal to help inform choice of treatments based 
on our network meta-analysis. 
Overall, our results do not provide sufficient clinical or cost-effectiveness justification 
for the use of baseline characteristics in the development of subgroups for low back 
pain. We would however suggest such methods are applied in other clinical areas where 
subgroups may be important. The exploratory outputs from our Bayesian network meta-
analysis provides some scope for deciding on optimal therapies. This however would 
need to be empirically testing before clinical recommendation.  
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PLAIN ENGLISH SUMMARY 
Low back pain is a common and costly disorder for both the patient and the health 
service which can be managed using different treatment approaches; some of which are 
delivered in a physiotherapy department. The benefits of treatments delivered by 
therapist are small on average; that is they get small improvements. If we could predict 
which patients would be most likely to benefit from different treatments it would be 
possible to improve the overall effectiveness of treatments and potentially save the 
National Health Service resources. To address this we pooled together data from 19 
back pain trials from around the world. This provided us with a dataset of 9,328 patients. 
We developed novel statistical methods to identify sub-populations (groups of people 
with similar characteristics) likely to benefit from certain treatments. Of the three 
methods developed, two allowed us to identify sub-populations. The additional benefits 
for individuals in the sub-populations were modest and unlikely to be of clinical 
importance. Our third method was exploratory and allowed us to identify the chance of 
a particular treatment choice being effective for a particular patient.  
Overall we did not find any sub-populations that would benefit from treatment. Neither 
did we find that such an approach to identifying patients would be cost effective. We 
have developed new ways of identifying sub-populations and would recommend the 
application of these methods to other clinical conditions. We have also developed from 
prior trials a data-pool that will now become a resource for back pain researchers to 
help them answer other questions in the field .  
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CHAPTER 1 – OVERVIEW OF THE PROGRAMME 
In this chapter we have provided the background and rational for our programme to 
improve the clinical and cost-effectiveness of low back pain (LBP) treatment by 
identifying groups who may gain maximum benefit from therapist delivered treatments.  
1.1 BACKGROUND 
Chronic non-specific low back pain (CNSLBP) is a common problem affecting a large 
proportion of the population.1-4 In the UK around 70 to 80% of adults will experience 
back pain at some point in their life.5 Some argue that episodic LBP is a universal part 
of human experience.6, 7 Half of the adult population in the UK (49%) report LBP 
lasting at least 24 hours in a one year period.5 The 2010 Global Burden of Disease study 
identified LBP as the leading cause of years lived with disability internationally.8 Low 
back pain affects around a third of the world’s population.8 
Most episodes of back pain are short lived, resolving without the need for any specific 
treatment. It is the minority of episodes that develop into CNSLBP that create the 
greatest health need. The natural history of LBP is untidy; around 70% of those affected 
will experience at least one recurrent episode within a 12 month period.9  
The true prevalence of CNSLBP is difficult to estimate as definitions and populations 
vary between studies and countries. However, a review of prevalence studies, reported 
between 1966 to 1998, a 12% to 33% point prevalence; 22% to 65% 1-year prevalence 
and up to 84% life time prevalence.10  
Since this review further reviews on the prevalence focusing on older people and 
adolescents have been published.3, 11 A 2012 systematic review synthesised the global 
prevalence of LBP in studies published between 1980 and 2009. The greatest 
prevalence was in females aged 40 to 80 years. After adjusting for methodological 
variations the point prevalence of back pain lasting more than one day was 11.9% (95% 
confidence interval (CI), 7.98 to 15.82) and one month period prevalence was estimated 
at 23.2% (95% CI, 17.52 to 28.88).12 
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1.2 DEFINING LOW BACK PAIN  
The International Association of the Study of Pain (IASP) define pain as ‘an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage.’13 The British Pain Society defines acute pain as 
‘short term lasting less than 12 weeks duration’ whereas chronic pain is defined as 
‘long-term pain of more than 12 weeks or after the time that healing would have been 
thought to have occurred in pain after trauma or surgery.’14  
Low back pain is diagnosed based on the presence of pain and discomfort in the 
lumbosacral area.15 Some people also experience pain in the upper leg as a result of 
LBP. In the majority of cases it is difficult to identify a single cause for back pain. A 
2013 systematic review of studies of new presentations of LBP found a combined 
prevalence of 1.5% for fracture and malignancy in primary care; in secondary and 
tertiary care prevalence was 6.5%.16 Once specific causes for LBP have been excluded 
(malignancy, fracture, infection, inflammatory disorders such as ankylosing 
spondylitis) then a diagnosis of non-specific low back pain (NSLBP) is made. This 
recognises the difficulty in producing robust classification criteria to identify different 
populations of people affected by chronic LBP.  
There is no evidence for a reduction in the population burden of LBP over time. 
Between 1990 and 2010, in the UK, the number of Disability Adjusted life Years 
attributable to LBP increased by 3.7% from 2231/100 000 (95% CI 1555 to 3015) to 
2313/100 000 (95% CI, 1574 to 3113) of the age standardised population.17  
1.3 ECONOMIC BURDEN OF LOW BACK PAIN 
Low back pain is a costly condition to society, healthcare and the individual. It is the 
leading cause of sickness absence and health care use.18-21 In the UK the direct 
healthcare costs of back pain in 1998 was £1632 million. However the larger burden is 
that of the indirect costs related to lost production and informal care which were 
estimated to be at least £5,018 million.22 More up to date UK estimates are not available. 
The current cost is likely to be substantially larger. It is difficult to make direct 
comparisons of the cost of LBP internationally because of varying health and social 
care systems.23  
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Low back pain results in approximately 4% of the UK population taking time off work. 
This translates to around 90 million working days lost and between eight and 12 million 
General Practitioner (GP) consultations per year.22, 24 In 2013 the Office of National 
Statistics reported a 131 million lost working days due to sickness absences in that year 
in the UK; 30.6 million of these (23%) were lost due to musculoskeletal conditions 
including back and neck pain.25  
1.4 TREATMENT OPTIONS FOR LOW BACK PAIN 
People experiencing LBP will often seek medical and drug therapies as well as therapist 
delivered complementary therapies; such as acupuncture, chiropractic or osteopathy, to 
help relieve pain.26 Until comparatively recently there were few robust trials of 
treatments for LBP and no convincing evidence for the effectiveness of any back pain 
treatments. Guidance on its management was based largely on expert opinion, custom 
and practice. Since the mid-1990s, there has been a substantial investment in high 
quality randomised control trials (RCTs) of different treatments for NSLBP. We now 
have good evidence to show that several therapist delivered treatment approaches are 
effective, and for some of these there is also evidence that they are cost-effective.15, 27 
By therapist delivered interventions we mean non-drug, non-surgical, approaches to the 
treatment of LBP. Typically these are delivered by physiotherapists or health/clinical 
psychologists, but they may be delivered by, doctors, health trainers, registered 
complementary practitioners such as osteopaths, or chiropractors or by sometimes 
unregistered professionals providing treatments such as acupuncture or Alexander 
technique. The types of interventions offered include acupuncture, manual treatments, 
exercise regimens, cognitive behavioural approaches or combinations of these. 
A number of therapist delivered interventions are superior to ‘treatment as usual’ (GP 
care) for participants with chronic LBP. There are numerous treatment options for LBP 
and several guidelines recommending treatment including the National Institute for 
Health and Care Excellence (NICE), the European Corporation in Science and 
Technology and the American College of Physicians and American Pain Society 
guidelines. Such guidance is typically framed as examining independent treatment 
modalities. Any recommendation for a treatment modality, is inevitably, 
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recommending a package of care including both the non-specific effects of the therapist 
encounter and the specific effects of the treatment modality in question. 
In 2009 NICE guidance advised that all people with persistent LBP should be given 
advice and encouraged to self-manage. As part of this advice they are encouraged to 
remain physically active and to engage in daily activity. Subsequently those affected 
should be offered a course of acupuncture needling, exercise, or manual therapy.15 The 
decision on which treatment to select should be a collaborative decision taking into 
account the patients treatment preferences. If the selected treatment option is not 
effective then the patient should be offered another option from the remaining 
recommended treatments. If the patient is still troubled by back pain they should be 
considered for an intense physical and psychological intervention. NICE is currently 
revising their LBP guidelines.  
1.5 EFFECTIVENESS AND COST EFFECTIVENESS OF TREATMENTS FOR 
LOW BACK PAIN 
Whilst the effectiveness of adding a range of therapist delivered interventions to best 
usual care or to no treatment has been well established, the typical mean effect sizes 
are, at best, modest. By way of illustration the minimally important (within person) 
change in the Roland Morris Disability Questionnaire (RMDQ),28 the most commonly 
used outcome measure in back pain trials has been established as five points.29, 30 
Typical between group differences in high-quality randomised controlled trials are in 
the order of 1 to 2 points on the Roland Morris Disability Questionnaire; although a few 
studies have found larger effect sizes (Table 1). These modest mean differences 
probably translate into numbers needed to treat in the order of 5 to 10.29, 31 These are of 
a similar to the numbers needed to treat found with antidepressant or anti-epileptic 
drugs used to treat chronic painful disorders.32 
The cost per quality adjusted life year (QALY) for some of these treatments are well 
within cost-effectiveness thresholds usually used by NICE. In spite of this evidence 
access to such treatments within the National Health Service (NHS) remains patchy. 
The guideline endorsed treatments of interdisciplinary rehabilitation, exercise, 
acupuncture, spinal manipulation and cognitive-behavioural therapy for sub-acute or 
chronic LBP have been shown to be cost-effective, but evidence for other endorsed 
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treatments for NSLBP do not yield conclusive or consistent evidence about their 
relative cost effectiveness.33 The scarcity of economic evaluations for some guideline 
endorsed treatments means well-conducted economic evaluations are required to 
strengthen the evidence-base of treatments for LBP.  
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Table 1 Between group differences for the Roland Morris Disability Questionnaire 
   Mean Difference in RMDQa (95% CI),p-value 
Study Control Intervention 3 month 12 month 
UK BEAMb 34 GP care Exercise 1.36 (0.63, 2.10); 0.34 0.39 (-0.41, 1.19); 0.10 
Manipulation 1.57 (0.82, 2.32); 0.39 1.01 (0.22, 1.81); 0.25 
Manipulation plus 
exercise 
1.87 (1.15, 2.60); 0.47 1.30 (0.54, 2.07); 0.33 
A-TEAMc 35 Usual care Massage 1.96 (0.74, 3.18); 0.39 0.58 (0.77, 1.94); 0.12 
Alexander technique  
(6 sessions) 
1.71 (0.47, 2.95); 0.34 1.40 (0.03, 2.77); 0.28 
Alexander technique  
(12 sessions) 
2.91 (1.66, 4.16); 0.58 3.40 (2.03, 4.76); 0.68 
BeSTd 31, 36 Advice only Cognitive behavioural 
therapy 
1.10 (0.38, 1.71); 0.22 1.30 (0.56, 2.06); 0.27 
York Yoga 37 Usual care Yoga 2.17 (1.03, 3.31); 0.50 1.57 (0.42, 2.71); 0.36 
a RMDQ, Roland Morris disability questionnaire; b UK BEAM, United Kingdom Back pain Exercise And Manipulation; c A-TEAM, 
Alexander technique lessons, exercise, and massage; d BeST, Back Skills Training Trial. 
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1.6 SUBGROUPING 
Identifying which participants are likely to gain the greatest benefit from different 
treatments for LBP is an identified high research priority internationally and was one 
of the key recommendations for future research in the 2009 NICE guidelines for the 
management of persistent LBP. Current research does not provide any robust data on 
how to match back pain treatments to participants to maximise effects on outcomes 
relevant to the participant and cost-effectiveness for the health service.  
Since different treatment options are agued to work in very different ways it is a 
reasonable hypothesis that by matching people with LBP to those treatments more 
likely to be effective for their back pain will be a more efficient use of health care 
resources and improve patient outcomes. One might expect that people with high levels 
of psychological distress related to their back pain may gain greater benefit from a 
psychologically oriented intervention such as cognitive behavioural therapy, those with 
marked loss of physical fitness to benefit most from an exercise intervention, or those 
with poor back function to benefit most from manual therapy interventions. Developing 
an evidence base to inform the development of such a stratified care approach has great 
potential to improve outcomes for people with LBP. 
We are aware of one trial of a stratified care approach, published after this programme 
of work started. The StartBack trial successfully demonstrated that a combination of 
using a stratification tool, and enhanced physiotherapy packages for selected 
participants, improves outcomes, and reduces costs, when compared to usual 
physiotherapy care.38 This study does not, however, allow the performance of the 
stratification tool to identify subgroups to be assessed.  
There are a myriad of RCTs that could be designed to address individual components 
of this problem. High quality trials in this area are very costly and time consuming and 
can only address one small part of this complex problem. Alternative approaches, which 
make the best possible use of existing data can produce timely answers to a range of 
important research questions and provide substantial added-value to the money already 
invested in this area.  
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We present a programme of work, using systematic reviews, methodological 
development, and secondary analyses of existing datasets to identify strategies to 
improve outcomes for people seeking treatment for back pain, by improving how 
participants, clinicians, and purchasers choose treatments. Our programme of work 
ensures that the maximum information is gleaned from existing substantial trial 
datasets. The analysis plan for these data and modelling of clinical – cost effectiveness 
are informed by our literature reviews.  
1.7 AIM AND OBJECTIVES 
The overall aim was to improve the clinical and cost-effectiveness of LBP treatment by 
providing participants, their clinical advisors, and health service purchasers with better 
information about which participants are most likely to benefit from which treatment 
choices. To achieve this, our objectives were to:  
1. synthesise what is already known about the validity, reliability and predictive 
value of possible treatment moderators 
2. develop a repository of individual participant data from RCTs testing therapist-
delivered interventions for LBP 
3. determine which participant characteristics, if any, predict clinical response to 
different treatments for LBP 
4. determine which participant characteristics, if any, predict the most cost-
effective treatments for LBP. 
We have defined a therapist as a person trained in administering any of the available 
recommended treatments, excluding drug interventions and surgical interventions, for 
the management of LBP. 
1.8 STRUCTURE OF THIS REPORT 
This report has been structured as shown in Figure 1.  In this report we use some 
specific terminology that needs additional definition to aid understanding.  We have 
defined these in the glossary at the start of this report and in more detail at relevant 
points in the report. 
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Figure 1 The structure of the current report  
  
Chapter 2
• LITRATURE REVIEWS - Provides a background to the literature reviews 
conducted as part of this programme grant (Objective 1).
Chapter 3
• COLLATING DATA - Outlines how trial data was obtained and managed 
for analyses (Objective 2). 
Chapter 4
• CREATING THE REPOSITORY DATABASE AND DATA CONTROL - Details 
how the clinical and economic data were coded and how the database 
was programmed to enable pooling of trials (Objective 2). 
Chapter 5
• CROSSWALKING BETWEEN DISABILITY QUESTIONNAIRE SCORES -
Explores the mapping of outcome measures to inform the pooling of 
data.
Chapter 6
• PRELIMINARY STATISTICAL ANALYSES AND RESULTS (Objective 3). 
Chapter 7
• RECURSIVE PARTITIONING - methodological development and results 
(Objective 3 & 4). 
Chapter 8
• ADAPTIVE REFINEMENT BY DIRECTED PEELING - methodological 
development and results (Objectives 3 & 4). 
Chapter 9
• IDENTIFICATION OF COST-EFFECTIVE SUBGROUPS BY DIRECTED
PEELING - methodological development and results (Objective 4). 
Chapter 10
• INDIVIDUAL PARTICIPANT DATA INDIRECT NETWORK META-ANALYSIS -
methodological development and results (Objective 3 & 4). 
Chapter 11
• DISCUSSION AND CONCLUSION
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CHAPTER 2 – LITERATURE REVIEWS 
As part of this programme of work we carried out two systematic reviews. In this 
chapter we have presented the details and results of each review followed by an overall 
summary.  
2.1 SYSTEMATIC REVIEW 1 – IDENTIFICATION OF POTENTIAL 
MODERATORS  
This review has been published in Physiotherapy. Here we present a summary of the 
paper.39  
2.1.1 ABSTRACT 
Background: Within randomised controlled trials, moderators are baseline 
characteristics that predict whether an intervention will be more or less effective for an 
individual in the trial. For our final individual participant data meta-analyses we needed 
to select potential moderators grounded in existing data to inform our selection. 
Aim: To identify potential moderators from existing studies of therapist delivered 
interventions for LBP to apply to our dataset.  
Methods: We developed a review protocol detailing the inclusion and exclusion 
criteria, search strategy, data extraction process and quality assessment method. We 
conducted electronic searches in MEDLINE, EMBASE, Web of Science and Citation 
Index and Cochrane Central Register of Controlled Trials (CENTRAL) databases for 
studies reporting moderator analyses. Two researchers independently screened the titles 
and abstracts. Additionally we searched the reference lists of relevant articles for any 
further potential references. We included randomised controlled trials with ≥500 
participants, and cohort studies of ≥1000 participants. We classified potential 
moderators into those with strong (p<0.05) or weaker evidence (p<0.20, ≥0.05). 
Results: We identified 914 potential citations. We selected 64 papers for detailed 
evaluation. Four papers, all randomised controlled trials, were included. We identified 
potential moderators with strong evidence (p<0.05) in one or more studies as age, 
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employment status and type, back pain status, narcotic medication use, treatment 
expectations and education. Potential moderators with weaker evidence (0.05<p≤0.20) 
include gender, psychological distress, pain/disability and quality of life. 
Conclusion: The overall data obtained from this review was weak and lacking in rigour 
to inform clinical practice. However this review has helped us to identify potential 
moderators of treatment effect with some weak evidence to inform our further analyses. 
2.1.2 BACKGROUND 
The ability to identify which patients are likely to gain the greatest benefit from a 
treatment would have significant implications in clinical practice. To explore this it is 
crucial to identify moderators of treatment response. These are factors measured prior 
to randomisation and subsequently influence the effect of the treatment.40 To identify 
such moderators large datasets are required to provide sufficient statistical power to 
detect any interaction between the moderator and treatment.41  
2.1.3 AIMS 
The purpose of this review was to identify potential moderators which we could test in 
our individual participant data pooled repository. 
2.1.4 METHOD 
Originally this review was conducted up until September 2011. Searches were updated 
in July 2014. Electronic searches were conducted using the following databases:   
 MEDLINE  
 Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 
 EMBASE  
 Web of Science 
 Citation Index and Cochrane Central Register of Controlled Trials 
(CENTRAL)  
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To ensure we had not overlooked useful data identifying possible treatment moderators 
we searched for both RCTs and observational studies that had tested for effect 
modification. 
2.1.4.1 Search strategy 
We started our searches using the terms ‘low back pain’ combined with keywords 
including ‘subgroup’, ‘effect modifier’ and ‘moderator’. The results from this 
preliminary search only allowed identification of publications which used the term 
‘subgroup’ in the title and/or the abstract, it failed to pick up papers that used the term 
in the main body of the text. We therefore re-ran searches using keywords (‘trial’) for 
RCTs and (‘Observational’, ‘Cohort’, ‘Prospective studies’) for non-RCTs or 
observational studies separately and then combining them with terms ‘low back pain’. 
Hand searching and screening of included studies were carried out for additional 
studies.  
2.1.4.2 Minimum sample size for included studies 
To allow us to pick up meaningful interactions it was critical to select research based 
on an adequate sample size. We made the following assumptions to determine the 
sample size criterion: 
 the outcome of interest is continuous and normally distributed 
 there are two treatment arms (intervention and control)  
 the potential moderator is binary.  
To determine the minimum sample needed to test for an interaction we used a model 
proposed by Lachenbruch.42 To test for a long-term (12 months) moderate standardised 
effect size (between group difference/baseline standard deviation) of 0.5 for the 
interaction at a 0.05 level of significance and 80% power for the primary outcome, a 
minimum data-set of 503 participants was needed. Recognising the inherent risk of bias 
in observational studies we set a higher threshold of 1,000 participants for any 
observational studies included. 
  13 
A priori we estimated that we needed to include RCTs with at least 500 participants to 
identify a moderate standardised mean difference (between group difference/baseline 
standard deviation) of 0.5 for the interaction at a 0.05 level of significance and 80% 
power. The standardised mean differences in high-quality RCTs of therapist delivered 
interventions for LBP are typically in range 0.1 to 0.7 (see Chapter 1, Table 1). Smaller 
trials would only be able to detect treatment moderation, at this level, if the moderation 
effect was substantially larger than the main treatment effect. Thus, even having set 
quite a large entry criterion by size we would run the risk of failing to consider potential 
treatment effect moderators that did not reach the conventional level of statistical 
significance. Therefore any variables identified as moderators of treatment effect at 
p<0.05 were classed as potential moderators with strong evidence and those at 
0.05<p≤0.20 as potential moderators with weak evidence. For our final analyses we 
considered potential moderators with both strong and weak evidence to be worth 
exploring further. 
2.1.4.3 Inclusion and exclusion criteria 
See Box 1 for an outline of the inclusion and exclusion criteria for this review.  
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Box 1 Review 1 - Inclusion and exclusion criteria 
Inclusion Criteria 
 Aged 18 and over 
 NSLBP of any duration  
 Therapist delivered interventions 
 RCTs with sample size of ≥500 
 non-RCTs and observational studies with sample size ≥1,000 
 English language 
 Primary and secondary analysis seeking to identify predictors of response to 
treatment using ‘a priori’ and ‘post hoc’ subgroups and those looking for 
interaction between baseline variable and treatment.  
Exclusion Criteria 
 Studies with no comparison between two treatment groups  
 Studies that did not report effect sizes for treatment by using moderator 
interactions. 
 
2.1.4.4 Screening and data extraction 
At all stages two researchers (TG & DE) worked independently to screen titles and 
abstracts based on the inclusion criteria. All agreed full papers were obtained for data 
extraction. Data were extracted onto a standardised extraction form and any 
discrepancies were resolved using a third reviewer (DM). As no relevant observational 
studies were identified we do not address methodological considerations related to 
observational studies further. 
2.1.4.5 Risk of bias and quality assessment 
Both reviewers independently assessed risk of bias for the between group comparison 
using the Cochrane Collaboration risk of bias tool.43 From this tool the criteria used 
were: 
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 method of randomisation 
 allocation concealment 
 incomplete outcome data 
 selective outcome reporting 
 other sources of bias.  
To assess quality we used the criteria developed by Pincus et al44 whereby the answers 
to the five questions presented below allowed evidence to be classified as 
‘confirmatory’ or ‘exploratory’: 
1. Was the subgroup analysis specified a priori? 
2. Was the selection of subgroup factors for analysis theory/evidence driven? 
3. Were subgroup factors measured prior to randomisation? 
4. Was measurement of subgroup factors measured by adequate (reliable and 
valid) measurements, appropriate for the target population? 
5. Does the analysis contain an explicit test of the interaction between moderator 
and treatment? 
To reduce conflicts of interest members of the reviewing team who were authors on any 
included studies did not participate in the quality assessment exercises.  
2.1.5 RESULTS 
Our initial electronic searches generated 7,208 hits; 6,294 were removed based on title, 
abstract and duplicates. We obtained 64 papers for detailed review; of these 60 were 
excluded (see Figure 2). Four studies were included in this review (see Table 2). All 
four trials were RCTs comprising of a total sample of n = 5,514.  
Once we had identified these paper we revisited our search results to include any studies 
with a sample size of ≥300 in a two group comparison because the trial by Cherkin et 
al was a four arm trial with a sample of n = 638 whereas our sample size calculation of 
≥500 was based on a two arm trial. As this paper generated some useful moderators for 
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our exploratory work we decided to include it. We did not identify any additional 
relevant studies with between 300 and 499 participants. 
Although the Witt et al paper provided insufficient data to judge the quality of its 
exploratory analysis it did include a specific test for interaction. The data presented did 
not allow for any pooling of moderator analyses across studies testing similar 
interventions.  
 
Figure 2 Review 1 - Quorum statement flow diagram 
Total number of citation identified 
from search strategy: n =7,208 
Studies discarded on the basis of titles and 
abstract and duplicates: n =6,294 
Titles and abstracts of potentially 
relevant studies identified and 
retrieved for further assessment 
n = 914 
Not relevant studies n = 850 
 
Full text studies retrieved and 
reviewed n = 64 
Final studies included in review n = 4 
 
Reason for exclusion: n = 60 
Too small sample size n = 30 
Studies with no subgroup analysis n = 13 
Age <18 years, included both specific and 
nonspecific LBP or neck pain n = 5 
Studies with no comparator n = 7 
Inappropriate subgroup analysis n = 2 
Studies about predictors n =3 
  17 
Table 2 Review 1 - Included studies 
Study  Country Sample Interventions  
UK BEAM45 UK 1,334 Group exercise, manual therapy and 
combination therapy 
BeST46 UK 701 Group cognitive behavioural approach 
Witt47 Germany 2,841 Acupuncture 
Cherkin48 USA 638 Acupuncture 
 
2.1.5.1 Risk of bias and methodological quality for subgroups 
To assess risk of bias and quality of subgroups we used both the original main trial 
papers and the associated secondary papers where appropriate (see Table 3 and Table 
4).  
  18 
Table 3 Review 1 - Results of the risk of bias assessment 
Quality of the study based on 
main trial paper/s 
UK 
BEAM34 
BeST31, 36 Witt47 Cherkin48, 49 
Random sequence generation L L L L 
Allocation concealment L L L L 
Blinding of participants and 
personnel  
H H H H 
Blinding of outcome 
assessment 
L L H L 
Incomplete outcome data  L L U L 
Selective reporting L L U L 
Generalisability L L L L 
Sample size calculation L L U L 
Conflict of interest L L H L 
Source of funding MRCa NIHR 
HTAb 
Social 
Health 
Fund 
Providers 
National 
Institutes of 
Health 
L, Low risk of bias; H, High risk of bias; U, Unclear; a MRC, Medical Research 
Council; b, NIHR  HTA,, National Institute for Health Research Health Technology 
Assessment 
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Table 4 Review 1 - Results of methodological quality assessments 
Quality of the moderator 
analyses based on subgroup 
paper/s 
UK BEAM BeST Witt Cherkin 
Was the subgroup analysis 
specified a-priori? 
N Y N N 
Was the selection of subgroup 
factors for analysis 
theory/evidence driven? 
N Y N N 
Were subgroup factors 
measured prior to 
randomization? 
Y Y U Y 
Was measurement of 
subgroup factors measured by 
adequate (reliable and valid) 
measurements, appropriate 
for the target population? 
Y Y N Y 
Does the analysis contain an 
explicit test of the interaction 
between moderator and 
treatment? 
Y Y U Y 
Strength of evidence EE CE for two 
potential 
moderators 
IE  EE 
Y, Yes N, No; U, Unclear; EE, exploratory evidence - fulfils three, four or five criteria 
for moderator studies; CE, confirmatory evidence- fulfils all five criteria for moderator 
studies, IE, insufficient evidence to judge quality. 
Table 5 presents the potential moderators with strong and/or weak evidence from the 
four included trials. The many interactions tested that were not statistically significant 
are not reported here. 
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Table 5 Mean difference (95% CI) of potential moderators with strong evidence (p < 0.05) and weak evidence (p< 0.20, ≥ 0.05) 
Study ID 
Potential 
moderators 
Significant interaction on selected outcomes (12 months) 
RMDQa MVKb pain MVK disability 
BeST36, 46 
Troublesomeness 
(Very/Extremely – 
Moderately) 
p = 0.190 
-1.01 (-2.52, 0.50) 
p = 0.184 
-5.04 (-12.47, 2.40) 
NSc 
Age ( ≥54 years – <54 
years) 
p = 0.035 
-1.58 (-3.05, -0.12) 
NS NS 
Female – Male 
p = 0.102 
-1.27 (-2.79, 0.25) 
NS NS 
Left FT Education 
(>16 years of age – 
≤16 years of age) 
p = 0.098 
1.29 (-0.24, 2.82) 
NS NS 
Employed – Not 
Employed 
p = 0.011 
1.89 (0.43, 3.35) 
p = 0.181 
5.01 (-2.33, 12.34) 
NS 
HADS – Anxiety (≥11 
– <11) 
p = 0.195 
-1.12 (-2.83, 0.58) 
NS NS 
HADS – Depression 
(≥11 – <11) 
p = 0.135 
-2.07 (-4.79, 0.65) 
NS 
p = 0.051 
-14.58 (-29.19, 0.03) 
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Study ID 
Potential 
moderators 
Significant interactions; outcome, Roland Morris Disability Questionnaire  (RMDQa) 
8 Weeks 52 Weeks 
IAd StAe SiAf IA StA SiA 
Cherkin48, 49 
Age NS 
p = 0.08 
0.08 (-0.02, 0.18) 
NS NS 
p = 0.15 
0.07 (-0.03, 0.17) 
NS 
Self-efficacy 
p = 0.04 
-6.17 (-12.01,  
-0.33) 
NS NS NS NS NS 
RMDQ (B/L)g 
P < 0.0001 
-0.48 (-0.72,  
-0.24) 
p = 0.004 
-0.37 (-0.62,  
-0.12) 
p = 0.001 
-0.41 (-0.66,  
-0.16) 
p = 0.07 
-0.23 (-0.48, 0.02) 
p = 0.07 
-0.24 (-0.49, 0.01) 
NS 
Bothersomeness score 
(B/L) 
NS 
p = 0.10 
0.47(-0.10-1.04) 
NS NS NS NS 
Heavy lifting 
p = 0.03 
4.29 (0.43, 8.15) 
p = 0.13 
3.00 (-0.86, 6.86) 
p = 0.18 
2.73 (-1.27, 6.73) 
p = 0.01 
5.19 (1.17, 9.21) 
p = 0.15 
3.03 (-1.05, 7.11) 
p = 0.04 
4.45 (0.28, 8.62) 
Sedentary NS NS NS 
p = 0.12 
2.73 (-0.72, 6.18) 
p = 0.15 
2.47 (-0.90, 5.84) 
NS 
Use of narcotic 
medication 
p = 0.08 
3.52 (-0.38, 7.42) 
NS 
p = 0.01 
4.81 (0.97, 8.65) 
NS 
p = 0.04 
4.06 (0.18, 7.94) 
p = 0.19 
2.71 (-1.31, 6.73) 
Acupuncture 
expectation (top tertile) 
p = 0.05 
-2.65 (-5.28,  
-0.02) 
NS NS NS 
p = 0.17 
-1.9 (-4.60, 0.80) 
p = 0.03 
-2.91 (-5.56, -0.26) 
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Study ID 
Potential 
moderators 
Significant interactions; outcome, bothersomeness score 
8 Weeks 52 Weeks 
Cherkin48, 49 
 
(cont) 
Age NS 
p = 0.09 
0.04 (0.001, 0.08) 
p = 0.07 
0.04 (0.001, 0.08) 
NS 
p = 0.15 
0.04 (-0.02, 0.10) 
p = 0.08 
0.05 (-0.01, 0.11) 
Self-efficacy 
p = 0.14 
-2.21 (-5.13, 
0.71) 
NS NS NS NS NS 
Baseline RMDQ score 
p = 0.01 
-0.15 (-0.27,  
-0.03) 
NS 
p = 0.0005 
-0.22 (-0.34,  
-0.10) 
p = 0.16 
-0.09 (-0.23, 0.05) 
NS NS 
Heavy lifting 
p = 0.05 
1.97 (0.03, 3.91) 
NS 
p = 0.04 
2.10 (0.10, 4.10) 
p = 0.02 
2.51 (0.43, 4.59) 
NS NS 
Light/medium lifting NS 
p = 0.12 
-1.28 (-2.87, 0.31) 
NS 
p = 0.12 
1.35 (-0.36, 3.06) 
NS NS 
Sedentary NS NS NS 
p = 0.19 
1.20 (-0.58, 2.98) 
NS NS 
Acupuncture 
expectation (top tertile) 
p = 0.10 
-1.10 (-2.41, 
0.21) 
NS NS 
p = 0.051 
-1.44 (-2.87,  
-0.01) 
NS 
p = 0.06 
-1.29 (-2.64, 0.06) 
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Study ID 
Potential 
moderators 
3 months for RMDQ outcome 12 months for RMDQ outcome 
Combined treatment Combined treatment 
UK BEAM 34, 
45 
Quality of life 
p = 0.174 
-0.1 (-0.26, 1.43) 
NS 
Treatment expectation 
(helpful) 
p = 0.073 
-3.2 (-6.74, 0.30) 
p = 0.038 
-3.8 (-7.39, -0.20) 
Treatment expectation 
(very helpful) 
p = 0.192 
-2.2 (-5.49, 1.11) 
p = 0.019 
-4.0 (-7.38, -0.67) 
 Manipulation Manipulation 
Beliefs 
p = 0.07 
-0.8 (-1.62, 0.06) 
NS 
Quality of life 
p = 0.118 
1.4 (-0.35, 3.07) 
NS 
Pain/Disability 
p = 0.176 
-1.9 (-4.61, 0.85) 
p = 0.143 
-2.2 (-5.16, 0.75) 
Treatment expectation 
(helpful) 
NS 
p = 0.083 
-0.1 (-0.16,0.01) 
Treatment expectation 
(very helpful) 
p = 0.113 
1.6 (-0.38, 3.60) 
NS 
  
  24 
Study ID 
Potential 
moderators 
Outcome, Hannover functional ability questionnaire for measuring back-pain related functional limitations (FFbHR) 
Witt47 
Worse initial back 
function 
p < 0.001  Back function and pain improvement at 3 months with acupuncture treatment 
Younger p < 0.001 
>10 years of schooling p = 0.01 
a RMDQ, Roland Morris disability questionnaire; b MVK, Modified Von Korff; c NS, no significant interaction found; d IA, individualised acupuncture; e StA: standardised 
acupuncture; f SiA, simulation acupuncture; g B/L, baseline. 
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2.1.5.1.1 Moderator variables identified 
Potential moderators with strong evidence (p < 0.05) in one or more studies include age 
(younger participants may gain more benefit), employment status and type (those 
employed or in sedentary occupations may gain greater benefit), back pain status (those 
who are worse may gain greater benefit), narcotic medication use (users may benefit 
less), treatment expectations (those with a greater positive expectation gained more 
benefit) and education (those with greater than 10 years of schooling gained a greater 
benefit). Potential moderators with weaker evidence (0.05 < p ≤ 0.20) include gender 
(female participants may gain greater benefit), psychological distress (those with 
anxiety and depressive symptoms may benefit more), pain/disability (those with greater 
pain/disability at baseline may benefit more) and quality of life (those with a better 
quality of life may benefit more). It should be noted that these findings might just be a 
chance finding, particularly as these conclusions come from different studies. 
Age 
The BeST, Cherkin and Witt trials found an interaction with age.46, 48, 50 In BeST, 
younger participants gained more benefit from cognitive behavioural therapy than older 
participants on the RMDQ score.46 The treatment difference was -1.58 (p = =0.035; 
95% CI -3.05 to -0.12). As the p-value was <0.05, the interactions provided strong 
evidence. Witt found a statistically significant additional benefit from acupuncture 
treatment in younger participant (p <0.001).50 
Gender  
BeST found that gender had a moderating effect on treatment.46 In this trial, females 
had comparatively greater improvement following group cognitive behavioural therapy 
compared to males. The treatment difference between male and female was -1.27 
(p  = 0.102; 95% CI -2.79 to 0.25) for the RMDQ score. As the p-value was 
0.05 < p ≤ 0.20 the interaction provides weak evidence.  
Employment status 
Employment was found to be one of the positive moderating factors. In BeST, the 
authors found that employed participants gained additional benefit from a cognitive 
behavioural approach when compared to those who were not employed. The treatment 
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difference between employed and not employed was 1.89 (p = 0.011; 95% CI 0.43 to 
3.35) and 5.01 (p = 0.181; 95% CI -2.33 to 12.34) for the RMDQ and MVK pain score 
respectively. The interaction effect in the analysis of the MVK pain score was weak.46  
The Cherkin trial found some moderating effect according to types of employment 
status. The participants in this trial received acupuncture therapy.48 Those participants 
whose job involved lifting heavy materials showed positive moderating effect against 
back related dysfunction score at eight weeks (p = 0.03 to 0.18) and 52 weeks (p = 0.01 
to 0.04). Those participants doing medium/light lifting at work showed positive 
moderating effect in terms of the bothersomeness score (p = 0.12) at eight and 52 
weeks, however the interaction was weak. Finally those participants with sedentary 
work showed positive moderating effect at 52 weeks (p = 0.12 to 0.19). The interaction 
was generally weak.  
Education 
BeST found that participants who had left full-time education after the age of 16 had 
better improvement from cognitive behavioural therapy compared to participants who 
left full time education aged 16 years or less.46 The treatment difference was 1.29 
(p = 0.098; 95% CI -0.24 to 2.82) for the RMDQ score. The interaction effect was 
greater than 0.05 therefore this provides weak evidence. Witt found that those 
participants who have had more than 10 years of schooling gained a greater benefit 
from acupuncture (p = 0.01).50 
Back pain status  
In the Cherkin and Witt trials participants with a worse initial back pain status (baseline 
RMDQ) gained an increased benefit from acupuncture when compared to those with a 
better back pain status at baseline (p-values ranged from <0.001 to 0.16).48, 50 The extent 
to which LBP inconveniences participants, how troublesome or bothersome it is, was 
found to be a moderator in two trials with a greater benefit from treatment in those with 
a more troublesome/bothersome condition. The interaction was weak with the p-values 
being greater than 0.05. In the Cherkin trial, the p-value was 0.10 while in the BeST 
trial, the treatment difference for the RMDQ score was -1.01 (p = 0.190; 95% CI -2.52 
to 0.50) and -5.04 (p  =1.184; 95% CI -12.47 to 2.40) for MVK pain score.46, 48  
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Pain/disability 
Similarly, those participants with greater pain/disability at baseline seemed to benefit 
more at three months (p = 0.176) and 12 months (p = 0.143) for the RMDQ score with 
manipulation treatment (UK BEAM) (see Table 5). The p-values are greater than 0.05 
and less than 0.2 therefore providing weak evidence.45 
Narcotic 
Cherkin found that use of medication such as narcotics had a negative moderating effect 
in those receiving acupuncture. The p-value for this interaction ranged from 0.01 to 
0.19, demonstrating a spectrum of strong to weak evidence.48 
Treatment expectations  
Having better expectations about the treatment was found to be a moderating factor in 
two trials.45, 48 The p-values ranged between p = 0.03 and p  = 0.192 demonstrating a 
spectrum of strong to weak evidence for the interactions.48  
Cherkin found that participants with higher expectation of acupuncture treatment 
helpfulness gained more benefit in the back related dysfunction score (p = 0.03 to 0.17) 
and bothersomeness score (p = 0.05 to 0.10).48 In the UK BEAM trial, manipulation at 
three months (p = 0.113) and 12 months (p = 0.083) or a combined treatment of 
manipulation and exercise (p = 0.03 to 0.192) at both three and 12 months showed 
positive moderating effect as was demonstrated by the RMDQ score.45 Overall, the 
interactions were found to range between a spectrum of strong to weak evidence. 
Quality of life 
Good quality of life showed weak evidence for a moderating effect on treatment 
outcome for both manipulation treatment (p = 0.118) and a combined manipulation and 
exercise treatment (p = 0.174).45  
Psychosocial status 
In BeST, psychosocial status moderated treatment effect. The trial investigated whether 
psychological status moderated better outcome from a cognitive behavioural therapy. 
Participants with higher levels of anxiety at baseline gained more benefit from treatment 
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in terms of the RMDQ score. The treatment difference was found to be -1.12 (p = 0.195; 
95% CI -2.83 to 0.58), demonstrating a weak interaction. Similarly those participants 
who were depressed considerably gained more benefit from the treatment than those 
who were less depressed as was found in the RMDQ and MVK disability score. The 
treatment difference was found to be -2.07 (p = 0.135; 95% CI -4.79 to 0.65) and -14.58 
(p = 0.051; 95% CI -29.19 to 0.03) for the RMDQ and MVK disability score 
respectively.46 
2.1.6 DISCUSSION & CONCLUSION 
In this review we aimed to identify potential moderators of treatment effect to test in 
our Repository of data. Only four trials were included. We considered any variables 
identified as moderators of treatment effect at p<0.05 as potential moderators with 
strong evidence and those at p<0.20, ≥0.05 as potential moderators with weak evidence. 
Only for two comparisons, in one study, were any confirmatory analyses performed. 
Any apparently positive findings need to be interpreted with considerable caution. We 
have set the threshold for potential moderation with weak evidence at p = 0.02 and the 
included studies included many comparisons meaning that any positive results may well 
be no more than chance findings. Nevertheless, we have identified some domains where 
there is some weak evidence of moderation that is worth exploring further.  
2.2 SYSTEMATIC REVIEW 2 – QUALITY OF SUBGROUP ANALYSES IN 
LOW BACK PAIN TRIALS  
This review has been published in Spine.51 Here we present a summary of the paper.  
2.2.1 ABSTRACT 
Background: Trials of back pain interventions have generally shown small to moderate 
positive effects. Therefore identifying subgroups in this population is a research 
priority. This review evaluates the quality, conduct and reporting of subgroup analyses 
performed in the NSLBP literature.  
Aim: To evaluate the quality, conduct and reporting of subgroup analyses performed in 
randomized controlled trials of therapist delivered interventions for NSLBP. 
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Method: Electronic databases were searched for randomized controlled trials of 
therapist delivered interventions for NSLBP. We only included papers reporting 
subgroup analyses (confirmatory or exploratory). The quality of subgroup analyses and 
quality of conduct and reporting were also evaluated.  
Results: Thirty-nine papers were included in the final review. Of these, only three (8%) 
tested hypotheses about moderators (confirmatory findings); 18(46%) generated 
hypotheses about moderators to inform future research (exploratory findings), and 
18(46%) provided insufficient findings. The appropriate statistical test for interaction 
was performed in 27 of the papers, of which ten reported results from interaction tests, 
four incorrectly reported results within individual subgroups and the remaining papers 
either reported p-values or nothing at all.  
Conclusion: Subgroup analyses performed in NSLBP trials have been severely 
underpowered, are only able to provide exploratory or insufficient findings and have 
rather poor quality of reporting. Using current approaches, few definitive trials of 
subgrouping in back pain are very likely to be performed. There is a need to develop 
new approaches to subgroup identification in back pain research. 
2.2.2 BACKGROUND 
The identification of subgroups that gain the most benefit from interventions for the 
management of LBP is an important research priority internationally.15, 52-54 Although 
several trials claim to have performed subgroup analyses, the quality, conduct and 
reporting of the analyses performed has not been critically reviewed. There is some 
confusion in the papers between investigating ‘subgroup effects’ and investigating 
‘differential subgroup effects’ where the former investigates a specific subset or 
subpopulation of the entire sample for a main effect and the latter investigates treatment 
effect heterogeneity using an interaction test between subgroups defined by factors 
measured prior to treatment.55 
2.2.3 AIMS 
The objective of this literature review is to firstly identify randomized controlled trials 
of therapist delivered interventions for NSLBP that have performed secondary analyses 
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in the form of subgroup analyses. All identified literature was assessed using a set of 
methodological criteria to evaluate the quality of subgroup analyses. Furthermore, the 
conduct and reporting of subgroup analyses was also assessed.  
2.2.4 METHOD 
This literature review work was done as part of the PhD studentship funded in this 
programme of work.  
The same search strategy described above in our previous review was used in this 
review to identify potential papers of RCTs looking at therapist delivered interventions 
for LBP. Originally the following databases were searched until September 2011. 
Searches were updated in July 2014. Electronic searches were conducted using the 
following databases:   
 MEDLINE  
 Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 
 EMBASE  
 Web of Science 
 Citation Index and Cochrane Controlled Trial Registered (CENTRAL)  
2.2.4.1 Search strategy 
As described above we started our searches using the terms ‘low back pain’ combined 
with keywords including ‘subgroup’, ‘effect modifier’ and ‘moderator’. This only 
yielded publications which used the term ‘subgroup’ in the title and/or the abstract, it 
failed to pick up papers that used the term in the main body of the text. Therefore we 
re-ran searches to identify all ‘low back pain’ and ‘RCTs’ which we filtered for therapist 
delivered interventions.  
2.2.4.2 Inclusion and exclusion criteria 
Box 2 outlines the inclusion and exclusion criteria for this review.  
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Box 2 Review 2 - Inclusion and exclusion criteria.  
Inclusion criteria: 
 Randomised controlled trials 
 Participants aged 18 years or more with history of NSLBP 
 Therapist delivered interventions for NSLBP (including psychological 
interventions and intensive rehabilitation programmes) 
 Primary or secondary analysis of RCTs reporting that a subgroup analysis had 
been conducted. 
Exclusion criteria: 
 LBP with known likely cause (fracture, infection, malignancy specific cause, 
ankylosing spondylitis and other inflammatory disorders) 
 Studies investigating disorders additional to NSLBP e.g. NSLBP and neck pain 
 Outcome not a valid clinical measure of NSLBP e.g. number of days sick leave  
 Testing a clinical prediction rule 
 Treatment effect modification over time i.e. treatment x moderator x time 
 Pooled datasets of similar trials. 
Reproduced with permission from Lippincott, Williams & Wilkins publishers  
2.2.4.3 Screening and data extraction 
We screened titles and abstracts based on the predetermined inclusion criteria. We 
selected all papers potentially reporting subgroup analysis for further investigation. All 
agreed full papers were obtained for data extraction. Data were extracted onto a 
standardised extraction form and any discrepancies were resolved using a second 
reviewer. 
2.2.4.4 Quality assessment of subgroup analysis 
We used the same Pincus et al criteria described in the previous review (see 2.1.4.5 Risk 
of bias and quality assessment) the review above to assess the quality of subgroups.44 
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Three independent reviewers (DM, SP, SWH) assessed quality of the identified papers. 
All discrepancies were addressed and resolved through discussion. 
To reduce conflicts of interest members of the reviewing team who were authors on any 
included studies did not participate in the quality assessment exercises.  
2.2.4.5 Analysis 
To assess the conduct and reporting of subgroup analysis we referred to existing 
authoritative reviews.56, 57 Papers were assessed for: 
 Design and methods – for all papers 
 Results   
 Interpretation and discussion   
Each paper was examined to see it if they conformed to four key recommendations in 
the area of subgroup analyses (see Box 3).  
Only for those papers that used interaction 
tests for subgroup analyses 
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Box 3 Key recommendations in the area of subgroup analyses. 
Key recommendations: 
 Exact subgroup definitions should be given beforehand for continuous and 
categorical variables along with some justification to avoid post-hoc data 
dependent definitions of subgroups. 
 Subgroup analyses should be performed on the primary outcome in the study. This 
is simply because trials are designed to detect differences in the primary outcome 
only; therefore performing subgroup analyses on any other outcome measure will 
substantially reduce the power. 
 A differential subgroup effect should be formally evaluated using a statistical test 
for interaction and the interaction effect reported. Performing tests within 
individual subgroups and then comparing the results is an incorrect approach to 
subgroup analyses as it does not directly evaluate the subgroup effect. 
 The number of subgroup analyses to be performed should be kept to a minimum. 
This is to avoid the issue of false-positive discovery (type-I error inflation) due to 
multiple testing; a well-known issue if there are several subgroups of interest. Any 
concerns regarding multiplicity should be acknowledged and addressed 
appropriately e.g. applying a Bonferroni or Sidak correction. 
Reproduced with permission from Lippincott, Williams & Wilkins publishers  
2.2.5 RESULTS  
Our initial search identified 5,581 papers. All titles and abstracts were screened to 
identify potential papers reporting results of RCTs of therapist delivered interventions 
for LBP. We excluded 5,521 papers during the screening process. The full text for the 
remaining 60 papers were then thoroughly examined to look for subgroup analyses of 
which 21 were excluded as they either did not meet the inclusion criteria or they met 
one or more of the exclusion criteria. We included 39 papers in the final review (see 
Figure 3). 
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Figure 3 Review 2 - Quorum statement flow diagram.  
A summary of the included studies is given in Table 6 and excludes studies in Appendix 
1. A total of 63% of the included papers were from the Netherlands, UK or USA. The 
median study size was 223 and ranged from 100 to 3,093.  
Total number of citation 
identified from search strategy: 
n = 5,581 
 
Excluded on the basis of titles and 
abstract: n = 5,521 
Full text papers retrieved and 
reviewed n = 60 
Final papers included in review 
n = 39 
Reason for exclusion: n = 21 
Included participants aged less than 18 years n = 3 
Intervention not delivered by therapist n = 3 
Looked at effect modification over time n = 2 
Looked at an additional disorder n = 2 
Outcome in subgroup analysis not a clinical outcome n = 6 
Pooled datasets of similar trials n = 1 
Testing a clinical prediction rule n = 2 
HTA report. Secondary subgroup analyses paper published 
elsewhere and used instead n = 2 
Reproduced with permission from Lippincott, Williams & Wilkins publishers  
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Table 6 Summary of included papers in descending order by subgroup quality assessment. 
Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Confirmatory 
Findings 
Sheets58 2012 Australia 148 
First-line care group 
vs McKenzie group 
Pain measured at 1 
week and 3 weeks. 
Global perceived effect 
at 3 weeks. 
None 
Smeets59 2009 
Australia & 
New 
Zealand 
259 
Exercise and advice 
vs Exercise and sham 
advice vs Sham 
exercise and advice vs 
Sham exercise and 
sham advice 
Pain intensity (11 point 
scale) and patient 
specific function scale 
(0-10 scale) measured 
at baseline 6 weeks 
and 52 weeks 
None 
Underwood46 2011 UK 701 
Advice plus Cognitive 
behavioural 
intervention vs 
Advice only 
RMDQa and MVKb 
measured at baseline, 3 
months, 6 months and 
12 months 
Age & 
Employment 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Exploratory 
Findings 
Becker60 2008 Germany 1,378 
Multifaceted 
guideline 
implementation (GI) 
vs GI plus 
motivational 
counselling (MC) vs 
Postal dissemination 
of guideline (Control) 
Hannover Functional 
Ability Questionnaire 
measured at baseline 
and 6 months 
None 
Exploratory 
Findings 
Cecchi61 2012 Italy 210 
Back school vs 
Individual 
physiotherapy vs 
Spinal manipulation 
RMDQ measured at 
baseline, 3 months, 6 
months and 12 months 
None 
Exploratory 
Findings 
Cherkin62 1998 USA 321 
Physical therapy vs 
Chiropractic 
manipulation vs 
Educational booklet 
Bothersomeness of 
symptoms and RMDQ 
measured at baseline, 4 
weeks and 12 weeks 
Mental Health 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Exploratory 
Findings 
Cherkin63 2001 USA 262 
Chinese acupuncture 
vs Therapeutic 
Massage vs Self-care 
education 
Bothersomeness of 
symptoms and RMDQ 
measured at baseline, 4 
weeks, 10 weeks and 1 
year 
None 
Exploratory 
Findings 
Cherkin49 2009 USA 638 
Individualised 
acupuncture vs 
Standardized 
acupuncture vs 
Simulated 
acupuncture vs Usual 
care 
Bothersomeness of 
symptoms and RMDQ 
measured at baseline, 8 
weeks, 26 weeks and 1 
year 
None 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Exploratory 
Findings 
Hansen64 1993 Denmark 180 
Intensive dynamic 
back-muscle exercise 
vs Conventional 
physiotherapy vs 
Placebo control (semi 
hot packs and light 
traction) 
Pain level (10 point 
scale) measured at 
baseline, 4 weeks, 6 
weeks and 1 year 
None 
Exploratory 
Findings 
Hay65 2005 UK 402 
Brief pain 
management vs 
Manual physiotherapy 
RMDQ measured at 
baseline, 3 months and 
12 months 
None 
Exploratory 
Findings 
Juni66 2009 Switzerland 104 
Standard care alone vs 
Standard care plus 
Spinal Manipulative 
Therapy (SMT) 
Pain intensity (11 point 
scale) and analgesic 
use measured at 
baseline, days 1 to 14 
and 6 months 
None 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Exploratory 
Findings 
Karjalainen67 2004 Finland 170 
Mini-intervention 
group vs Worksite 
visit group vs Usual 
care group 
Pain intensity (11 point 
scale) measured at 
baseline, 3 months, 6 
months, 1 year and 2 
years 
Perceived risk 
for not 
recovering & 
type of 
occupation 
(comparing 
mini-
intervention vs 
usual care and 
worksite visit 
vs usual care) 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Exploratory 
Findings 
Kole-Snijders68 1999 Netherlands 159 
Operant behavioural 
treatment with 
cognitive coping skills 
training (OPCO) vs 
Operant behavioural 
treatment with group 
discussion (OPDI) vs 
Waiting list control 
(WLC) 
Main outcome unclear. 
Outcomes measured at  
post-treatment, 6 
months and 1 year 
None 
Exploratory 
Findings 
Roche69 2007 France 132 
Active individual 
therapy (AIP) vs 
Functional restoration 
program (FRP) 
Main outcome unclear. 
Outcomes measured at 
baseline and 5 weeks 
Sorenson score 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Exploratory 
Findings 
Sherman48 2009 USA 638 
Individualised 
acupuncture vs 
Standardized 
acupuncture vs 
Simulated 
acupuncture vs Usual 
care 
Bothersomeness of 
symptoms and RMDQ 
measured at baseline, 8 
weeks, 26 weeks and 1 
year 
Baseline RMQ 
Exploratory 
Findings 
Smeets70 2006 Netherlands 223 
Active physical 
treatment (ATP) vs 
Cognitive behavioural 
treatment (CBT) vs 
Combined APT and 
CBT (CT) vs Waiting 
list (WL) 
RMDQ measured at 
baseline, 10 weeks, 6 
months and 12 months 
Baseline RMQ 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Exploratory 
Findings 
Smeets71 2008 Netherlands 223 
Active physical 
treatment (ATP) vs 
Graded activity with 
problem solving 
training (GAP) vs 
Combination 
treatment (CT) vs 
Waiting list (WL) 
RMDQ measured at 
baseline, 10 weeks, 6 
months and 12 months 
None 
Exploratory 
Findings 
Tilbrook37 2011 UK 313 Yoga vs Usual care 
RMDQ measured at 
baseline, 3 months, 6 
months and 12 months 
None 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Exploratory 
Findings 
Underwood45 2007 UK 1,334 
Control (Best care in 
General Practice) vs 
Exercise programme 
vs Spinal 
manipulation vs 
Combined treatment 
(manipulation and 
exercise) 
RMDQ measured at 
baseline, 3 months and 
1 year 
Expectation 
Exploratory 
Findings 
van der Hulst72 2008 Netherlands 163 
Roessingh Back 
Rehabilitation (RRP) 
vs Usual care 
RMDQ measured at 
baseline, 1 week after 
treatment and 4 
months after treatment 
Pain intensity 
& Depression 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Exploratory 
Findings 
Witt50 2006 Germany 3,093 
Acupuncture vs 
Control (delayed 
acupuncture treatment 
3 months later) 
Hannover Functional 
Ability Questionnaire 
(0-100 scale) measured 
at baseline, 3 months 
and 6 months 
Initial back 
pain, age & 
years of 
schooling 
Insufficient 
Findings 
Bendix73 1998 Denmark 816 
Functional restoration 
(FR) program vs 
Outpatients program 
(Control) 
Main outcome unclear. 
Outcomes measured at 
baseline and 1 year 
 
Insufficient 
Findings 
Beurskens74 1995 Netherlands 151 
Traction vs Sham 
traction 
GPE and severity 
measured on visual 
analogue scale (VAS) 
at baseline and 5 
weeks 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Insufficient 
Findings 
Bishop75 2011 USA 112 
Supine thrust 
technique vs Side-
lying thrust vs Non-
thrust technique 
ODIc measured at 1 
week, 4 weeks and 6 
months 
None 
Insufficient 
Findings 
Carr76 2005 UK 237 
Group exercise 
programme vs 
Individual 
physiotherapy 
RMDQ measured at 
baseline, 3 months and 
6 months 
 
Insufficient 
Findings 
Ferreira77 2009 Australia 191 
General exercise vs 
Motor control 
exercise vs Spinal 
manipulative therapy 
GPEd (11 point scale), 
Patient specific 
functional status, 
RMDQ, Pain intensity 
(10 point scale) and 
spinal stiffness 
measured at baseline 
and 8 weeks 
None 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Insufficient 
Findings 
Glasov78 2009 Australia 100 
Laser acupuncture vs 
Sham acupuncture 
(control) 
Pain (VAS) measured 
at baseline, 
immediately after 
treatment, 6 weeks and 
6 months 
 
Insufficient 
Findings 
Gudavalli79 2006 USA 235 
Flexion distraction 
(FD) vs Active trunk 
exercise protocol 
(ATEP) 
Perceived pain (VAS), 
RMDQ and SF-36 
measured at baseline, 4 
weeks, 3 months, 6 
months and 1 year 
 
Insufficient 
Findings 
Hsieh80 2004 China 146 
Acupressure vs 
Physical therapy 
Short-form pain 
questionnaire 
measured at baseline, 4 
weeks and 6 months 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Insufficient 
Findings 
Jellema81 2005 Netherlands 314 
Minimal intervention 
strategy (MIS) vs 
Usual care 
RMDQ, perceived 
recovery (7 point 
scale) and sick leave 
measured at baseline, 6 
weeks, 13 weeks, 26 
weeks and 1 year 
 
Insufficient 
Findings 
Johnson82 2007 UK 234 
Group exercise and 
education using a 
cognitive behavioural 
approach vs Usual 
care 
Pain (VAS) and 
RMDQ measured at 
baseline, 3 month, 9 
month and 15 months 
Patient 
preference 
Insufficient 
Findings 
Kalauokalani83 2001 USA 166 
Acupuncture vs 
Massage (Subanalysis 
of Cherkin 2001 
paper) 
RMDQ measured at 
baseline, 4 weeks, 10 
weeks and 1 year 
Patient 
expectations 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Insufficient 
Findings 
Mellin84 1989 Finland 456 
Inpatient treatment vs 
Outpatient treatment 
vs Control (Advice) 
Low back pain 
disability index (scale 
0-45) measured at 
baseline and 3 months 
 
Insufficient 
Findings 
Klaber 
Moffett85 
2004 UK 187 
Exercise vs Usual 
care 
RMDQ measured at 
baseline, 6 weeks, 6 
months and 1 year 
 
Insufficient 
Findings 
Myers86 2008 USA 444 
Usual care vs Usual 
care plus patient 
choice of 
acupuncture, 
chiropractic or 
massage 
RMDQ measured at 
baseline, 5 weeks and 
12 weeks 
None 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Insufficient 
Findings 
Seferlis87 1998 Sweden 180 
Manual therapy 
program (MTP) vs 
Intensive training 
program (ITP) vs 
General practitioner 
program (GPP) 
Main outcome unclear. 
Outcomes measured at 
baseline, 1 month, 3 
months and 12 months 
 
Insufficient 
Findings 
Thomas88 2006 UK 241 
Traditional 
acupuncture vs Usual 
care 
Bodily pain dimension 
of the SF-36 (0-100 
scale) measured at 
baseline, 3 months, 12 
months and 24 months 
Expectation 
Insufficient 
Findings 
van der Roer89 2008 Netherlands 114 
Intensive group 
training protocol vs 
Guideline group 
RMDQ measured at 
baseline, 6 weeks, 13 
weeks, 26 weeks and 
52 weeks 
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Subgroup Quality 
Assessment 
Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure and 
follow-up* 
Subgroups 
Identified 
(Interaction 
test only) 
Insufficient 
Findings 
Vollenbroek-
Hutten90 
2004 Netherlands 163 
Roessing Back 
Rehabilitation (RRP) 
vs Usual care 
RMDQ measured at 
baseline, 1 week after 
treatment and 4 
months after treatment 
 
a RMDQ, Rolland and Morris Disability Questionnaire; b MVK, Modified Von Korff (pain and disability); c ODI, Oswestry disability index; d 
GPE, Global perceived effect; Reproduced with permission from Lippincott, Williams & Wilkins publishers 
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2.2.5.1 Methodological Quality of Subgroup Analyses 
The methodological quality of the subgroup analyses performed in the identified papers 
was assessed to determine the strength of evidence that they provide. Of the 39 papers: 
 Three (8%) papers met all five criteria and therefore provided confirmatory 
evidence; Sheets53 , Smeets54, & Underwood46, 58, 59. Two of these were too 
small to anticipate finding any important interaction if it were present (n = 148 
& 259) 
 Eighteen (46%) papers provided exploratory evidence i.e. they met criteria 
three, four and five (see Table 6) 
 Eighteen (46%) papers provided insufficient evidence (see Table 6).  
2.2.5.2 Assessment of conduct and reporting of subgroups 
We examined the conduct and reporting of subgroups in terms of design and methods 
and found: 
 One study had sufficient power to detect an interaction however subgroups of 
interest were not pre-specified a priori50 
 Thirty-one (79%) studies did not pre-specify subgroups of interest 
 Eight studies reported pre-specified subgroups for confirmatory analyses46, 58, 59, 
64, 65, 75, 79, 82; six of these also carried out exploratory analyses without clear 
distinction between analysis types. 
 Sometimes it was not clear from methods that subgroups analyses were going 
to be performed; they were just presented in the results62, 69, 74, 80 
 All papers measured subgroups of interest prior to randomisation, with most 
using adequate measurements 
 Prior to performing analyses only one paper reported the expected size and 
direction of the subgroup effect.58 A further three papers predicted the direction 
of the subgroup effect  
 A third (13/39) of the papers provided some justification regarding the choice 
of subgroups to be analysed.  
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 In two papers around sixty interaction tests were conducted substantially 
increasing the chances of detecting false positive findings.45, 59 Of the three 
papers that provided confirmatory findings, only one of them adjusted for 
multiplicity. The authors applied a Bonferroni correction to their confirmatory 
subgroup analyses.46 
 Twelve (31%) of the papers did not use a statistical test for interaction to assess 
for treatment effect modification. Of these, two of the papers did not give any 
indication as to what statistical method they used.74, 87 Two papers looked at 
correlations between individual subgroups and outcomes within each treatment 
arm separately.73, 84 Two papers used t-tests between treatment groups within 
individual subgroups.79, 80 Five papers used either multiple linear regression or 
multiple logistic regression for each individual subgroup.76, 81, 85, 89, 90 One paper 
compared the medians across three trial arms within individual subgroups using 
Kruskal-Wallis tests.64 
We examined the conduct and reporting of subgroups in terms of reporting of results 
and found:  
 A statistical test for interaction was reported to have been used in 27 (69%) of 
papers 
 Six studies reported both the interaction effect sizes with confidence intervals 
and the corresponding p-values45, 48, 61, 72, 75, 77 
 Four studies reported only the interaction effect sizes with confidence 
intervals46, 58, 59, 82  
 Eight studies reported the p-values only37, 50, 66, 67, 69, 83, 86, 88 
 Nine papers did not report either the interaction effect sizes or confidence 
intervals or p-values.49, 60, 62-65, 68, 70, 71 
 Four studies reported subgroup analyses within individual subgroups rather than 
between group interaction.60, 66, 70, 88 
We examined the conduct and reporting of subgroups in terms of reporting of 
interpretation and discussion and found:  
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 Four out of 27 papers that performed interaction tests reported subgroup 
analyses within individual subgroups and thus based the interpretations and 
discussion on this as well. 
 Reference to other relevant studies (supporting or contradicting) were made in 
around a third of the papers.  
 The limitations of subgroup analyses were reported in 12 papers.  
2.2.6 DISCUSSION & CONCLUSION 
Subgroup analyses have been attempted in several papers however there is confusion 
between investigating ‘subgroup effects’ and ‘differential subgroup effects’.55 The 
overall quality of the subgroups is poor, with most papers only providing exploratory 
or insufficient findings. The overall reporting in papers for subgroups is generally of 
poor standard. The sample sizes of the trials have been small and thus underpowered to 
detect interactions. Only one trial was appropriately powered for the analysis, however 
the authors failed to specify the subgroups a priori.50 The recommended guidelines 
should be used when performing subgroup analyses to ensure that they are reliable and 
of a good standard.56, 91 The current approaches are not suitable to address the research 
question. New methods to perform subgroup analyses are required to address the 
methodology concerns highlighted. 
2.3 SUMMARY OF REVIEWS 
Both reviews conducted during this programme of work have been informative in 
developing our understanding of subgrouping in LBP.  
Review 1 looked at identifying potential moderators to be tested within the back pain 
repository. The literature on moderators is weak and subsequently lacking in rigour to 
inform clinical practice. Despite this, the review has helped us to identify some potential 
moderators of treatment effect including age, educational attainment, employment 
status, symptoms of anxiety or depression, longer history of back pain and treatment 
expectations in at least one trial. We used these variables in our later analyses within 
our repository of data. 
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Review 2 looked at the quality of subgroup analyses conducted in the LBP literature. 
This review concluded that the overall quality was poor. To design a trial that is 
sufficiently powered to detect subgroups would need to be approximately four times 
larger than a traditional trial powered to detect a main effect of the same magnitude.92 
This would be a timely and costly undertaking where care would also need to be taken 
to select moderators that could be easily applied clinically.  
In addition to these reviews we have previously published a systematic review which 
summarised findings from randomised controlled trials testing the effects of a clinical 
prediction rule for NSLBP.93 Clinical prediction rules have been developed and are 
being used in clinical practice to help clinicians make decisions on treatment however 
the overall effect of such tools is unclear. Multi-component clinical prediction rules 
have the potential to be much more powerful tools for targeting treatments than single 
component measures. We identified 1,821 potential citations after all duplications had 
been removed. Two people independently screened the titles and abstracts, consensus 
was reached on obtaining 35 papers for full detailed evaluation. Of these only three 
papers were included in the review. The results from the available trials do not 
convincingly support the use of clinical prediction rules in the management of NSLBP. 
We concluded the existing RCTs looking to validate clinical prediction rules in LBP to 
be limited. Methodologies for the validation of these rules lack clarity and subsequently 
the evidence for, and development of, the existing prediction rules in LBP is generally 
weak. 
Current approaches have failed to provide the data needed to target treatments for LBP. 
There is therefore a need to look at alternative methods to address this problem. We 
propose three recommendations:    
1. Develop new and novel methods to identify multiple participant characteristics 
or clusters of moderators that would identify who is most or least likely to 
benefit.94-96 
2. To apply individual participant data meta-analysis to homogenous pooled 
datasets as this would improve statistical power.  
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3. To develop subgroups, and suggested interventions, based on clinical reasoning 
and test these within trials to determine if the targeted intervention produces a 
larger average effect size than existing non-specific interventions. 
In this programme we address points one and two, leaving point three for others in the 
back pain research community to consider and address. 
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CHAPTER 3 – COLLATING DATA 
In this chapter we detail the process of identifying and approaching chief investigators 
and/or data custodians for trial data for inclusion in our repository of back pain trials.  
3.1 IDENTIFICATION OF POTENTIAL TRIALS  
We used the search results generated from Review 1 – Identification of potential 
moderators (described in Chapter 2) as a starting point for identifying trials of interest. 
In the first instance we were only interested in: 
 randomised control trials 
 trials of therapist delivered interventions 
 those with a sample size of >179 participants. 
Based on these criteria we filtered the original search output to identify 658 citations. 
These were systematically screened by two members of the team independently (see 
Figure 2). Additionally we also obtained further data through snowballing; essentially 
we were offered data from trials not on our original list by researchers aware of the 
project. Although some of the trials obtained through the snowballing process are 
smaller in sample size than our target studies, we decided to include these to add power 
to our analysis.  
3.2 JUSTIFICATION OF SAMPLE SIZE 
We started with an original lower limit of 200 for the sample size. Allowing for some 
loss to follow-up a trial of 200 participants would have 90% statistical power to identify 
a standardised mean difference of 0.5 between two treatment groups. Any individual 
trials smaller than this are likely to be seriously underpowered for their primary 
outcome. Upon screening the trials there were many that obtained a final sample size 
of just under 200; typically these were studies aiming for around 200 participants that 
fell short of the final target. We therefore revised our inclusion to >179. From a practical 
perspective of approaching trial investigators, this yielded a manageable number of 
trials to approach; large trials (those of thousands of participants) and small trials (less 
than 100 participants) each create a similar amount of work to collate.  
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3.3 PROCESS FOR APPROACHING INVESTIGATORS 
We identified 42 trials which fitted our inclusion criteria. For these trials we identified 
the Chief Investigator and the best e-mail contact for them. Between 2011 and 2012 
each investigator was sent an email to invite them to participate in the Repository. Each 
email included the following attachments: 
 a formal invitation letter (see Appendix 2) 
 information sheet (see Appendix 3) 
 sample data sharing agreement (see Appendix 4) 
If a response was not received within a six to eight week period a reminder e-mail was 
then sent. If a response was received indicating an interest in sharing data then the data 
sharing agreement was personalised and sent back to the investigator for review and 
signature. Once the signed document was received by the University the investigator 
was provided with details on how to securely send the data to us. We used the University 
of Warwick secure file transfer service. 
3.4 SECURE DATA TRANSFER 
We requested all data for a trial. Investigators were advised that any datasets being 
sent to us needed to be anonymised and encrypted using an open-source compression 
software programme such as 7Zip (http://www.7-zip.org/). Investigators were then 
provided with details on how to securely transfer this data to the University of 
Warwick (see Appendix 5) using an upload system set up for the project available at 
https://files.warwick.ac.uk/repositorylbpdata/sendto  
Once this data were received it was the responsibility of the team’s statisticians and/or 
health economists to transform the original data to the repository standard. To help aid 
this process we requested all trial specific information including the protocol and 
questionnaires if they were available.     
3.5 FINAL DATA SET OBTAINED 
We obtained 14 (33%) trial datasets from the original 42 trials we approached. A further 
five trials were obtained through snowballing, resulting in a total of 19 datasets (see 
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Figure 4). We were unsuccessful in getting a response from 15(36%) investigators and 
a further six (14%) datasets were not available for data sharing. We still have seven 
(17%) datasets in negotiation where we were unable to agree on the data sharing before 
starting our formal analysis, therefore these trials have not been included in this report.  
Through the process of snowballing, further smaller datasets were offered to be 
included in the repository. The offer of these trials were carefully considered by the 
research team and it was decided that any additional data would be helpful in increasing 
power. Therefore of the 19 trials obtained three (16%) have a sample size <179. 
 
Figure 4 Quorum statement flow diagram for database identification 
Total number of citation identified from 
search strategy: n = 658 
Studies discarded on the basis of titles and 
abstract: n = 588 
Titles and abstracts of potentially relevant 
studies identified and retrieved for further 
assessment, n = 70 
 
Multiple publications, n = 24 
Not in English, n = 1 
Not therapist delivered, n = 2 
Exercise vs exercise, n = 1 
Trials to approach, n = 42  
Trials obtained, n = 14 (from search) plus, n 
= 5 from snowballing 
Total trials obtained, n = 19 
No response, n = 15 
In negotiation, n = 7 
Not available, n = 6 
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Table 7 shows the trials that were excluded and the reason for the exclusion. Details of 
papers excluded due to multiple publications can be found in Appendix 6. A list of trials 
that were unavailable due to a lack of response for the investigator, datasets not 
available and those still under negotiation are documented in Appendix 7. A final table 
of included trials and associated papers is presented in Table 8. 
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Table 7 Trials excluded and reason for exclusion, n = 4 
Author Number of participants Reason for exclusion 
Jellema P et al97 314 Not therapist delivered 
Kainz B et al98 1,274 Paper not in English 
Long A et al99 312 Trial of exercise vs exercise 
Von Korff M et al100 255 Not therapist delivered 
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Table 8 Trials included and associated publications, n=19  
Name of  / 
given name of 
trial 
Corresponding 
author/ Chief 
Investigator 
Relevant publications related to the trial of interest 
Number of 
participants 
Witt Witt 
Witt CM, Jena S, Selim D, Brinkhaus B, Reinhold T, Wruck K et al. Pragmatic randomized trial 
evaluating the clinical and economic effectiveness of acupuncture for chronic low back pain. Am J 
Epidemiol 2006;164(5):487-96.  
3,093 
UK BEAM Underwood 
Underwood MR, Harding G, Klaber Moffett J. Patient perceptions of physical therapy within a trial 
for back pain treatments (UK BEAM) [ISRCTN32683578]. Rheumatology (Oxford) 
2006;45(6):751-6. 
 
Underwood MR, Morton V, Farrin A. Do baseline characteristics predict response to treatment for 
low back pain? Secondary analysis of the UK BEAM dataset [ISRCTN32683578]. Rheumatology 
(Oxford) 2007;46(8):1297-302. 
1,334 
Haake Haake 
Haake M, Müller HH, Schade-Brittinger C, Basler HD, Schäfer H, Maier C et al. Acupuncture 
Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial 
with 3 groups. Arch Intern Med 2007;167(17):1892-8. 
1,163 
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Name of  / 
given name of 
trial 
Corresponding 
author/ Chief 
Investigator 
Relevant publications related to the trial of interest 
Number of 
participants 
BeST Lamb 
Lamb SE, Hansen Z, Lall R, Castelnuovo E, Withers EJ, Nichols V, et al. Group cognitive 
behavioural treatment for low-back pain in primary care: a randomised controlled trial and cost-
effectiveness analysis. Lancet 2010;375(9718):916-23. 
 
Lamb SE, Lall R, Hansen Z, Castelnuovo E, Withers EJ, Nichols V, et al. A multicentred 
randomised controlled trial of a primary care-based cognitive behavioural programme for low back 
pain. The Back Skills Training (BeST) trial. Health Technol Assess 2010;14(41):1-253, iii-iv. 
701 
Keele Hay 
Hay EM, Mullis R, Lewis M, Vohora K, Main CJ, Watson P, et al. Comparison of physical 
treatments versus a brief pain-management programme for back pain in primary care: a randomised 
clinical trial in physiotherapy practice. Lancet 2005;365(9476):2024-30. 
 
Whitehurst DG, Lewis M, Yao GL, Bryan S, Raftery JP, Mullis R, et al. A brief pain management 
program compared with physical therapy for low back pain: results from an economic analysis 
alongside a randomized clinical trial. Arthritis Rheum 2007;57(3):466-73. 
402 
Brinkhaus Brinkhaus 
Brinkhaus B, Witt CM, Jena S, Linde K, Streng A, Wagenpfeil S, et al. Acupuncture in patients 
with chronic low back pain: a randomized controlled trial. Arch Intern Med 2006;166(4):450-7. 
298 
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Name of  / 
given name of 
trial 
Corresponding 
author/ Chief 
Investigator 
Relevant publications related to the trial of interest 
Number of 
participants 
Dufour Dufour 
Dufour N, Thamsborg G, Oefeldt A, Lundsgaard C, Stender S. Treatment of chronic low back pain: 
a randomized, clinical trial comparing group-based multidisciplinary biopsychosocial rehabilitation 
and intensive individual therapist-assisted back muscle strengthening exercises. Spine (Phila Pa 
1976) 2010;35(5):469-76. 
286 
Pengel Pengel 
Pengel LH, Refshauge KM, Maher CG, Nicholas MK, Herbert RD, McNair P. Physiotherapist-
directed exercise, advice, or both for subacute low back pain: a randomized trial. Ann Intern Med 
2007;146(11):787-96. 
 
Smeets RJ, Maher CG, Nicholas MK, Refshauge KM, Herbert RD. Do psychological 
characteristics predict response to exercise and advice for subacute low back pain? Arthritis Rheum 
2009;61(9):1202-9. 
260 
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Name of  / 
given name of 
trial 
Corresponding 
author/ Chief 
Investigator 
Relevant publications related to the trial of interest 
Number of 
participants 
YACBAC Thomas 
Thomas KJ, MacPherson H, Thorpe L, Brazier J, Fitter M, Campbell MJ, Roman M, Walters SJ, 
Nicholl J. Randomised controlled trial of a short course of traditional acupuncture compared with 
usual care for persistent non-specific low back pain. BMJ 2006;333(7569):623.  
 
Ratcliffe J, Thomas KJ, MacPherson H, Brazier J. A randomised controlled trial of acupuncture 
care for persistent low back pain: cost effectiveness analysis. BMJ 2006;333(7569):626.  
 
Thomas KJ, MacPherson H, Ratcliffe J, Thorpe L, Brazier J, Campbell M et al. Longer term 
clinical and economic benefits of offering acupuncture care to patients with chronic low back pain. 
Health Technol Assess 2005;9(32):iii-iv, ix-x, 1-109. 
241 
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Name of  / 
given name of 
trial 
Corresponding 
author/ Chief 
Investigator 
Relevant publications related to the trial of interest 
Number of 
participants 
Hancock Hancock 
Hancock MJ, Maher CG, Latimer J, Herbert RD, McAuley JH. Independent evaluation of a clinical 
prediction rule for spinal manipulative therapy: a randomised controlled trial. Eur Spine J 
2008;17(7):936-43. 
 
Hancock MJ, Maher CG, Latimer J, Herbert RD, McAuley JH. Can rate of recovery be predicted in 
patients with acute low back pain? Development of a clinical prediction rule. Eur J Pain 
2009;13(1):51-5. 
 
Hancock MJ, Maher CG, Latimer J, McLachlan AJ, Cooper CW, Day RO, et al. Assessment of 
diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment 
for acute low back pain: a randomised controlled trial. Lancet 2007;370(9599):1638-43. 
240 
Von Korff 
BIA 
Von Korff 
Von Korff M, Balderson BH, Saunders K, Miglioretti DL, Lin EH, Berry S et al. A trial of an 
activating intervention for chronic back pain in primary care and physical therapy settings. Pain 
2005;113(3):323-30. 
240 
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Name of  / 
given name of 
trial 
Corresponding 
author/ Chief 
Investigator 
Relevant publications related to the trial of interest 
Number of 
participants 
HullExPro Carr 
Carr JL, Klaber MJA, Howarth E, Richmond SJ, Torgerson DJ, Jackson DA, et al. A randomized 
trial comparing a group exercise programme for back pain patients with individual physiotherapy in 
a severely deprived area. Disability and Rehabilitation 2005;27(16):929-37. 
237 
Von Korff 
SC2 
Moore 
Moore JE, Von Korff M, Cherkin D, Saunders K, Lorig K. A randomized trial of a cognitive-
behavioral program for enhancing back pain self care in a primary care setting. Pain 
2000;88(2):145-53. 
226 
Smeets Smeets 
Smeets RJ, Vlaeyen JW, Hidding A, Kester AD, van der Heijden GJ, van Geel AC, et al. Active 
rehabilitation for chronic low back pain: cognitive-behavioral, physical, or both? First direct post-
treatment results from a randomized controlled trial [ISRCTN22714229]. BMC Musculoskelet 
Disord 2006;7:5. 
223 
Cecchi Cecchi 
Cecchi F, Molino-Lova R, Chiti M, Pasquini G, Paperini A, Conti AA, et al. Spinal manipulation 
compared with back school and with individually delivered physiotherapy for the treatment of 
chronic low back pain: a randomized trial with one-year follow-up. Clin Rehabil 2010;24(1):26-36. 
210 
York BP Torgerson 
Moffett JK, Torgerson D, Bell-Syer S, Jackson D, Llewlyn-Phillips H, Farrin A et al. Randomised 
controlled trial of exercise for low back pain: clinical outcomes, costs, and preferences. BMJ 1999 
31;319(7205):279-83. 
187 
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Name of  / 
given name of 
trial 
Corresponding 
author/ Chief 
Investigator 
Relevant publications related to the trial of interest 
Number of 
participants 
Macedo Macedo 
Macedo LG, Latimer J, Maher CG, Hodges PW, McAuley JH, Nicholas MK et al. Effect of motor 
control exercises versus graded activity in patients with chronic nonspecific low back pain: a 
randomized controlled trial. Phys Ther 2012;92(3):363-77. 
172 
Carlsson Carlsson 
Carlsson CP, Sjölund BH. Acupuncture for chronic low back pain: a randomized placebo-
controlled study with long-term follow-up. Clin J Pain 2001;17(4):296-305. 
50 
Kennedy Kennedy 
Kennedy S, Baxter GD, Kerr DP, Bradbury I, Park J, McDonough SM. Acupuncture for acute non-
specific low back pain: a pilot randomised non-penetrating sham controlled trial. Complement Ther 
Med 2008;16(3):139-46. 
48 
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3.6 SUMMARY OF THE INCLUDED TRIALS IN THE REPOSITORY 
The agreed and included trials in this repository are detailed in Table 9. 
Table 9 Summary of the included trials in the Repository 
Name of /given name 
of trial 
Witt, n = 3,09350 
Country 
Germany 
Interventions 
 
In the RCT part of study there were two arms:  
 Acupuncture  
 Control – received acupuncture after 3 months 
Recruitment 
 
Patients consulting a physician for LBP that were insured by one of the participating social health insurance funds were recruited. 
Details of the study were provided to those patients requesting acupuncture or where the physician considered acupuncture to be a 
suitable treatment option. 
Inclusion criteria 
Age ≥18 years with the ability to provide informed consent. A diagnosis of CLBP with a duration of more than 6 months.  
Exclusion criteria 
 
Disc prolapse /  protrusion of with concurrent neurologic symptoms; previous back surgery; infectious spondylopathy; low back pain 
caused by inflammatory, malignant, or autoimmune disease; congenital deformation fracture caused by osteoporosis; spinal stenosis; 
and spondylolysis or spondylolisthesis. 
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Name of/given name 
of trial 
UK BEAM including feasibility study, n = 1,33445, 101 
Country 
United Kingdom 
Interventions 
 
 Exercise programme – group exercise including cognitive behavioural principles delivered over up to eight 60 minute sessions 
over four to eight weeks. A refresher session was provided 12 weeks after randomisation.  
 Spinal manipulation – a package of care was developed by chiropractors, osteopathic and physiotherapy professions in the 
UK. Patients were randomised to private or NHS manipulation. Up to eight 20 minute sessions provided over 12 weeks. 
 Combined treatment – provision of eight session of manipulation over six weeks plus eight sessions of exercise over the next 
six weeks plus a final refresher session at 12 weeks.  
 Best care in general practice – patients were advised to remain active and provided with a copy of The Back Book. 
Recruitment 
Recruited from GP practices after searching computerise records for potential eligible participants. 
Inclusion criteria 
Aged between 18 and 65 years; consulted with LBP; score of four or more on RMDQ at randomisation, pain experienced every day 
for the 28 days before randomisation or 21 out of 28, agreement to avoid other physical treatments during the treatment period. 
Exclusion criteria 
Aged 65 or over, potential spinal disorder, including malignancy, osteoporosis, ankylosing spondylitis, cauda equine compression, 
and infection, pain primarily below the knee, previous spinal surgery, another musculoskeletal disorder reported to be more 
troublesome than the back pain, a previous referral or attendance at a pain management clinic, a severe psychiatric or psychological 
disorder, other medical condition that could interfere with therapy, moderate to severe hypertension, intake of anticoagulants or long 
term steroids, inability to walk 100m when free of back pain, inability to get up off the floor unaided, receipt of physical therapy in 
the preceding three months, RMDQ score of ≤3 on the day of randomisation, inability to read and write English fluently. 
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Name of/given name 
of trial 
Haake, n = 1,163102 
Country 
Germany 
Interventions 
All groups received ten 30-minute sessions (2 per week). Five additional sessions were offered if  after the tenth session patients 
experienced a 10% to 50% reduction in pain intensity (Von Korff Chronic Pain Grade Scale) 
 Verum acupuncture – Sterile disposable needles used to needle fixed points plus additional points from a pre-specified list. 
14-20 needles used and manual stimulation to elicit de Qi  
 Sham acupuncture – Number of and type of needles were the same as verum acupuncture. Needling verum points or meridians 
avoided and needles were inserted superficially and without stimulation.  
 Conventional therapy – this was a multimodal treatment programme where patients received ten sessions with a physician or 
physiotherapist who administered physiotherapy and exercise. 
Recruitment 
Patients were recruited through advertising in newspapers, magazines, radio, and television 
Inclusion criteria 
Aged ≥18 years with a clinical diagnosis of CLBP of six months or longer, no previous experience of acupuncture for LBP. Grade 
one or higher for mean Von Korff Chronic Pain and a Hanover Functional Ability Questionnaire score of less than 70%. 
Exclusion criteria 
Any previous spinal surgery or fractures, infectious or tumorous spondylopathy; and chronic pain caused by other diseases. 
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Name of/given name 
of trial 
BeST, n = 70131, 36 
Country 
United Kingdom 
Interventions 
 Intervention arm received an initial 15 minute advice session and were provided with The Back Book. Subsequently they 
attended six 1.5 hour group sessions which covered cognitive behavioural topics   
 Control arm - 15 minute advice session and provided with The Back Book. 
Recruitment 
Recruited from GP practices after being identified from patient records or from consultation with the GP or practice nurse. 
Inclusion criteria 
Aged ≥18 years, with at least moderately troublesome sub-acute or chronic low back pain, with a minimum of six weeks’ duration, 
consultation with the GP for low-back pain within the preceding six months. 
Exclusion criteria 
Low back pain related to a serious cause such as infection, fracture, malignancy, those with severe psychiatric or psychological 
disorders, and individuals with previous experience of a cognitive behavioural intervention for low-back pain. 
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Name of/given name 
of trial 
Keele, n = 40265, 103 
Country 
United Kingdom 
Interventions 
 Brief pain management program – Patients were encouraged to return to normal activity using functional goal setting and 
strategies to overcome psychosocial barriers. A management plan was developed covering psychological, physical and 
functional topics. Exercises were done both at the session and home. 
 
 Manual physiotherapy – this was aimed at spinal manual-therapy techniques. The aim was to diagnose and treat biomechanical 
dysfunction of the spine using manual-therapy methods and exercises. An individualised home exercise programme was also 
provided.  
Recruitment 
Recruited from GP practices. 
Inclusion criteria 
Adults aged 18–64 years consulting with NSLBP for the first or second time of less than 12 weeks’ duration, able to give informed 
consent. 
Exclusion criteria 
Those with signs of red flags, sick leave or >12 weeks, diagnosed with osteoporosis or inflammatory arthritis, taking systemic steroids 
for longer than 12 weeks, pregnant, previous fracture or hip/back surgery, any abdominal surgery in the preceding three months, 
receipt of treatment by any other professional for the current episode of back pain.  
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Name of/given name 
of trial 
Brinkhaus, n = 298104 
Country 
Germany 
Interventions 
The acupuncture and minimal acupuncture treatments consisted of 12, 30 min sessions delivered over 8 weeks. 
 Acupuncture treatment – this was semi-standardised. Single use sterile disposable needles were used. Physicians were 
instructed to achieve de qi (an irradiating feeling), if possible. Manual stimulation of needles at least once during each session.  
 Minimal acupuncture – therapist were advised to needle at least six of ten predefined non-acupuncture points using a 
superficial insertion with fine needles. None of the points were in the area of the lower back. De qi and manual stimulation 
of the needles were avoided.  
 Waiting list group – Patients received acupuncture 8 weeks after randomisation. At this point they received 12 sessions as per 
the acupuncture treatment group. 
Recruitment 
Primary recruitment method was via advertisement in local newspapers and snowballing from that.  
Inclusion criteria 
Aged between 40-75 years with a clinical diagnosis of chronic low back pain present for more than six months, a VAS of ≥40 for 
average pain intensity over the previous seven days and the use of only oral NSAIDs in the preceding four weeks before treatment. 
Exclusion criteria 
Disc prolapse/protrusion of with concurrent neurological symptoms; radicular pain, previous back surgery; infectious spondylopathy; 
LBP caused by inflammation, malignancy or autoimmune disease; congenital spine problems excluding minor lordosis or scoliosis; 
compression fracture caused by osteoporosis; spinal stenosis; spondylolysis or spondylolisthesis; those with diagnoses with Chinese 
medicine warranting treatment with moxibustion and receipt of acupuncture treatment in the preceding 12 months. 
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Name of/given name 
of trial 
Dufour, n = 286105 
Country 
Denmark 
Interventions 
 
 Multidisciplinary biopsychooscial rehabilitation – 12 week programme split into three periods of four weeks. Period 1 - 
exercise was performed 3 times a week in 2-hour sessions. Exercise comprised of warm-up, stretching, aerobic training and 
training to strengthen the muscles. Machines and circuit training were used. Biweekly session on anatomy, postural 
techniques, and pain management were provide by a physiotherapist and back care and lifting techniques by an occupational 
therapist. Period 2 - twice weekly 2-hour exercise sessions at the study site and once a week at home or a fitness centre. Period 
3 – three times a week, 2-hour exercise sessions at home or in a fitness centre.  
 
 Individual strength training exercises encouraged by a specially trained therapist. Sessions ran for one hour twice a week for 
12 weeks. The therapist initially supported the patient then over time reduced the amount of assistance.  
Recruitment 
Rheumatologists and GPs referred patients. 
Inclusion criteria 
Patients aged 18-60 with LBP of more than 12 weeks with or without pain radiating into the leg(s). The lumber spine was assessed 
through radiography, CT or MRI scans. Physical examinations were also used. 
Exclusion criteria 
Those with symptoms of spinal pathology including malignancy, osteoporosis, vertebral fracture and spinal,  stenosis, clinical 
symptoms of an acute herniated disc accompanied by nerve root entrapment, unstable spondylolisthesis, spondylitis, other health 
conditions preventing engagement in exercise and language problems. 
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Name of/given name 
of trial 
Pengel, n = 26059, 106 
Country 
Australia 
Interventions 
 
 Exercise – individualised exercise programme using principles of cognitive behavioural therapy. 
 Sham exercise – sham pulsed ultrasonography and sham pulsed short-wave diathermy (neither provided output but acted as 
though they did) 
 Advice – to address unhelpful beliefs and fear avoidance and encourage return to normal activities.  
 Sham advice – In this session the participant was free to talk about their back pain and any other problems. The physiotherapist 
was emphatic but did not give advice.  
Recruitment 
 
Recruited by referral to trial from health care professional, invitation to those on a waiting list for physiotherapy and advert in 
newspaper. 
Inclusion criteria 
Those aged 18-80 years, NSLBP lasting for at least six weeks but no longer than 12 weeks. 
Exclusion criteria 
Those who have had spinal surgery in the past 12 months, any serious spinal abnormality, pregnancy, nerve root compromise, limited 
understanding of English and a contraindication to exercise. 
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Name of/given name 
of trial 
YACBAC, n = 24188, 107 
Country 
United Kingdom 
Interventions 
 Traditional acupuncture – up to ten session over three months 
 Usual care – this group received treatment as usual determined by the GP 
Recruitment 
Recruited from GP practices. 
Inclusion criteria 
18-65 with non-specific low back pain of 4-52 weeks’ duration. 
Exclusion criteria 
Patients currently having acupuncture, those with possible spinal disease, motor weakness, prolapsed central disc, past spinal surgery, 
bleeding disorders or pending litigation.  
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Name of/given 
name of trial 
Hancock, n = 240108-110 
Country 
Australia 
Interventions 
 Spinal manipulation - Patients in this arm received two to three session of treatment per week limited to a maximum of 12 
treatments over 4 weeks. Manipulation was provided as per a protocol. 
 Placebo spinal manipulation - Detuned pulsed ultrasound was used.  
 Both active and placebo manipulative therapy sessions were matched in time (30–40 minutes initial session followed by 20 
minute follow-up sessions). 
Four arms in the trial: 
 spinal manipulative therapy group (placebo drug and active spinal manipulative therapy);  
 spinal manipulative therapy and NSAIDs group (diclofenac and active spinal manipulative therapy).  
 NSAIDs group (diclofenac and placebo spinal manipulation); 
 Control group (placebo drug and placebo spinal manipulative therapy) 
Recruitment 
Recruited from GP practices 
Inclusion criteria 
Pain present in the region between the 12th rib and buttock crease causing moderate pain and moderate disability 
Exclusion criteria 
Present episode of pain not preceded by a pain-free period of at least 1 month, suspected or known serious spinal pathology; nerve root 
compromise); presently taking NSAIDs or undergoing spinal manipulation; any spinal surgery within the preceding 6 months; and 
contraindication to paracetamol, diclofenac, or spinal manipulative therapy. 
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Name of/given 
name of trial 
Von Korff BIA, n = 240111 
Country 
United States of America  
Interventions 
 Brief individualised programme – aimed to reduce fear and increase activity levels. This was delivered over four sessions, the 
first lasting 90 minutes with a psychologist, the second 60 minutes with a physiotherapists, the third 30 minutes with a 
physiotherapist and the final visit 30 minutes with a psychologist. Intervention patients also received up to three bonus visits, a 
book on back pain self-management and video on back pain self-care.  
 Usual care – As provided to patients not participating in a trial. This care varied but included the use of medication, primary 
care consultations and secondary care referrals. 
Recruitment 
Invitations were sent to patients that had consulted in primary care for their back pain who were enrolled in the group Health 
Cooperative. 
Inclusion criteria 
Patients with back pain aged 25-65 years, those with an RMDQ of seven or more on a 23 item scale 
Exclusion criteria 
Those waiting for back surgery, seeing a physical therapist or psychologist, patients planning to unenrolled from the Group Health 
Cooperative.  
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Name of/given 
name of trial 
HullExPro, n = 23776 
Country 
United Kingdom 
Interventions 
 Back to fitness exercise programme – patients were invited to attend eight one hour sessions aimed at increasing activity over 
a four week period. There was an underpinning cognitive behavioural approach.  
 Individual physiotherapy – treatments were provided at the discretion of the therapist.  
Recruitment 
Physiotherapy departments at acute hospitals. 
Inclusion criteria 
Those with mechanical low back pain lasting at least six weeks. 
Exclusion criteria 
Those with sciatica, recent significant surgery, the presence of a neurological or systemic condition, psychiatric illness or pregnancy. 
Individuals who have had spinal surgery, in receipt of physiotherapy in the six weeks prior. 
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Name of/given 
name of trial 
Von Korff SC2, n = 226112 
Country 
United States of America  
Interventions 
 Self-care arm – this was a group intervention of between 12-16 patients delivered over two, two hour sessions led by a 
psychologists covering a range of topics. Each patient had an individual 45 minute session with the psychologist to develop a 
personal self-care plan. Patients also received one brief follow-up telephone call to encourage continued action on the self-care 
plan. Patients were also provided with book on managing back pain, 40-min videotape on back pain self-care and a 25-min 
videotape demonstrating exercises.  
 Usual care group - received usual care plus a book on back pain.  
Recruitment 
Patients were recruited from primary care by mail six to eight weeks after a back pain visit to a Group Health primary care physician. 
 
Inclusion criteria 
Patients with back pain, aged 25-70 years, patients that had been enrolled into Group Health for at least one year. 
Exclusion criteria 
Those being considered for surgery. 
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Name of/given name 
of trial 
Smeets, n = 22370 
Country 
The Netherlands 
Interventions 
 Active physical treatment – this consisted of aerobic and strength training. This was delivered by two physiotherapists in a maximum group 
of four. Sessions were delivered three times a week lasting one hour and 45 minutes.  
 Cognitive behavioural treatment – this aimed to help patients reach their goals, manage beliefs and increase activity levels. Therapists used 
graded activity and problem solving training. 
 Active Physical Therapy (APT) – aimed at increasing aerobic capacity and muscle conditioning.  
 Cognitive behavioural treatment (CBT) – aimed at helping individuals reach their goals to increase activity levels and manage beliefs. 
Graded activity was used to encourage gradual increase or pacing of activities important to them. The frequency of the sessions gradually 
decreased from three to one session a week. In total 11 1/2 hours of treatment 
 Combined treatment (CT) – aim was to improve functioning by increasing fitness, behaviour change and management of beliefs. CT 
consisted of APT together with problem solving training.  
 Waiting list – Patients needed to wait 10 weeks before they were offered individual rehabilitation treatment. Whilst on the waiting list 
patients were unable to have diagnostic or therapeutic procedures because of their CLBP. 
Recruitment 
Patients referred for the first time to a rehabilitation centre by their GP or other medical professional were invited to the study. 
Inclusion criteria 
Aged 18-65 years with CLBP of more than three months with or without radiation to leg, an RMDQ score of > 3 and ability to walk at least 100 
meters without interruption. 
Exclusion criteria 
Vertebral fracture, spinal inflammatory disease, spinal infections or malignancy, current nerve root pathology, spondylolysis or spondylolisthesis, 
lumbar spondylodesis. A co-morbidity preventing exercise, ongoing treatment or investigation for CLBP at the time of referral or a clear treatment 
preference. Use of other treatments for back pain except pain medication. Any psychopathology affecting ability to take part. Not proficient in Dutch, 
pregnancy and substance abuse. 
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Name of/given 
name of trial 
Cecchi, n = 210113 
Country 
Italy 
Interventions 
All patients got an educational booklet on the back  
 Back school – 15 one hour sessions delivered over 15 days. The first five sessions focused on back physiology and pathology. 
Remaining ten sessions looked at relaxation techniques, group and individual exercises. Groups were made up of eight patients 
and two therapists.  
 Individual physiotherapy – therapists were able to select from exercises in a protocol to suit the patient. There were 15 sessions 
lasting 60 minutes delivered over 15 days.  
 Spinal manipulation – four to six weekly sessions of 20 minutes each over four to six weeks. 
Recruitment 
Rehabilitation out patients department by psychiatrists. 
Inclusion criteria 
NSLBP over at least the last six month reported as present ‘often’ or ‘always.’ 
Exclusion criteria 
Neurological signs or symptoms, spondylolisthesis, spinal stenosis, scoliosis >20 degrees, rheumatoid arthritis/spondylitis, previous 
vertebral fracture, psychiatric condition, cognitive impairment or pain related litigation. 
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Name of/given 
name of trial 
York BP, n = 187114 
Country 
United Kingdom 
Interventions 
 Exercise programme – delivered as a group intervention over eight one hour session over a four week period. The sessions 
comprised of stretching, low level aerobic exercises, and strengthening. The programme used cognitive behavioural principles 
and patients were encouraged increase their activity levels. 
 Controls—Patients received usual care form their GP.  
Recruitment 
Recruited from GP practices. 
Inclusion criteria 
Patients aged between 18-60 years with LBP which has lasted at least four weeks but less than six months who had consulted their GP. 
Patients had to be deemed fit to be able to undertake exercise. 
Exclusion criteria 
Those with a potentially serious pathology, unable to attend or participate in the classes and those receiving ongoing physiotherapy. 
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Name of/given name 
of trial 
Macedo, n = 172115 
Country 
Australia 
Interventions 
In both arms patients received 12 one hour sessions over an eight week period. Home exercises were encouraged in both groups. The 
home exercises and treatment sessions totalled 20 hours.  
 Graded activity – The aim of graded activity was to get patients to engage in activities they found difficult due to back pain. 
Patients were provided with an individualised progressively increasing exercise programme to address functional problems. 
A cognitive behavioural approach was use by the physiotherapist.  
 Motor control exercise – the aim is to retain optimal control and coordination of the lumbar spine and pelvis. Stage one 
involves regaining basic control strategies. In stage 2 participants progressed through to more complex static and dynamic 
tasks, and training of functional activities. At all progressions the therapist evaluates and corrects trunk muscle recruitment 
strategies, posture, movement patterns and breathing.  
Recruitment 
Recruitment via GPs, physiotherapists and public hospitals. 
Inclusion criteria 
Aged 18-80 with NSLBP of at least three months and seeking care. English speaking, living in the study region for the duration of the 
study, fit to engage in exercise, score of moderate or grater for  amount of bodily pain in the past week and interference of pain with 
normal activities. 
Exclusion criteria 
Serious spinal pathology suspected or known, patients who have had spinal surgery or due to have such surgery during the study 
period, nerve root compromise, any comorbidities preventing participation in exercise. 
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Name of/given name 
of trial 
Carlsson, n = 50116 
Country 
Sweden 
Interventions 
 Manual acupuncture – Needle acupuncture was used in predefined areas. There was a gradual increase in the number of 
needles from eight to 14 to 18 during the first three or four treatments. The de-qi feeling was sought. Treatment sessions lasted 
20mins and needles were stimulated on three occasions during this time. 
 Electroacupunture – The first two or three sessions were manual acupuncture followed by treatments consisting of electrical 
stimulation of four needles in the low back. A similar number of needles as in the manual acupuncture group were inserted 
and manually activated.  
 Placebo stimulation – this was a mock transcutaneous electrical nerve stimulation (TENS) given by a disconnected stimulator. 
The area targeted was the most painful area in the low back. During the session patients were able to see a flashing lamp.  
Recruitment 
Patients with CLBP that were referred to an outpatient pain clinic during a three-year period were included. 
Inclusion criteria 
Patients with LBP without radiation below the knee for greater than six months, normal neurologic examination function of 
lumbosacral nerve. 
Exclusion criteria 
Those who have had previous acupuncture treatment, patients with major trauma or systemic disease and pregnancy. 
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Name of/given name 
of trial 
Kennedy, n = 48117 
Country 
United Kingdom 
Interventions 
 Verum acupuncture plus The Back Book – acupuncture was based on a western approach. Between three and 12 session 
provided over a four to six week period. At each session eight to 13 needles were inserted and manually stimulated until de 
qi was achieved. 
 Sham acupuncture plus The Back Book – The Park Sham Device was used with acupuncture needles.  
 Control intervention - The Park Sham Device was used with non-penetrating needles which touched the skin but did not 
penetrate the skin. 
Recruitment 
Patients put on a waiting list for physiotherapy by their GP  
Inclusion criteria 
Adults aged 18-70 years, who are able to give informed consent with NSLBP, with or without referred pain, of up to 12 weeks 
duration. 
Exclusion criteria 
Those with red flags, pain that has lasted more than 12 weeks, those with a contra-indications to acupuncture or previous acupuncture 
treatment, any other conflicting or ongoing treatments. 
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3.7 GROUPING OF INTERVENTIONS 
Initial examination of the data showed that no two trials studied identical interventions. 
Even the usual care arms of included studies are likely to differ according to 
jurisdiction, site of recruitment and age of the study. Even with our initial large sample 
size it was clear that to be able to make meaningful comparisons we would need to 
broadly pool interventions into groups for our analyses. As a first stage we identified 
the control interventions and classified these as either usual care or as a sham control. 
There is, for example, evidence from the acupuncture literature that the difference 
between sham acupuncture and usual care is greater than any difference between sham 
and verum acupuncture.118 We therefore opted to separate the sham interventions from 
the usual care control in our analyses comparing different treatments with control or 
with each other. 
There may be qualitative differences between sham treatments. For example, sham 
acupuncture where the participant has had the sensation of being needled might have a 
different effect from a sham educational intervention. In some analyses we have 
included sham interventions; typically sham acupuncture as a separate category.  For 
this reason we have, where appropriate, specified the nature of the sham intervention 
considered.  
We used the following approach to developing our final grouping of interventions:  
1) Careful reading of each trial intervention to decide on core groups (individual 
physiotherapy, exercise, manipulation, advice/education, psychological 
therapy, graded activity, acupuncture, combination therapy, mock TENS, sham 
acupuncture and control). We listed all the trials contributing to each of the core 
groups together with the number of participants. Subsequently links were made 
between core groups to indicate potential direct and indirect comparisons (see 
Figure 5). 
2) To explore further the potential direct and indirect comparisons a second figure 
was constructed (see Figure 6). This shows the same groups presented in the 
first step with the additional information on the number of trials and total 
number of participants contributing to each of the comparisons.  
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3) Finally to allow for any meaningful comparisons we split the groups mentioned 
in steps one and two into three broad categories, namely, active physical 
(exercise and graded activity), passive physical (individual physiotherapy, 
manipulation and acupuncture) and psychological (advice/education and 
psychological therapy) (see Table 10).  
In this programme of work we are not seeking to estimate the true effect size of any 
individual intervention. Rather, we are seeking to identify predictors of treatment 
response. These analyses were constrained by the availability of data on potential 
moderators that could be pooled across trials. Considering the potential mechanisms 
through which the potential moderators might affect outcome, the study team concluded 
that it was reasonable to pool interventions that might under other circumstances appear 
rather heterogeneous. In particular, the decision to include several superficially 
different interventions as passive physiotherapy might surprise some readers. Our view, 
however, is that these are very distinctly different from active exercise based 
interventions, or those working though a psychological approach. Essentially they all 
consist of an assessment, whatever reassurance and education is provided as part of the 
treatment session, plus whatever modality is being offered; be it 
massage/mobilisation/manipulation or needling. We consider these to be conceptually 
sufficiently close in their mode of action that it is unlikely there will be distinctions in 
how the potential moderators included in our analyses might affect outcomes. They are, 
however, distinctly different from their active physical or psychological interventions 
in how treatment moderation might operate. 
In organising the data we also identified combined interventions but there were too few 
data points for it to worthwhile pursuing theses analyses. For this reason these were 
excluded from our final analyses.  
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Figure 5 Step one – Classification of trials into core groups 
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m, Number of trials; n, total number of participants 
Figure 6 Step two – Classification of trials with indication of number of trials and participants for direct and indirect comparisons
  91 
Table 10 Step 3 - Final grouping of treatment arms for analyses 
Parent group Subgroup Sub-type 
Intervention 
Active physical 
Exercise 
Graded activity 
Passive 
physical 
Acupuncture 
Manual therapy 
Individual physiotherapy 
Psychological 
Advice/education 
Psychological (cognitive behavioural approach) 
Sham control  
Sham acupuncture 
Sham electrotherapy 
Mock transcutaneous electrical nerve 
stimulation   (TENS) 
Sham advice/education 
Control 
(GP/usual care) 
 
General practitioner (GP) 
Waiting list 
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CHAPTER 4 – CREATING THE REPOSITORY DATABASE AND 
DATA CONTROL 
4.1 TYPOGRAPHICAL CONVENTIONS 
This chapter presents the methods we used to create the repository database. To distinguish 
database vocabulary and commands from regular texts different typographical fonts are used. 
Database object-class vocabulary are printed in sans-serif font [like this] and the command for 
mapping and transformation procedures are printed in monospaced typewriter font [like 
this]. Also, coloured command fonts in the text are for ease of referencing between program 
commands shown in figures and text explanations. 
4.2 BACKGROUND 
Clinical trial datasets can be stored in a tabular format, for example, Microsoft Excel or SPSS. 
A tabular format typically uses each row to represent data from a participant and each column 
to represent an item from a case report form (CRF).  
Tabular formats have the advantage of being intuitive, relatively simple to create and machine-
readable. However, this format can be susceptible to excessive growth, especially when clinical 
and non-clinical items are measured across multiple time points. Data collected for withdrawn 
participants or non-responders would still require columns for all variables irrespective if they 
were used or not. Repeating questions pose a similar problem whereby storage space must be 
allocated across the whole domain to accommodate all responses. For example, asking for a 
participant’s medical history of prescribed drugs would require a new column to be added for 
every drug listed. If only one participant documented a long list of drugs many columns would 
have to be created for all participants.  
Tabular formats are only effective for the smallest of trials and quickly become inefficient and 
difficult to maintain when the range of data collected increases. For larger trials a more robust 
solution is to use a relational database. The relational database model allows individual tables 
to be created for each CRF and for repeating sets of questions. Normalisation rules are often 
applied to define the columns for each table and the logical relationships used to create table 
joins.119 
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Figure 7 shows sample data in a tabular format and the normalised equivalent in a relational 
database. The sample data consist of the subject identification, recruitment date, demographic 
data, and the Roland Morris Disability Questionnaire (RMDQ) scores taken at baseline and at 
three-month follow-up. The data is normalised into four tables, namely, SUBJECT, 
DEMOGRAPHICS, RMDQ (for the RMDQ measurement) and FU. The latter is used to store 
the time points for each follow-up visit. 
Each table has a primary key (PKey) column for storing a unique record identifier that is used 
as the basis for creating relationships between tables (see Figure 7(B)). The relationship 
between SUBJECT and DEMOGRAPHICS is one-to-zero-or-one, that is, a subject can have 
zero or one demographic record. The primary key from the SUBJECT table is copied to the 
DEMOGRAPHICS tables thereby creating a join using a shared value. 
The relationships between SUBJECT and RMDQ is one-to-zero-or-many, that is, a subject can 
have zero or many RMDQ completed questionnaires. The FU table is joined to the RMDQ 
table using a one-to-zero-or-many relationship. This join allows a RMDQ score to be 
associated with either a baseline or three-month follow-up time point. 
To create the relationships to the RMDQ table, the primary keys from both the SUBJECT and 
FU tables are added as foreign keys. This has the result of allowing a subject to have either 
zero or many RMDQ scores at all time-points. A composite unique constraint is applied to the 
Subject Fkey and FU FKey columns to prevent a subject from having duplicate RMDQ scores 
for the same time point.  
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Figure 7 (A) A sample of original tabular format data. (B) Normalised relational 
interpretation of the original tabular data. 
The repository differs from a typical clinical trial database in that it is not possible to 
predetermine requirements by using annotated CRFs. The repository relies on data from 
multiple trials to be periodically reviewed and classified and must be frequently altered to 
accommodate new discoveries. The relational database is not a suitable model for such a 
scenario because modifications to the schema can be time consuming and complex often 
requiring the expertise of IT specialists. Thus, the database for this project needs to be flexible 
so that the end users, namely, statisticians and health economists, can carry out modifications 
without having to change the database schema.  
Our solution is to create a hybrid database that is a cross between an entity-attribute-value 
(EAV) open schema model and a relational database. This hybrid database has the flexibility 
of storing sparse heterogeneous data that allows dynamic changes whilst enforcing data 
integrity.  
Section 4.3 describes the architecture of the hybrid database. Section 4.4 describes the rules 
used to map and transform the original source data to the repository standard. Section 4.5 shows 
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how the repository database is manipulated such that the data can be viewed in an analysis 
friendly format from any statistical program that supports Open Database Connectivity 
(ODBC). Section 4.6 describes how data from multiple RCTs were extracted, transformed and 
harmonised to the repository standard and finally, loaded to the repository database.  
4.3 SYSTEM ARCHITECTURE 
Tables and columns in a relational database can be represented as classes and attributes in an 
EAV model.120 In the subsequent text the terms class and attribute will be used to conform to 
the EAV vocabulary. The term entity is interchangeable with the term object and can be thought 
of as providing a similar role to a table row but with the significant difference of only storing 
a pointer to the data and not the actual data itself. The entity-relationship diagram for the hybrid 
database is shown in Figure 8.  
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Primary Source
Data Type
Class
Subject
Attribute
EAV
Object
prms_IDPK
prms_TrialName
dtyp_IDPK
dtyp_Name
cls_IDPK
cls_Name
cls_Description
subj_IDPK
subj_PrimarySourceIDFK
subj_OriginalID
subj_RDate
subj_EDate
attr_IDPK
attr_ClassIDFK
attr_ShortName
attr_LongName
attr_DataTypeIDFK
attr_Length
attr_Precision
attr_Scale
eav_ObjectIDFKPK
eav_Value
obj_IDPK
obj_ClassIDFK
obj_AncestorIDFK
eav_AttributeIDFKPK
obj_SubjectIDFK
prms_Description
prms_ImportDate
 
Figure 8 The entity-relationship diagram for the hybrid repository database depicting 
the fixed schema with the sub-schema entity-attribute-value (EAV) tables. 
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We anticipated that there would be some consistent data present in all RCTs for describing the 
trial and for identifying the trial’s subjects. The two tables Primary Source and Subject were 
created with fixed schemas to store this data (see Figure 8). The Primary Source table stores 
the name of the RCT (prms_TrialName), a brief description of the trial (prms_Description) and 
the date the data were imported into the repository (prms_ImportDate). The Subject table 
stores the original identifier assigned to the trial participant (subj_OriginalID), the date the 
participant enrolled into the trial (subj_EDate), the date the participant was randomised 
(subj_RDate) and a unique identifier generated by the system (subj_ID). A foreign key 
relationship is created to link each subject to the Primary Source.  
The EAV model uses a sub-schema consisting of tables for classes, attributes, objects and the 
EAV data. The Class table is used to hold a list of all the identified domains, for example, 
Roland Morris disability questionnaire, Demographics, etc. These domains generally map to a 
CRF but can also be used to describe a sub-set of repeating questions, for example, repeated 
medical prescriptions.  
The Attribute table is used to hold a list of all identified variables that typically map to a CRF 
question. The Attribute table has columns for storing a short name, a verbose name, a reference 
to the containing class and data type details. The short name is used to store a standardised 
version of the original CRF question. 
The Object table stores a unique identifier for each instance of a class and a reference to the 
class itself. A foreign key relationship is created to link each Object to a Subject. This 
relationship essentially makes the EAV model subject-centric, that is, all data stored in the 
Object and EAV tables must be directly related to an imported subject. Relationship between 
objects is possible by using an ‘ancestor column’ to store the unique identifier of a related 
object. For example, an object used for repeated medical prescriptions will store the unique 
identifier of the related follow-up object in the ‘ancestor column’. 
The EAV data table has three columns and is used to store all the repository’s RCT data. Two 
columns hold references to the related objects and attributes with the other column used for 
storing the actual value of each object/attribute combination. The references to the objects and 
attributes take the form of foreign keys to the object and attribute tables. The format of the 
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value is coerced into a string regardless of the intended data type. The intended data type, for 
example, binary data, small integers or strings, details are stored in the related attribute table.  
A simplification of how tabular data is represented in an EAV table is shown in Figure 9. In 
this example, the tabular data has one row for each subject (see Figure 9(A)). When the data is 
shown in the EAV table there are four rows for subject #1000, three rows for subject #1001 
and three rows for subject #1002. For each populated cell in the tabular data a row is created 
in the EAV table. Subject #1000 has all cells populated and therefore has a row for each entry. 
Only three rows are entered for the other subjects because there was no RMDQ baseline score 
for #1001 and age was not recorded for #1002 (see Figure 9(C)). 
 
Figure 9 (A) A sample of original tabular format clinical data. (B) The XML mapping 
and transformation instructions. (C) The sample data represented as EAV.  
In reality the EAV table will use the column Attribute ID to store the unique attribute identifier 
and not the text value as shown in Figure 9(C). Also, the column Object ID stores a reference 
to the object and not the subject ID. It is the related object that links back to the subject and to 
the class.  
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4.4 MAPPING AND TRANSFORMATION 
Early evaluation of datasets from various RCTs in the project identified large variations 
between variable naming and coding conventions. For example, the Roland Morris Disability 
Questionnaire (RMDQ) was used to measure back pain disability and participant would tick 
all the items that were applicable to them on that day. There are 24 items in the questionnaire 
and the score is the sum of all ticked items. One trial might name each column ‘rm1’, ‘rm2’ 
and so on until ‘rm24’ for all 24 individual items and ‘rmscore’ as the RMDQ score measured 
at baseline, ‘rm1_3mo’, ‘rm2_3mo’, …, ‘rm24_3mo’ and ‘rmscore_3mo’ for the 3-month 
follow-up data, and so on. Another trial might name them ‘rdq1’, ‘rdq2’, …, ‘rdq24’ and ‘rdq’ 
for items measured at baseline, ‘rdq11fu’, ‘rdq21fu’, …, ‘rdq241fu’ and ‘rdq1fu’ for items 
measured at the first follow-up which could have been one month or three months post 
randomisation depending on the protocol. In addition, some trials might use numerical value 
‘1’ to represent a tick for that item and ‘0’ if it was not ticked. Other trials might use ‘1’ as 
ticked and ‘2’ as not. 
4.4.1 PILOT MAPPING AND TRANSFORMATION 
A system was required to efficiently extract, transform and load (ETL) the original trial datasets 
into the repository. After evaluating a number of commercial and open source ETL software 
packages a prototype was developed using Microsoft SQL Server Integration Services (SSIS) 
and spreadsheets for documenting mapping and transformation instructions. The spreadsheet 
instructions were passed from the statisticians and health economists to the programmer who 
in turn created the SSIS program. 
The pilot was deemed to be an inadequate solution. The versatility of SSIS as a data integration 
and transformation tool become a hindrance when attempting to customise a solution 
specifically for the repository. Setting up and configuring SSIS was found to be a laborious 
task made even more difficult by frequent change requests and the manual interpretation of the 
mapping and transformation instructions. It became apparent that using SSIS was not viable 
and a decision was made to develop a bespoke ETL application. 
4.4.2 XML AND XSD FOR MAPPING AND TRANSFORMING 
The method used to store mapping and transformation instructions was vastly improved by 
using extensible mark-up language (XML). XML is a free and open source standard governed 
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by the World Wide Web Consortium (WC3) and can be used to define a set of rules for 
encoding documents in a format that is both readable by human and machine.121 The mapping 
and transformation XML document is made up of simple and intuitive keywords that both 
statisticians and health economists can easily interpret and apply. Having non-programmers 
directly enter the mapping and transformation rules forgoes the requirement to pass these 
instructions onto a programmer which in turn saves resources and decreases misinterpretation 
errors. 
To ensure all mapping and transformation rules were specified in the correct format and the 
correct order, an XML schema (XSD) was applied to validate the XML document. The XSD 
is a separate document that defines the permitted structure of the XML document. 
4.4.3 MAPPING CLINICAL DATA 
Figure 9(B) shows an example of the XML mark-up to map the original data to the equivalent 
repository attributes. The standard attributes age and sex from the DEMOGRAPHICS class 
are mapped to the original variables age and gender. RMDQ scores for baseline and three-
month follow-up are mapped to the RDQ attribute from the RMDQ class. 
The XML element attributeName accepts values for the original variable name 
(originalName) and the follow-up time point (fu) as XML attributes. The value of the 
attributeName XML element is set to the name of the repository attribute. In the example 
for class RMDQ the attribute name is RDQ. 
Unlike in the original tabular data, the repository does not store different attribute names for 
each time point. Instead each time point will trigger a new object to be created. The XML fu 
attribute is used to track which time point an original variable belongs to. 
4.4.4 TRANSFORMING CLINICAL DATA 
The original demographics and RMDQ scores have to be transformed into the repository 
standard before the data can be loaded into the repository database. Table 11 shows that the 
standard value for male is represented numerically by 1 and female is 2 for attribute SEX. 
Based on the same example (see Figure 9(A)), the values for male and female in the original 
data were entered as M and F, respectively. Thus, the transformation for the SEX attribute uses 
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two match rules to find values M and F. When the value M is matched, the rule has been set to 
update the attribute’s value to 1. Likewise, when the value F is matched, the attribute’s value 
is updated to 2. There is no transformation rule for AGE attribute as the repository accepts any 
valid integer value. 
Table 11 A sample of the repository standard attributes and values. 
Class 
Attribute 
short name 
Attribute 
long name 
Data 
type Value Label 
DEMO-
GRAPHICS 
SEX 
Participant's 
sex 
Integer 1 Male 
    2 Female 
DEMO-
GRAPHICS 
AGE 
Participant's 
age 
Integer > 0  
RMDQ RDQ 
RMDQ 
score 
Integer range, 0 – 24 
HE RP 
Recall 
period 
Integer > 0  
HE TYPE 
Types of 
resource 
String 1a Primary care doctor 
   String 3a Physiotherapist 
   String 4M01 
Non-steroidal anti-
inflammatory drugs 
    6 Aids and adaptations 
HE REASON 
Resource 
reason 
Integer 2 Low back pain 
    4 Any condition 
HE LOCATION 
Resource 
location 
Integer 1 Primary care clinic 
    3 Private clinic 
    4 Community clinic 
HE UNIT 
Resource 
units 
Integer 1 Visit 
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Class 
Attribute 
short name 
Attribute 
long name 
Data 
type Value Label 
    3 Prescription 
    4 Item 
HE QUANTITY  Integer > 0  
HE COST  Integer > 0  
HE PAYER 
Resource 
payer 
Integer 1 Public health service 
    4 Individual 
 
In the example for class RMDQ, the transformation uses a range rule to only allow values 
between 0 and 24 to be imported. If any RDQ value falls outside this range the system will 
transform the value to Null (empty). 
4.4.5 MAPPING AND TRANSFORMING HEALTHCARE RESOURCE-USE DATA 
Mapping healthcare resource-use variables was more challenging because the different types 
of resources used across all RCTs do not conform to any standard and are completely variable. 
However, each question and answer in a typical healthcare resource-use questionnaires can be 
broken down to: the recall period, the type of resource, the reason for using the resource, the 
location of the resource, the unit of measurement, the quantity, the cost or expenses incurred 
and the payer.  
Figure 10 shows a simplified version of a typical healthcare resource-use questionnaire. In this 
example participants were asked to record all the healthcare resources they used at the three-
month follow-up time point (see Figure 10(A)). The answers provided by the participants were 
stored in a tabular format that used 12 columns to capture all responses to the five questions 
(see Figure 10(B)). By using this format, the number of required columns to accommodate the 
data would grow in line with the maximum number of responses provided by any one 
individual. For example, if only one participant listed three items the bought over-the-counter 
to treat their LBP, the number of columns required would have to be increased from 12 to 13. 
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Figure 10(C) shows a view of the repository healthcare resources data generated from the EAV 
tables. This view displays the eight standard repository healthcare resource-use attributes (table 
columns) and an additional attribute called ‘Text’ which is used to store all characters that are 
captured as comments in the CRF. 
The process for creating the transformed healthcare resource-use data involves splitting the 
original questions into a number of derived parts that will map to the standard attributes. For 
example, question one asked how many times the participant had consulted their doctor or any 
primary care doctor for any reason in the last three months. From using the information 
contained in the question the recall period is set to ‘3’, the type of resource is ‘GP’, the reason 
for using the resource is ‘Any condition’, the location of the resource is ‘Primary Care Setting’, 
the unit of measurement is ‘Visit’, the payer is ‘Public Health Service’. All these values are 
derived solely on the information contained in the original question as opposed to the value of 
the variable. Only the attribute ‘Quantity’ is directly mapped to the original variable’s value. 
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Figure 10 (A) A sample of questions in a case report form at 3-month follow-up. (B) A 
sample of original tabular format healthcare resource-use data. (C) A sample of how the 
healthcare resource-use data populate the repository standard.  
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The healthcare resource-use data is stored in the EAV tables by creating relationships between 
objects. For each time-point, one or many resource-use objects can be created. The HE class is 
only used to define the time points for collecting the healthcare resource-use data. The actual 
resource-use data is defined in the HE-DATA class and the time point value is used to link an 
HE-DATA object to an HE object. The XML schema was modified to allow related classes to 
be describe, which in turn gets interpreted by the system to create the relationships in the 
Object table. 
Figure 11 shows the HE-DATA class being used as a child class, that is, it has the HE class as 
its parent. Creating child classes signifies to the system that a relationship exists between two 
classed. The linkedValue attribute is used to specify a shared value between the parent and 
child classes. In a relational database, this shared value would be created as a foreign key 
constraint. In the example shown in Figure 11, an HE class has been defined for the three-
month follow-up time point using the attribute fu: <attributeName 
fu="3"></attributeName>. A child HE-DATA class has been defined and linked to the 
parent HE class by specifying the value "3" for the linkedValue: <childClass 
name="HE-DATA" linkedValue="3">. This corresponds with the three-month follow-
up time point specified in the HE class. 
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Figure 11 The XML mapping and transformation instructions for the sample data in 
Figure 10. 
Child classes in the XML use groupName elements to signify the number of objects that need 
to be created. In a relational database, this would result in adding a new groupName element 
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for every table row to be inserted. The value for the groupName element has no significance 
except that it must be unique. In the example shown in Figure 11, six groups have been created 
for the three-month resource-use data, namely, 3moResource1, 3moResource2, 
3moResource3, 3moResource4, 3moResource5, and 3moResource6. These groups 
represent each question in the CRF shown in Figure 10(A) and the data shown in Figure 10(B). 
The original tabular data required 13 columns across three rows to store all the data for the 
three participants. Instead of creating a new column for every resource, the repository creates 
a new object. The seven groups are used to create objects for GP visit (Pri1), NHS 
physiotherapist visit (Pri2), private physiotherapist visit (nPriv1), two instances of 
prescribed medicine (pmed1, pmed2) and two instances of aids or medications bought over 
the counter (bmed1, bmed2). Although seven groups have been defined in this example, the 
ETL system will only create objects where data exists. For example, subject #1000 will only 
create four objects for GP visit (Pri1), NHS physiotherapist visit (Pri2), private 
physiotherapist visit (nPriv1) and medicine prescribed by GP (pmed1). 
Once all resources have been identified and a group has been defined, the mapping rules are 
used to populate the repository’s standard resource-use attributes. Within the <mapping/> 
structure, the groupName is used to allow the system to locate the correct object to process 
and the originalName is used to store the name of the original variable. The 
attributeName element stores the name of the mapped repository attribute. 
The original variable Pri1 stores the quantity of doctor visits and hence Pri1 is mapped to 
the repository attribute Quantity for the group 3moResource1. The other information 
require to make sense of this value are hard coded to the repository standard within the 
<staticValue/> structure which is within the <transform/> structure. For example, 
the recall period (RP), the type (Type), the reason (Reason), the location (Location), the 
unit (Unit) and the payer (Payer) of the resource allocated in 3moResource1 group is 
hard coded to 3, 1a, 4, 1, 1 and 1, respectively (see Table 11 for list of values and 
corresponding labels). These values can be hard coded in the XML because they are known 
based on the CRF and does not affect the original data. When the system processes this 
mapping instruction subject #1000 would have a healthcare resource-use object that show there 
was one GP visit made during the three-month follow-up time point (see Figure 10(B)). 
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Other <transform/> rules can be applied to manipulate the original healthcare resource-
use data. For example, the original medicines prescribed have to be transformed to the 
repository standard to the standardised drug coding. Figure 11 shows a transformation for the 
Type attribute that uses a match rule to check for the value Ibuprofen. If matched, the rule 
has been set to update the attribute’s value to 4M01. 
The XML mapping and transformation instructions shown in Figure 11 were based on only 
one follow-up time point. For mapping data from more than one follow-up time point, simply 
create more HE objects, and map and transform healthcare resource data within the child class 
HE-DATA that is linked to that follow-up time point, for example: 
<class name="HE"> 
<mapping> 
<attributeName fu="3"></attributeName> 
<attributeName fu="6"></attributeName> 
... 
<attributeName fu="n"></attributeName> 
</mapping> 
 
<childClass name="HE-DATA" linkedValue="3"> 
<grouping> 
<groupName>3moResource1</groupName> 
... 
<groupName>3moResourceN</groupName> 
</grouping> 
<mapping> 
<attributeName originalName="Pri1" groupName="3moResource1">Quantity</attributeName> 
... 
<attributeName originalName="cmed2" groupName="3moResource6">Cost</attributeName> 
</mapping> 
<transform> 
... 
</transform> 
</childClass> 
 
<childClass name="HE-DATA" linkedValue="6"> 
<grouping> 
<groupName>6moResource1</groupName> 
... 
<groupName>6moResourceN</groupName> 
</grouping> 
<mapping> 
<attributeName originalName="Pri1" groupName="6moResource1">Quantity</attributeName> 
... 
<attributeName originalName="cmedN" groupName="6moResourceN">Cost</attributeName> 
</mapping> 
<transform> 
... 
</transform> 
</childClass> 
… 
 
<childClass name="HE-DATA" linkedValue="n"> 
<grouping> 
<groupName>nmoResource1</groupName> 
... 
<groupName>nmoResourceN</groupName> 
</grouping> 
<mapping> 
<attributeName originalName="Pri1" groupName="nmoResource1">Quantity</attributeName> 
... 
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<attributeName originalName="cmedN" groupName="nmoResourceN">Cost</attributeName> 
</mapping> 
<transform> 
... 
</transform> 
</childClass> 
 
</class> 
 
4.5 USING EAV DATA 
Using the EAV/CR data in its raw state for any kind of analysis work would be extremely 
difficult due to the fragmented nature of the EAV schema. For analysis purposes, it is therefore 
necessary to piece together the data to form complete datasets that are comparable to the 
datasets outputted from relational or tabular data sources. This task is achieved by processing 
the EAV table to derive a table for each class, a column for each attribute and a row for every 
object. An excerpt of the SQL statement to join the various data to extract the required data 
items for class RMDQ (whose identifier is 1 in this example) is shown below 
SELECT  
    eav_objectid, 
    prms_TrialName, 
    subj_ID, 
    subj_OriginalID,  
    attr_ShortName,  
    eav_Value  
FROM  
    attribute  
    inner join eavobject  
        on eav_AttributeID = attr_ID  
    inner join  
        object on obj_Id = eav_ObjectID  
    inner join  
        subject on obj_SubjectID = subj_ID  
    inner join  
        primarysource on prms_ID = subj_PrimarySourceID 
WHERE 
    obj_ClassID = 1 
      
The statement produces a table in a long format which was subsequently pivoted to produce a 
row for each object and a column for every attribute. The outcome of this query is a dataset 
that resembles a tabular structure that can easily be processed for further analysis. 
Although this solution provides a means for generating a usable tabular format, the scalability 
is severely limited. The server performance was found to decrease as the volume of data 
increase and multiple pivot operations were used for transforming object relationships. 
Querying the derived datasets directly was also impractical because of the huge amounts of 
data that can be generated in the server’s temporary database, causing the server to be unstable. 
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An initial solution used to overcome these issues was to disconnect from the actual query by 
using the in-built functionality of the statistical analysis software to create a copy of the query 
results. A more permanent solution which is the current practice is to periodically create a copy 
of the query results into actual tables within the database. 
4.6 EXTRACT, TRANSFORM AND LOAD (ETL) 
The bespoke extract, transform and load (ETL) application was required to read the original 
source data, automatically apply mapping and transformation rules from an XML document 
and to load the processed data into the repository. In addition to these basic functions, the ETL 
application was also required to permit end users to setup new RCTs for import, create new 
classes and attributes and make changes to existing ones, and to switch between a testing and 
live environment. 
The bespoke ETL application was distributed as a Windows desktop application. It works by 
first uploading the original dataset and the XML mapping and transformation rules. The 
instructions defined in the XML file are applied to the original dataset and the transformed data 
is loaded into the repository database. The ETL application allows the statistician and health 
economist to execute these steps from their desktop computers. The ability to switch between 
a test and live environment gives the users the flexibility and convenience of checking whether 
or not the instructions that they have delineated in the XML file are correct before loading the 
datasets into the live database. 
4.7 DATA VALIDATION 
Data integrity is vital throughout the repository ETL process. To check that the mapping and 
transformation procedures were done correctly, the repository data was routinely checked 
against the original datasets. To achieve this, at each time point (baseline and all follow-ups), 
a random sample of data was extracted and manually cross checked against the source data. 
Any inconsistency were flagged and if required, the XML instructions were amended. This 
process was repeated until the data was deemed to have been transformed correctly. 
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4.8 STORAGE 
In condition of our data sharing agreements to hold the RCT datasets and to meet local 
governance and standard operating procedures the repository database server is held in a secure 
data centre with a robust disaster recovery policies in place. 
The appeal of having this hybrid system architecture is that the structure takes up very little 
space in the server, and the time needed to query and retrieve data is very little, too. Naturally, 
the disk space needed to store the data in this repository will grow in proportion in accordance 
to the number of data points. 
4.9 FUTURE DATA SHARING 
At the end of this programme of work we would like to make the pooled data available for 
future analyses. We will go back to all of the PIs/data custodians with a new data sharing 
agreement to enable us to share their pooled data. Once these agreements have been signed we 
will set up a website with details of how to apply for the data. All requests will be: 
1) forwarded to the study statistician who will carry out  internal checks to ensure the 
data being requested can be provided. The response from the study statistician will be 
supplied with the original request for the independent committee consideration. 
 
2) sent via email to an independent committee who will review the application and make 
a final decision on data sharing. For the data requested, if a PI/data custodian has: 
a. Agreed to sharing the data but has asked to see a copy of the request, a copy 
will be sent to them via email for information purposes only. 
b. Not agreed to sharing their data, this dataset will be removed from the pooled 
data before provided the requested data to the applicant.   
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CHAPTER 5 – CROSSWALKING BETWEEN DISABILITY 
QUESTIONNAIRE SCORES 
This chapter presents our methodological development exploring how to most accurately map 
multiple participant-reported outcome measures that measure the same domain, to a common 
scale (crosswalking). This work has now been published in Spine.122 We sought to develop a 
‘crosswalk’ of values from multiple measures of the same domain to a common single outcome 
score. This would allow us to pool measures more accurately than normalising to a single scale 
(e.g. 0-100) or expressing values as a proportion of their standard deviation. The first step in 
this work is to ensure that changes in outcomes from two measures in the same individuals are 
both correlated and similarly responsive to change. The results from this work would inform 
us how, and if, we could pool various back pain related disability outcomes into a single 
outcome for the main analyses (see Chapter 6).  
5.1 BACKGROUND 
There are six participant-reported outcomes measures (PROMs) that  have been used in one or 
more study within the repository that aim to measure back pain related disability, namely, 
Chronic Pain Grade (CPG) disability score which is one of the two domains in the CPG that 
aims to grade chronic pain status,123 Hannover Functional Ability Questionnaire (FFbHR),124 
Oswestry disability index (ODI),125 Pain Disability Index (PDI),126 Patient Specific Functional 
Scale (PSFS)127  and Roland Morris Disability Questionnaire (RMDQ).28 Some trials also 
included generic health-related quality of life instruments such as SF-12128 or SF-36129 where 
the physical component summary (PCS) measures the physical functioning. As mentioned in 
Section 6.3.3, no common instrument was used by the trials included in the repository. We 
sought to assess the agreement of these instruments by determining their correlation and 
responsiveness at a trial level, in order to decide whether data pooling was feasible. After we 
had completed this work a National Institute for Health taskforce identified developing 
crosswalking values for ‘legacy’ measures of back pain outcome as a key priority for back pain 
research.130 
5.2 DATA 
We used data from 11 trials which had used at least two of the following measurements: CPG, 
FFbHR, PCS, PSFS, PDI, ODI and RMDQ. For all of these analyses we used the short-term 
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change score as this is where any treatment effects are likely to be greatest. For the purposes 
of this report we have defined a short term follow-up as a measurement taken between two and 
three months post randomisation or entry to the trial. The short term change score is the 
difference between the baseline and the short term follow-up Section 6.3.2. In each case we 
have standardised the reporting so that a positive change score is interpreted as an 
improvement. Where appropriate we used the standardised response; change score divided by 
the standard deviation of the change. We used this in preference to the standardised effect size 
(change score divided by the standard deviation of the measure at baseline) so that all the 
standardised scores had a standard deviation of one. This enables visual comparisons to be 
made between all the scatterplots. 
5.3 OUTCOME CONVERSION 
All comparisons between instruments were done at an individual trial level. Each pair of 
outcome measures were fitted with simple linear regression models. Denoting the change 
scores for the two outcome measures by x and y, the simple linear model was 
 y =  + x +  (1) 
where the intercept, , and the coefficient, , are parameters to be estimated and  is the error 
term. For the conversion to be meaningful the standardised change scores have to be correlated 
and have similar responsiveness, where the latter is explained below.131 
5.4 CORRELATION 
Correlation was assessed by scatterplots and Pearson’s correlation coefficient with a correlation 
coefficient considered at least moderately high if it was greater than 0.5. 
5.5 RESPONSIVENESS 
Responsiveness is the ability to detect a change in condition; if a participant’s condition 
improves or worsens over time then this should be reflected by a change in the participant’s 
score. If two outcome measures do not have similar responsiveness then combining them in a 
meta-analysis may introduce heterogeneity which could be falsely attributed to other sources, 
such as the treatment effect. 
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Similarity of responsiveness of two outcome measures was examined by categorising the 
change scores as negative change (change score < 0), no change (change score = 0) or positive 
change (change score > 0), and applying Cohen’s kappa to these categorisations.132 We 
considered > 0.4 to indicate sufficiently similar responsiveness.133 These broad categories 
were chosen to demonstrate whether or not the outcome measures had similar responsiveness 
in the most basic sense (improved, worsened, or no change). We also planned to examine 
narrower categorisations in the event that the agreements within these three categories were 
good (> 0.4). However, as there was no standard on the levels of categorisations, a few would 
be examined. 
For it to be acceptable to pool two measures they needed to meet two criteria; to be at least 
moderately correlated (correlation greater than 0.5) and to have at least moderately similar 
responsiveness (Cohen’s kappa greater than 0.4). 
5.6 RESULTS 
Eleven trials (n = 6,089) and seven instruments were included in these analyses (see Table 12). 
There were a total of 21 within trial pairwise comparisons between two outcomes. Figure 12, 
Figure 13, Figure 14, Figure 15 and Figure 16 show scatterplots of standardised change scores 
for each such pair of outcome measures. See Appendix 8 for scatterplots between raw change. 
It is clear from these plots that the outcomes were positively correlated. Note also that the 
standardised change scores were widely scattered around the reference line suggesting that 
there was a lack of agreement between the outcomes.  
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Table 12 Instruments used and number of participants by trial. 
Trial n Outcome measures 
BeST31 426 RMDQa CPGb PCSc 
Brinkhaus104 281 PCS FFbHRd PDIe 
Haake102 1,110 CPG FFbHR PCS 
Hancock109 235 RMDQ PSFSf  
HULLEXPRO76 203 RMDQ PCS  
Macedo115 158 RMDQ PCS PSFS 
Pengel106 232 RMDQ PSFS  
UK BEAM34 885 RMDQ CPG PCS 
VKBIA111 227 RMDQ CPG  
Witt50 2,229 PCS FFbHR  
YACBAC134 206 PCS ODIg  
a RMDQ, Roland Morris disability questionnaire; b CPG, Chronic Pain Grade disability 
scale; c PCS, Physical Component Summary of SF-12 or SF-36; d FFbHR, Hannover 
Functional Ability Questionnaire; e PDI, Pain Disability Index; f PSFS, Patient Specific 
Functional Scale; and g ODI, Oswestry disability index. 
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PCS, physical component scale of SF-12/36; CPG, chronic pain grade disability score; FFbHR, 
Hannover functional ability questionnaire for measuring back-pain related functional limitations. 
Figure 12 Scatterplots of standardised change scores for PCS vs. CPG (n = 2451) and 
PCS vs. FFbHR (n = 3620) outcome measures.  
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PCS, physical component scale of SF-12/36; RMDQ, Roland Morris disability questionnaire; ODI, 
Oswestry disability index. 
Figure 13 Scatterplots of standardised change scores for PCS vs. RMDQ (n = 1694) and 
PCS vs. ODI (n = 206) outcome measures  
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PCS, physical component scale of SF-12/36; CPG, chronic pain grade disability score; FFbHR, 
Hannover functional ability questionnaire for measuring back-pain related functional limitations; PSFS, 
patient specific functional scale. 
Figure 14 Scatterplots of standardised change scores for PCS vs. PSFS (n = 158) and 
CPG vs. FFbHR (n = 1110) outcome measures  
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CPG, chronic pain grade disability score; RMDQ, Roland Morris disability questionnaire; PSFS, patient 
specific functional scale. 
Figure 15 Scatterplots of standardised change scores for CPG vs. RMDQ (n = 1661) and 
PSFS vs. RMDQ (n = 625) outcome measures  
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PCS, physical component scale of SF-12/36; FFbHR, Hannover functional ability questionnaire for 
measuring back-pain related functional limitations; PDI, pain disability index. 
Figure 16 Scatterplots of standardised change scores for PDI vs. PCS (n = 281), FFbHR 
vs. and PDI (n = 284) outcome measures 
The correlations between outcomes ranged from 0.21 to 0.70; implying that the linear 
associations between them range from weak to moderately strong (see Table 13). Three trials 
had both SF-12/36 PCS and FFbHR data and their correlations were very similar, about 0.58. 
Another three trials had both SF-12/36 PCS and CPG and the correlations were reasonably 
similar, ranging from 0.41 to 0.56, and four trials had both SF-12/36 PCS and RMDQ with 
range 0.38 to 0.52, again similar. However, correlations between other outcomes were quite 
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wide ranging; between CPG and RMDQ (m = 3 trials; range, 0.21 to 0.47) and between PSFS 
and RMDQ (m = 3; range, 0.40 to 0.70). 
Table 13 Pearson correlation and Cohen’s kappa agreement for responsiveness of each 
pairwise comparison of outcome measures by trial. 
Outcome 
measure 1 
Outcome 
measure 2 Trial 
Pearson 
correlation 
Cohen’s 
kappa 
CPGa RMDQb BeST 0.44 0.22 
  UK BEAM 0.47 0.27 
  VKBIA 0.21 0.12 
CPG FFbHRc Haake 0.48 0.25 
PCSd RMDQ BeST 0.38 0.17 
  HULLEXPROB 0.45 0.29 
  Macedo 0.52 0.27 
  UK BEAM 0.51 0.33 
PCS CPG BeST 0.41 0.27 
  Haake 0.49 0.27 
  UK BEAM 0.56 0.31 
PCS FFbHR Brinkhaus 0.59 0.30 
  Haake 0.58 0.29 
  Witt 0.59 0.27 
PCS PSFS Macedo 0.36 0.17 
PCS ODIe YACBAC 0.60 0.28 
RMDQ PSFSf Hancock 0.70 0.38 
  Macedo 0.40 0.26 
  Pengel 0.53 0.18 
PDIg FFbHR Brinkhaus 0.55 0.32 
PDI PCS Brinkhaus 0.54 0.31 
a CPG, Chronic Pain Grade disability scale; b RMDQ, Roland Morris 
disability questionnaire; c FFbHR, Hannover Functional Ability 
Questionnaire; d PCS, Physical Component Summary of SF-12 or SF-36; 
e ODI, Oswestry disability index; f PSFS, Patient Specific Functional Scale; 
g PDI, Pain Disability Index.  
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Cohen’s kappa was less than 0.4 for all 21 comparisons. Some were similar between trials, 
namely for PCS and FFbHR (range, 0.27 to 0.30) and for PCS and CPG (range, 0.27 to 0.31). 
However, the level of agreement was never more than fair.133 As the kappa agreement was not 
greater than 0.4 narrower categorisations were not investigated. 
There were no pairs of outcome that satisfied both criteria of at least moderately correlated 
(correlation greater than 0.5) and at least moderately similar responsive (Cohen’s kappa greater 
than 0.4). Therefore, it was not meaningful to convert any outcome to another one. 
5.7 CONCLUSION 
In view of the lack of correlation and responsiveness, it is not recommended to map any 
physical disability outcome measures to another considered in this investigation.  
For each of our subsequent analyses we have only pooled data where the same participant 
reported outcomes are available from multiple trials. The one exception is that the SF-12 and 
SF-36 are explicitly designed to have similar measurement properties when converted into their 
physical and mental component scores. We have therefore pooled the mental component score 
(MCS) and physical component score (PCS) from studies using SF-12 or SF 36. 
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CHAPTER 6 – PRELIMINARY STATISTICAL ANALYSES AND 
RESULTS 
6.1 BACKGROUND 
In this chapter we present the results of preliminary statistical analyses performed on the 
individual participant data; specifically the ANCOVA analysis comparing all treatments with 
all controls (usual care plus sham) to identify individual potential moderators to take forward 
into our main analyses. The methodological development work to identify multiple covariates  
baseline characteristics that moderate treatment effect are presented in later chapters (see 
Chapters 7-10). We do not, in this preliminary analysis, seek to define sub-groups using 
multiple parameters.  
6.2 STATISTICAL ANALYSIS PLAN (SAP) 
In accordance with the standard operating procedure in Warwick Clinical Trials Unit a detailed 
statistical analysis plan was written by the study’s statistician (SWH) and health economist 
(JJ). The plan was subsequently reviewed and approved by the study team and members of 
repository oversight committee (Appendix 9) whereas the overview of the plan is described in 
following sections. 
6.3 DEFINITIONS 
6.3.1 TREATMENT ARMS 
Treatments are broadly classified into intervention, sham control and control. The intervention 
grouping may be further classified into three broad categories, namely, active physical, passive 
physical and psychological. Exercise and graded activity are considered as active physical; 
acupuncture, manual therapy and individual physiotherapy are considered as passive physical; 
and advice or education, and a cognitive behavioural approach or, cognitive behavioural 
therapy are considered as psychological interventions. Sham control may be sham acupuncture, 
sham electrotherapy, mock transcutaneous electrical nerve stimulation (TENS), or sham advice 
or education. The control arm is the non-active usual care, namely, general practitioner (GP) 
treatment or a waiting list control. Sham acupuncture may be a special case of a sham 
intervention. If it is the sensation of needling that is the active ingredient of acupuncture then 
the location of any needling, whether skin penetration takes place, or depth of any needling 
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might have little effect on outcomes seen. Thus sham acupuncture might be considered to be a 
‘true’ intervention and included in our analyses of passive physical treatments.  
6.3.2 FOLLOW-UP TIME POINT 
The follow-up times are classified into short-term, mid-term and long-term. A short-term 
follow-up is measurement taken between two and three months post randomisation or entry to 
the trial. A mid-term follow-up is measurement taken at six months post randomisation or entry 
to the trial. A long-term follow-up is measurement taken at 12 months post randomisation or 
entry to the trial. Data collected at immediate follow-up (less than two months post 
randomisation or entry to the trial) and beyond the long-term follow-up (after 12 months post 
randomisation or entry to the trial) were also entered into the repository but were not considered 
for analysis.  
6.3.2.1 Selection of follow-up time points 
Some RCTs collected weekly data. For the short-term follow-up, data from the three-month 
follow-up were considered for analysis. If data were missing (non-response), data from the 
nearest week to the three-month follow-up were used so long as the time point was within the 
two- and three-month follow-up time point. 
6.3.3 OUTCOME VARIABLES 
6.3.3.1 Clinical outcomes 
The response for each of the outcome variables of interest is presented as change score and 
standardised change score. The change score is the change from baseline to the follow-up time 
point. A positive change score is interpreted as an improvement.  
6.3.3.2 Health economic outcomes 
For the initial economic analysis presented here, the outcome of Quality Adjusted Life Years 
(QALYs) was used. Estimated QALY gains from treatment were compared with the mean 
estimated costs of treatment to assess cost-effectiveness. Individual participant data on resource 
use or costs were available for some trials, but after allowing for availability of EQ-5D or SF-
12/36 scores (required to calculate QALYs) and of a common set of moderator variables, no 
two studies provided both individual-level cost and QALY data for a common comparison. We 
were, therefore, unable to generate pooled cost/QALY data. 
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The heterogeneous nature of the trials posed some challenges for the economic analysis. In 
order to pool the data across trials a consistent health outcome measure over time was required. 
The QALY is a standardised measure of health outcomes used for economic analysis, which 
summarises patients’ profiles of health-related quality of life (‘utility’) over time. The QALY 
score for each patient was estimated using the EQ-5D, which is a generic measure of quality 
of life suitable for calculation of QALYs. The EQ-5D index score, calculated using the UK 
Tariff, measures an individual’s health state at a single time point.135 EQ-5D index scores can 
be integrated over time to estimate QALYs. QALYs were calculated for trial participants over 
one year of follow-up, using the area under the curve method. For each participant the area 
under the curve was calculated from the EQ-5D index scores captured at each follow-up point 
for that participant from baseline to 52 weeks (with linear interpolation between observations). 
Trials with more follow-up points arguably have greater resolution and therefore the QALY 
estimated will be more precise. However in all regression analyses differences between trials 
were controlled for, so this potential issue was mitigated.  
For one trial (Haake)102, EQ-5D data were not available, but full data on patient responses to 
the SF-12 instrument were recorded. The SF-12 is a generic measure of health similar to the 
EQ-5D, and a number of methods to estimate a utility index score from the SF-12 instrument 
have been published. In order to ensure the index scores provided by the SF-12 are comparable 
to those obtained for the other trials using the EQ-5D, a mapping approach was applied. This 
mapped the SF-12 item responses onto the EQ-5D index scores. The specific mapping 
approach applied was based on the work of Gray et al (2006);136 in this study, a multi-nominal 
logit model was used to estimate the probability a particular EQ-5D dimension level would be 
chosen, based on the participants SF-12 responses. The authors have made available an 
algorithm applying this method as an add-on programme in Stata12. This mapping approach 
was compared to other published methods by Rowen, Brazier and Roberts (2009).137 They 
found similar levels of performance across the alternative approaches. In our analysis, the 
mapped SF-12 index scores were integrated over time in the same manner as the EQ-5D scores 
to estimate an individual-level QALY. Use of SF-6D to EQ-5D mapping might have introduced 
additional error or bias, although the method was well developed and has been subject to 
validation.  The potential for bias should also have been mitigated by the method of analysis: 
with a mixed model accounting for differences between trials.  Furthermore, the outcomes of 
interest were the treatment-subgroup coefficients, rather than the magnitude of main effects per 
se.     
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One trial (Haake)102 only had data up to 26 weeks. For this trial, it was assumed that the quality 
of life score measured at 26 weeks persisted up to 52 weeks, which allowed QALYs over one 
year to be estimated in the same way as for the other trials.  This assumption might be seen as 
a limitation, but again the potential for bias from this source should have been reduced through 
the inclusion of trial as a random effect and the focus on treatment-subgroup interactions. 
It is important to adjust for any baseline differences in EQ-5D scores when comparing QALY 
estimates between treatment groups. There are two ways of making this adjustment: by 
calculating a ‘change from baseline’ QALY at the individual level; or adding the baseline EQ-
5D score as a covariate in regression analysis. The latter approach has been used in the analyses 
presented here, as it is recommended as more efficient.138   
6.3.3.3 Selection of instrument 
Clinical outcomes are classified broadly into physical disability, pain, psychological distress 
and non-utility quality of life. Nine instruments in the repository have been identified as 
measurement for physical disability and four instruments for pain (see Appendix 9). No single 
instrument was used by all RCTs to measure physical disability, hence, we explored how to 
map some of these instruments to one single outcome. The mapping methodology is described 
in Chapter 5. We concluded that it was not possible to map to one single outcome. Therefore, 
analyses were done on common outcomes only. 
Most of the RCTs in the repository had asked participant to rate or mark on a numerical rating 
scale or a visual analogue scale that described either their average or worst pain at the present 
time or over a defined weeks or months. This item was presented either as a single standalone 
instrument or as an item that was part of a collective pain measurement, for example, in the 
McGill Pain Questionnaire where a visual analogue scale was presented as a line that anchors 
with ‘no pain’ at one end and ‘worst possible pain’ at the other end.139 For the analyses of 
average pain, one of the following instruments from each trial, where available, was chosen (in 
descending order): 
1. individual visual analogue scale (VAS) on average pain today,  
2. average pain over the past one week,  
3. average pain over the past two weeks, average pain over the past one month,  
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4. average pain over the past three months,  
5. the individual item of the Chronic Pain Grade (CPG) pain intensity score that is 
equivalent to the VAS if it is available,123  
6. the summary score of the CPG pain intensity score otherwise, or  
7. the bodily pain domain of SF-12/36.128, 129  
Where a numerical rating scale (range, 0 to 10) was used, it was scaled to an analogue scale so 
that it gives a range from 0 to 100.  
There are two dimensions of psychological distress that are of interest; depression and anxiety. 
Six and four instruments have been identified to measure depression and anxiety, respectively 
(see Appendix 9). Within each instrument there is usually a classification system that is widely 
used to classify participants into ordinal category, for example, with minimal, moderate or 
severe level of depression. Thus, all instruments were mapped into a single ordinal categorical 
variable. Instruments with no threshold guideline to discriminate level of risk or severity was 
categorised into tertiles to discriminate the low and high risk or severity from the moderate risk 
or severity group.  Other psychosocial measures; catastrophising, coping, and fear avoidance 
were handled in the same manner. In each case the reference standard for comparison was the 
tertile with the least favourable score. 
6.4 DATASETS 
Individual participant data without treatment assignment were excluded from the repository. 
This exclusion criterion applies to individual participants whose data were included in the 
dataset but the treatment allocation was not available in the dataset. We were not able to 
allocate these participants to a treatment group and they were thus excluded. 
6.4.1 CLINICAL ANALYSIS 
The main analysis which is to confirm proof of concept was based on complete case analysis. 
Missing data due to non-responders or withdrawals were not imputed. Missing items were 
imputed and the method for imputation is as described in the statistical analysis plan (see 
Appendix 9). Where available individual items were used to obtain the composite score for 
each measurement, otherwise the composite score provided to the repository were used for all 
analyses. 
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For the overall exploration of moderation by single variables the sham control was grouped 
with non-active usual care. All direct analyses were based on pairwise comparisons, that is, 
only two treatment arms were compared each time. For the overall analysis, intervention was 
compared against control/placebo arm where intervention was any therapist delivered 
intervention either given singly or in combination with another intervention and the 
control/placebo arm was either the non-active usual care control or sham treatment. Other 
pairwise comparisons considered were; active physical against non-active usual care control, 
passive physical against non-active usual care control, psychological against non-active usual 
care control, and sham against non-active usual care control. In all cases for the pairwise 
comparisons we separated sham and usual care controls as this reflects more accurately the 
clinical choice than adding of an intervention onto a sham control intervention. 
Direct analyses were performed if the individual participant data are from at least two trials. 
That is, no direct analysis was performed if the individual participant data were from one single 
trial. 
6.4.2 HEALTH ECONOMIC ANALYSIS 
The health economic analysis focused on the QALY score as the outcome measure. QALYs 
were calculated for individuals, using the estimated EQ-5D index scores or a mapped SF-12 
outcome at multiple follow-up points. This means that missing data can be more of a problem 
than for outcomes measured at a single time point. If data are missing at any follow-up point, 
the QALY cannot be estimated and the entire observation is lost. An observation was also lost 
if data on the moderator at baseline was missing. All analyses were based on complete cases 
only therefore caution must be taken in interpretation of the results as the missing data may be 
a source of bias.  
In order to simplify the analysis it was split into four overarching comparisons; all interventions 
collectively against non-active usual care, active physical interventions against non-active 
usual care, passive physical interventions against non-active usual care and active physical 
against passive physical. For each analysis, the treatment arms for the included trials were 
pooled appropriately by the type of treatment and used collectively as the intervention group 
for each of the respective analyses. Seven trials in total were included in the analysis. The first 
three analyses described limited the sample to a maximum of six trials which included a non-
active usual care as the control arm and reporting EQ-5D outcomes or a mapped SF-12 
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outcome. The comparison between active physical and passive physical allowed the inclusion 
of one additional trial. Data for comparisons against a sham treatment arm were excluded from 
this analysis as these are not plausible choices for a health economic analysis.  
6.5 METHODS 
6.5.1 DESCRIPTIVE SUMMARY 
The baseline data were summarised by treatment arm (non-active usual care, active physical, 
passive physical, psychological, combination or sham control). The continuous data were 
summarised as mean and standard deviation, and the categorical data were summarised as the 
number of participants and percentage. 
6.5.2 ONE-STEP META-ANALYSIS 
In a one-step meta-analysis, individual participant data from all studies were modelled 
simultaneously in a single model adjusting for the study effect.140 It can be viewed analogously 
as an analysis of a multicentre study where instead of multi centres in a study we have multi 
trials in a study. The one-step meta-analysis was performed to explore the efficacy between 
treatment arms. A mixed-effects model was used as analysis where the intercept and the 
interaction between treatment arm and trial were modelled as random effects, and treatment 
arm as the fixed effect.  
6.5.3 MODERATOR IDENTIFICATION 
6.5.3.1 Systematic review 
We identified potential moderators from the literature via a systematic review. Details of this 
review and the outcomes are presented in Chapter 2. 
6.5.3.2 ANCOVA analysis 
Analysis of covariance (ANCOVA) were performed to identify any covariate that moderates 
outcomes. Similarly, the one-step meta-analysis approach was used, that is, all available 
individual participant data were pooled into a single mixed-effects model where the intercept 
and the interaction between treatment and trial were modelled as random effects. The treatment 
arm (intervention against control), covariate and the interaction between treatment and 
covariate were modelled as fixed effects. For analysis with QALYs as the outcome measure, 
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the baseline EQ-5D score was also included as a fixed effects in the mixed-effects model 
described above.  
As stated in the statistical analysis plan covariates were declared weakly statistically significant 
at the two-sided 20% level and statistically significant at the two sided 5% level. This ensured 
that covariates that approach the conventional statistical significance at 5% level would not be 
missed for the final clinical and health economic prediction rule analyses. All moderators 
identified from the systematic review and ANCOVA analysis were considered for the clinical 
and health economic prediction rule analyses. The prediction rule analyses were to determine 
which participant characteristics at baseline were optimal to different treatments and associated 
with the endpoints of interest, namely, disability or pain, or cost-effective treatments for LBP. 
The methodology of identifying a combination of characteristics is presented in detail in 
Chapters 7-10. 
As seen in the results from the one-step meta-analysis, the estimated efficacy between 
intervention and control/placebo arm for most of the outcomes at mid- and long-term were not 
statistically significant. Therefore, ANCOVA was not performed for the mid- and long-term 
outcomes. In addition, the short-term outcomes were where the maximum clinical effects were 
observed between intervention and control/placebo. This is where the largest differential 
subgroups effects are likely to be seen. In the absence of substantial short-term effect 
moderation there is little point in exploring mid- and long-term effect moderation. 
The list of moderators assessed for each of the short-term clinical outcomes and QALY were 
presented. As not all of trials have the same moderators, the sample size varied depending 
which moderator was being assessed and for which outcome. 
6.6 RESULTS 
6.6.1 DESCRIPTIVE 
Table 14 shows the response rates for each of the outcome of interest per treatment groups in 
different time points. Most trials collected data three months post randomisation or entry to the 
trial and this is recorded as 13 weeks whereas one RCT had specifically mentioned in their 
protocol to collect data at 12 weeks and thus this was recorded as per protocol. 
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Most of the RCTs collected short- and mid-term outcomes and some collected more immediate 
outcome (typically measured within 6 weeks post randomisation or entry to the trial) (see Table 
14). Two RCTs collected longer term effects (outcomes measured at or after 12 months post 
randomisation or entry to the trial). Each of the randomised controlled trials was designed with 
a unique protocol and this was apparent from the choice of different instruments used to 
measure the physical disability, pain and psychological distress outcomes, and at different time 
points. 
There were 9328 participants in the trials included in the repository. Table 15 shows the 
demographics and clinical characteristics at baseline by treatment arms. All the trials were able 
to provide information on sex and age. Of the 9326 participants (missing data from two 
participants), 5316 (57%) were females. The proportion of males and females was similar 
across all treatment arms. The average age of the participants in the repository was 49 years 
(standard deviation, SD, 14). The average age of participants from trials that had active physical 
treatments was slightly lower, 44 years (n = 914; SD, 12) compare to the average age from 
trials that had passive and psychological treatments, 49 years (n = 3270; SD, 14) and 50 years 
(n = 1118; SD, 14), respectively. This difference is mainly due to the inclusion criteria of the 
trials. 
Most of the participants with data in the repository had similar physical disability or functional 
limitation at baseline. One trial (n = 239) used the Oswestry disability index (ODI) as their 
outcome measure and the average baseline score was 33 (SD, 15), which was somewhere 
between no disability and moderate disability. Three trials (n = 4176) used the Hannover 
Functional Ability Questionnaire for Measuring Back-Pain Related Functional Limitations 
(FFbHR) and the average baseline score was 58 (SD, 21) which was slightly above moderate 
functional limitation. Fourteen trials (n = 4710) used the Roland Morris disability 
questionnaire (RMDQ) as their outcome measure and the average baseline score was 10 (SD, 
5) which was slightly below moderate disability.  
Nine trials (n = 6695) collected quality of life information with either the SF-12 or SF-36 
instruments. The mean physical component scale (PCS) at baseline was 36 (SD, 8) and the 
mean mental component scale (MCS) at baseline was 45 (SD, 12). The mean values were 
similar across treatment arms. 
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Only a minority of the RCTs provided information on psychological distress at baseline and 
were insufficient to provide any qualitative comparison across treatment arms. 
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Table 14 Number of trials (m) and participants (n) for each outcome by follow-up time points and treatment arms. 
Outcomes 
Follow-
up 
(weeks) 
Active physical 
(m = 7; 
n = 914) 
Passive 
physical 
(m = 12; 
n = 3270) 
Psychological 
(m = 7; 
n = 1120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2885) 
All 
(m = 19; 
n = 9326) 
Physical 
disability 
   
 
  
   
CPG-DSa 0 m=1; n=284 m=2; n=721 m=2; n=572 m=1; n=312 m=1; n=387 m=4; n=1052 m=5; n=3328 
  4 m=1; n=228 m=1; n=315 - m=1; n=280 - m=1; n=262 m=4; n=1085 
  8 - - m=1; n=109 - - m=1; n=120 m=2; n=229 
  13 m=1; n=214 m=2; n=653 m=1; n=345 m=1; n=252 m=1; n=376 m=3; n=797 m=5; n=2637 
  26 - m=1; n=377 m=2; n=491 - m=1; n=376 m=3; n=656 m=2; n=1900 
  52 m=1; n=212 m=1; n=267 m=2; n=473 m=1; n=254 - m=3; n=530 m=5; n=1736 
  104 - - m=1; n=94 - - m=1; n=92 m=2; n=186 
FFbHRb 0 - m=3; n=1927 - - m=2; n=460 m=3; n=1789 m=3; n=4176 
  6 - m=1; n=370 - - m=1; n=375 m=1; n=362 m=1; n=1107 
  8 - m=1; n=140 - - m=1; n=70 m=1; n=74 m=1; n=284 
  13 - m=2; n=1723 - - m=1; n=376 m=2; n=1605 m=2; n=3704 
  26 - m=3; n=1825 - - m=2; n=446 m=3; n=1620 m=3; n=3891 
  52 - m=1; n=137 - - m=1; n=68 m=1; n=70 m=1; n=275 
ODIc 0 - m=1; n=159 - - - m=1; n=80 m=1; n=239 
  13 - m=1; n=146 - - - m=1; n=71 m=1; n=217 
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Outcomes 
Follow-
up 
(weeks) 
Active physical 
(m = 7; 
n = 914) 
Passive 
physical 
(m = 12; 
n = 3270) 
Psychological 
(m = 7; 
n = 1120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2885) 
All 
(m = 19; 
n = 9326) 
  52 - m=1; n=136 - - - m=1; n=57 m=1; n=193 
  104 - m=1; n=114 - - - m=1; n=50 m=1; n=164 
PDId 0 - m=1; n=146 - - m=1; n=73 m=1; n=79 m=1; n=298 
  8 - m=1; n=140 - - m=1; n=70 m=1; n=74 m=1; n=284 
  26 - m=1; n=138 - - m=1; n=70 m=1; n=73 m=1; n=281 
  52 - m=1; n=137 - - m=1; n=66 m=1; n=69 m=1; n=272 
PSFSe 0 m=2; n=150 m=1; n=119 m=2; n=148 m=1; n=62 m=2; n=188 - m=3; n=667 
  1 - m=1; n=119 - - m=1; n=118 - m=2; n=237 
  2 - m=1; n=119 - - m=1; n=119 - m=1; n=238 
  4 - m=1; n=118 - - m=1; n=117 - m=1; n=235 
  6 m=1; n=58 - m=1; n=54 m=1; n=57 m=1; n=59 - m=1; n=228 
  8 m=1; n=82 - m=1; n=76 - - - m=1; n=158 
  12 m=1; n=57 - m=1; n=56 m=1; n=58 m=1; n=61 - m=1; n=232 
  13 - m=1; n=118 - - m=1; n=117 - m=1; n=235 
  26 m=1; n=81 - m=1; n=74 - - - m=1; n=155 
  52 m=2; n=136 - m=2; n=132 m=1; n=56 m=1; n=56 - m=2; n=380 
RMDQf 0 m=7; n=907 m=7; n=1087 m=7; n=1120 m=3; n=446 m=3; n=212 m=6; n=938 m=14; n=4710 
  1 - m=1; n=119 - - m=1; n=118 - m=1; n=237 
  2 - m=2; n=119 - - m=1; n=118 - m=1; n=237 
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Outcomes 
Follow-
up 
(weeks) 
Active physical 
(m = 7; 
n = 914) 
Passive 
physical 
(m = 12; 
n = 3270) 
Psychological 
(m = 7; 
n = 1120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2885) 
All 
(m = 19; 
n = 9326) 
  4 m=1; n=234 m=2; n=436 - m=1; n=283 m=1; n=117 m=1; n=264 m=2; n=1334 
  6 m=2; n=144 m=1; n=23 m=1; n=55 m=1; n=58 m=2; n=81 m=1; n=94 m=3; n=455 
  8 m=1; n=82 - m=2; n=186 - - m=1; n=120 m=2; n=388 
  10 m=1; n=107 - - m=1; n=55 - m=1; n=50 m=1; n=212 
  12 m=1; n=58 - m=1; n=58 m=1; n=59 m=1; n=61 - m=1; n=236 
  13 m=3; n=433 m=7; n=963 m=4; n=670 m=1; n=255 m=2; n=135 m=3; n=537 m=9; n=2993 
  26 m=4; n=371 m=2; n=262 m=5; n=706 m=1; n=53 - m=5; n=474 m=8; n=1866 
  52 m=7; n=722 m=5; n=771 m=7; n=903 m=3; n=365 m=1; n=56 m=6; n=690 m=12; n=3507 
  104 m=1; n=83 m=1; n=95 m=1; n=94 - - m=1; n=92 m=2; n=364 
Troublesome
ness 
0 m=2; n=344 m=3; n=556 m=1; n=426 m=1; n=312 - m=3; n=604 m=4; n=2242 
  4 m=1; n=225 m=1; n=313 - m=1; n=279 - m=1; n=262 m=1; n=1079 
  13 m=2; n=280 m=3; n=494 - m=1; n=253 - m=2; n=318 m=3; n=1345 
  52 m=2; n=302 m=3; n=493 - m=1; n=252 - m=2; n=297 m=8; n=1344 
  104 - m=1; n=113 - - - m=1; n=50 m=3; n=162 
Pain          
CPG-PSg 0 m=1; n=283 m=2; n=721 m=2; n=582 m=1; n=312 m=1; n=387 m=4; n=1054 m=4; n=3339 
  4 m=1; n=228 m=1; n=316 - m=1; n=281 - m=1; n=261 m=1; n=1086 
  6 - m=1; n=370 - - m=1; n=375 m=1; n=362 m=1; n=1107 
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Outcomes 
Follow-
up 
(weeks) 
Active physical 
(m = 7; 
n = 914) 
Passive 
physical 
(m = 12; 
n = 3270) 
Psychological 
(m = 7; 
n = 1120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2885) 
All 
(m = 19; 
n = 9326) 
  8 - - m=1; n=110 - - m=1; n=120 m=1; n=230 
  13 m=1; n=214 m=2; n=653 m=1; n=354 m=1; n=252 m=1; n=376 m=3; n=799 m=3; n=2648 
  26 - m=1; n=377 m=2; n=497 - m=1; n=376 m=3; n=661 m=3; n=1911 
  52 m=1; n=211 m=1; n=269 m=2; n=491 m=1; n=253 - m=4; n=536 m=3; n=1760 
  104 - - m=1; n=94 - - m=1; n=92 m=1; n=186 
Visual 
analogue 
scale 
   
 
  
   
Average pain 
today 
0 m=2; n=253 m=3; n=461 m=1; n=196 m=1; n=61 m=1; n=120 m=1; n=51 m=3; n=1142 
  1 - m=1; n=119 - - m=1; n=119 - m=1; n=238 
  2 - m=1; n=119 - - m=1; n=119 - m=1; n=238 
  3 - m=1; n=118 - - m=1; n=118 - m=1; n=236 
  4 m=1; n=83 m=1; n=118 m=1; n=80 - m=1; n=118 - m=2; n=399 
  6 - m=1; n=36 - - m=1; n=38 - m=1; n=74 
  8 m=1; n=81 m=1; n=24 m=1; n=79 - m=1; n=23 - m=2; n=207 
  10 m=1; n=107 m=1; n=16 - m=1; n=55 m=1; n=18 m=1; n=49 m=2; n=245 
  11 - m=1; n=15 - - m=1; n=17 - m=1; n=32 
  12 - m=1; n=15 - - m=1; n=17 - m=1; n=32 
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Outcomes 
Follow-
up 
(weeks) 
Active physical 
(m = 7; 
n = 914) 
Passive 
physical 
(m = 12; 
n = 3270) 
Psychological 
(m = 7; 
n = 1120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2885) 
All 
(m = 19; 
n = 9326) 
  13 m=1; n=81 m=1; n=153 m=2; n=231 - - - m=1; n=465 
  17 m=1; n=79 - m=1; n=75 - - - m=1; n=154 
  21 m=1; n=81 - m=1; n=76 - - - m=1; n=157 
  26 m=2; n=186 - m=1; n=75 m=1; n=53 - - m=2; n=314 
  30 m=1; n=79 - m=1; n=72 - - - m=1; n=151 
  34 m=1; n=81 - m=1; n=73 - - - m=1; n=154 
  39 m=1; n=80 - m=1; n=74 - - - m=1; n=154 
  43 m=1; n=78 - m=1; n=74 - - - m=1; n=152 
  47 m=1; n=76 - m=1; n=71 - - - m=1; n=147 
  52 m=2; n=183 m=1; n=164 m=2; n=238 m=1; n=53 - - m=6; n=638 
Average pain 
over past one 
week 
0 m=2; n=150 m=2; n=235 m=3; n=349 m=1; n=63 m=2; n=84 - m=4; n=881 
  1 - m=1; n=235 - - m=1; n=119 - m=1; n=238 
  2 - m=1; n=235 - - m=1; n=119 - m=1; n=238 
  3 - m=1; n=235 - - m=1; n=118 - m=1; n=237 
  4 m=1; n=82 m=2; n=152 m=1; n=80 - m=2; n=134 - m=3; n=448 
  6 m=1; n=59 m=1; n=49 m=1; n=55 m=1; n=58 m=2; n=97 - m=2; n=306 
  8 m=1; n=81 m=1; n=24 m=1; n=79 - m=1; n=24 - m=2; n=208 
  138 
Outcomes 
Follow-
up 
(weeks) 
Active physical 
(m = 7; 
n = 914) 
Passive 
physical 
(m = 12; 
n = 3270) 
Psychological 
(m = 7; 
n = 1120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2885) 
All 
(m = 19; 
n = 9326) 
  10 - m=1; n=16 - - m=1; n=19 - m=1; n=35 
  11 - m=1; n=11 - - m=1; n=17 - m=1; n=33 
  12 m=1; n=58 m=1; n=15 m=1; n=58 m=1; n=59 m=2; n=78 - m=2; n=268 
  13 m=1; n=81 m=2; n=180 m=2; n=231 - m=1; n=9 - m=3; n=501 
  17 m=1; n=79 - m=1; n=75 - - - m=1; n=154 
  21 m=1; n=81 - m=1; n=76 - - - m=1; n=157 
  26 m=1; n=81 m=1; n=21 m=1; n=75 - m=1; n=6 - m=2; n=183 
  30 m=1; n=79 - m=1; n=72 - - - m=1; n=151 
  34 m=1; n=81 - m=1; n=73 - - - m=1; n=154 
  39 m=1; n=80 - m=1; n=74 - - - m=1; n=154 
  43 m=1; n=78 - m=1; n=74 - - - m=1; n=152 
  47 m=1; n=77 - m=1; n=71 - - - m=1; n=148 
  52 m=2; n=140 m=1; n=163 m=3; n=297 m=1; n=57 m=1; n=56 - m=3; n=713 
Average pain 
over past one 
month 
0 - m=1; n=24 - - m=1; n=24 - m=1; n=48 
  6 - m=1; n=23 - - m=1; n=22 - m=1; n=45 
  13 - m=1; n=22 - - m=1; n=18 - m=1; n=40 
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Outcomes 
Follow-
up 
(weeks) 
Active physical 
(m = 7; 
n = 914) 
Passive 
physical 
(m = 12; 
n = 3270) 
Psychological 
(m = 7; 
n = 1120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2885) 
All 
(m = 19; 
n = 9326) 
Worst pain 
today 
0 m=1; n=111 - - m=1; n=61 - m=1; n=51 m=1; n=223 
  10 m=1; n=107 - - m=1; n=53 - m=1; n=49 m=1; n=209 
  26 m=1; n=103 - - m=1; n=53 - - m=1; n=156 
  52 m=1; n=103 - - m=1; n=52 - - m=1; n=155 
Worst pain 
over past one 
month 
0 - m=2; n=24 - - m=1; n=24 - m=2; n=48 
  6 - m=1; n=23 - - m=1; n=22 - m=2; n=45 
  13 - m=1; n=22 - - m=1; n=18 - m=2; n=40 
Quality of 
life 
   
 
  
   
SF-12/36h 
PCS 
0 m=4; n=617 m=7; n=2544 m=2; n=507 m=1; n=305 m=2; n=460 m=6; n=2262 m=9; n=6695 
  4 m=1; n=214 m=1; n=300 - m=1; n=264 - m=1; n=249 m=1; n=1027 
  8 m=1; n=82 m=1; n=139 m=1; n=76 - m=1; n=69 m=1; n=73 m=2; n=439 
  13 m=3; n=415 m=6; n=2276 m=1; n=332 m=1; n=243 m=1; n=376 m=5; n=2006 m=7; n=5648 
  26 m=2; n=185 m=4; n=1850 m=2; n=436 - m=2; n=444 m=4; n=1711 m=6; n=4626 
  52 m=4; n=469 m=5; n=719 m=2; n=449 m=1; n=235 m=1; n=68 m=4; n=545 m=7; n=2485 
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Outcomes 
Follow-
up 
(weeks) 
Active physical 
(m = 7; 
n = 914) 
Passive 
physical 
(m = 12; 
n = 3270) 
Psychological 
(m = 7; 
n = 1120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2885) 
All 
(m = 19; 
n = 9326) 
  104 m=1; n=83 m=2; n=206 - - - m=1; n=49 m=2; n=338 
SF-12/36 
MCSi 
0 m=4; n=617 m=7; n=2544 m=2; n=507 m=1; n=305 m=2; n=460 m=6; n=2262 m=9; n=6695 
  4 m=1; n=214 m=1; n=300 - m=1; n=264 - m=1; n=249 m=1; n=1027 
  8 m=1; n=82 m=1; n=139 m=1; n=76 - m=1; n=69 m=1; n=73 m=2; n=439 
  13 m=3; n=415 m=6; n=2276 m=1; n=332 m=1; n=243 m=1; n=376 m=5; n=2006 m=7; n=5648 
  26 m=2; n=185 m=4; n=1850 m=2; n=436 - m=2; n=444 m=4; n=1711 m=6; n=4626 
  52 m=4; n=469 m=5; n=719 m=2; n=449 m=1; n=235 m=1; n=68 m=4; n=545 m=7; n=2485 
  104 m=1; n=83 m=2; n=206 - - - m=1; n=49 m=2; n=338 
Health utility          
EQ-5D-3L 0 m=1; n=85 - - - - m=1; n=94 m=1; n=179 
  6 m=1; n=85 - - - - m=1; n=94 m=1; n=179 
  26 m=1; n=77 - - - - m=1; n=86 m=1; n=163 
  52 m=1; n=82 - - - - m=1; n=88 m=1; n=170 
a CPG-DS, chronic pain grade disability score; b FFbHR, Hannover functional ability questionnaire for measuring back-pain related functional limitations; c 
ODI, Oswestry disability index; d PDI, pain disability index; e PSFS, patient specific functional scale; f RMDQ, Roland Morris disability questionnaire; g 
CPG-PS, chronic pain grade pain intensity score; h PCS, physical component scale of SF-12/36; i MCS, mental component scale of SF-12/36.
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Table 15 Demographics and clinical characteristics at baseline by treatment arms. 
Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
Demographics               
Age, years               
No. of trials, m 7 12 7 3 6 10 19 
n 914 3,270 1,118 451 688 2,885 9,326 
Mean 43.67 49.39 50.08 43.77 48.54 50.51 48.92 
SD 11.74 14.13 14.22 12.51 15.22 13.37 13.88 
Sex        
No. of trials, m 7 12 7 3 6 10 19 
Female (%) 497 (54.4) 1,907 (58.3) 655 (58.5) 237 (52.6) 412 (59.9) 1,641 (56.9) 5,349 (57.4) 
Male (%) 417 (45.6) 1,363 (41.7) 464 (41.5) 214 (47.5) 276 (40.1) 1,243 (43.1) 3,977 (42.6) 
Ethnicity        
No. of trials, m 1 1 4 - - 4 5 
White (%) 65 (75.6) 159 (100.0) 667 (87.8) - - 478 (89.4) 1,369 (88.9) 
Mixed - - 4 (0.5) - - 3 (0.6) 7 (0.5) 
Black - - 26 (3.4) - - 21 (3.9) 47 (3.1) 
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
Asian (Indian, Pakistani, 
Bangladeshi, others) 
7 (8.1) - 37 (4.9) - - 17 (3.2) 61 (4.0) 
Chinese 1 (1.2) - 1 (0.1) - - 1 (0.2) 3 (0.2) 
Others 13 (15.1) - 25 (3.3) - - 15 (2.8) 53 (3.4) 
Smoking status        
No. of trials, m 5 3 3 1 1 1 6 
No (%) 333 (66.7) 211 (52.4) 167 (76.3) 52 (82.5) 54 (79.4) 69 (70.4) 886 (65.6) 
Yes (%) 167 (33.3) 192 (47.6) 52 (23.7) 11 (17.5) 14 (20.6) 29 (29.6) 465 (34.4) 
Employment status        
No. of trials, m 5 6 5 1 1 6 11 
Full time employment (%) 307 (51.3) 424 (51.7) 360 (42.2) 165 (64.7) 4 (25.0) 485 (54.3) 1,745 (50.8) 
Part time employment (%) 120 (20.0) 130 (15.9) 132 (15.5) 60 (23.5) - 190 (21.3) 632 (18.4) 
No employment (%) 172 (28.7) 266 (32.4) 362 (42.4) 30 (11.8) 12 (75.0) 218 (24.4) 1,060 (30.8) 
BMIa        
No. of trials, m 2 4 2 - 2 2 5 
n 222 811 156 - 453 462 2,104 
Mean 27.03 26.60 26.52 - 26.45 26.42 26.57 
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
SD 5.31 4.60 5.22 - 4.73 4.48 4.73 
Physical disability        
CPG-DSb (0 to 100; 
100=worst)a 
       
No. of trials, m 1 2 2 1 1 5 4 
n 284 721 572 312 387 1,052 3,328 
Mean 47.44 51.82 49.38 44.76 55.36 49.87 50.16 
SD 22.66 20.9 23.77 21.86 18.92 22.14 21.99 
FFbHRc (0 to 100; 
100=best)               
No. of trials, m - 3 - - 2 3 3 
n - 1,927 - - 460 1,789 4,176 
Mean - 58.33 - - 48.01 59.38 57.64 
SD - 20.63 - - 16.14 20.69 20.5 
ODI d (0 to 100; 100=worst)        
No. of trials, m - 1 - - - 1 1 
n - 159 - - - 80 239 
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
Mean - 33.72 - - - 31.36 32.93 
SD - 15.40 - - - 14.24 15.03 
PDIe (0 to 70; 70=worst)        
No. of trials, m - 1 - - 1 1 1 
n - 146 - - 73 79 298 
Mean - 28.92 - - 31.53 30.95 30.10 
SD - 11.12 - - 11.14 13.27 11.75 
PSFSf (0 to 10; 10=best)        
No. of trials, m 2 1 2 1 2 - 3 
n 150 119 148 62 188 - 667 
Mean 3.57 3.78 3.76 3.83 3.97 - 3.79 
SD 1.79 1.60 1.67 1.94 1.84 - 1.76 
RMDQg (0 to 24; 24=worst)               
No. of trials, m 7 7 7 3 3 6 14 
n 907 1,087 1,120 446 212 938 4,710 
Mean 10.07 10.89 9.85 9.59 11.09 8.57 9.91 
SD 5.08 5.03 5.33 4.33 5.95 4.69 5.09 
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
Troublesomeness               
No. of trials, m 2 3 1 1 - 3 4 
Not at all troublesome (%) 3 4 - - - 4 11 
Slightly troublesome (%) 41 62 26 29 - 51 209 
Moderately troublesome (%) 146 213 211 154 - 284 1,008 
Very troublesome (%) 115 205 151 107 - 211 789 
Extremely troublesome (%) 39 72 38 22 - 54 225 
Pain               
CPG-PSh (0 to 100; 
100=worst)a 
          
  
  
No. of trials, m 1 2 3 1 1 5 5 
n 283 721 582 312 387 1054 3,339 
Mean 60.82 64.93 58.93 59.91 67.60 62.65 62.66 
SD 17.62 16.79 18.53 17.91 13.16 17.41 17.31 
Average pain (0 to 100; 
100=worst)b               
No. of trials, m 4 6 6 3 5 6 12 
  146 
Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
n 472 922 969 380 493 1118 4354 
Mean 52.42 59.79 48.20 50.63 65.54 52.53 54.40 
SD 22.49 20.96 24.74 21.50 15.20 24.64 23.18 
Quality of life               
SF-12/36 PCSi (0 to 100; 
100=best)               
No. of trials, m 4 7 2 1 2 6 9 
n 617 2,544 507 305 460 2,262 6,695 
Mean 37.14 36.03 37.15 38.14 32.87 36.30 36.19 
SD 7.42 8.05 9.06 7.46 7.09 8.74 8.29 
SF-12/36 MCSj (0 to 100; 
100=best)               
No. of trials, m 4 7 2 1 2 6 9 
n 617 2,544 507 305 460 2,262 6,695 
Mean 43.94 44.89 44.38 44.84 46.61 45.89 45.22 
SD 11.66 12.23 11.28 10.84 11.42 11.90 11.90 
Health utility               
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
EQ-5D-3L (-0.11 to 
1;1=best)               
No. of trials, m 4 4 2 2 - 5 7 
n 593 740 652 371 - 724 3,080 
Mean 0.57 0.61 0.6 0.58 - 0.59 0.59 
SD 0.27 0.27 0.29 0.25 - 0.26 0.27 
Depression               
DASSk-DE (0 to 42; 
42=worst)               
No. of trials, m 1 - 1 1 1 - 1 
n 65 - 62 63 68 - 258 
Mean 7.11 - 7.55 7.08 7.06 - 7.19 
SD 7.84 - 7.67 8.79 7.61 - 7.94 
DRAMl               
No. of trials, m 2 1 - 1 - 2 2 
Type Nm (%) 135 (36.49) 122 (36.75) - 116 (37.54) - 184 (44.88) 557 (39.20) 
Type Rn (%) 147 (39.73) 147 (44.28) - 120 (38.83) - 158 (38.54) 572 (40.25) 
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
Type DDo (%) 55 (14.86) 41 (12.35) - 46 (14.89) - 49 (11.95) 191 (13.44) 
Type DSp (%) 33 (8.92) 22 (6.63) - 27 (8.74) - 19 (4.63) 101 (7.11) 
HADSq-DE (0 to 21; 
21=worst)               
No. of trials, m - - 1 - - 1 1 
n - - 464 - - 231 695 
Mean - - 6.04 - - 5.54 5.87 
SD - - 3.81 - - 3.6 3.75 
MZDIr (0 to 69; 69=worst)             
No. of trials, m 2 2 1 1 - 2 3 
n 411 485 148 309 - 411 1724 
Mean 19.77 21.44 22.41 21.24 - 19.77 21.06 
SD 10.75 10.55 9.37 10.93 - 10.75 10.70 
Anxiety              
DASSk-AN (0 to 42; 
42=worst)               
No. of trials, m 1 - 1 1 1 - 1 
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
n 65 - 62 63 68 - 258 
Mean 6.22 - 5.23 4.76 5.35 - 5.40 
SD 7.57 - 7.44 6.68 6.92 - 7.14 
HADSq-AN (0 to 21; 
21=worst)               
No. of trials, m - - 1 - - 1 1 
n - - 458 - - 230 688 
Mean - - 8.22 - - 7.49 7.98 
SD - - 4.3 - - 4.43 4.35 
Fear avoidance             
ALBPSQs-FA (0 to 30; 
30=worst)               
No. of trials, m 2 - 2 1 1 - 2 
n 121 - 117 36 33 - 307 
Mean 18.14 - 18.58 17.14 18.42 - 18.22 
SD 6.91 - 6.16 5.97 5.90 - 6.40 
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
FABQt-PC (0 to 24; 
24=worst)               
No. of trials, m 2 3 1 1 2 4 5 
n 366 840 443 311 506 1,016 3,482 
Mean 14.70 16.65 13.59 14.96 17.79 15.85 15.84 
SD 5.27 5.24 6.34 5.30 4.87 5.65 5.61 
TSKu (16 to 68; 68=worst)               
No. of trials, m 2 1 4 2 1 3 5 
n 176 177 472 124 68 285 1302 
Mean 39.08 44.05 41.64 39.33 38.07 39.71 40.79 
SD 7.44 7.09 8.14 7.51 8.16 8.58 8.12 
Catastrophising (CAT)               
CSQv-CAT (0 to 36; 
36=worst)               
No. of trials, m 1 1 2 - - - 2 
n 86 193 282 - - - 561 
Mean 10.84 7.83 9.62 - - - 9.19 
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
SD 7.61 6.65 7.22 - - - 7.16 
PRSSw-CAT (0 to 45; 
45=worst)               
No. of trials, m 1 1 1 1 2 - 2 
n 65 119 62 63 188 - 497 
Mean 17.92 16.43 17.9 17.29 17.23 - 17.22 
SD 8.61 8.12 10.55 9.05 8.53 - 8.77 
Coping (CSS)               
CSQv-CSS (0 to 36; 
36=best)               
No. of trials, m - 1 1 - - - 1 
n - 198 196 - - - 394 
Mean - 25.13 25.33 - - - 25.23 
SD - 6.23 6.64 - - - 6.43 
PRSSw-CSS (0 to 45; 
45=best)               
No. of trials, m 1 2 1 1 2 - 2 
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
n 65 119 62 63 188 - 497 
Mean 30.18 31.26 30.06 30.37 31.97 - 31.13 
SD 7.34 6.95 8.36 6.81 6.85 - 7.15 
PSEQ x (0 to 60; 60=best)               
No. of trials, m 3 1 3 1 1 1 4 
n 268 117 601 63 67 223 1,339 
Mean 40.49 36.85 40.12 44.38 43.70 41.15 40.46 
SD 12.93 10.94 13.17 12.77 13.38 12.54 12.90 
Somatic perception               
MSPQy (0 to 39; 39=worst)               
No. of trials, m 2 2 1 1 - 2 3 
n 372 526 195 310 - 411 1,814 
Mean 6.78 6.43 5.58 7.07 - 6.14 6.45 
SD 5.52 5.38 4.29 5.43 - 5.34 5.32 
Sensory index (SE)               
McGill-SE (0 to 33; 
33=worst)               
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Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
No. of trials, m - 1 1 - - - 1 
n - 185 170 - - - 355 
Mean - 14.21 14.26 - - - 14.24 
SD - 6.10 6.36 - - - 6.22 
SESz-SE (10 to 40; 
40=worst)               
No. of trials, m - 1 - - 1 1 1 
n - 146 - - 73 79 298 
Mean - 49.7 - - 49.11 49.77 49.57 
SD - 9.05 - - 8.39 11.06 9.45 
Affective index (AF)               
McGill-AF (0 to 12; 
12=worst)               
No. of trials, m - 1 1 - - - 1 
n - 192 187 - - - 379 
Mean - 4.21 4.25 - - - 4.23 
SD - 3.31 3.36 - - - 3.33 
  154 
Characteristics 
Active 
physical 
(m = 7; 
n = 914) 
Passive physical 
(m = 12; 
n = 3,270) 
Psychological 
(m = 7; 
n = 1,120) 
Combination 
(m = 3; 
n = 451) 
Sham 
(m = 6; 
n = 688) 
Control 
(m = 10; 
n = 2,885) 
All 
(m = 19; 
n = 9,328) 
SES-AF (14 to 56; 
56=worst)             
No. of trials, m - 1 - - 1 1 1 
n - 146 - - 73 79 298 
Mean - 50.19 - - 50.88 50.01 50.31 
SD - 8.38 - - 8.17 9.34 8.57 
a BMI. body mass index; b CPG-DS, chronic pain grade disability score; c FFbHR, Hannover functional ability questionnaire for measuring back-
pain related functional limitations; d ODI, Oswestry disability index; e PDI, pain disability index; f PSFS, patient specific functional scale; g 
RMDQ, Roland Morris disability questionnaire; h CPG-PS, chronic pain grade pain intensity score; i  PCS, physical component scale of SF-12/36; 
j MCS, mental component scale of SF-12/36; k DASS, depression anxiety stress scales; l DRAM, distress and risk assessment method; m Type N, 
normal; n Type R, at risk; o Type DD, distressed-depressive; p Type DS, distressed-somatic; q HADS, hospital anxiety and depression scale; r 
MZDI, modified Zung depression index; s ALBPSQ, acute low back pain screening questionnaire; t FABQ, fear-avoidance beliefs questionnaire; 
u TSK, Tampa scale for kinesiophobia; v CSQ, coping strategy questionnaire; w PRSS, pain related self-statement; x PSEQ, pain self-efficacy 
questionnaire; y MSPQ, modified somatic perception questionnaire; z SES, pain experience scale. 
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6.6.2 ONE-STEP META-ANALYSIS 
Boxplots of change of outcome measures from baseline to short-, mid- and long-term follow-
up by treatment arms show that  participants in all groups are behaving as expected with all 
groups improving over time (data not shown). This observation was examined further in the 
one-step meta-analysis (adjusting for study effects) and the results are shown in Figure 17, 
Figure 18 and Figure 19 and Table 16. There was a statistically significant difference between 
control and intervention for all outcomes at the short-term follow-up. 
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(A) FFbHR 
 
(B) RMDQ 
 
Abbreviations: m, number of trials; UC, number of participants in the control arm; AT, number 
of participants in the intervention arm; Est (95% CI), estimated treatment efficacy and 95% 
confidence interval; p, p-value. 
Figure 17 The estimated efficacy between control (non-active usual care and 
sham) and intervention treatments from one-step meta-analysis for (A) 
Hannover functional ability questionnaire for measuring back-pain related 
functional limitations (FFbHR) and (B) Roland-Morris Disability 
Questionnaire (RMDQ) 
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(A) Average pain (VAS) 
 
(B) SF-12/36 PCS 
 
Abbreviations: m, number of trials; UC, number of participants in the control arm; AT, number 
of participants in the intervention arm; Est (95% CI), estimated treatment efficacy and 95% 
confidence interval; p, p-value.  
Figure 18 The estimated efficacy between control (non-active usual care and 
sham) and intervention treatments from one-step meta-analysis for (A) 
average pain (based on visual analogue scale) and (B) physical component 
scale of SF-12/36 (PCS) 
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(A) SF-12/36 MCS 
 
(B) EQ-5D 
 
Abbreviations: m, number of trials; UC, number of participants in the control arm; AT, number 
of participants in the intervention arm; Est (95% CI), estimated treatment efficacy and 95% 
confidence interval; p, p-value.  
Figure 19 The estimated efficacy between control (non-active usual care and 
sham) and intervention treatments from one-step meta-analysis for (A) 
mental component scale of SF-12/36 (MCS) and (B) EQ-5D. 
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Table 16 One-step meta-analysis - estimated mean change from baseline to short-term 
follow-up by treatment arms and the estimated difference between treatment arms (95% 
confidence interval).a 
Outcomes 
No. of 
trials, 
m Intervention Controlb Differencec p-value 
FFbHRd 3 n = 1841 n = 2118   
  13.88 5.80 8.08 0.0165 
  (1.24, 26.51) (-6.93, 18.53) (3.46, 12.69)  
RMDQe 8 n = 1778 n = 897   
  4.43 2.97 1.46 <0.0001 
  (1.56, 7.29) (0.10, 5.84) (1.10, 1.81)  
Average 
painf 10 n = 2061 n = 1546   
  18.03 11.57 6.46 <0.0001 
  (8.65, 27.41) (2.18, 20.97) (4.86, 8.06)  
PCSg  6 n = 2793 n = 2415   
  6.86 3.72 3.15 0.0006 
  (4.90, 8.83) (1.75, 5.68) (1.99, 4.30)  
MCSh 6 n = 2793 n = 2415   
  2.69 0.62 2.07 0.0044 
  (1.54, 3.84) (-0.55, 1.79) (0.93, 3.20)  
EQ-5D 4 n = 1271 n = 503   
  0.1065 0.03422 0.072 <0.0001 
  (0.008, 0.205) (-0.059, 0.127) (0.04538, 0.099) 
 a Adjusted by random intercept, trial and interaction between treatment and trial effects; b 
Control, Usual care/GP and sham control; c Difference, Intervention − Control (thus, positive 
= favours intervention arm); d FFbHR, Hannover functional ability questionnaire for 
measuring back-pain related functional limitations; e RMDQ, Roland Morris disability 
questionnaire; f Obtained from either visual analogue scale or pain intensity score of chronic 
pain grade scale (see Section 6.3.3.3); g PCS, physical component scale of SF-12/36; h MCS, 
mental component scale of SF-12/36. 
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6.6.3 ANCOVA ANALYSIS 
Table 17 shows the list of moderators for each of the outcomes of interest at short-term follow-
up, namely, FFbHR, RMDQ, average pain, PCS, MCS. There were three trials with FFbHR 
short-term outcome and the explanatory variables that may potentially be treatment moderators 
provided by these trials were age, sex, SF-12/36 PCS and SF-12/36 MCS. For the change of 
FFbHR from baseline to short-term follow-up the treatment effect for younger participant was 
weakly statistically significant (p=0.2018). Participants with lower value of FFbHR at baseline 
(more physical disability) had larger treatment effect and this was statistically significant 
(p<0.0001). Similarly, participants with lower value of PCS at baseline (substantial physical 
limitations) had larger treatment effect (p<0.0001). Therefore, age, and the baseline values of 
FFbHR and PCS were considered for inclusion in further analyses. 
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Table 17 ANCOVA analysis for short-term outcomes (change from baseline to short-term follow-up)a. 
Outcome Covariates No. of trials, m 
No. of 
participants, 
ATb:UCc 
Estimate 
(interaction 
term) LCId UCIe p-value 
FFbHRf             
 Age 3 1841:2118 -0.051 -0.131 0.028 0.2018 
 Sex (male vs. female)l 3 1841:2118 -0.684 -2.851 1.483 0.5361 
 FFBHR 3 1841: 2118  -0.177 -0.229 -0.125 <.0001 
 PCS (<50 vs. ≥50)m 3 1718:2000 2.521 -2.361 7.403 0.3114 
 PCS (continuous) 3 1718:2000 -0.318 -0.451 -0.186 <.0001 
 MCS (<50 vs. ≥50) 3 1718:2000 0.612 -1.618 2.842 0.5903 
 MCS (continuous) 3 1718:2000 -0.039 -0.130 0.051 0.3949 
RMDQg             
 Age 8 1778:897 -0.009 -0.036 0.018 0.514 
 Sex (male vs. female) 8 1778:896 0.136 -0.591 0.863 0.7133 
 RMDQ 8 1778:897  -0.017 -0.085 0.050 0.6176 
 Average pain 8 1649:790 -0.003 -0.018 0.011 0.6548 
 PCS (continuous) 2 1009:401 -0.016 -0.076 0.044 0.594 
 PCS (<50 vs. ≥50) 2 1009:401 0.546 -1.463 2.556 0.5939 
 MCS (continuous) 2 1009:401 -0.002 -0.046 0.042 0.9177 
  162 
Outcome Covariates No. of trials, m 
No. of 
participants, 
ATb:UCc 
Estimate 
(interaction 
term) LCId UCIe p-value 
 
MCS (<50 vs. ≥50) 2 1009:401 -0.423 -1.435 0.589 0.4123 
EQ-5D 3 1201:460 -0.366 -2.162 1.429 0.6892 
 Anxiety 4 1388:523       0.3332 
 Low riskn   -0.295 -1.713 1.123 0.6832 
 Moderate risko   0.452 -1.089 1.994 0.5649 
 Depression 4 1387:525       0.5684 
 Low risk   0.078 -1.337 1.492 0.9143 
 Moderate risk   0.559 -0.933 2.051 0.4622 
 Catastrophising 2 293:178       0.2360 
 Positivep   0.387 -2.271 3.046 0.7747 
 Moderateq   2.030 -0.461 4.521 0.1099 
 Coping 3 620:348       0.6797 
 Positiver   0.428 -1.127 1.982 0.5895 
 Moderates   0.729 -0.904 2.362 0.3813 
 Fear avoidance 7 1706:858       0.1933 
 Positivet    0.786 -0.125 1.697 0.0907 
 Moderateu    0.714 -0.225 1.653 0.1361 
Average painh             
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Outcome Covariates No. of trials, m 
No. of 
participants, 
ATb:UCc 
Estimate 
(interaction 
term) LCId UCIe p-value 
 Age 10 2061:1546 -0.047 -0.162 0.068 0.4216 
 Sex (male vs. female) 10 2061:1545 0.784 -2.381 3.950 0.6272 
 RMDQ 8 1657:794 0.156 -0.293 0.604 0.497 
 Average pain 10 2061: 1546  0.047 -0.017 0.111 0.1451 
 PCS (continuous) 3 1390:1144 -0.167 -0.400 0.066 0.1587 
 PCS (<50 vs. ≥50) 3 1390:1144 1.569 -8.473 11.610 0.7594 
 MCS (continuous) 3 1390:1144 0.111 -0.047 0.268 0.1677 
 MCS (<50 vs. ≥50) 3 1390:1144 -1.270 -4.942 2.403 0.498 
 EQ-5D 3 1208:464 -3.192 -13.603 7.219 0.5477 
 Anxiety 4 1394:528       0.2488 
 Low risk    -6.939 -15.111 1.233 0.096 
 Moderate risk    -5.509 -14.423 3.405 0.2256 
 Depression 4 1394:530       0.9355 
 Low risk    -1.519 -9.809 6.772 0.7195 
 Moderate risk    -1.076 -9.843 7.692 0.8099 
 Catastrophising 2 198:85       0.9797 
 Positive   -0.400 -19.050 18.250 0.9664 
 Moderate   -1.573 -17.280 14.133 0.8438 
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Outcome Covariates No. of trials, m 
No. of 
participants, 
ATb:UCc 
Estimate 
(interaction 
term) LCId UCIe p-value 
 Coping 3 544:264       0.4009 
 Positive   -6.107 -14.999 2.786 0.178 
 Moderate   -2.864 -11.995 6.266 0.5382 
 Fear avoidance 8 1991:1505       0.3577 
 Positive   1.396 -2.525 5.317 0.4851 
 Moderate   2.808 -1.031 6.646 0.1516 
SF-12/36 PCSi            
 Age 6 2793:2415 -0.034 -0.068 0.001 0.0538 
 Sex (male vs. female) 6 2793:2414 -0.176 -1.106 0.755 0.7111 
 FFbHR 3 1675:1955 -0.016 -0.045 0.013 0.2766 
 RMDQ 2 966:383 0.012 -0.210 0.234 0.9187 
 Average pain 3 1346:1125 -0.011 -0.044 0.023 0.5313 
 PCS (continuous) 6 2793:2415 -0.057 -0.109 -0.005 0.0313 
 PCS (<50 vs. ≥50) 6 2793:2415 1.995 0.018 3.973 0.048 
 MCS (continuous) 6 2793:2415 0.023 -0.015 0.060 0.2395 
 MCS (<50 vs. ≥50) 6 2793:2415 -0.913 -1.827 0.002 0.0504 
 EQ-5D 3 1046:425 1.216 -2.364 4.795 0.5054 
 Anxiety 3 1051:428       0.6537 
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Outcome Covariates No. of trials, m 
No. of 
participants, 
ATb:UCc 
Estimate 
(interaction 
term) LCId UCIe p-value 
 Low risk   1.315 -1.638 4.267 0.3826 
 Moderate risk   1.398 -1.750 4.545 0.3839 
 Depression 3 1053:430       0.6277 
 Low risk   1.261 -1.640 4.163 0.3939 
 Moderate risk   1.462 -1.559 4.483 0.3427 
 Fear avoidance 3 1332:1114       0.8438 
 Positive   -0.311 -2.029 1.408 0.7229 
 Moderate   0.211 -1.435 1.857 0.8019 
 Somatic symptoms 2 805:365       0.9147 
 Positivev   0.542 -1.989 3.072 0.6746 
 Moderatew   0.249 -1.907 2.405 0.8206 
SF-12/36 
MCSj            
 Age 6 2793:2415 0.008 -0.035 0.050 0.7273 
 Sex (male vs. female) 6 2793:2414 -0.324 -1.470 0.822 0.579 
 FFbHR 3 1675:1955 -0.046 -0.081 -0.011 0.0093 
 RMDQ 2 966:383 -0.011 -0.298 0.276 0.9395 
 Average pain 3 1346:1125 -0.007 -0.048 0.034 0.7423 
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Outcome Covariates No. of trials, m 
No. of 
participants, 
ATb:UCc 
Estimate 
(interaction 
term) LCId UCIe p-value 
 PCS (continuous) 6 2793:2415 -0.035 -0.102 0.033 0.3133 
 PCS (<50 vs. ≥50) 6 2793:2415 0.649 -1.821 3.118 0.6067 
 MCS (continuous) 6 2793:2415 -0.052 -0.093 -0.011 0.0128 
 MCS (<50 vs. ≥50) 6 2793:2415 1.490 0.442 2.539 0.0054 
 EQ-5D 3 1046:425 -0.059 -4.576 4.458 0.9795 
 Anxiety 3 1051:428       0.4267 
 Low risk   -1.201 -4.918 2.517 0.5265 
 Moderate risk   0.406 -3.558 4.369 0.8409 
 Depression 3 1053:430       0.863 
 Low risk   -0.334 -3.983 3.314 0.8573 
 Moderate risk   0.343 -3.456 4.142 0.8594 
 Fear avoidance 3 1332:1114       0.7926 
 Positive   0.732 -1.378 2.843 0.4964 
 Moderate   0.278 -1.744 2.299 0.7877 
 Somatic symptoms 2 805:365       0.575 
 Least   -0.978 -4.351 2.395 0.5695 
 Moderate   0.789 -2.087 3.665 0.5906 
EQ-5D            
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Outcome Covariates No. of trials, m 
No. of 
participants, 
ATb:UCc 
Estimate 
(interaction 
term) LCId UCIe p-value 
 Age 4 1271:503 0.001 -0.001 0.003 0.503 
 Sex (male vs. female) 4 1271:502 -0.040 -0.094 0.015 0.1543 
 RMDQ 3 1177:455 0.007 0.001 0.013 0.0219 
 Average pain 3 1183:459 0.002 0.000 0.003 0.0094 
 PCS (continuous) 3 1068:439 -0.004 -0.008 -0.001 0.0128 
 PCS (<50 vs. ≥50) 3 1068:439 0.045 -0.072 0.162 0.4494 
 MCS (continuous) 3 1068:439 -0.002 -0.004 0.001 0.1834 
 MCS (<50 vs. ≥50) 3 1068:439 0.024 -0.034 0.082 0.4102 
 EQ-5D 4 1271: 503 -0.054 -0.144 0.035 0.2358 
 Anxiety 4 1269:500       0.0032 
 Low risk   -0.143 -0.232 -0.055 0.0015 
 Moderate risk   -0.086 -0.180 0.009 0.0753 
 Depression 4 1265:500       0.5331 
 Low risk   -0.033 -0.120 0.054 0.4573 
 Moderate risk   -0.003 -0.094 0.088 0.9511 
 Fear avoidance 3 1163:450       0.0533 
 Positive   -0.001 -0.072 0.071 0.9856 
 Moderate   0.073 -0.002 0.147 0.0565 
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Outcome Covariates No. of trials, m 
No. of 
participants, 
ATb:UCc 
Estimate 
(interaction 
term) LCId UCIe p-value 
QALYk        
 Age 6 1539:814 0.001 -0.0003 0.002 0.1850 
 RMDQ 4 1092:422 0.003 -0.001 0.008 0.1270 
 PCS (continuous) 4 1273:715 -0.001 -0.003 0.0004 0.1160 
 MCS (continuous) 4 1273:715 -0.0001 -0.002 0.001 0.8340 
 EQ-5D 4 1273:715 -0.018 -0.082 0.045 0.5730 
a Mixed effects models with intercept, trials and interaction between treatments and trials as random effects, and covariate and interaction 
between covariates; b AT, number of patients in the intervention arm (active physical, passive physical, psychological, or combination); c 
UC, number of patients in the control arm (usual care/GP or sham); d LCI, lower limit of the 95% confidence interval; e UCI upper limit of 
the 95% confidence interval; f FFbHR, Hannover functional ability questionnaire for measuring back-pain related functional limitations; g 
RMDQ, Roland Morris disability questionnaire; h Obtained from either visual analogue scale or pain intensity score of chronic pain grade 
scale (see Section 6.3.3.3); i PCS, physical component scale of SF-12/36; j MCS, mental component scale of SF-12/36; k QALY, quality-
adjusted life year; l estimate of the treatment effect for male was less as opposed to female; m estimate of the treatment effect for participants 
with SF-12/36 PCS score lower than general norm (<50) was greater as opposed to those with score at or above the general norm (≥50); n 
estimate of the treatment effect for participants with low risk of anxiety was less as opposed to those with the high risk; o estimate of the 
treatment effect for participants with moderate risk of anxiety was greater as opposed to those with the high risk; p estimate of the treatment 
effect for participants with positive attitude of catastrophising (low catastrophising score) was greater as opposed to those with the negative 
attitude (high catastrophising score); q estimate of the treatment effect for participants with moderate attitude of catastrophising was greater 
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Outcome Covariates No. of trials, m 
No. of 
participants, 
ATb:UCc 
Estimate 
(interaction 
term) LCId UCIe p-value 
as opposed to those with the negative attitude; r estimate of the treatment effect for participants with positive attitude of coping strategy (high 
coping score) was greater as opposed to those with the negative attitude (low coping score); s estimate of the treatment effect for participants 
with moderate attitude of coping strategy was greater as opposed to those with the negative attitude; t estimate of the treatment effect for 
participants with positive belief (low fear avoidance) of fear avoidance belief was greater as opposed to those with the negative attitude; u 
estimate of the treatment effect for participants with moderate belief of fear avoidance was greater as opposed to those with the negative 
attitude; v estimate of the treatment effect for participants with least general somatic symptoms was greater as opposed to those with more 
general somatic symptoms; w estimate of the treatment effect for participants with moderate general somatic symptoms was greater as 
opposed to those with more general somatic symptoms. 
 
. 
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6.6.3.1 RMDQ 
There were up to eight trials with RMDQ short-term outcome and the explanatory covariates 
provided by them were age, sex, RMDQ, average pain, PCS, MCS, EQ-5D, anxiety level, 
depression level, catastrophising, coping strategy and fear avoidance at baseline. Seven trials 
provided information on fear avoidance at baseline and the original values were mapped to a 
single ordinal categorical variable. The covariate was weakly statistically significant, at our 
lower threshold for inclusion in further analyses (p<0.20), in moderating the change of RMDQ 
over the short-term where those with either positive or moderate attitude (lower fear avoidance 
score) had greater treatment effect than those with negative attitude (high fear avoidance score). 
Although the covariate catastrophising was not statistically significant (p = 0.236) in predicting 
the change of RMDQ at short-term, there was a weakly statistically significant difference 
between the moderate and negative statement (mean difference=2.03, p = 0.1099), that is, those 
with moderate attitude towards catastrophising had greater treatment effect than those with a 
negative attitude. Therefore, both fear avoidance and catastrophising were considered for the 
prediction rule analyses. 
6.6.3.2 Pain 
Ten trials provided an average pain short-term outcome. The list of covariates that were 
considered in the analysis of covariance were age, sex, RMDQ, average pain, PCS, MCS, EQ-
5D, anxiety level, depression level, catastrophising, coping strategy and fear avoidance at 
baseline. Similar to the results seen for the change of RMDQ at short-term, anxiety level, 
coping strategy and fear avoidance were not statistically significant but there was weakly 
significant difference between the low and high risk of anxiety level (p = 0.0960), between the 
positive and negative statement of coping strategy (p = 0.1780) and between the moderate and 
negative statement of fear avoidance (p = 0.1516). Similar to the results seen above, those with 
moderate fear avoidance belief had greater treatment effect than those with negative attitude. 
However, those with low risk of anxiety had less treatment effect as opposed to those with high 
risk of anxiety. Similarly, those with positive attitude of coping strategy had less treatment 
effect than those with negative strategy. As the average pain increased the estimated treatment 
effect was greater, that is, as participants had worse average pain, they gained greater treatment 
effect and this was weakly significant at p = 0.1451. The estimated treatment effect decreased 
as PCS increased, that is, as participant’s physical functioning score got worse, they had greater 
treatment effect (p = 0.1587). The interaction term between treatment and MCS was also 
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weakly statistically significant (p = 0.1677) where participants with higher (better) mental 
component score had larger treatment effect. Therefore, average pain, PCS, MCS, anxiety 
level, coping strategy and fear avoidance at baseline were considered for the prediction rule 
analyses. 
6.6.3.3 MCS and PCS 
There were six trials with PCS and MCS short-term outcomes and the covariates considered 
were age, sex, FFbHR, RMDQ, average pain, PCS, MCS, EQ-5D, anxiety level, depression 
level, fear avoidance and somatic symptoms. Psychological distress at baseline measured by 
the MCS instrument was not significant in predicting the change of PCS at short-term but when 
the score was dichotomised to <50 against ≥50, that is, below the norm against at or above the 
general population norm, participants with more psychological distress (<50) had worse 
treatment effect and this was possibly statistically significant at p = 0.0504. Also, age and PCS 
at baseline were significant where those who were younger and those with substantial physical 
limitations had larger treatment effect. Therefore, age, PCS and MCS scores at baseline were 
included for the prediction rule analyses for the change of SF-12/36 PCS at short-term. 
For the short-term MCS outcome only FFbHR and MCS at baseline were found to be 
statistically significant in predicting the change of SF-12/36 MCS at short-term. Those with 
higher physical disability and more psychologically distress had a greater treatment effect. 
Therefore, both FFbHR and MCS scores at baseline were included for the prediction rule 
analyses for the change of SF-12/36 MCS at short-term. 
6.6.3.4 EQ-5D 
Four trials provided health utility measured by EQ-5D at short-term. The covariates examined 
in the analysis of covariance were age, sex, RMDQ, average pain, PCS, MCS, EQ-5D, anxiety 
level, depression level and fear avoidance. Of these, seven of them were statistically or weakly 
significant in predicting the change of EQ-5D at short-term and they are sex, RMDQ, average 
pain, PCS, MCS, anxiety level and fear avoidance at baseline. Female had greater treatment 
effect (p = 0.1543) and so were those with worse physical disability (RMDQ, p = 0.0219; 
average pain, p = 0.0094; PCS, p = 0.0128). Participants with more psychological distress at 
baseline; high risk of anxiety, high risk of depression, negative beliefs about physical activity 
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affecting their LBP (fear avoidance) or frequent psychological distress (MCS) had larger 
treatment effect. Therefore, these were considered for the prediction rule analyses. 
6.6.3.5  QALY 
There were up to six trials with QALY data. Age, and baseline scores of RMDQ and PCS were 
possibly statistically significant in moderating QALY. The age by treatment interaction was 
possibly significant with a coefficient of 0.001 and a p-value of 0.19. The coefficient was 
positive, suggesting that older participants within this sample achieved a higher treatment 
effect. The RMDQ by treatment interaction was significant (p=0.13) at our pre-specified level 
of 0.2. The coefficient of 0.003 was positive. The scale on the RMDQ is such that lower scores 
denote better health states, therefore participants with better (lower) RMDQ scores should be 
peeled off first for the health economic prediction rule analyses (Chapter 9). The coefficient of 
PCS by treatment interaction was -0.001 (p=0.12). The negative coefficient indicates 
participants with a worse physical functioning score at baseline achieved a greater treatment 
effect than those with better physical functioning scores at baseline. The baseline scores of EQ-
5D and MCS were not significant. The EQ-5D by treatment interaction was not significant with 
a coefficient of -0.018 (p= 0.57). The coefficient was negative suggesting that participants with 
worse baseline EQ-5D scores achieved better treatment outcomes. However, this result should 
not be considered reliable given the low level of significance. The coefficient of MCS by 
treatment interaction was -0.0001 (p=0.83). 
6.6.3.6 Summary 
This analysis has provided the largest analysis of possible treatment moderation in LBP. 
Overall these analyses do not provide strong evidence for substantial effect moderation. Using 
conventional criteria for statistical significance we can only conclude that overall; that back 
pain disability moderates effect size on back pain disability outcomes (FFbHR moderates 
FFbHR) that physical state and back pain moderate effect size on physical outcomes, (PCS and 
FFbHR moderate PCS), that psychological state moderates effect size on psychological 
outcomes (MCS moderates MCS), that overall psychological state and anxiety moderate effect 
size on quality of life (PCS and anxiety moderate EQ-5D), and that back pain severity 
moderates effect size on psychological outcomes (FFbHR moderates MCS).  
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Age, gender, back pain disability, pain severity, MCS, PCS, anxiety, catastrophising, and 
coping were all at least weakly statistically significant (p<0.2) in one, or more, ANCOVA and 
were considered further for our main analyses. 
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CHAPTER 7 – METHODOLOGY AND STATISTICAL 
DEVELOPMENTS 1: SUBGROUP IDENTIFICATION WITH 
RECURSIVE PARTITIONING 
7 x 
In Chapter 2 we concluded that current approaches using test for interactions on single 
potential moderators may not be the best approach to identifying subgroups; specifically in the 
case of LBP but this may be generalisable to other disorders. We argued that new statistical 
methods may be needed to improve subgroup identification. In the succeeding chapters we 
describe our exploration of different methods we have applied to addressing this problem. In 
particular we have been interested in how subgroups might be defined using multiple 
parameters. We first describe two recursive partitioning approaches, then an adaptive peeling 
approach and finally an indirect meta-analytical approach. 
This chapter presents the two methodological developments using recursive partitioning to 
identify subgroup characteristics that moderate response to treatment. Both methods were the 
works of a PhD project which was part of this programme grant.141 The other methods are 
described in later chapters (see Chapters 8-10). 
7.1 BACKGROUND 
Two methods were considered as suitable and appropriate to perform subgroup analyses using 
a recursive partitioning approach. They are the interaction tree (IT) and subgroup identification 
based on a differential effect search (SIDES).94, 96 These methods were initially developed and 
implemented in a single trial setting. Therefore, they have to be extended so that they can be 
applied in an individual participant data (IPD) meta-analyses framework. The extended IT and 
SIDES methods are known as IPD-IT and IPD-SIDES, respectively. Details of each of these 
methods are given below. 
Both IT and SIDES are tree-based methods that rely on technique referred as recursive 
partitioning. This technique recursively forms binary splits of the covariate space in order to 
grow a tree-like structure. An example of a tree structure is displayed in Figure 20. In this 
example, we start off with the root node of the tree which consists of the entire dataset. The 
method then searches all possible binary splits for every covariate to find the best split that 
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maximises some splitting criterion. Suppose sex is identified as the first best split. The method 
therefore splits the root node using the sex covariate to form two child nodes; females (left 
child node) and males (right child node). The newly formed child nodes are also referred to as 
internal nodes. The same search process is then conducted on all of the internal nodes of the 
tree, that is, the two child nodes, to try and identify the next best split. No additional splits are 
identified for the left child node and hence the node is not split any further. This node is thus 
referred to as a terminal node since it cannot be split any further and is represented by a square 
box in Figure 20. For the right child node, the method identifies age ≤ 50 as the next best split 
and thus forms two new child nodes accordingly. In the same manner, this search process is 
repeated until a full tree is grown. 
 
Figure 20 Example of a tree structure. 
The objective of both the IPD-IT and IPD-SIDES methods are somewhat different. The aim of 
the IPD-IT method is to identify moderators of treatment effect whereas the aim of the IPD-
SIDES method is to identify candidate subgroups with enhanced treatment effect. In other 
words the IPD-IT method is driven by identifying the split that results in the largest interaction 
effect whilst the IPD-SIDES method is driven by identifying the spilt that maximises the 
overall treatment benefit in one of the subgroups formed from the split.  
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7.2 IPD-INTERACTION TREE (IPD-IT) 
The IPD-IT method primarily consists of three steps:  
1) Growing an initial tree 
2) Pruning the initial tree 
3) Selecting the best tree 
The third and final step in the process will either result in tree structure with just the root node, 
that is, no moderators identified, or a larger tree structure that stems from the root node, that 
is, some moderators identified. In the latter case, the subgroups identified by the final selected 
tree are interpreted using its terminal nodes. 
1. Growing an initial tree 
The first iteration of the procedure starts at the root node and evaluates a splitting criterion that 
assesses the interaction effect for every possible binary split of each covariate in order to 
identify an optimal split. For a continuous or discrete ordered covariate, the total number of 
binary split points is just one fewer than the total number of distinct values. For example, a 
discrete ordered covariate with 10 distinct values will have 10 – 1 = 9 possible split points. For 
a categorical covariate with k different categories, there are 2k – 1 – 1 different split points. For 
example, a categorical covariate such as ethnicity with four different categories (White, 
Asian/Asian British, Black/African/Caribbean/Black British, and other) will have seven 
possible ways of forming two groups using a binary split. 
The splitting criterion is used to evaluate the interaction effect for any particular split. The 
original IT method used a splitting criterion that was equivalent to the square of the t-test 
statistic of the interaction term in a linear regression model consisting of a treatment indicator 
variable T, a covariate indicator representing a particular split X and the interaction between T 
and X. Since we are now applying this method to individual patient data from different trials, 
we extended the original method so that the splitting criterion adjusts for the between-trial 
variability when evaluating the interaction. This was done by fitting the same linear regression 
model but also including dummy variables for each trial, i.e. fitting a fixed-effect model.141 A 
split with a larger splitting criterion value indicates a larger interaction effect. Therefore, an 
optimal split is defined as the split that maximises the splitting criterion having searched every 
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possible split point of each covariate. Having defined the splitting criterion, the algorithm for 
growing a full tree can be applied as follows: 
 Start at the root node consisting of the entire dataset 
 Iteration: 
o Step 1 – Evaluate the splitting criterion for all possible splits for every 
single covariate. 
o Step 2 – Select the optimal split from step 1 and form a split to create two 
new child nodes. 
o Step 3 – Repeat steps 1 and 2 for each of the newly formed child nodes. 
o Step 4 – Repeat steps 1 to 3 until either a full tree is grown or until some 
stopping criterion is satisfied, for example, minimum number of 
observations in a node is 30.  
2. Pruning the initial tree 
The fully grown tree is well fitted to the available data, however, it would be quite poorly fitted 
and unstable if applied to new data. For this reason, a pruning procedure is applied to the full 
tree to sequentially remove any branches of the tree that least contribute to the overall 
predictive accuracy of the tree. The procedure continues until we are just left with the root node 
and thus have a sequence of sub-trees from which the optimal final sub-tree will be chosen. A 
more detailed description of the pruning procedure can be found elsewhere.94, 141, 142 
3. Selecting the best tree 
Once the sequence of sub-trees has been determined, an interaction complexity measure is used 
to evaluate the quality of each tree. The interaction complexity is basically the total amount of 
interaction of the internal nodes for a tree. Although the interaction-complexity measure is 
computed for each of the sub-trees, these estimates are known to be over-optimistic and thus 
need to be validated to obtain more reliable estimates. To validate the tree selection, the method 
applies a bootstrapping procedure, used by LeBlanc and Crowley, for validating the trees.143 
As a guideline, LeBlanc and Crowley suggested that around 25 to 100 bootstrap samples is 
sufficient. The sub-tree with the largest interaction-complexity measure estimated from the 
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bootstrapping procedure is chosen as the best tree. Conclusions can then be drawn from the 
best tree by simply computing the treatment effect in each of the terminal nodes of the tree.  
7.3 IPD-SUBGROUP IDENTIFICATION BASED ON A DIFFERENTIAL EFFECT 
SEARCH (IPD-SIDES) 
The IPD-SIDES method consists of two key steps: 
1) Growing an initial tree 
2) Selecting the final candidate subgroups 
The tree growing procedure for the IPD-SIDES method (step 1) relies on two different criteria; 
a splitting criterion to help search the covariate space for the best splits and a continuation 
criterion to control the complexity of the tree. Details given below. Unlike the IPD-IT 
procedure, the IPD-SIDES method does not require a pruning step as the tree complexity is 
controlled using the continuation criterion. Ultimately after step 2, the method outputs a list of 
candidate subgroups that have enhanced treatment effect. 
1. Growing an initial tree 
We first describe the algorithm for the IPD-SIDES procedure followed by a more detailed 
description of the splitting criterion and the continuation criterion. The algorithm for growing 
the tree is as follows: 
 Start at the root node consisting of the entire dataset  
 Iteration: 
o Step 1 - Evaluate the splitting criterion for all splits of every covariate, 
excluding any covariates already used to define the parent node, retaining 
only the best split for each covariate. Order the covariates from smallest 
adjusted p-value to largest adjusted p-value where the adjusted p-values 
are computed using the Sidak-based multiplicity adjustment.  
o Step 2 - Select the best M covariates from the ordered best splits. The value 
of M is specified by the user where the recommended value is 5. For each 
of the M splits, form the split creating two child nodes and retain the child 
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node with the larger positive treatment effect, provided it satisfies the 
continuation criterion. The retained nodes now become parent nodes for 
the next iteration. 
o Step 3 – Repeat steps 1 and 2 for the newly formed parent nodes. 
o Step 4 – Repeat steps 1 to 3 until either a pre-specified maximum number 
of levels is reached or if no more splits can be formed i.e. the continuation 
criterion is not satisfied. In both cases, the previously formed parent nodes 
become terminal nodes. 
The IPD-SIDES procedure starts at the root node consisting of the entire dataset. The method 
then evaluates the splitting criterion for all splits for every covariate retaining only the single 
best split for each covariate. The original SIDES method used a splitting criterion in a single 
trial setting that tested the difference in the treatment effect precision between two child nodes 
with the aim of identifying the subgroup or child node with the most significant treatment 
effect. This objective is different to what we require the method to do; we require the method 
to test the differential treatment effect between the two groups in an IPD meta-analyses setting. 
For this reason, a new splitting criterion was proposed which uses the same fixed effect model 
described earlier for the IPD-IT method but instead uses the p-value of the interaction effect 
where a smaller p-value is indicative of a larger interaction effect. If a covariate has more than 
two distinct cut-points, the p-value computed using the splitting criterion is adjusted to 
overcome variable selection bias; a well-known issue with recursive partitioning based 
methods where covariates with a larger number of splits have a greater probability of being 
chosen as the splitting variable.144, 145 The method adjusts the p-value by applying a Sidak-
based multiplicity adjustment as described in the original SIDES method paper.96  
Continuation Criterion 
In step 2 of the IPD-SIDES iteration algorithm, a child node with a large positive treatment 
effect is retained only if it satisfies the continuation criterion. The continuation criterion is 
given by equation (2): 
𝑝𝑐 ≤ 𝛾 ∙ 𝑝𝑝 (2) 
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where 𝑝𝑐 is the treatment effect p-value of the child node, 𝑝𝑝 is the treatment effect p-value of 
the parent node and 𝛾 is the relative improvement parameter that controls the complexity of 
the tree. Prior to running the method, the user must specify the maximum number of covariates, 
L, that defines a subgroup; where the recommended value is three. This means that any 
identified subgroups will at most be defined by L covariates; hence the tree will have at most 
L levels. Each level of the tree has a relative improvement parameter value that ranges from 0 
to 1 where a smaller value makes the procedure more selective. The values for each level can 
be either user specified or optimally selected using a cross-validation procedure as described 
by the authors.96 Hence, once the relative improvement parameter values are in place, a child 
node is only retained provided its treatment effect p-value is less than or equal to the right hand 
side of the continuation criterion.  
2. Selecting the final candidate subgroups 
The first step of the IPD-SIDES procedure grows the tree and produces a list of candidate 
subgroups. Many of these subgroups may be spurious findings and thus need to be removed. 
To control for this, the authors of the original SIDES method proposed a resampling based 
procedure that computes an adjusted treatment effect p-value for each of the identified 
candidate subgroups to control the overall type I error in the weak sense.96 Comparing the 
unadjusted p-value to the adjusted p-value gives a good indication as to whether the identified 
subgroups are spurious or not. 
7.4 ANALYSES 
Two sets of analyses were performed using the repository data. In the first analyses (Analysis 
1) we grouped all of the interventions together as being one arm and grouped the non-active 
usual care and sham control together as being the comparator arm. We then sought to identify 
subgroups within these data by applying the IPD-IT and IPD-SIDES methods. These analyses 
were performed for all of the following absolute change from baseline to short-term follow-up 
outcome variables: average pain, EQ-5D, Hannover functional ability questionnaire for 
measuring back-pain related functional limitations (FFbHR), mental component scale of SF-
12/36 (MCS), physical component scale of SF-12/36 (PCS) and Roland Morris Disability 
Questionnaire (RMDQ). 
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In addition to the above outcome measures, we also looked at the quality adjusted life years 
(QALYs) health economics outcome. This analysis provides proof of principal that the 
analytical techniques are robust when used with real data rather than simply in the simulated 
datasets in which we originally developed our techniques.141 
In the second set of analyses (Analysis 2), the following interventions against the non-active 
usual care comparisons were investigated for subgroups: 
1. Active physical against non-active usual care 
2. Passive physical against non-active usual care 
3. Psychological against non-active usual care 
4. Sham against non-active usual care 
Both the IPD-IT and IPD-SIDES methods were applied to the above for each of the short-term 
outcomes common to all trials. For example, active physical against non-active usual care may 
consist of three trials with RMDQ, MCS and PCS as common short-term outcome measures. 
Thus the analyses would be applied to only these three outcome measures. 
Prior to performing each of the analyses, any observations with missing data were removed 
from the dataset. A mixed-effects model was then applied to adjust for the clustering inherent 
within the data and thus obtain an estimate of the overall treatment effect. In both sets of 
analyses, the potential moderator variables identified from the univariate analyses as well as 
those moderators identified in systematic review 1 (Chapter 2) were considered. From this set 
of moderator variables, only the variables that were most common across all trials were entered 
into each of the analyses in order to retain as much data as possible.  
The IPD-IT and IPD-SIDES methods both require certain parameters to be pre-specified to aid 
or control the methods when applied to the data. For both methods, the minimum number of 
participants in any given node of a tree was set to r = 1/20 of the population being analysed. 
The maximum number of splits for the fully grown IPD-IT tree was set as 15. For the IPD-
SIDES methods, the maximum number of levels i.e. the maximum number of covariates 
defining any particular subgroup, was set as being the number of potential moderators being 
considered. Moreover, the maximum number of best splits to consider for each node during the 
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IPD-SIDES procedure was set to three with a restriction of p ≤ 0.20 placed on the splitting 
criterion. This is the same constraint we set in the identification of promising moderator. 
Before applying the IPD-SIDES method, we performed a grid search to obtain an optimal 
sequence of complexity control parameters for the first three levels of the tree. The grid search 
considered all permutations from 0.2 to one in steps of 0.2 at the first level and then from zero 
to one in steps of 0.2 at levels two and three. When validating or selecting the final subgroups, 
we used 500 bootstraps for the IPD-IT procedure and used 1,000 repetitions of the resampling 
procedure for the IPD-SIDES procedure. Any identified subgroups from the analyses were then 
summarised using the treatment effect and 95% confidence interval (CI). All analyses were 
performed using R version 3.0.3. 
7.5 RESULTS 
7.5.1 ANALYSIS 1 
The intervention (active physical, passive physical or psychological given either singly or as 
combined regimen with the other interventions) against control/placebo data were searched for 
subgroups for the first set of analyses. Table 18 provides a summary of the trials included and 
the variables used to search for subgroups for each short-term outcome measure. Number 
included from each trial is dependent on the number of complete cases available for each 
analysis. 
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Table 18 Summary of the included trials and variables used for each short-term outcome measure in analysis –1. 
Outcomea Trials Variables 
Average Pain 
m = 2; n = 1377 
UK BEAMb (n = 910), BeSTc (n = 467) 
Age, sex, anxiety, fear avoidance, MCS, PCS, average pain and 
RMDQ at baseline 
EQ-5D 
m = 2; n = 1339 
UK BEAM (n = 883), BeST (n = 456) 
Age , sex, anxiety, fear avoidance, MCS, PCS RMDQ and average 
pain at baseline 
FFbHRd 
m = 3; n = 3718 
Brinkhause (n = 284), Haakef (n = 1110), Wittg (n = 2324) 
Age, sex, PCS, FFbHR and MCS at baseline 
MCSh 
m = 3; n = 3630 
Brinkhaus (n = 281), Haake (n = 1110), Witt (n = 2239) 
Age, sex, FFbHR, MCS and PCS at baseline 
PCSi 
m = 6; n = 5208 
UK BEAM (n = 893), BeST (n = 470), Brinkhaus (n = 281), Haake 
(n = 1110), Witt (n = 2248), YACBACj (n = 206) 
Age, sex, MCS and PCS at baseline 
RMDQk 
m = 7; n = 2564 
UK BEAM (n = 951), BeST (n = 488), Hancockl (n = 235), Pengelm (n = 236), 
Smeetsn (n = 212), VK BIAo (n = 229), VK SC2p (n = 213) 
Age, sex, fear avoidance and RMDQ at baseline 
QALYq 
m = 4; n = 1514 
UK BEAM (n = 728), BeST (n = 468), Smeets (n = 151), YorkBPr (n = 167) 
Age and RMDQ at baseline 
a Change from baseline to short-term follow-up (between two and three months post-randomisation or entry to the trial); b UK BEAM (Exercise, spinal manipulation, combined, best care); c BeST (Cognitive behavioural 
approach, control); d FFbHR, Hannover functional ability questionnaire for measuring back-pain related functional limitations; e Brinkhaus (Acupuncture, minimal acupuncture, waiting list); f Haake (Verum acupuncture, 
sham acupuncture, conventional therapy); g Witt (Acupuncture, control); h MCS, mental component scale of SF-12/36; i PCS, physical component scale of SF-12/36; j YACBAC (Traditional acupuncture, usual care); 
k RMDQ, Roland Morris disability questionnaire; l Hancock (Spinal manipulation, placebo spinal manipulation, advice); m Pengel (Exercise, sham exercise, advice, sham advice); n Smeets (Active physical therapy, 
cognitive behavioural treatment, combined treatment, waiting list); o Von Korff BIA (Brief individualised programme, usual care); Von Korff SC2p (Self-care, usual care); q QALY, quality adjusted life year which was 
measured over one year of follow-up using the area under the curve method; r York BP (Exercise, control) 
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7.5.1.1 Subgroups identified by the IPD-IT method 
The IPD-IT method did not identify any subgroups that moderate treatment effect when 
comparing any intervention vs usual care control/sham. 
7.5.1.2 Subgroups identified by the IPD-SIDES method 
The application of the IPD-SIDES method for the first set of analyses found candidate 
subgroups for three of the short-term outcome measures when comparing intervention vs 
control/placebo (see Table 19); namely, short-term FFbHR (Figure 21), SF-12/36 MCS 
(Figure 22) and SF-12/36 PCS (Figure 23). No candidate subgroups were identified for the 
average pain, EQ-5D and RMDQ short-term outcomes as well as the QALY health outcome 
measure. 
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Table 19 Candidate subgroups identified by the IPD-SIDES method for the intervention vs control/placebo comparisona 
Subgroups n 
Treatment effect (95% 
confidence interval, CI) Interaction effect Unadjusted p-value 
Outcome: short-term FFbHRb         
Overall treatment effect (95% CI): 8.93 (7.81, 10.05)         
Candidate 1         
FFbHR ≤ 54.2 1,709 11.31 (9.38, 13.23) 4.69 < 0.001 
FFbHR > 54.2 2,009 6.62 (5.46, 7.78)     
        
Candidate 2       
FFbHR ≤ 54.2 AND Age ≤ 60 1,043 13.17 (10.56, 15.77) 5.03 0.019 
FFbHR ≤ 54.2 AND Age > 60 666 8.14 (5.47, 10.80)     
        
Candidate 3       
FFbHR ≤ 54.2 AND Age ≤ 66 1,367 12.26 (10.06, 14.46) 5.14 0.043 
FFbHR ≤ 54.2 AND Age > 66 342 7.12 (3.42, 10.82)     
        
Outcome: short-term MCSc       
Overall treatment effect (95% CI): 2.61 (1.92, 3.29)       
Candidate 1       
MCS ≤ 54.4 2,541 3.46 (2.62, 4.30) 2.62 0.002 
MCS > 54.4 1,089 0.84 (0.01, 1.67)     
        
  186 
Subgroups n 
Treatment effect (95% 
confidence interval, CI) Interaction effect Unadjusted p-value 
Outcome: short-term PCSd       
Overall treatment effect (95% CI): 3.48 (3.01, 3.96)       
Candidate 1       
MCS > 50.9 2,082 4.09 (3.32, 4.87) 0.97 0.033 
MCS ≤ 50.9 3,126 3.12 (2.54, 3.71)     
        
Candidate 2       
MCS > 50.9 AND Sex = Female 1,125 4.72 (3.67, 5.78) 1.38 0.097 
MCS > 50.9 AND Sex = Male 957 3.34 (2.20, 4.48)     
        
Candidate 3       
MCS > 50.9 & PCS ≤ 43.2 1,666 4.62 (3.75, 5.49) 2.61 0.020 
MCS > 50.9 & PCS > 43.2 416 2.01 (0.69, 3.33)     
        
Candidate 4       
MCS > 50.9 & PCS ≤ 40.0 1,457 4.89 (3.96, 5.82) 2.61 0.007 
MCS > 50.9 & PCS > 40.0 625 2.28 (1.12, 3.44)     
a The first row of each candidate subgroup is the selected subgroup with enhanced treatment effect; b FFbHR, Hannover functional ability questionnaire for 
measuring back-pain related functional limitations ranging from 0-100 where a lower score represents greater disability; c MCS, mental component scale of 
SF-12/36 ranging from 0-100 where a lower score represents worse mental functioning; d PCS, physical component scale of SF-12/36 ranging from 0-100 
where a lower score represents worse physical functioning.  
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7.5.1.2.1 Short-term Hannover functional ability questionnaire for measuring back-pain 
related functional limitations (FFbHR) outcome 
For the short-term FFbHR outcome, five variables were included in the IPD-SIDES analyses. 
The overall treatment effect for the FFbHR outcome was 8.93 (95% confidence interval, CI, 
7.81 to 10.05). Three candidate subgroups with enhanced treatment effect were identified by 
the IPD-SIDES procedure. Those with baseline FFbHR ≤ 54.2 had a treatment effect of 11.31 
(95% CI, 9.38 to 13.23), those with baseline FFbHR ≤ 54.2 and age ≤ 60 had a treatment effect 
of 13.17 (95% CI, 10.56 to 15.77) and those with FFbHR ≤ 54.2 and age ≤ 66 had a treatment 
effect of 12.26 (95% CI, 10.06 to 14.46). 
 Those with more disability at baseline and who are younger are likely to gain a 
greater benefit on disability. 
7.5.1.2.2 Short-term mental component scale of SF-12/36 (MCS) outcome 
For the short-term MCS outcome, five variables were included in the IPD-SIDES analyses. 
The overall treatment effect for the MCS outcome was 2.61 (95% CI, 1.92 to 3.29). Only one 
candidate subgroup was identified for MCS outcome. Those with baseline MCS ≤ 54.4 had a 
treatment effect of 3.46 (95% CI, 2.62 to 4.30).  
 Those with more psychological distress at baseline will get better outcomes on 
psychological distress. 
7.5.1.2.3 Short-term physical component scale of SF-12/36 (PCS) outcome 
For the short-term PCS outcome, four variables were included in the analyses and four 
candidate subgroups were identified. The overall treatment effect for the PCS outcome was 
3.48 (95% CI, 3.01 to 3.96). Those with baseline MCS > 50.9 had a treatment effect of 4.09 
(95% CI, 3.32 to 4.87), those with baseline MCS > 50.9 and who are female had a treatment 
effect of 4.72 (95% CI, 3.67 to 5.78), those with baseline MCS > 50.9 and baseline PCS ≤ 43.2 
had a treatment effect of 4.62 (95% CI, 3.75 to 5.49) and finally those with baseline MCS > 
50.9 and baseline PCS ≤ 40.0 had a treatment effect of 4.89 (95% CI, 3.96 to 5.82).  
 Those with less psychological distress and worse physical status will get better 
outcomes on physical status. 
 Women with low levels of psychological distress will get better outcomes on 
physical status. 
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These analyses do not consider any differences between different treatment approaches.  
 
 
Figure 21 Candidate subgroups identified (shaded blue) by the IPD-SIDES method when 
applied to change from baseline to short-term Hannover functional ability questionnaire 
for measuring back-pain related functional limitations (FFbHR – range 0-100; lower 
score implies greater disability) outcome for the intervention against control/placebo 
comparison. Results presented as treatment effect (95% confidence interval) in each 
node. 
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Figure 22 Candidate subgroup identified (shaded blue) by the IPD-SIDES method when 
applied to change from baseline to short-term SF-12/36 MCS outcome (range 0-100; 
lower score implies worse mental functioning) for the intervention against 
control/placebo comparison. Results presented as treatment effect (95% confidence 
interval) in each node. 
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Figure 23 Candidate subgroups identified (shaded blue) by the IPD-SIDES method when applied to change from baseline to short-term 
SF-12/36 PCS outcome (range 0-100; lower score implies worse physical functioning) for the intervention against control/placebo 
comparison. Results presented as treatment effect (95% confidence interval) in each node. 
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7.5.2 ANALYSIS 2: PAIRWISE COMPARISONS 
Each of the subgrouped interventions (active physical, passive physical or psychological) 
against non-active usual care data were searched for subgroups for the second set of analyses. 
Table 20 provides a summary of the trials included and the variables used to search for 
subgroups for each short-term outcome measure analysed for the different comparisons.  
7.5.2.1 Subgroups identified by the IPD-IT method 
The IPD-IT method did not identify any subgroups that moderate treatment effect when 
comparing any of the subgrouped interventions against non-active usual care. 
7.5.2.2 Subgroups identified by the IPD-SIDES method 
The application of the IPD-SIDES method for the second set of analyses found candidate 
subgroups for one or more short-term outcome measures for the passive physical against non-
active usual care (see Table 21), psychological against non-active usual care (see Table 22) and 
sham against non-active usual care (see Table 23). No candidate subgroups were identified for 
the active physical against non-active usual care comparison.  
7.5.2.2.1 Passive physical vs non-active usual care results 
Short-term FFbHR outcome 
The overall treatment effect for the FFbHR short-term outcome was 9.95 (95% CI, 8.80 to 
11.11). Four candidate subgroups were identified for the FFbHR short-term outcome. Those 
with baseline FFbHR ≤ 54.2 had a treatment effect of 12.86 (95% CI, 10.81 to 14.91), those 
with baseline FFbHR ≤ 54.2 and age ≤ 57 had a treatment effect of 15.86 (95% CI, 12.80 to 
18.92), those with FFbHR ≤ 54.2 and age ≤ 53 had a treatment effect of 16.67 (95% CI, 13.16 
to 20.18) and those with baseline FFbHR ≤ 41.7 had a treatment effect of 15.03 (95% CI, 12.06 
to 18.01).  
 Overall, those with more disability and who are younger are likely to gain a greater 
benefit on disability from passive physical treatments 
Short-term SF-12/36 MCS outcome 
The overall treatment effect for the SF-12/36 MCS short-term outcome was 2.96 (95% CI, 2.31 
to 3.61). Three candidate subgroups were identified for the MCS short-term outcome. Those 
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with baseline MCS ≤ 54.3 had a treatment effect of 3.76 (95% CI, 2.97 to 4.55), those with 
MCS ≤ 54.3 and PCS ≤ 43.9 had a treatment effect of 4.27 (95% CI, 3.39 to 5.15) and those 
with MCS ≤ 51.3 had a treatment effect of 3.83 (95% CI, 2.96 to 4.70).  
 These results suggest that those with more psychological distress and worse 
physical status at baseline will get better outcomes on psychological distress from 
passive physical treatments 
Short-term SF-12/36 PCS outcome 
The overall treatment effect for the SF-12/36 PCS short-term outcome was 4.10 (95% CI, 3.56 
to 4.63). Nine candidate subgroups were identified for the PCS short-term outcome. Those with 
baseline PCS ≤ 43.6 had a treatment effect of 4.39 (95% CI, 3.78 to 4.99), those with baseline 
PCS ≤ 43.6 and age ≤ 44 had a treatment effect of 5.35 (95% CI, 4.21 to 6.49), those with 
baseline PCS ≤ 37.8 had a treatment effect of 4.61 (95% CI, 3.90 to 5.32), those with PCS ≤ 
37.8 and age ≤ 62 had a treatment effect of 5.08 (95% CI, 4.21 to 5.94), those with baseline 
PCS ≤ 37.8 and MCS > 44.0 had a treatment effect of 5.48 (95% CI, 4.55 to 6.41), those with 
PCS ≤ 37.8 and MCS > 51.8 had a treatment effect of 5.77 (95% CI, 4.63 to 6.91), those with 
PCS ≤ 37.8, MCS > 51.8 and are female had a treatment effect of 6.64 (95% CI, 5.12 to 8.16), 
those with PCS ≤ 40.3 had a treatment effect of 4.51 (95% CI, 3.85 to 5.16) and finally those 
with PCS ≤ 40.3 and MCS > 51.5 had a treatment effect of 5.43 (95% CI, 4.37 to 6.48). Broadly 
speaking, these results suggest that: 
 younger patients with worse physical status at baseline will get better outcomes on 
physical status from passive physical treatments 
 those with worse physical status but less psychological distress at baseline will get 
better outcomes on physical status from passive physical treatments 
 females with worse physical status and less psychological distress at baseline will 
get better outcomes on physical status from passive physical treatments 
7.5.2.2.2 Psychological vs non-active usual care results 
Short-term RMDQ outcome 
The overall treatment effect for the RMDQ short-term outcome was 1.40 (95% CI, 0.89 to 
1.91). One candidate subgroup was identified for the RMDQ short-term outcome. Those with 
baseline RMDQ > 4 had a treatment effect of 1.72 (95% CI, 1.12 to 2.31).  
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 This suggests that those with worse disability at baseline gain more benefit from 
psychological treatment on disability when compared to usual care control 
7.5.2.2.3 Sham vs non-active usual care results 
Short-term SF-12/36 MCS outcome 
Two trials were included in the analyses and the sham treatment in both was sham acupuncture. 
The overall treatment effect for the MCS short-term outcome was 2.59 (95% CI, 1.13 to 4.04). 
Two candidate subgroups were identified for the MCS short-term outcome. Those with age ≤ 
65 at baseline had a treatment effect of 3.42 (95% CI, 1.80 to 5.04) and those with baseline 
PCS ≤ 42.0 had a treatment effect of 3.10 (95% CI, 1.55 to 4.65). No candidate subgroups were 
identified for the FFbHR and PCS short-term outcomes.  
 This suggest that younger people and those with worse physical status at baseline 
have a greater benefit from sham treatment on psychological distress when 
compared to a usual care control  
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Table 20 Summary of the trials included and variables used for each change from baseline to short-term outcome measure and the QALY 
health outcome measure analysed for the different comparisons 
 Short-term outcome measures 
 FFbHRa RMDQb MCSc PCSd QALYe 
Comparison Trials* Variables Trials* Variables Trials* Variables Trials* Variables Trials* Variables 
Active vs non-
active usual 
care 
- - 
m = 2; 
n = 576 
UK BEAM 
(n = 421), 
Smeets 
(n = 155) 
Fear 
avoidance, 
age, sex, 
RMDQ, 
average pain 
today, 
EQ5D, 
HADS 
anxiety, 
HADS 
depression 
- - - - 
m = 2; 
n = 496 
UK BEAM 
(n = 329), 
YorkBP 
(n = 167) 
Age, RMDQ 
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 Short-term outcome measures 
 FFbHRa RMDQb MCSc PCSd QALYe 
Comparison Trials* Variables Trials* Variables Trials* Variables Trials* Variables Trials* Variables 
Passive vs 
non-active 
usual care 
m = 3;  
n = 3272 
Brinkhaus 
(n = 214), 
Haake 
(n = 734), 
Witt 
(n = 2324) 
Age, PCS, 
FFbHR, sex, 
MCS 
- - 
m = 5; 
n = 3879 
UK BEAM 
(n = 479), 
Brinkhaus 
(n = 212), 
Haake 
(n = 734), 
Witt 
(n = 2248), 
YACBAC 
(n = 206) 
MCS, age, 
sex, PCS 
m = 5; 
n = 3879 
UK BEAM 
(n = 479), 
Brinkhaus 
(n = 212), 
Haake 
(n = 734), 
Witt 
(n = 2248), 
YACBAC 
(n = 206) 
Age, MCS, 
PCS, sex 
m = 3; 
n = 1209 
UK BEAM 
(n = 379), 
Haake 
(n = 716), 
YACBAC 
(n=114) 
Age, PCS 
Psychological 
vs non-active 
usual care 
- - 
m = 3; 
n = 928 
BeST 
(n = 487), 
VKBIA 
(n = 229), 
VKSC2 
(n = 212) 
Fear 
avoidance, 
age, sex, 
RMDQ, 
average pain 
today 
- - - - - - 
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 Short-term outcome measures 
 FFbHRa RMDQb MCSc PCSd QALYe 
Comparison Trials* Variables Trials* Variables Trials* Variables Trials* Variables Trials* Variables 
Sham vs non-
active usual 
care 
m = 2; 
n = 881 
Brinkhaus 
(n = 144), 
Haake 
(n = 737) 
Age, PCS, 
FFbHR, sex, 
MCS 
- - 
m = 2; 
n = 879 
Brinkhaus 
(n = 142), 
Haake 
(n = 737) 
MCS, age, 
sex, PCS 
m = 2; 
n = 879 
Brinkhaus 
(n = 142), 
Haake 
(n = 737) 
Age, MCS, 
PCS, sex 
- - 
a FFbHR, Hannover functional ability questionnaire for measuring back-pain related functional limitations; b RMDQ, Roland Morris disability 
questionnaire; c MCS, mental component scale; d PCS, physical component scale; e QALY, quality adjusted life years;  
* UK BEAM (Exercise, spinal manipulation, combined, best care); Smeets (Active physical therapy, cognitive behavioural treatment, combined 
treatment, waiting list); York BP (Exercise, control); Brinkhaus (Acupuncture, minimal acupuncture, waiting list); Haake (Verum acupuncture, sham 
acupuncture, conventional therapy); Witt (Acupuncture, control); YACBAC (Traditional acupuncture, usual care); BeST (Cognitive behavioural 
approach, control); Von Korff BIA (Brief individualised programme, usual care); Von Korff SC2 (Self-care, usual care); 
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Table 21 Candidate subgroups identified by the IPD-SIDES method for the passive 
physical vs non-active usual care comparison.a, b 
Subgroups n 
Treatment effect 
(95% confidence 
interval, CI) 
Interaction 
effect 
Unadjusted 
p-value 
Outcome: short-term FFbHR     
Overall treatment effect (95% 
CI): 9.95 (8.80, 11.11)     
Candidate 1     
FFbHR ≤ 54.2 1,424 12.86 (10.81, 14.91) 5.45 <0.001 
FFbHR > 54.2 1,848 7.41 (6.23, 8.59)   
     
Candidate 2     
FFbHR ≤ 54.2 AND Age ≤ 57 731 15.86 (12.80, 18.92) 6.63 0.002 
FFbHR ≤ 54.2 AND Age > 57 693 9.23 (6.64, 11.82)   
     
Candidate 3     
FFbHR ≤ 54.2 AND Age ≤ 53 571 16.67 (13.16, 20.18) 6.85 0.001 
FFbHR ≤ 54.2 AND Age > 53 853 9.83 (7.43, 12.22)   
     
Candidate 4     
FFbHR ≤ 41.7 792 15.03 (12.06, 18.01) 6.71 <0.001 
FFbHR > 41.7 2,480 8.32 (7.19, 9.45)   
     
Outcome: short-term MCS     
Overall treatment effect (95% 
CI): 2.96 (2.31, 3.61)     
Candidate 1     
MCS ≤ 54.3 2,714 3.76 (2.97, 4.55) 2.82 <0.001 
MCS > 54.3 1,165 0.93 (0.10, 1.76)   
     
Candidate 2     
MCS ≤ 54.3 AND PCS ≤ 43.9 2,171 4.27 (3.39, 5.15) 2.43 0.019 
MCS ≤ 54.3 AND PCS > 43.9 543 1.85 (0.11, 3.59)   
     
Candidate 3     
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Subgroups n 
Treatment effect 
(95% confidence 
interval, CI) 
Interaction 
effect 
Unadjusted 
p-value 
MCS ≤ 51.3 2,327 3.83 (2.96, 4.70) 2.57 <0.001 
MCS > 51.3 1,552 1.26 (0.52, 1.99)   
     
Outcome: short-term PCS     
Overall treatment effect (95% 
CI): 4.10 (3.56, 4.63)     
Candidate 1     
PCS ≤ 43.6 3,103 4.39 (3.78, 4.99) 1.61 0.013 
PCS > 43.6 776 2.77 (1.87, 3.67)   
     
Candidate 2     
PCS ≤ 43.6 AND Age ≤ 44 942 5.35 (4.21, 6.49) 1.45 0.040 
PCS ≤ 43.6 AND Age > 44 2,161 3.90 (3.20, 4.60)   
     
Candidate 3     
PCS ≤ 37.8 2,326 4.61 (3.90, 5.32) 1.23 0.025 
PCS > 37.8 1,553 3.37 (2.66, 4.09)   
     
Candidate 4     
PCS ≤ 37.8 AND Age ≤ 62 1,682 5.08 (4.21, 5.94) 1.97 0.016 
PCS ≤ 37.8 AND Age > 62 644 3.11 (1.94, 4.28)   
     
Candidate 5     
PCS ≤ 37.8 AND MCS > 44.0 1,396 5.48 (4.55, 6.41) 1.80 0.011 
PCS ≤ 37.8 AND MCS ≤ 44.0 930 3.68 (2.64, 4.71)   
     
Candidate 6     
PCS ≤ 37.8 AND MCS > 51.8 932 5.77 (4.63, 6.91) 1.78 0.012 
PCS ≤ 37.8 AND MCS ≤ 51.8 1,394 3.99 (3.11, 4.87)   
     
Candidate 7     
PCS ≤ 37.8 AND MCS > 51.8 
AND Sex = Female 520 6.64 (5.12, 8.16) 1.73 0.167 
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Subgroups n 
Treatment effect 
(95% confidence 
interval, CI) 
Interaction 
effect 
Unadjusted 
p-value 
PCS ≤ 37.8 AND MCS > 51.8 
AND Sex = Male 412 4.91 (3.17, 6.65)   
     
Candidate 8     
PCS ≤ 40.3 2,715 4.51 (3.85, 5.16) 1.61 0.006 
PCS > 40.3 1,164 2.90 (2.11, 3.68)   
     
Candidate 9     
PCS ≤ 40.3 AND MCS > 51.5 1,086 5.43 (4.37, 6.48) 1.38 0.042 
PCS ≤ 40.3 AND MCS ≤ 51.5 1,629 4.05 (3.24, 4.85)   
a The baseline FFbHR score ranges from 0-100 where a lower score represents greater 
disability. The baseline MCS and PCS scores range from 0-100 where a lower score 
represents worse mental and physical functioning; b The first row of each candidate 
subgroup is the selected subgroup with enhanced treatment effect. 
Table 22 Candidate subgroups identified by the IPD-SIDES method for the psychological 
vs non-active usual care comparison.a, b 
Subgroups n 
Treatment effect 
(95% CI) 
Interaction 
effect 
Unadjusted 
p-value 
Outcome: short-term RMDQ     
Overall treatment effect (95% 
CI): 1.40 (0.89, 1.91)     
Candidate 1     
RMDQ > 4 697 1.72 (1.12, 2.31) 1.07 0.038 
RMDQ ≤ 4 231 0.65 (-0.11, 1.40)   
a The baseline RMDQ score ranges from 0-24 where a higher score represents greater 
disability; b, The first row of each candidate subgroup is the selected subgroup with 
enhanced treatment effect 
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Table 23 Candidate subgroups identified by the IPD-SIDES method for the sham vs non-
active usual care comparison.a, b 
Subgroups n 
Treatment effect 
(95% CI) 
Interaction 
effect 
Unadjusted 
p-value 
Outcome: short-term MCS     
Overall treatment effect (95% 
CI): 2.59 (1.13, 4.04)     
Candidate 1     
Age ≤ 65 705 3.42 (1.80, 5.04) 4.32 0.019 
Age > 65 174 -0.90 (-4.16, 2.35)   
     
Candidate 2     
PCS ≤ 42.0 791 3.10 (1.55, 4.65) 4.99 0.043 
PCS > 42.0 88 -1.89 (-6.07, 2.28)   
a The baseline PCS score ranges from 0-100 where a lower score represents worse physical 
functioning; b The first row of each candidate subgroup is the selected subgroup with 
enhanced treatment effect 
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CHAPTER 8 – METHODOLOGY AND STATISTICAL 
DEVELOPMENTS 2: SUBGROUP IDENTIFICATION USING AN 
ADAPTIVE REFINEMENT BY DIRECTED PEELING (ARDP) 
ALGORITHM 
8.1 BACKGROUND 
The adaptive risk group refinement introduced by LeBlanc et al. aims to identify subgroups of 
participants with poor prognosis whereby the subgroups are defined by cut-offs for the 
covariates resulting in box-shaped subgroups which are easy to interpret.146 The approach is 
based on a so-called ‘adaptive refinement by directed peeling’ (ARDP) algorithm. Starting with 
the whole data set the algorithms peels off fractions of the data in a series of locally optimal 
steps optimising a prognostic indicator (for example, median survival in the paper by LeBlanc 
et al..146 We aim to identify subgroups of participants that benefit in particular from a specific 
treatment in that they respond particularly well to the treatment. The approach to subgroup 
identification presented in this chapter builds on the work by LeBlanc et al. and extends it in 
two ways: (1) the criterion for optimisation is now based on the interaction effects between 
treatment and subgroup; and (2) data from multiple trials can now be analysed allowing 
between-trial heterogeneity in the treatment-by-subgroup interactions thereby generalising the 
ARDP algorithm from a single study setting to individual participant data meta-analysis setting. 
With regard to the latter this is similar to the interaction tree (IT) and subgroup identification 
based on a differential effect search (SIDES) methods (see Chapter 7). In the following we 
describe the modified ARDP algorithm for individual participant data meta-analysis. 
8.2 ADAPTIVE REFINEMENT BY DIRECTED PEELING IN IPD META-ANALYSIS 
(ARDP-MA) 
The ARDP-MA algorithm to construct a region that predicts the best or worst response to 
treatment consists of the following steps: 
1. In order to determine the covariates to be included and their direction of peeling run 
regression analyses on the entire data set to investigate interactions of covariates with 
treatment. For the identified moderators the sign of the interaction effect determines the 
direction of peeling. If larger values of a covariate lead to larger treatment effects, then 
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peel off the cases with a smaller value of this covariate. Correspondingly if smaller 
values of the covariate lead to larger treatment effects then peel off the larger values of 
the covariate.  
2. Start with a ‘subgroup’ 𝐵0 that includes all observations, n. 
3. The proportion of data to be removed in one step is denoted by  and the minimum 
number of observations to be peeled off is denoted by 𝑛𝑚𝑖𝑛. For each variable we move 
the threshold so that max⁡(𝛼𝑛, 𝑛𝑚𝑖𝑛) observations are removed; the resulting subgroups 
for the L covariates we denote by 𝐵𝑗
𝑚, 𝑗 = 1,… , 𝐿. For each subgroup 𝐵𝑗
𝑚 calculate the 
treatment-by-subgroup interaction effect and select the 𝐵𝑗
𝑚 which gives the largest 
improvement on the interaction effect in comparison to the previous iteration 
standardised by change in subgroup size. In the setting of data from multiple trials the 
interaction effects estimated from the individual trials are combined in a random-effects 
meta-analysis (two-stage procedure); alternatively an equivalent hierarchical model can 
be fitted (one-step procedure). 
4. The selected subgroup is then called 𝐵𝑚+1. 
5. Estimate the treatment effects for the outcome of interest for subgroup 𝐵𝑚+1. 
6. Repeat steps 3 to 5 until the size of the remaining region is not smaller than r. 
Figure 24 is a schematic illustrating the ARDP algorithm for the identification of subgroups of 
treatment responders. Expecting a large number of covariates to be included in the analyses we 
developed this algorithm earlier on in the project. However, it turned out that situations with a 
small number of covariates were most relevant for the data sets to be analysed. Restricting the 
number of covariates to four we could do far more extensive searches by considering all 
possible combinations of boxes described in the ARDP algorithm above. This allowed us to 
interrogate the data sets more thoroughly. 
Note that this algorithm can be applied to various kinds of endpoints as we only assume that 
appropriate regression models can be fitted modelling the outcome. For instance, Gaussian 
linear models could be applied to continuous outcomes, logistic regression to binomial 
outcomes, Cox proportional hazard models to time-to-event data. No distributional assumption 
regarding the covariates is required, but they should be ordinal and have a sufficient number 
of possible outcomes so that the peeling in several steps makes sense. If a covariate is not 
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ordinal, then an order could be imposed on it by ordering the outcomes by the regression 
coefficients estimated in Step 1 of the algorithm.146 
 
Figure 24 Schematic of the ARDP algorithm to identify subgroups of treatment 
responders. Here the subgroups are defined by thresholds for the two covariates A and 
B. 
8.3 ANALYSES 
The minimum sample size of the subpopulation was defined as r = 0.10 of the population 
analysed. The appeal of the ARDP-MA method is the ability to remove a small proportion of 
participants at each iteration. Categorical covariates that delineate participants into three or 
fewer categories would cause the ARDP-MA method to remove a large proportion of 
participants, an unappealing feature. As all the categorical covariates identified in the analyses 
of covariance have three or fewer categories, none of them was considered in the ARDP-MA 
analyses. 
Similar to analyses seen in Section 7.4, two sets of analyses were performed. The first one was 
to confirm proof of concept where all interventions (active physical, passive physical and 
psychological delivered singly or in combination with the others) were grouped together as 
being one arm and the non-active usual care grouped with the sham as a control/placebo arm. 
Analyses were performed for these measurements: average pain, EQ-5D, Hannover functional 
ability questionnaire for measuring back-pain related functional limitations (FFbHR), mental 
component scale of SF-12/36 (MCS), physical component scale of SF-12/36 (PCS) and Roland 
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Morris Disability Questionnaire (RMDQ). The outcome was the absolute change from baseline 
to short-term follow-up. 
In the second set of analyses, similarly, two treatments are compared and the pairwise 
comparisons investigated were: active physical against non-active usual care, passive physical 
against non-active usual care, psychological against non-active usual care and sham against 
non-active usual care. 
8.4 RESULTS 
We programmed the ARDP-MA method to do a full search but this limits the number of 
covariates. As the number of covariates increased, the computational time and resources 
needed to store the data increased exponentially causing a massive strain on the system server. 
Therefore, up to four covariates when necessary were included in the analyses. 
8.4.1 ANALYSIS 1 OVERALL COMPARISON TREATMENT VS. CONTROL 
Table 24 shows the summary of the trials and continuous variables used in the ARDP-MA 
algorithm to construct a region that predicts the best or worst response for each of the short-
term outcome measures.  
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Table 24 Summary of included trials and variables considered to construct a region that 
predicts the best or worst response to treatmenta. 
Outcomeb Trials Variables 
Average pain 
m = 3; n = 2534 
UK BEAM (n=926), BeST (n = 498), 
Haake (n = 1,110) 
Age, average pain, PCS and 
MCS at baseline 
EQ-5D 
m = 2; n = 1,365 
UK BEAM (n = 890), BeST (n = 475) 
RMDQ, average pain, PCS 
and MCS at baseline 
FFbHRc 
m = 3; n = 3718 
Brinkhaus (n=284), Haake (n = 1,110), 
Witt (n = 2,324) 
Age, FFbHR, PCS and MCS 
at baseline 
MCSd 
m = 3; n = 3,630 
Brinkhaus (n = 281), Haake (n = 1,110), 
Witt (n=2,239) 
Age, FFbHR, PCS and MCS 
at baseline 
PCSe 
m = 6; n = 5,208 
UK BEAM (n = 893), BeST (n = 470), 
Brinkhaus (n = 281), Haake (n = 1,110), 
Witt (n = 2,248), YACBAC (n = 206) 
Age, PCS and MCS at 
baseline 
RMDQf 
m = 8; n = 2,675 
UK BEAM (n=995), BeST (n=514), 
Hancock (n = 235), Kennedy (n = 40), 
Pengel (n = 236), Smeets (n = 212), 
VKBIA (n = 230), VKSC2 (n = 213) 
Age and RMDQ at baseline 
a Any active intervention (active physical, passive physical or psychological delivered either 
singly or in combination with other intervention) against control/placebo which is either GP 
usual care or sham; b Change from baseline to short-term follow-up (between two and three 
months post-randomisation or entry to the trial); c FFbHR, Hannover functional ability 
questionnaire for measuring back-pain related functional limitations; d MCS, mental 
component scale of SF-12/36; e PCS, physical component scale of SF-12/36; f RMDQ, 
Roland Morris disability questionnaire 
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8.4.1.1 Short-term average pain outcome 
Figure 25 shows the trajectory plot for the treatment effect for the short-term outcome of 
average pain. The treatment effect increased as more and more participants were excluded from 
the subgroup. However Table 25 shows that age and average pain might not be important 
covariates in improving the treatment effect as their thresholds fluctuate. Of note was that 
substantial physical limitation (low PCS score) seemed to gain benefit in short-term average 
pain. 
 
Figure 25 Trajectory plot for the treatment effect against the size of the constructed 
region for the average pain short-term outcome. 
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Table 25 Thresholds for selected size of subgroup for the short-term average pain as seen 
in Figure 25. 
Subgroup size Age (<) Pain (>) PCSa (<) MCSb (>) Treatment effect 
0.106c 50 50 33.62 38.21 14.04 
0.206 67 50 31.34 28.93 13.18 
0.217 67 40 31.34 28.93 12.10 
0.227 67 0 31.34 28.93 13.48 
0.238 62 50 33.62 28.93 11.49 
0.247 91 50 31.34 28.93 13.22 
0.255 91 0 31.34 34.18 11.86 
0.262 91 40 31.34 28.93 12.38 
0.275 91 0 31.34 28.93 13.08 
0.285 91 40 31.34 9.46 10.81 
0.300 91 0 31.34 9.46 12.23 
0.307 67 30 33.62 28.93 10.11 
0.402 91 50 35.66 28.93 11.20 
0.414 67 50 47.59 38.21 9.39 
0.426 91 20 40.45 42.95 9.77 
0.434 67 20 43.62 42.95 10.07 
0.442 67 0 43.62 42.95 10.34 
0.459 91 30 35.66 28.93 9.30 
0.501 91 0 43.62 42.95 9.58 
0.600 91 0 40.45 34.18 8.76 
0.710 67 40 47.59 9.46 7.72 
0.804 91 30 47.59 28.93 8.23 
a PCS, physical component scale of SF-12/36; b MCS, mental component scale of SF-12/36; 
c for about 10.6% of the population with age < 50, average pain score > 50, SF-12/36 PCS < 
33.62 and SF-12/36 MCS > 38.21, the treatment effect was 14.04. 
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8.4.1.2 Short-term EQ-5D outcome 
Figure 26 shows the trajectory plot for the short-term outcome of health utility measured by 
EQ-5D. As seen in Table 26 approximately 90% of the initial 1,365 participants (corresponding 
to PCS < 68 and MCS < 60, regardless of the average pain and RMDQ at baseline) had an 
average treatment effect of 0.073. The treatment effect increased sharply to 0.100 after 
approximately 30% of the participants were excluded in the model. From then on the treatment 
effect was quite ‘stable’ despite a further 40% of participants were excluded from the analysis. 
There was a markedly increased of treatment effect for about 20% of the population 
(corresponding to PCS < 31, MCS < 72, average pain > 0 and RMDQ > 6) where the average 
treatment effect was about 0.160. 
 
Figure 26 Trajectory plot for the treatment effect against the size of the constructed 
region for the EQ-5D short-term outcome 
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Table 26 Thresholds for selected size of subgroup for the short-term EQ-5D as seen in 
Figure 26. 
Subgroup size PCSa (<) MCSb (<) Pain (>) RMDQc (>) Treatment effect 
0.101d 35.66 60.35 0.00 14 0.208 
0.119 38.01 60.35 0.00 14 0.196 
0.127 38.01 72.11 0.00 14 0.185 
0.136 47.59 60.35 0.00 14 0.185 
0.144 47.59 72.11 0.00 14 0.174 
0.151 31.34 56.82 0.00 0 0.170 
0.166 31.34 60.35 0.00 6 0.158 
0.171 31.34 60.35 0.00 0 0.153 
0.188 31.34 72.11 20.00 6 0.157 
0.190 31.34 72.11 0.00 6 0.160 
0.210 33.62 56.82 0.00 6 0.134 
0.219 40.45 47.17 20.00 10 0.125 
0.221 40.45 47.17 0.00 10 0.127 
0.233 33.62 60.35 0.00 6 0.126 
0.244 38.01 47.17 0.00 6 0.124 
0.259 33.62 72.11 30.00 6 0.122 
0.267 33.62 72.11 0.00 6 0.124 
0.303 40.45 47.17 0.00 6 0.123 
0.407 67.75 72.11 57.00 0 0.106 
0.415 43.62 50.61 20.00 6 0.095 
0.429 40.45 56.82 30.00 6 0.099 
0.437 38.01 72.11 20.00 6 0.099 
0.446 40.45 56.82 0.00 6 0.106 
0.451 47.59 50.61 30.00 6 0.094 
0.464 47.59 72.11 50.00 6 0.102 
0.477 40.45 60.35 20.00 6 0.102 
0.482 40.45 60.35 0.00 6 0.103 
0.498 43.62 56.82 30.00 6 0.093 
0.505 40.45 72.11 30.00 6 0.098 
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Subgroup size PCSa (<) MCSb (<) Pain (>) RMDQc (>) Treatment effect 
0.512 47.59 56.82 20.00 7 0.099 
0.530 40.45 72.11 0.00 6 0.100 
0.540 47.59 53.87 0.00 6 0.095 
0.541 67.75 60.35 40.00 6 0.095 
0.552 47.59 56.82 30.00 6 0.099 
0.570 43.62 60.35 0.00 6 0.100 
0.574 67.75 56.82 30.00 6 0.097 
0.581 47.59 56.82 20.00 6 0.102 
0.593 47.59 56.82 0.00 6 0.103 
0.610 67.75 56.82 20.00 6 0.099 
0.704 47.59 60.35 20.00 5 0.085 
0.803 47.59 60.35 0.00 0 0.080 
0.909 67.75 60.35 0.00 0 0.073 
a PCS, physical component scale of SF-12/36; b MCS, mental component scale of SF-
12/36; c RMDQ, Roland Morris disability questionnaire; d for about 10.1% of the 
population with SF-12/36 PCS < 35.66, SF-12/36 MCS < 60.35, average pain > 0 and 
RMDQ > 14, the treatment effect was 0.208. 
 
8.4.1.3 Short-term FFbHR outcome 
Figure 27 shows the trajectory plot for the treatment effect against the size of the constructed 
region for the change of FFbHR between baseline and short-term follow-up. In the first 
iteration approximately 10% of the initial 3718 participants were excluded from the subgroup 
box and these participants had high value of PCS at baseline, that is, the remaining 90% in the 
subgroup correspond to any age, FFBHR < 100, PCS < 48 and MCS < 72. The average 
treatment effect was 8.5 (see Table 27). The average treatment effect increased as more 
participants were excluded from the subgroup box. The average treatment effect for the last 
10% of the participants (corresponding to any age, FFbHR < 29, PCS < 68 and MCS < 57) was 
16.8. Although an increase of 8 units of the FFbHR score may be of clinical importance, the 
proportion of participants who would benefit from such improvement is very small. 
Nevertheless, those with more functional limitation (greater disability) and more psychological 
distress would benefit greater on the FFbHR disability outcome at short-term. If we were 
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interested in an improvement from an average of 8.5 to at least 12 then approximately 30% of 
the participants (age < 67, FFbHR < 54, PCS < 40 and MCS < 72) would benefit greater on the 
disability outcome at short-term, a similar result to that observed in the IPD-SIDES Analysis 1 
where participants with FFbHR ≤ 54.2 and age ≤ 66 had an enhanced treatment effect (see 
7.5.1.2). It is of note that results from both methods suggest that MCS may not be an essential 
covariate in improving treatment effect. 
 Those with more functional limitation at baseline and younger would gain 
greater improvement in short-term functional ability as measured by the 
FFbHR. 
 
Figure 27 Trajectory plot for the treatment effect against the size of the constructed 
region for the FFbHR short-term outcome. 
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Table 27 Thresholds for selected size of subgroup for the short-term FFbHR outcome as 
seen in Figure 27. 
Subgroup size Age (<) FFbHRa (<) PCSb (<) MCSc (<) Treatment effect 
0.102d 91 29.17 67.75 56.82 16.79 
0.118 54 58.33 40.45 47.17 16.35 
0.121 54 45.83 67.75 60.35 16.07 
0.132 54 45.83 67.75 72.11 15.97 
0.150 54 62.50 33.62 72.11 14.92 
0.155 54 54.17 40.45 56.82 14.43 
0.163 58 45.83 40.45 72.11 14.49 
0.171 54 54.17 40.45 60.35 14.06 
0.190 54 54.17 40.45 72.11 14.35 
0.200 54 54.17 43.62 72.11 13.74 
0.206 54 54.17 67.75 72.11 14.18 
0.308 62 54.17 67.75 72.11 12.72 
0.314 67 54.17 40.45 60.35 11.90 
0.327 62 58.33 40.45 72.11 12.05 
0.340 67 54.17 67.75 60.35 11.70 
0.345 58 62.50 67.75 72.11 11.82 
0.352 67 54.17 40.45 72.11 12.03 
0.361 62 58.33 67.75 72.11 11.76 
0.378 67 54.17 67.75 72.11 11.82 
0.385 91 54.17 40.45 60.35 11.33 
0.400 62 70.83 40.45 60.35 11.32 
0.402 67 58.33 40.45 72.11 11.20 
0.509 67 62.50 67.75 72.11 10.36 
0.513 62 100.00 40.45 72.11 10.30 
0.528 91 75.00 40.45 56.82 9.99 
0.535 91 58.33 67.75 72.11 10.16 
0.548 91 62.50 40.45 72.11 10.37 
0.553 91 83.33 40.45 56.82 9.82 
0.570 67 75.00 40.45 72.11 9.95 
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Subgroup size Age (<) FFbHRa (<) PCSb (<) MCSc (<) Treatment effect 
0.573 91 70.83 40.45 60.35 10.22 
0.582 91 62.50 43.62 72.11 9.96 
0.599 67 75.00 47.59 60.35 9.37 
0.602 91 75.00 40.45 60.35 9.96 
0.702 91 75.00 47.59 60.35 9.14 
0.808 91 100.00 47.59 60.35 8.59 
0.906 91 100.00 47.59 72.11 8.47 
a FFbHR, Hannover functional ability questionnaire for measuring back-pain related 
functional limitations; b PCS, physical component scale of SF-12/36; c MCS, mental 
component scale of SF-12/36; d for about 10.2% of the population with age < 91, FFbHR 
< 29.17, SF-12/36 PCS < 67.75 and SF-12/36 MCS < 56.82, the treatment effect was 
16.79. 
 
 
8.4.1.4 Short-term SF-12/36 MCS outcome 
Figure 28 is the trajectory plot for the treatment effect for the short-term outcome of MCS. 
Table 28 shows a selection of constructed regions and the corresponding thresholds for 
covariates age, FFbHR, PCS and MCS. The average treatment effect of approximately 90% of 
the initial 3,630 participants (corresponding to age > 16, FFbHR < 100, PCS < 48 and MCS < 
72) was 2.23 and this increased to 5.98 for approximately 10% of the participants 
(corresponding to age > 16, FFbHR < 100, PCS < 29 and MCS < 51). Approximately 55% of 
the participants (corresponding to age > 31, FFbHR < 63, PCS < 44 and MCS < 72) had an 
average treatment effect of 3 units. A smaller region consisting of 30% of the participants 
(corresponding to age > 54, FFbHR < 75, PCS < 44 and MCS < 57) would gain greater 
improvement in psychological outcome, that is, an average treatment effect of 4 units. Of 
interest is the conflicting cut-off suggested by FFbHR and PCS at baseline in constructing these 
regions where the former seemed not to play a critical role and the latter suggested that those 
with poor physical status would gain greater improvement. 
 Those with more psychological distress and younger would gain greater 
improvement in short-term psychological outcome as measured by the SF-12/36 
MCS. 
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Figure 28 Trajectory plot for the treatment effect against the size of the constructed 
region for the SF-12/36 MCS short-term outcome. 
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Table 28 Thresholds for selected size of subgroup for the short-term SF-12/36 MCS as 
seen in Figure 28. 
Subgroup size Age (>) FFbHRa (<) PCSb (<) MCSc (<) Treatment effect 
0.108d 16 100.00 28.84 50.61 5.98 
0.159 58 75.00 35.66 53.87 5.23 
0.163 58 83.33 35.66 53.87 5.11 
0.176 58 70.83 38.01 53.87 4.90 
0.181 58 75.00 38.01 53.87 5.16 
0.194 31 75.00 31.34 53.87 4.76 
0.207 31 45.83 43.62 50.61 4.72 
0.301 54 75.00 43.62 56.82 4.05 
0.317 31 54.17 47.59 53.87 4.08 
0.328 31 54.17 40.45 56.82 3.93 
0.334 45 62.50 38.01 60.35 3.84 
0.341 31 54.17 43.62 56.82 3.93 
0.351 31 54.17 67.75 56.82 3.86 
0.365 45 62.50 40.45 60.35 3.81 
0.373 31 70.83 38.01 53.87 3.64 
0.384 45 62.50 43.62 60.35 3.86 
0.401 45 62.50 67.75 60.35 3.64 
0.505 31 75.00 38.01 60.35 3.37 
0.515 45 75.00 67.75 60.35 3.27 
0.526 31 83.33 38.01 60.35 3.28 
0.535 31 100.00 38.01 60.35 3.29 
0.541 31 100.00 67.75 50.61 3.25 
0.551 31 62.50 43.62 72.11 3.03 
0.568 37 75.00 43.62 60.35 3.10 
0.577 31 100.00 47.59 53.87 3.05 
0.582 31 70.83 43.62 60.35 3.17 
0.597 31 100.00 43.62 56.82 2.96 
0.604 45 100.00 67.75 60.35 2.94 
0.701 16 75.00 47.59 60.35 2.75 
0.807 16 100.00 47.59 60.35 2.55 
0.907 16 100.00 47.59 72.11 2.23 
a FFbHR, Hannover functional ability questionnaire for measuring back-pain related functional limitations; b 
PCS, physical component scale of SF-12/36; c MCS, mental component scale of SF-12/36; d for about 10.8% of 
the population with age > 16, FFbHR < 100, SF-12/36 PCS < 28.84 and SF-12/36 MCS < 50.61, the treatment 
effect was 5.98. 
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8.4.1.5 Short-term SF-12/36 PCS outcome 
Figure 29 shows the trajectory plot for the treatment effect for the short-term outcome of PCS. 
Although it shows a general trend of higher treatment effect as subgroups were removed from 
the initial pool of 5208 participants, the treatment effect increased but was not monotonic and 
the improvement did not increase very much to warrant a clinical importance. Table 29 shows 
a selection of constructed regions and the corresponding thresholds for covariates age, PCS 
and MCS. We thus conclude that there was also no subgroup who would gain benefit in short-
term SF-12/36 PCS. 
 
Figure 29 Trajectory plot for the treatment effect against the size of the constructed 
region for the SF-12/36 PCS short-term outcome. 
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Table 29 Thresholds for selected size of subgroup for the short-term SF-12/36 PCS as 
seen in Figure 29. 
Subgroup size Age (<) PCSa (<) MCSb (>) Treatment effect 
0.110c 54 40.45 56.82 5.30 
0.153 54 35.66 47.17 5.14 
0.169 67 31.34 47.17 5.29 
0.176 91 31.34 50.61 4.95 
0.189 67 40.45 56.82 5.15 
0.193 67 33.62 50.61 4.89 
0.202 91 31.34 47.17 5.03 
0.211 58 35.66 42.95 4.76 
0.224 62 35.66 47.17 4.98 
0.233 67 35.66 50.61 4.87 
0.245 62 43.62 53.87 4.47 
0.253 67 40.45 53.87 4.82 
0.263 58 40.45 47.17 4.79 
0.270 67 35.66 47.17 4.98 
0.289 67 43.62 53.87 4.42 
0.292 91 40.45 53.87 4.38 
0.307 62 43.62 50.61 4.67 
0.316 67 40.45 50.61 4.78 
0.326 67 47.59 53.87 4.15 
0.334 54 40.45 34.18 4.14 
0.348 62 47.59 50.61 4.23 
0.360 58 43.62 42.95 4.39 
0.366 62 40.45 42.95 4.58 
0.372 67 40.45 47.17 4.77 
0.385 67 35.66 34.18 3.85 
0.391 62 67.75 50.61 4.14 
0.409 91 43.62 50.61 4.29 
0.413 62 47.59 47.17 4.21 
0.427 91 40.45 47.17 4.50 
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Subgroup size Age (<) PCSa (<) MCSb (>) Treatment effect 
0.430 67 40.45 42.95 4.47 
0.443 58 40.45 28.93 3.86 
0.459 91 47.59 50.61 4.05 
0.467 62 67.75 47.17 3.93 
0.471 58 67.75 42.95 3.75 
0.486 91 43.62 47.17 4.17 
0.496 91 40.45 42.95 4.22 
0.508 91 67.75 47.17 3.85 
0.609 67 40.45 28.93 3.73 
0.703 91 40.45 28.93 3.59 
0.802 91 43.62 28.93 3.37 
0.903 91 47.59 28.93 3.26 
a PCS, physical component scale of SF-12/36; b MCS, mental component scale of SF-
12/36; c for about 11.0% of the population with age < 54, SF-12/36 PCS < 40.45 and SF-
12/36 MCS > 56.82, the treatment effect was 5.30. 
8.4.1.6 Short-term RMDQ outcome 
As seen in Figure 30, the non-monotonic trajectory plot for the short-term outcome of RMDQ 
suggested that there was no subgroup who would gain greater improvement in short-term 
disability outcome as measured by the RMDQ. 
Table 30 shows a selection of subgroup of participants with thresholds for covariate age and 
RMDQ at baseline and their treatment effects. 
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Figure 30 Trajectory plot for the treatment effect against the size of the constructed 
region for the RMDQ short-term outcome. 
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Table 30 Thresholds for selected size of subgroup for the short-term RMDQ as seen in 
Figure 30. 
Subgroup size Age (<) RMDQa (<) Treatment effect 
0.110b 45 5 1.13 
0.111 41 6 1.29 
0.123 31 24 0.88 
0.138 37 9 1.15 
0.144 45 6 1.27 
0.152 37 10 1.10 
0.169 54 5 1.18 
0.178 45 7 1.30 
0.184 50 6 1.36 
0.199 37 14 1.56 
0.216 37 16 1.35 
0.225 50 7 1.35 
0.242 37 24 1.56 
0.250 58 6 1.26 
0.310 50 9 1.37 
0.318 91 6 1.13 
0.322 45 12 1.34 
0.335 41 24 1.46 
0.341 62 7 1.56 
0.405 50 12 1.37 
0.416 54 10 1.29 
0.426 58 9 1.33 
0.443 45 24 1.55 
0.460 50 14 1.48 
0.506 50 16 1.48 
0.523 62 10 1.39 
0.539 91 9 1.30 
0.626 54 16 1.51 
0.645 58 14 1.46 
0.707 58 16 1.47 
0.903 91 16 1.46 
a RMDQ, Roland Morris disability questionnaire; b for about 11.0% of the 
population with age < 45 and RMDQ < 5, the treatment effect was 1.13. 
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8.4.2 ANALYSIS 2: PAIRWISE COMPARISONS 
Similar to the analyses seen in Section 7.5.2, a further examination of the treatment effect 
between active physical and non-active usual care (usual care/GP or waiting list only), between 
passive physical and non-active usual care, between psychological and non-active usual care, 
and between sham and non-active usual care arms were performed for selected short-term 
outcomes. Table 31 summarises the trials and variables considered in the construction of a 
region that predicts the best or worst response for each pairwise comparison for selected short-
term outcomes measures. 
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Table 31 Summary of included trials and variables considered to construct a region that predicts the best of worst response to treatment 
for different direct comparisons. 
Outcome FFbHRa  RMDQb  MCSc  PCSd  
Comparison Trials Variables Trials Variables Trials Variables Trials Variables 
Active physical 
vs. non-active 
usual caree 
  
m = 2; n = 622 
UK BEAM 
(n = 465), 
Smeets (n = 157) 
Age and 
RMDQ at 
baseline 
    
Passive physical 
vs. non-active 
usual caree 
m = 3; n = 3,272 
Brinkhaus 
(n=214), Haake 
(n = 734), Witt 
(n = 2,324) 
Age, 
FFbHR, 
PCS and 
MCS at 
baseline 
  
m = 5; n = 3,879 
UK BEAM 
(n = 479), 
Brinkhaus 
(n = 212), Haake 
(n = 734), Witt 
(n = 2,248), 
YACBAC 
(n = 206) 
Age, PCS  and 
MCS  at baseline 
m = 5; n = 3,879 
UK BEAM 
(n = 479), 
Brinkhaus 
(n = 212), Haake 
(n = 734), Witt 
(n = 2,248), 
YACBAC 
(n = 206) 
Age, PCS  
and MCS  at 
baseline 
Psychological vs. 
non-active usual 
caree 
  
m = 3; n = 957 
BeST (n = 514), 
VK BIA 
(n = 230), VK 
SC2 (n = 213) 
Age  and 
RMDQ  at 
baseline 
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Outcome FFbHRa  RMDQb  MCSc  PCSd  
Comparison Trials Variables Trials Variables Trials Variables Trials Variables 
Sham vs. non-
active usual 
caree 
m = 2; n = 881 
Brinkhaus 
(n = 144), Haake 
(n = 737) 
Age, 
FFbHR, 
PCS  and 
MCS  at 
baseline 
  
m = 2; n = 879 
Brinkhaus 
(n = 142), Haake 
(n = 737) 
Age, PCS  and 
MCS  at baseline 
m = 2; n = 879 
Brinkhaus 
(n = 142), Haake 
(n = 737) 
Age, PCS  
and MCS  at 
baseline 
a FFbHR, Hannover functional ability questionnaire for measuring back-pain related functional limitations; b RMDQ, Roland Morris disability 
questionnaire; c MCS, mental component scale of SF-12/36; d PCS, physical component scale of SF-12/36; e Control treatment is usual care/GP or 
waiting list. 
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8.4.2.1 Active physical vs. non-active usual care 
8.4.2.1.1 Short-term RMDQ outcome 
Figure 31 shows the trajectory plot for the treatment effect between active physical and non-
active usual care for the short-term RMDQ outcome. The figure shows similar result seen in 
Section 8.4.1.6, that is, there was no subgroup that would have a substantial improvement in 
treatment effect. Table 32 shows the average treatment effect for selected constructed regions 
with the corresponding thresholds. 
 
Figure 31 Trajectory plot for the treatment effect between active physical and non-active 
usual care against the size of the constructed region for the RMDQ short-term outcome. 
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Table 32 Thresholds for selected size of subgroup for the short-term RMDQ as seen in 
Figure 31. 
Subgroup size Age (>) RMDQa (>) Treatment effect 
0.109 45 14 3.54 
0.190 33 14 2.66 
0.211 52 6 2.63 
0.291 43 10 2.09 
0.314 33 12 2.26 
0.405 43 7 2.22 
0.495 43 5 2.14 
0.527 43 4 2.14 
0.592 40 5 1.90 
0.605 33 7 1.87 
0.807 19 6 1.76 
0.908 19b 5 1.73 
a RMDQ, Roland Morris disability questionnaire; b minimum 
age=19 
 
8.4.2.2 Passive physical vs. non-active usual care 
8.4.2.2.1 Short-term FFbHR outcome 
Figure 32 shows the trajectory plot for the treatment effect between passive physical and non-
active usual care against the size of the constructed region for short-term outcome of FFbHR. 
Table 33 shows that the average treatment effect for approximately 90% of the population 
(corresponding to FFbHR < 86 regardless of age, PCS and MCS values at baseline) was 10.41 
which was slightly higher than the average treatment effect between any therapist delivered 
intervention (active, passive, psychological or any combination treatment) and control/placebo 
(usual care/GP and sham treatment) which was 8.5. Approximately 20% of the population 
(corresponding to age < 59, FFbHR < 50, PCS < 68 and MCS < 72) gained at least an average 
treatment effect of 16 units. Younger participants with substantial physical disability (low 
FFbHR score) gained the most benefit. The PCS and MCS at baseline did not play an influential 
role in improving treatment effect. 
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Figure 32 Trajectory plot for the treatment effect between passive physical and non-
active usual care against the size of the constructed region for the FFbHR short-term 
outcome. 
Table 33 Thresholds for selected size of subgroup for the short-term FFbHR as seen in 
Figure 32. 
Subgroup size Age (<) FFbHRa (<) PCSb (<) MCSc (<) Treatment effect 
0.101 55 41.67 67.75 72.11 18.42 
0.196 68 41.67 67.75 72.11 16.18 
0.207 59 50.00 67.75 72.11 16.14 
0.306 68 50.00 67.75 72.11 14.57 
0.407 91 54.17 40.41 72.11 12.97 
0.503 63 86.36 40.41 72.11 12.08 
0.602 91 79.17 40.41 60.38 11.62 
0.702 68 79.17 47.80 72.11 11.10 
0.807 91 100.00 43.73 72.11 10.64 
0.904 91 86.36 67.75 72.11 10.41 
a FFbHR, Hannover functional ability questionnaire for measuring back-pain related functional 
limitations; b PCS, physical component scale of SF-12/36; c MCS, mental component scale of 
SF-12/36 
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8.4.2.2.2 Short-term SF-12/36 MCS outcome 
Figure 33 shows the trajectory plot for the treatment effect between passive physical and non-
active usual care which is quite similar to the one seen in 8.4.1.4 where approximately 90% of 
the initial 3,879 participants (corresponding to age < 68, PCS < 68 and MCS < 71) had an 
average treatment effect of 3.06 (see Table 34). The treatment effect increased as more 
participants were excluded from the region to a clinical important difference of 6.3 but this was 
only applicable to a small proportion of participants, approximately 10% of them 
(corresponding to age < 51, PCS < 44 and MCS < 38). That is, only younger participants with 
substantial physical limitations and psychological distress would benefit from greater 
improvement in passive physical treatment against control. 
 
Figure 33 Trajectory plot for the treatment effect between passive physical and non-
active usual care against the size of the constructed region for the SF-12/36 MCS short-
term outcome. 
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Table 34 Thresholds for selected size of subgroup for the short-term SF-12/36 MCS as 
seen in Figure 33  
Subgroup size Age (<) PCSa (<) MCSb (<) Treatment effect 
0.105 51 43.50 37.86 6.33 
0.193 68 35.54 47.60 4.38 
0.208 63 47.65 37.86 5.26 
0.296 91c 67.75 37.86 4.45 
0.307 63 43.50 47.60 4.05 
0.392 91 43.50 47.60 4.21 
0.403 91 37.84 54.15 3.99 
0.496 91 67.75 47.60 3.77 
0.500 63 47.65 54.15 3.27 
0.594 91 67.75 51.02 3.67 
0.603 55 67.75 71.32 2.88 
0.706 91 43.50 60.37 3.57 
0.802 91 47.65 60.37 3.22 
0.904 68 67.75 71.32 3.06 
a PCS, physical component scale of SF-12/36; b MCS, mental component scale 
of SF-12/36; c Maximum age =91 
 
8.4.2.2.3 Short-term SF-12/36 PCS outcome 
The trajectory plot for the treatment effect between passive physical and non-active usual care 
is shown in Figure 34. The trajectory indicates an increase of improvement as regions narrowed 
but the fluctuation of the treatment effect suggests that there might be no definite subgroup that 
would gain substantial treatment effect. Table 29 summarised the average treatment for 
selected constructed regions with the corresponding thresholds for the comparison seen in 
Figure 34. 
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Figure 34 Trajectory plot for the treatment effect between passive physical and non-
active usual care against the size of the constructed region for the SF-12/36 PCS short-
term outcome. 
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Table 35 Thresholds for selected size of subgroup for the short-term SF-12/36 PCS as 
seen in Figure 34. 
Subgroup size Age (<) PCSa (<) MCSb (>) Treatment effect 
0.107 63 31.19 51.02 6.17 
0.192 68 35.54 51.02 5.84 
0.205 91c 31.19 43.02 5.99 
0.292 68 43.50 51.02 5.30 
0.310 55 40.28 33.48 5.09 
0.394 68 35.54 28.47 4.56 
0.406 91 43.50 47.60 4.93 
0.495 91 40.28 37.86 5.02 
0.503 68 43.50 37.86 4.95 
0.599 91 37.84 9.46 4.45 
0.604 91 67.75 43.02 4.33 
0.709 68 43.50 9.46 4.47 
0.802 91 67.75 33.48 4.14 
0.904 68 67.75 9.46 3.88 
a PCS, physical component scale of SF-12/36; b MCS, mental component scale 
of SF-12/36; ; c Maximum age =91 
 
8.4.2.3 Psychological vs. non-active usual care 
8.4.2.3.1 Short-term RMDQ outcome 
Figure 35 shows the trajectory plot for the treatment effect between psychological and non-
active usual care for the short-term RMDQ outcome and Table 36 shows the average treatment 
effect for selected constructed regions with the corresponding thresholds. The results are very 
similar to that seen in Section 8.4.1.6, that is, there was no subgroup that would gain a 
substantial improvement in treatment effect.  
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Figure 35 The size of the constructed region for the RMDQ short-term outcome. 
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Table 36 Thresholds for selected size of subgroup for the short-term RMDQ as seen in 
Figure 35. 
Subgroup size Age (<) RMDQa (>) Treatment effect 
0.107 41 7 2.84 
0.197 49 8 2.58 
0.214 69 13 1.46 
0.295 45 0 1.81 
0.305 49 5 2.52 
0.400 52 4 2.19 
0.493 56 4 2.02 
0.528 85b 8 1.39 
0.591 60 4 1.90 
0.606 63 5 1.79 
0.809 63 0 1.48 
0.909 69 0 1.39 
a RMDQ, Roland Morris disability questionnaire; b maximum 
age=85 
 
8.4.2.1 Sham vs. non-active usual care 
8.4.2.1.1 Short-term FFbHR outcome 
Three trials were included in the comparison between passive physical and non-active usual 
care. All three trials had acupuncture as the therapist delivered intervention. Of these two of 
them also had sham acupuncture. Figure 36 shows the trajectory plot for the treatment effect 
between sham acupuncture and non-active usual care. The average treatment effect was slightly 
lower seen between passive physical (acupuncture) and non-active usual care. However, the 
treatment effect increased as more and more participants were excluded from the ARDP-MA 
algorithm. Table 37 shows the average treatment effect between sham acupuncture and non-
active usual care for selected constructed regions with the corresponding thresholds. 
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Figure 36 The size of the constructed region for the FFbHR short-term outcome. 
Table 37 Thresholds for selected size of subgroup for the short-term FFbHR as seen in 
Figure 36. 
Subgroup size Age (<) FFbHRa (<) PCSb (<) MCSc (<) Treatment effect 
0.103 52 41.67 44.78 51.61 12.64 
0.199 52 54.17 60.47 51.61 12.58 
0.208 62 45.83 44.78 51.61 12.26 
0.301 62 45.83 60.47 72.11 9.85 
0.402 52 95.83 60.47 57.68 7.53 
0.510 68 58.33 41.50 61.38 6.49 
0.605 87 d 62.50 41.50 57.68 6.84 
0.700 68 66.67 44.78 61.38 6.00 
0.806 68 95.83 44.78 72.11 5.95 
a FFbHR, Hannover functional ability questionnaire for measuring back-pain related 
functional limitations; b PCS, physical component scale of SF-12/36; c MCS, mental 
component scale of SF-12/36; d maximum age = 87 
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8.4.2.1.2 Short-term SF-12/36 MCS outcome 
Figure 37 shows the trajectory plot for the treatment effect between sham and non-active usual 
care. The two trials included in this pairwise analysis had sham acupuncture. The figure shows 
that the average treatment effect did not improve much in the exclusion of the first 70% 
participants (see Table 38). Nevertheless, there was a markedly higher treatment effect which 
was 6.22 for approximately 20% of the participants (corresponding to PCS < 36 and MCS < 
39, regardless of age). 
 
Figure 37 Trajectory plot for the treatment effect between sham and non-active usual 
care against the size of the constructed region for the SF-12/36 MCS short-term outcome. 
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Table 38 Thresholds for selected size of subgroup for the short-term SF-12/36 MCS as 
seen in Figure 37. 
Subgroup size Age (<) PCSa (<) MCSb (<) Treatment effect 
0.104 43 36.48 51.97 7.86 
0.199 43 39.17 61.54 6.43 
0.201 87 36.48 39.07 6.22 
0.296 87 57.59 39.07 5.06 
0.300 65 42.29 44.25 4.01 
0.396 87d 39.17 48.42 4.40 
0.410 52 42.29 61.54 4.57 
0.501 61 57.59 55.18 3.09 
0.709 70 39.17 70.46 3.59 
0.809 70 42.29 70.46 3.67 
0.902 70 57.59 70.46 3.09 
a PCS, physical component scale of SF-12/36; b MCS, mental component scale 
of SF-12/36; c maximum age = 87 
 
8.4.2.1.3 Short-term PCS outcome 
The trajectory plot for the treatment effect between sham and non-active usual care is shown 
in Figure 38 and Table 39 summarised the average treatment for selected constructed regions 
with the corresponding thresholds. There was an increase of improvement as regions narrowed 
but the fluctuation of the treatment effect suggests that there might be no definite subpopulation 
that would gain substantial treatment effect.  
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Figure 38 Trajectory plot for the treatment effect between sham and non-active usual 
care against the size of the constructed region for the SF-12/36 PCS short-term outcome. 
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Table 39 Thresholds for selected size of subgroup for the short-term SF-12/36 PCS as 
seen in Figure 38. 
Subgroup size Age (<) PCSa (>) MCSb (<) Treatment effect 
0.100 70 39.17 48.42 6.26 
0.195 52 32.56 51.97 6.04 
0.206 70 36.48 55.18 5.37 
0.296 52 30.95 58.10 5.59 
0.303 70 30.95 48.42 5.43 
0.398 87c 34.31 70.46 4.46 
0.403 65 32.56 61.54 4.86 
0.495 87 26.96 51.97 4.55 
0.503 87 30.95 58.10 4.66 
0.598 87 30.95 70.46 4.06 
0.602 70 29.16 61.54 3.71 
0.801 65 14.41 70.46 3.46 
0.902 70 14.41 70.46 3.56 
a PCS, physical component scale of SF-12/36; b MCS, mental component scale of SF-12/36; 
c maximum age = 87 
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CHAPTER 9 – METHODOLOGY AND STATISTICAL 
DEVELOPMENTS 3:  IDENTIFICATION OF COST-EFFECTIVE 
SUBGROUPS BY DIRECTED PEELING 
9.1 INTRODUCTION 
The economic analysis sought to identify the most cost-effective treatments for subgroups of 
patients with LBP. A search algorithm, similar to that used in the previous chapter, was used 
to identify subgroups to maximise the expected QALY gain from treatment. Although some of 
the trials in the database provided individual-level data on use of healthcare resources, these 
data were not used in the analyses presented in this chapter. Instead, a threshold approach was 
used to assess the cost-effectiveness of treatment for defined groups of patients. This was done 
by comparing estimates of treatment cost from the literature with the maximum cost required 
to stay below the cost-effectiveness threshold (£20,000 to £30,000 per QALY, as recommended 
by NICE), given the estimated QALY gain from treatment.147 
The use of the QALY outcome reduced the available data for analysis more than for the short 
term clinical outcomes in the previous chapter. We therefore used a search algorithm that is 
suited to data with a lower signal to noise ratio: the directed peeling approach of LeBlanc et al, 
which works by ‘peeling‘ a fraction of patients (with the least favourable effect) from the 
subgroup in a series of steps.146 This differs from the full search algorithm described in the 
previous chapter, as each successively smaller subgroup is constrained to be a subset of the 
previous one. Both approaches use a ‘directed’ peeling approach, designed to provide simpler 
descriptions of groups for variables with a monotonic relationship with the outcome of interest. 
The LeBlanc et al algorithm was developed for analysis of data from a single trial, and so it 
was adapted here for IPD meta-analysis by incorporating random trial effects into the model.  
The analysis was split into four overarching comparisons; all interventions collectively vs best 
care, active physical interventions vs best care, passive physical interventions vs best care and 
active physical vs passive physical. Psychological interventions were not included in the 
comparison as only one trial had EQ-5D data necessary to calculate a QALY and a control arm. 
Data for comparisons against a ‘sham’ treatment arm were also excluded from this analysis. 
  239 
9.2 METHODS 
9.2.1  QALYS 
The outcome used for the analysis was the Quality Adjusted Life Year (QALY). We calculated 
QALYs for individuals based on EQ-5D utility scores at baseline, short, medium and long term 
follow up (up to one year). For trials with SF-36/12 outcomes but no EQ-5D, we used a 
mapping algorithm136 to estimate EQ-5D scores. QALYs were estimated using an area under 
the curve approach adjusting for baseline EQ-5D scores (see Section 6.3.3.2).  
9.2.2 MODERATOR IDENTIFICATION 
The specification of the search algorithm required an initial analysis to identify moderating 
variables, and to determine the direction of peeling. A mixed effect model was used to identify 
moderators with a significant interaction with treatment effect on the QALY outcome. The 
model was specified with moderator, treatment and treatment by moderator interaction as fixed 
effects, and trial and treatment by trial interaction as random effects (see Section 6.3.3). The 
sign on the moderator by treatment interaction coefficient dictated whether the algorithm 
should peel from the top or the bottom of the moderator range. A positive relationship with 
treatment effect suggested that peeling away individuals with lower values of the moderator 
would yield higher average treatment benefits. A negative relationship suggests that peeling 
individuals with higher values of the moderator would be best. 
9.2.3 PEELING ALGORITHM 
The peeling algorithm started by setting the subgroup indicator (B) to 1 for all individuals. 
Incremental QALY gain from treatment  for the whole patient sample was estimated using a 
mixed effect model with baseline EQ-5D score and treatment as fixed effects, and trial and 
‘treatment by trial’ interaction as random effects. 
The algorithm then looped through the following steps until the stopping criteria was met: 
 For each moderator, a small proportion of the data was peeled off, taking out the 
individuals with the highest (lowest) value of the moderator (depending on the direction 
of the moderator treatment interaction effect). The subgroup indicator (B) was set to 
one for the remaining individuals (the ‘in’ group) and zero for the peeled individuals 
(the ‘out’ group). 
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 The difference in incremental QALY gain was estimated for those inside the subgroup 
compared with those outside using a mixed effect model: with baseline EQ-5D, 
treatment effect, subgroup identifier and ‘treatment by subgroup’ interaction as fixed 
effects, and trial and ‘treatment by trial’ interaction as random effects.  
 The magnitude of the treatment by subgroup interaction effect was compared for each 
moderator. The peel decision was then based on the moderator with the greatest effect. 
 Summary statistics were calculated, including: the incremental QALY gain within the 
subgroup, the incremental QALY gain outside the subgroup and the weighted mean 
incremental QALY across the whole sample.  
 If the subgroup contained fewer individuals than a pre-set minimum number (nmin), the 
algorithm stopped. Otherwise the above steps were repeated. 
9.2.4 COST-EFFECTIVENESS 
Individual patient data on health care resource use was available for some trials in the 
repository. An initial analysis was conducted using the data from the UK BEAM trial using 
individual-level estimates of costs (C) and QALYs (Q) over the 12 month follow up period. 
From these data, the net monetary benefit (NMB) was calculated for each individual: NMB = 
λ * Q – C, where λ is a set cost-effectiveness threshold (£20,000 per QALY). This NMB 
variable was then used as outcome in the above search algorithm. However, we found that the 
addition of the cost data increased variation without increasing predictive power. The results 
of this analysis are not presented here, as a condition of use of the repository data is that all 
results must include at least two trials to avoid re-analysis of the original trial data. Given that 
the addition of the individual-level costs was not advantageous in the UK BEAM analysis, and 
also the heterogeneity in the resource use items recorded across those studies with data, we 
decided to focus on QALYs as the outcome for the economic analysis, and top use a threshold 
approach to assess cost-effectiveness. 
The threshold analysis presents the maximum incremental cost of intervention in order for a 
treatment subgroup to be deemed cost-effective based on the lower and upper limits of the 
NICE recommended threshold (£20,000-£30,000 per QALY). For example, if a treatment 
yields an average incremental QALY gain for a treatment population of 0.05, one would pay 
up to £1,000 (0.05*£20,000) for the treatment, using the lower threshold or £1,500 
(0.05*£30,000) at the upper threshold. 
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Published literature was used to provide indicative costs of treatment for comparison with the 
estimated thresholds. The incremental cost of passive treatment over one year, was estimated 
at £541(SD: £768) from the UK BEAM economic analysis: £147 for the intervention and £394 
relating to other healthcare costs (UK BEAM).34 Estimates for other treatments varied, ranging 
from £422 (£187 for the intervention, £235 for other healthcare costs) for a psychological 
intervention (BeST 2010)31 to £486 (SD: £907) comprised of £41 for the intervention and £445 
relating to other healthcare costs, for active therapies (UK BEAM)31.  
9.3 RESULTS 
Six analyses were run (see Table 40), dictated by the moderators with significant treatment 
interaction terms in the QALY analysis of covariance. These included the following 
comparisons: all interventions versus control; active physical versus control; passive physical 
versus control; and active physical versus passive physical. As noted above, analysis of 
psychological intervention and sham were omitted, as in each case only one study provided 
data for QALY calculation. 
As shown in Table 40, not all trials had data for all three potential moderators. We therefore 
conducted three analyses for the intervention versus control comparison: the first to include as 
many trials as possible with QALY data (age and PCS as moderators).   
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Table 40 ARDP-MA, analyses conducted on economic outcomes 
Analysis 
Outcome 
variable 
Moderators 
included 
Trials included Sample size I : C 
All interventions vs control 
9.3.1 QALYa Age, PCS
b 
UK BEAMc; BeSTd; 
YACBACe; Haake 
1,273 : 715 
9.3.2 QALY Age, RMDQ
f 
UK BEAM; BeST; 
York; Smeets 
1,092 : 422 
9.3.3 QALY Age, PCS, RMDQ UK BEAM; BeST 827 : 323 
Active physical interventions vs control 
9.3.4 QALY Age, RMDQ UK BEAM; York 232 : 264 
Passive physical interventions vs control 
9.3.5 QALY Age, PCS 
UK BEAM, YACBAC, 
Haake 
643 : 566 
Active physical vs passive physical interventions 
9.3.6 QALY Age, RMDQ 
UK BEAM, 
HullExProB 
232 : 288 
a QALY, quality adjusted life year; b PCS, physical component scale of SF-12/36; c 
Back pain Exercise And Manipulation; d BeST, Back Skills Training Trial; e YACBAC 
York Acupuncture Back Pain Trial; f RMDQ, Roland Morris Disability Questionnaire 
 
9.3.1 ALL INTERVENTIONS VS CONTROL. MODERATORS: AGE AND PCS 
The algorithm trace is shown in Figure 39. The y-axis shows the estimated treatment effect for 
the subgroup, i.e. the ‘Incremental QALYs’ gained from treatment compared with the control 
arm. The x-axis is the proportion of the starting population peeled away from the treatment 
group. Figure 40 shows the mean incremental QALYs for the whole sample, both inside and 
outside the treatment group. It can be seen that for the full sample, the incremental QALY is 
declining as a function of the treatment subgroup size. This suggests that those being peeled 
from the subgroup had a net QALY gain from treatment. However, there is no strong signal in 
these data. The peeling trace in Figure 39 shows no notable increase in QALY gain from 
treatment when up to 80% of the sample are removed from the treatment group. Full details of 
the peeling trace are available in Table 41 Both age and PCS were used for peeling, although 
over the trace the algorithm favoured peeling based on PCS score. There is a small rise in 
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QALY gain at the point where 90% of the sample had been removed; the subgroup comprising 
10% of the sample included participants between 54 and 84 years old with a PCS score between 
7 and 28. The estimated QALY gain from treating only this subgroup was 0.0852, whereas the 
estimated mean QALY gain from treating the whole population was lower, at 0.0624.  
Depending on the cost of intervention, and NHS ‘willingness-to-pay per QALY, it might be 
cost-effective for all patients to be offered treatment, or for treatment to be limited to a selected 
subgroup. For example, at a cost-effectiveness threshold of £20,000 per QALY, the maximum 
that the NHS would pay for the ‘intervention’ reflected here, would be £1,248 (per patient over 
the course of a year) if all patients were to be offered treatment, or £1,704 if only patients in 
the 10% subgroup were to be offered treatment. If the threshold of £30,000 was applied this 
will be £1,872 and £2,556 respectively. However, these results do not incorporate any measure 
of uncertainty and should only be considered as illustrative of the method.  
 Older patients with relatively worse physical functioning as measured using the PCS at 
baseline appear to have moderately better response to treatment 
 
Figure 39 Mean treatment effect in subgroup  
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Figure 40 Weighted mean treatment effect across treatment subgroup and non-
treatment subgroup 
Table 41 Algorithm output for analysis 9.3.1 (see Table 40) 
It
er
a
ti
o
n
 
M
o
d
er
a
to
r
 
D
ir
ec
ti
o
n
 p
ee
le
d
 
P
ro
p
o
rt
io
n
 i
n
 
su
b
g
ro
u
p
 
≈n 
Incremental 
QALYsa 
Age PCSb 
S
u
b
g
ro
u
p
 
A
ll
 
M
in
 
M
a
x
 
M
in
 
M
a
x
 
0 - - 1.00 1988 0.0624 0.0624 18 87 7 61 
1 PCS top 0.95 1889 0.0642 0.0610 18 87 7 50 
2 age bottom 0.90 1795 0.0648 0.0585 28 87 7 50 
3 age bottom 0.86 1706 0.0685 0.0588 32 87 7 50 
4 PCS top 0.82 1621 0.0700 0.0571 32 87 7 47 
5 PCS top 0.77 1540 0.0700 0.0542 32 87 7 45 
6 PCS top 0.74 1463 0.0718 0.0529 32 87 7 43 
7 PCS top 0.70 1390 0.0722 0.0505 32 87 7 42 
8 age bottom 0.66 1319 0.0718 0.0476 34 87 7 42 
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9 PCS top 0.63 1254 0.0688 0.0434 34 87 7 41 
10 PCS top 0.60 1192 0.0695 0.0417 34 87 7 40 
11 PCS top 0.57 1133 0.0677 0.0386 34 87 7 39 
12 PCS top 0.54 1077 0.0706 0.0383 34 87 7 38 
13 PCS top 0.52 1024 0.0668 0.0344 34 87 7 38 
14 PCS top 0.49 973 0.0674 0.0330 34 87 7 37 
15 PCS top 0.47 925 0.0679 0.0316 34 87 7 36 
16 PCS top 0.44 879 0.0664 0.0294 34 87 7 36 
17 PCS top 0.42 836 0.0645 0.0271 34 87 7 35 
18 PCS top 0.40 795 0.0663 0.0265 34 87 7 35 
19 PCS top 0.38 756 0.0696 0.0265 34 87 7 34 
20 age bottom 0.36 719 0.0686 0.0248 36 87 7 34 
21 age bottom 0.34 683 0.0652 0.0224 39 87 7 34 
22 PCS top 0.33 649 0.0652 0.0213 39 87 7 34 
23 PCS top 0.31 617 0.0688 0.0213 39 87 7 33 
24 PCS top 0.30 587 0.0691 0.0204 39 87 7 33 
25 PCS top 0.28 558 0.0682 0.0191 39 87 7 33 
26 age bottom 0.27 531 0.0655 0.0175 41 87 7 33 
27 age bottom 0.25 505 0.0698 0.0177 43 87 7 33 
28 age bottom 0.24 480 0.0716 0.0173 45 87 7 33 
29 age bottom 0.23 456 0.0687 0.0158 47 87 7 33 
30 age bottom 0.22 434 0.0694 0.0151 49 87 7 33 
31 age bottom 0.21 413 0.0671 0.0139 50 87 7 33 
32 age bottom 0.20 393 0.0652 0.0129 51 87 7 33 
46 PCS top 0.10 196 0.0852 0.0084 54 84 7 28 
a QALY, quality adjusted life year; b PCS, physical component scale of SF-12/36  
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9.3.2 ALL INTERVENTIONS VS CONTROL. MODERATORS: AGE AND RMDQ 
Figure 41 and Figure 42 illustrate the peeling trace with moderators age and RMDQ. The 
inclusion of the RMDQ limited the sample to four trials (see Table 40). As shown by Figure 
41, the peeling algorithm did achieve small but consistent gains in treatment effect within the 
subgroup, as participants with better (lower) baseline RMDQ scores and who were younger 
were removed from the treatment group. The algorithm favoured peeling based on RMDQ 
score during the earlier iterations. The apparent monotonicity of RMDQ with respect to 
treatment effect (as measured in QALYs) is consistent with the regression analysis used for 
moderator identification (see Table 17), as the RMDQ had a more significant relationship with 
treatment effect compared to age. Due to some correlation with RMDQ and age, some older 
patients were removed from the treatment subgroup as the algorithm peeled based on RMDQ. 
The peeling trace for analysis ii is shown in Table 42. The subgroup at 20% of the initial sample 
comprised participants aged over 34 with an RMDQ score of 13 or higher. A modest 
improvement in QALYs gained from treatment can be seen for this subgroup: from 0.043 if 
the whole population where to be offered treatment, to 0.076 for the subgroup. As described 
previously, the maximum willingness to pay for an intervention yielding these QALY gains 
would be £860 and £1,520 respectively for the whole population and for the subgroup where a 
threshold of £20,000 is applied, or £1,290 and £2,280 respectively at a threshold of £30,000 
per QALY. As there is no estimation of uncertainty, this result should be seen as illustrative. 
 Older patients, with worse baseline physical functioning as measured by the RMDQ at 
baseline appear to achieve moderately better response to treatment.  
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Figure 41 Mean treatment effect in subgroup  
 
Figure 42 Weighted mean treatment effect across treatment subgroup and non-treatment 
subgroup 
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Table 42 Algorithm output for analysis 9.3.2 (see Table 40) 
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0 - - 1.00 1514 0.0431 0.0431 18 85 0 24 
1 RMDQ bottom 0.95 1435 0.0463 0.0439 18 85 3 24 
2 RMDQ bottom 0.82 1245 0.0517 0.0425 19 84 5 24 
3 RMDQ bottom 0.73 1105 0.0525 0.0383 19 84 6 24 
4 age bottom 0.69 1050 0.0631 0.0437 28 84 6 24 
5 age bottom 0.66 998 0.0661 0.0436 32 84 6 24 
6 RMDQ bottom 0.58 881 0.0661 0.0385 32 84 7 24 
7 RMDQ bottom 0.50 756 0.0563 0.0281 32 84 8 24 
8 age bottom 0.47 719 0.0608 0.0289 34 84 8 24 
9 RMDQ bottom 0.41 625 0.0608 0.0251 34 84 9 24 
10 RMDQ bottom 0.35 537 0.0639 0.0227 34 84 10 24 
11 RMDQ bottom 0.31 466 0.0794 0.0244 34 82 11 24 
12 RMDQ bottom 0.26 387 0.0728 0.0186 34 82 12 24 
13 RMDQ bottom 0.20 304 0.0760 0.0153 34 82 13 24 
14 RMDQ bottom 0.15 232 0.0726 0.0111 34 79 14 24 
15 age bottom 0.14 217 0.1041 0.0149 38 79 14 24 
16 age bottom 0.14 206 0.1109 0.0151 39 79 14 24 
17 age bottom 0.13 194 0.1143 0.0146 41 79 14 24 
18 age bottom 0.12 179 0.1168 0.0138 44 79 14 24 
19 age bottom 0.11 170 0.1206 0.0135 44 79 14 24 
20 age bottom 0.11 161 0.1265 0.0134 46 79 14 24 
a QALY, quality adjusted life year; b RMDQ, Roland Morris disability questionnaire  
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9.3.3 ALL INTERVENTIONS VS CONTROL. MODERATORS:  AGE, PCS AND RMDQ 
Figure 43 and Figure 44 illustrate the peeling results for the analysis with age, PCS and 
RMDQ. As some trials did not have available PCS scores and others did not have RMDQ 
scores, the sample was restricted to two trials. The results of the peeling trace are very similar 
to those of analysis ii). The algorithm chose to peel almost exclusively on RMDQ and age. 
PCS was employed for the first iteration only. As the algorithm reduced the size of the 
treatment subgroup, the results showed that generally, older patients with worse (higher) 
RMDQ scores achieved better QALY gains from treatment. Although PCS was not much used 
for peeling, as the sample size was reduced participants with higher (better) PCS scores were 
removed from the treatment subgroup; this is unsurprising as RMDQ and PCS are correlated.  
As shown in Table 43 at the point where 19% of the starting sample was left in the treatment 
subgroup, the subgroup was comprised of participants aged 44 to 82 with an RMDQ score over 
12 and a PCS score between 7 and 49. At this point the treatment subgroup achieved a QALY 
gain of 0.0981 from treatment. When the whole population was treated, the mean QALY gain 
was lower at 0.0504. At a £20,000 per QALY cost-effectiveness threshold, the maximum 
willingness to pay for an intervention yielding these QALY gains would be £1,008 and £1,962 
for the whole population and the refined subgroup respectively. At £30,000 per QALY, these 
figures are £1,512 and £2,943 respectively. However as there is no measure of uncertainty 
reflected in these results, they should only be seen as illustrative. 
 Older patients with worse physical functioning as measured using the RMDQ at 
baseline appear to have moderately better response to treatment 
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Figure 43 Mean treatment effect in subgroup 
 
Figure 44 Weighted mean treatment effect across treatment subgroup and non-treatment 
subgroup 
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Table 43 Algorithm output for analysis 9.3.3 (see Table 40) 
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0 - - 1.00 1150 0.0504  18 85 7 61 0 24 
1 PCS top 0.95 1093 0.0534 -0.0086 18 85 7 51 0 24 
2 RMDQ bottom 0.90 1034 0.0533 0.0037 18 85 7 51 4 24 
3 RMDQ bottom 0.82 941 0.0574 -0.0133 19 84 7 51 5 24 
4 age bottom 0.78 894 0.0624 0.0187 29 84 7 51 5 24 
5 age bottom 0.74 850 0.0669 0.0087 32 84 7 51 5 24 
6 RMDQ bottom 0.65 748 0.0669 0.0087 32 84 7 51 6 24 
7 RMDQ bottom 0.56 648 0.0733 0.0100 32 84 7 51 7 24 
8 RMDQ bottom 0.48 554 0.0629 0.0354 32 84 7 51 8 24 
9 RMDQ bottom 0.41 472 0.0653 0.0410 32 84 7 51 9 24 
10 RMDQ bottom 0.35 397 0.0684 0.0438 32 84 7 49 10 24 
11 age bottom 0.33 378 0.0751 0.0429 35 84 7 49 10 24 
12 RMDQ bottom 0.28 321 0.0751 0.0429 35 82 7 49 11 24 
13 age bottom 0.27 305 0.0762 0.0394 38 82 7 49 11 24 
14 age bottom 0.25 290 0.0855 0.0367 40 82 7 49 11 24 
15 age bottom 0.24 276 0.0899 0.0363 42 82 7 49 11 24 
16 age bottom 0.23 263 0.0981 0.0343 44 82 7 49 11 24 
17 RMDQ bottom 0.19 213 0.0981 0.0343 44 82 7 49 12 24 
a QALY, quality adjusted life year; b PCS, physical component scale of SF-12/36; c 
RMDQ, Roland Morris disability questionnaire  
 
9.3.4 ACTIVE PHYSICAL INTERVENTION VS CONTROL. MODERATORS: AGE AND RMDQ 
Analysis so far has pooled all treatment modalities and compared these collectively with 
control. For analysis 9.3.4 (see Table 40) the intervention considered is made up of only active 
physical interventions, in this case exercise. The comparator arm is still control. This approach 
limited the data set to two trials. Figure 45 shows the peeling trace with RMDQ and age 
included as moderators within the algorithm.  
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The algorithm peeled almost exclusively based on the RMDQ score. As the algorithm reduced 
the sample size, patients with lower (better) RMDQ scores were removed, suggesting patients 
with worse baseline RMDQ scores achieve better treatment outcomes. At iteration 10, age was 
peeled on, removing patients who were younger.  
As can be seen in Figure 45, improvements in the mean incremental treatment effect for the 
subgroup were very small as no relevant subgroup could be identified from active physical 
treatment in these analyses.  
 
Figure 45 Mean treatment effect in subgroup   
9.3.5 PASSIVE PHYSICAL INTERVENTION VS CONTROL. MODERATORS: AGE AND PCS 
Analysis 9.3.5 (see Table 40) follows the same approach as 9.3.4 (see Table 40), however in 
this instance the treatment arm is comprised only of passive interventions; these included 
manipulation and acupuncture treatments the comparator remained as control. These 
conditions limited the dataset to three trials. The peeling algorithm was set to peel based on 
age and PCS. RMDQ score was not available for all the trials included in this analysis. 
As can be seen on Figure 46 there was very little change in the incremental treatment effect as 
the algorithm refined the treatment subgroup. No relevant subgroup could be identified 
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correlating age and/or PCS with above average treatment effect from passive physical 
treatment in these analyses. 
 
Figure 46 Mean treatment effect in subgroup   
9.3.6 ARDP-MA DIRECTED PEEL. ACTIVE PHYSICAL VS PASSIVE PHYSICAL 
INTERVENTIONS. MODERATORS: AGE AND RMDQ 
Analysis 9.3.6 (see Table 40) was a comparison of active physical interventions and passive 
physical interventions. The analysis includes data from two trials. The active treatment was 
made up of exercise and the passive treatment was made up of manual therapy. For the analysis, 
passive treatment was considered the reference case for all incremental estimates. The peel 
algorithm was set to refine the subgroup based on the age and RMDQ moderators. The 
algorithm elected to peel predominantly on the RMDQ score, removing patients with lower 
(better) RMDQ scores from the treatment group. As can be seen in Figure 47, the incremental 
effect of changing between these two treatment modalities was near zero. The result of the 
analysis suggests there is no difference in these two treatment modalities across the whole 
sample, or for any subgroup explored within the analysis of these data.  
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Figure 47 Mean treatment effect in subgroup 
9.4 DISCUSSION 
The application of the peeling algorithm was successful in identifying potentially interesting 
subgroups for the interventions vs control comparison. These subgroups comprised patients 
who were older with relatively worse physical functioning at baseline. The gain in treatment 
effect for the subgroup was small, therefore given the relatively low cost of the intervention 
treatment it is likely to be cost effective to offer treatment to the whole patient group. The 
algorithm, however, was not successful in finding any convincing subgroup in the pairwise 
comparison of active and passive physical treatment. This may be due to lack of power, or 
simply that there is no subgroup to be found. 
The QALY has some key advantages over the other available clinical outcomes. It is a holistic 
measure of health related quality of life designed to encompass both physical and mental 
aspects of a patient’s health state. Constructed using EQ-5D responses over time, the QALY 
also takes account of a patient’s recovery profile, integrating short and long term treatment 
response into a single measure. The EQ-5D is scored using the UK social tariff, this is validated 
and standardised allowing direct comparison of the treatment response for different 
interventions and diseases. The QALY estimated using the EQ-5D tariff is the accepted 
measure used by NICE for assessing the cost-effectiveness of new treatments for approval in 
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the NHS. The QALY did, however, raise some particular challenges for the analysis. The use 
of repeated measures to estimate the QALY restricted the size of the sample, as more 
observations were lost to missing data when compared to the point estimates used in the clinical 
analysis. This reduced the power of statistical analyses.  
The same approach was taken for moderator identification for the economic component of the 
analysis as for the clinical analyses. Three potential moderators (Age, PCS, RMDQ) of 
treatment response were identified for the economic analysis. However the relationship of the 
QALY with the moderators differed in some cases to that of the clinical outcome measures. 
For the short term clinical outcome of PCS, the age by treatment interaction was found to be 
negative and significant (p<0.2), suggesting that younger patients had a better treatment effect. 
For the outcome of FFbHR, the age treatment interaction was also negative but was just outside 
the significance threshold of p<0.2. For the other included clinical outcomes, age was not 
significant. When the QALY was used as the outcome measure, the age treatment interaction 
was significant at p<0.2 but the relationship was positive, indicating that older patients had a 
better treatment effect. The EQ-5D at short term follow up also exhibited a positive relationship 
with age, although this relationship was not significant. It may not be surprising that the 
relationship of the moderators with the different outcomes differed, as they measure different 
aspects of patient health. Furthermore, the QALY differs, by construction from the other 
outcome measures, as it is calculated as the area under the curve for a sequence of follow up 
points. However, it is also possible the results are susceptible to missing data bias. Patients 
with missing EQ-5D data at one or more follow up points were on average four years younger 
than patients with complete EQ-5D data (p<0.05). One could speculate that younger patients 
with better expected outcomes might have been excluded from our complete case analysis, as 
they failed to return follow up questionnaires. This could bias the treatment response down for 
younger patients. Four trials had short term EQ-5D data, comprising 1,774 patients (1,271 
Intervention; 503 Control) for which there was complete data. Of the 1,774 patient, 1,467 
(1,093 Intervention, 374 Control) had complete data at all EQ-5D follow up points, necessary 
to calculate a QALY estimate. This equates to an additional 17% missing data for QALYs 
compared with short term outcomes. This might possibly explain the difference in direction of 
relationship between age and treatment response by outcome measure, as the short term 
measures were less prone to missing data than the QALY. 
  256 
CHAPTER 10 – METHODOLOGY AND STATISTICAL 
DEVELOPMENTS 4: SUBGROUP IDENTIFICATION WITH 
INDIVIDUAL PARTICIPANT DATA INDIRECT NETWORK META-
ANALYSIS 
10.1 BACKGROUND 
The recursive partitioning and adaptive peeling approaches described in our analysis plan, 
whilst technically of a high standard, failed to identify clinically useful subgroups for whom 
treatment choices might be prioritised. We, therefore, also did an exploratory network meta-
analysis to identify groups who may gain the greatest benefit from different treatment choices 
from a Bayesian rather than a frequentist perspective. 
10.2 METHODS 
We carried out network meta-analyses of the repository trials to explore how the optimal choice 
of treatment for low back pain might vary across subgroups. Network meta-analysis (NWMA) 
is an extension of standard pair-wise meta-analysis applicable in situations where we have 
multiple treatments and an evidence base of trials which individually provide evidence on 
different subsets of all possible pairwise treatment combinations.148 NWMA involves 
analysing this network as a whole, by assuming consistency across treatment effects, so that a 
given pairwise comparison B vs C can be derived from trials against a common comparator (A 
vs B and A vs C trials) even if no B vs C trials exist.149 NWMA has become increasing popular 
in decision-making contexts because choosing among more than two treatments requires all 
pairwise treatment effects to be consistent in this way (the true treatment effects in the decision 
problem will always be consistent150, 151). Given their widespread use in Health Technology 
Assessment, NWMA commonly uses aggregate data, although there are examples illustrating 
the value of this approach when individual participant data (IPD) is available, particularly in 
understanding participant-level effect modification.152, 153  
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The standard model for pairwise meta-analysis involving a continuous normally-distributed 
outcome with linear effect modification can be written as equations (3) & (4). 
~ ( , )it it it ty Normal    (3) 
  it it t t itI d X X     (4) 
where 
ity is the outcome for participant i in trial t, it is the expected outcome for participant i 
if they had been given the control treatment for that trial, 
it is the expected impact of the 
treatment participant i received, 
itI takes value 0 if participant i is in the control arm of trial t, 
and 1 if they are in the intervention arm, 
td is the impact of the intervention for a reference 
participant, 
itX is a vector of covariate values for participant i, X is a vector of covariate values 
for the reference participant, and 
t is a vector of coefficients determining how the effect of 
the intervention evaluated in trial t varies as a function of the covariates of interest. It is possible 
to further allow for 
it to vary by participants, as shown by equation (5) 
 it t itb X X     (5) 
where 
t is the expected outcome in the control arm of trial t for the reference participant, and 
b is a vector of coefficients determining how the control outcome varies as a function of the 
covariates of interest.  
Network meta-analysis extends this analysis by introducing the consistency assumption as 
shown by equation (6) 
1, ( ) 1, ( )t active t control td d d   (6) 
where 
1, jd is defined as the treatment effect of any treatment j in the network compared to a 
reference treatment (such as standard care), and active(t) and control(t) are the active and 
control treatments in trial t, respectively. The consistency assumption can further be applied to 
the 
t  parameters as shown by equation (7) 
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1, ( ) 1, ( )t active t control t     (7) 
We carried out three separate NWMAs for the outcomes of interest – short-term change in 
Roland Morris disability questionnaire (RMDQ), short-term change in physical component 
scale of SF-12/36 (PCS), and short-term change in mental component scale of SF-12/36 
(MCS). All models explore age, sex and baseline PCS/MCS as covariates for both control 
outcome variation and effect modification. RMDQ models also include baseline RMDQ for 
both adjustments. Model estimation involved Bayesian Markov Chain Monte Carlo simulation 
carried out using WinBUGS 1.4.3, using NMWA models adapted for IPD analysis from 
aggregate-data NWMA models developed for the UK National Institute of Health and Care 
Excellence.154 
10.3 RESULTS 
10.3.1 SHORT-TERM RMDQ OUTCOME 
Thirteen trials (n = 3447) in the repository reported this outcome. The resulting network of 
evidence is illustrated in Figure 48.  
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Figure 48 Network of evidence for short-term RMDQ. Each line denotes the existence of 
head-of-trials of the two treatments being connected, and the accompanying information 
denotes the number and names of trials making the comparison. 
Table 44 gives the predicted treatment effects from the NWMA of these trials for any pairwise 
comparison of the five treatment classes in the network, assuming a participant profile 
representing a typical (male) participant. This shows that for the paradigmatic case of a male 
aged 50, male, and baseline values of RMQ=10, PCS=40 and MCS=40 all treatment choices 
are superior to usual care control treatment. For sham treatment, however, the point estimate 
for the 95% credible interval for RMDQ does include zero. Also the differences between any 
two treatment approaches can be estimated. For example, in this paradigmatic case there does 
not seem to be a meaningful difference between sham treatment and psychological treatment.  
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Table 44 Treatment effect with modification (absolute reduction in short term RMDQ, 
mean and 95% credible interval). Coefficients given for individual aged 50, male, 
RMQ=10, PCS=40 and MCS=40 at baselinea.  
  Comparator 
In
te
rv
en
ti
o
n
 
 Control Active 
Physical 
Passive Physical  Psychological 
Active 
Physical 
1.94  
(1.17, 2.72) 
   
Passive 
Physical 
2.17 
(1.39, 1.95) 
0.23  
(-0.61, 1.07) 
  
Psychological 
1.45  
(0.74, 2.15) 
-0.49  
(-1.31, 0.32) 
-0.72  
(-1.52, 0.08) 
 
Sham 
1.60  
(-1.07, 4.11) 
-0.34  
(-2.95, 2.1) 
-0.57 
(-3.2, 1.9) 
0.15  
(-2.47, 2.63) 
a Predicted change in condition without treatment adjusted for age, sex, and baseline values of 
RMDQ, SF-12/36 PCS and SF-12/36 MCS. 
Table 45 presents coefficient values reflecting the degree of effect modification for the 
participant characteristics of interest. The evidence for effect modification appears strongest 
for RMDQ; it is the only characteristic whose coefficient credible intervals for all three 
treatment verum interventions exclude zero; for sham treatment it does include zero. This 
analysis suggests that for each one point increase in baseline RMDQ an additional 0.17 to 0.26 
benefit from active treatments and a 0.43 point benefit from sham treatment will be achieved. 
However, the 95% credible intervals suggest the evidence for effect modification related to 
other covariates is less strong. To quantify the strength of evidence for effect modification, we 
calculated ‘Bayesian Probabilities of effect modification (BP)’, defined as the greater of two 
probabilities; that an increase in the characteristic predicts an increase in treatment effect, or 
that it predicts a decrease. A BP of 0.8, for example, suggests that we are 80% sure that a 
change in the characteristic will increase the effect of treatment. For RMDQ, the BPs are all 
above 0.99 (except for sham, with a BP of 0.92) - overwhelming evidence that the effect of 
treatment depends on baseline scores.  
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The Bayesian Probabilities indicate some, possibly important, differences in benefit by other 
baseline variables. For example, it is at least 70% likely that men respond more strongly than 
women to sham treatments and physical treatment but it is equally likely that men respond 
more or less strongly than women following psychological treatments. On the other hand 
baseline MCS has a BP of 85% of positively influencing response to psychological treatments 
(i.e. those with low levels of psychological distress respond more strongly to psychological 
treatments than those with high levels of psychological distress), but is almost equally likely to 
be positively or negatively related to outcomes following physical treatments or sham 
treatment. 
Table 45 Mean, 95% credible intervals and Bayesian Probabilities (BP) for impact of 
participant characteristics on effect of treatments (Vs. Control). 
 Active Physical Passive Physical  Psychological Sham 
Agea 
-0.02  
(-0.05, 0.02) 
BP = 0.83 
0.00  
(-0.03, 0.03) 
BP = 0.60 
-0.02  
(-0.05, 0.01) 
BP = 0.91 
-0.01  
(-0.08, 0.07) 
BP = 0.56 
Sex 
-0.22  
(-1, 0.56) 
BP = 0.71 
-0.38  
(-1.16, 0.4) 
BP = 0.83 
-0.01  
(-0.78, 0.77) 
BP = 0.51 
-1.12  
(-2.74, 0.49) 
BP = 0.91 
RMDQa 
0.18  
(0.06, 0.31) 
BP > 0.99 
0.26  
(0.14, 0.39) 
BP > 0.99 
0.17  
(0.05, 0.29) 
BP > 0.99 
0.43  
(-0.11, 0.93) 
BP = 0.92 
MCSa 
-0.01  
(-0.06, 0.05) 
BP = 0.59 
0  
(-0.05, 0.05) 
BP = 0.51 
0.03  
(-0.03, 0.08) 
BP = 0.85 
-0.06  
(-0.35, 0.24) 
BP = 0.59 
PCSa 
0.05  
(-0.03, 0.13) 
BP = 0.89 
0.04  
(-0.04, 0.12) 
BP = 0.84 
0.03  
(-0.04, 0.11) 
BP = 0.81 
-0.04  
(-0.53, 0.41) 
BP = 0.52 
a Positive value indicates greater reduction in RMDQ from treatment (Vs. Control) as covariate 
increases; b Positive value indicates greater reduction in RMDQ from treatment (Vs. Control) 
for females Vs. males. 
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All treatment effects increase but at different rate, so that the optimal treatment changes as 
RMDQ varies. Passive physical therapy is the optimal therapy for the participant as described 
in Table 45, whose RMDQ is 10. However, sham therapy becomes the optimal treatment if 
RMDQ increases beyond 14 points, while active physical therapy becomes optimal if RMDQ 
decreases beyond seven points. 
These thresholds depend on values for other effect modifiers, although their influence is less 
certain. The only other characteristics with a BP above 0.90 are age (psychological therapy) 
and sex (sham therapy). There is evidence, albeit inconclusive, that as age decreases active 
physical and psychological therapies are relatively more effective. Figure 49 and Figure 50 
show how this relationship can be used to define Age/RMDQ zones in which each treatment is 
optimal. Broadly speaking, passive physical therapy is optimal for older participants with mild-
to-moderate RMDQ at baseline, active physical therapy is optimal for participants with low 
RMDQ at baseline, and sham therapy is optimal for participants with high RMDQ at baseline. 
If we disregard sham treatments as an inappropriate choice for clinical guidelines, passive 
physical therapies would be optimal for all but the youngest participants with high RMDQ 
baseline scores (the division would be determined by extending the active-passive equal line 
into the right hand side of the graphs). There are no participant profiles for which no 
intervention is the optimal treatment. 
.  
Figure 49 RMDQ outcome; optimal treatment as a function of RMDQ at baseline and 
age for men with MCS=PCS=40, with proportion of male trial participants whose 
baseline RMDQ and age fit into each zone (n = 721) 
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Figure 50 RMDQ outcome; optimal treatment as a function of RMDQ at baseline and 
age for women with MCS=PCS=40, with proportion of female trial participants whose 
baseline RMDQ and age fit into each zone (n = 1,054) 
To quantify the strength of evidence for these optimal zones, we calculated the probability that 
each treatment is optimal for a representative participant profile in each zone. The results (see 
Table 46) show that there is considerable uncertainty around the optimal treatment – participant 
profile 1, for example, is in the passive physical optimal zone, but there is a 54% chance that 
this is not the optimal treatment for this profile. However, suboptimal treatments can be 
identified with a greater degree of certainty – psychological therapies, for example, are highly 
unlikely to be optimal for older participants, or those with high RMDQ at baseline (i.e. 
participant profiles 1, 3, 4 and 6).   
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Table 46 Probability that any given treatment is optimal for a range of participant 
profiles. 
 Probability that treatment is optimal for this participant profile 
 Active 
Physical 
Passive 
Physical Psychological Sham 
Participant profile 1: 
Male, RMDQ 10, Age 
50 
18% 46% <1% 35% 
Participant profile 2: 
Male, RMDQ 6, Age 30 
57% 11% 19% 13% 
Participant profile 3: 
Male, RMDQ 16, Age 
40 
8% 34% <1% 57% 
Participant profile 4: 
Female, RMDQ 14, Age 
50 
11% 46% 2% 41% 
Participant profile 5: 
Female, RMDQ 10,  
Age 30 
53% 14% 27% 6% 
Participant profile 6: 
Female, RMDQ 20, Age 
40 
8% 35% 2% 54% 
 
10.3.2 SHORT-TERM SF-12/36 PCS OUTCOME 
Nine trials (n = 5574) in the repository reported this outcome. The resulting network of 
evidence is illustrated in Figure 51. 
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Figure 51 Network of evidence for short-term PCS. Each line denotes the existence of 
head-of-trials of the two treatments being connected, and the accompanying information 
denotes the number and names of trials making the comparison. 
Table 47 gives the predicted treatment effects from the NWMA of these trials for any pairwise 
comparison of the five treatment classes in the network, assuming a participant profile 
representing a typical (male) participant. Table 48 presents coefficient values reflecting the 
degree of effect modification for the participant characteristics of interest. All characteristics, 
except for age, have at least one effect modification coefficient with a Bayesian Probability 
above 0.95.   
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Table 47 Treatment effect with modification (absolute increase in short term PCS, mean 
and 95% credible interval). Coefficients given for individual aged 50, male, PCS and 
MCS=40, Predicted change in condition without treatment adjusted for age, sex, MCS.  
  Comparator 
 Control 
Active 
Physical 
Passive 
Physical 
Psychological 
In
te
rv
en
ti
o
n
 
Active 
Physical 
3.93 
(2.55, 5.32) 
   
Passive 
Physical 
3.16 
(2.4, 3.92) 
-0.77 
(-2.13, 0.58) 
  
Psychological 
2.58 
(0.85, 4.29) 
-1.36 
(-3.36, 0.63) 
-0.58 
(-2.33, 1.18) 
 
Sham 
1.64 
(-0.03, 3.32) 
-2.29 
(-4.33, -0.25) 
-1.52 
(-3.18, 0.15) 
-0.93 
(-3.23, 1.38) 
 
Table 48 Mean, 95% credible intervals and Bayesian Probability for impact of 
participant characteristics on effect of treatments in the network 
 Active Physical Passive Physical Psychological Sham 
Agea 
0.02 
(-0.05, 0.08) 
BP = 0.68 
-0.01 
(-0.04, 0.03) 
BP = 0.71 
-0.04 
(-0.1, 0.03) 
BP = 0.87 
(-0.06, 0.06) 
BP = 0.52 
Sexb 
0.25 
(-1.25, 1.75) 
BP = 0.63 
0.95 
 (0.04, 1.87) 
BP = 0.98 
0.29 
 (-1.43, 2.01) 
BP = 0.63 
1.55 
(-0.15, 3.23) 
BP = 0.96 
MCS0a 
-0.01 
(-0.07, 0.06) 
BP = 0.59 
0.01 
(-0.02, 0.05) 
BP = 0.76 
0.03 
(-0.04, 0.11) 
BP = 0.80 
-0.07 
(-0.14, 0.00) 
BP = 0.97 
PCS0a 
-0.05 
(-0.15, 0.05) 
BP = 0.85 
-0.07 
(-0.13, -0.02) 
BP > 0.99 
-0.03 
(-0.13, 0.06) 
BP = 0.76 
-0.10 
(-0.22, 0.02) 
BP = 0.95 
a Positive value indicates greater increase in PCS from treatment (Vs. Control) as covariate 
increases; b Positive value indicates greater increase in PCS from treatment (Vs. Control) for 
females Vs. males. 
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Figure 52 and Figure 53 show how effect modification can be used to define PCS/MCS zones 
in which each treatment is optimal with short-term PCS as outcome of interest. Broadly 
speaking, passive physical therapy is optimal for participants with low PCS scores and high 
MCS scores, while active physical therapy is optimal for participants with high PCS scores and 
low MCS scores. Sham appears optimal for participants with low PCS and MCS scores at 
baseline. If we disregard sham as a valid optimal treatment, the optimal non-sham treatment 
zones can be identified by extending the active-passive equal line, as with the RMDQ-based 
zones. Again, there are no participant profiles for which no intervention is optimal.  
To quantify the strength of evidence for these optimal zones, we calculated the probability that 
each treatment is optimal for a representative participant profile in each zone.  
The results (see Table 49) show that, as with RMDQ, there is greater certainty around which 
treatments are sub-optimal than around which treatments are optimal. For the paradigmatic 
cases in Figure 52 and Figure 53, it is unlikely that psychological treatments would be the best 
choice for either gender, but a clear indication that there might be differences in proportions 
who might benefit from active or passive physical treatments if PCS/MCS and sex were the 
only parameters used for decision making. 
 
Figure 52 PCS outcome; optimal treatment as a function of MCS and PCS at baseline for 
men aged 50, with proportion of male participants whose MCS and PCS baseline scores 
fit into each zone (n = 2,296). 
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Figure 53 PCS outcome; optimal l treatment as a function of MCS and PCS at baseline 
for women aged 50, with proportion of female participants whose MCS and PCS baseline 
scores fit into each zone (n = 3,278). 
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Table 49 Probability that any given treatment is optimal for a range of participant 
profiles with PCS as outcome of interest. 
 Probability that treatment is optimal for this participant profile 
 Active 
Physical 
Passive 
Physical Psychological Sham 
Participant profile 1: 
Male, MCS 40 and PCS 
40 
81% 11% 7% <1% 
Participant profile 2: 
Male, MCS 70 and PCS 
20 
42% 43% 15% <1% 
Participant profile 3: 
Female, MCS 30 and 
PCS 50 
55% 18% 6% 21% 
Participant 4: Female, 
MCS 60 and PCS 30 
23% 68% 9% <1% 
Participant 5: Female, 
MCS 20 and PCS 20 
20% 11% 1% 68% 
 
10.3.3 SHORT-TERM SF-12/36 MCS OUTCOME 
The network of evidence for this outcome is the same as for SF-12/36 PCS. Table 50 gives the 
predicted treatment effects from the NWMA of these trials for any pairwise comparison of the 
five treatment classes in the network, assuming a participant profile representing a typical 
(male) participant. Table 51 presents coefficient values reflecting the degree of effect 
modification for the participant characteristics of interest. All characteristics, except for sex, 
have at least one effect modification coefficient with a Bayesian Probability above 0.95. It is, 
perhaps, worth noting here that for short-term MCS as an outcome that for our paradigmatic 
case it is passive physical therapy that has the largest effect size. At least for the comparison 
with active physical the 95% credibility interval does not cross zero. 
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Table 50 Treatment effect with modification (absolute change in short term MCS, mean 
and 95% credible interval). Coefficients given for individual aged 50, male, PCS and 
MCS=40. Predicted change in condition without treatment adjusted for age, sex, baseline 
values of SF-12/36 PCS and MCS. 
  Comparator 
  Control 
Active 
Physical 
Passive 
Physical 
Psychological 
In
te
rv
en
ti
o
n
 
Active 
Physical 
1.53 
(0.04, 3.02) 
   
Passive 
Physical 
3.04 
(2.23, 3.85) 
1.50 
(0.05, 2.96) 
  
Psychological 
2.59 
(0.80, 4.39) 
1.06 
(-1.04, 3.17) 
-0.44 
(-2.26, 1.39) 
 
Sham 
2.13 
(0.44, 3.82) 
0.60 
(-1.53, 2.73) 
-0.90 
(-2.59, 0.79) 
-0.46 
(-2.83, 1.90) 
 
Table 51 Mean, 95% credible intervals and Bayesian Probabilities (BP) for impact of 
participant characteristics on effect of treatments in the network. 
 Active Physical Passive Physical Psychological Sham 
Agea 
-0.02 
(-0.09, 0.05) 
BP = 74% 
-0.03 
(-0.07, 0.01) 
BP = 93% 
0.00 
(-0.06, 0.07) 
BP = 53% 
-0.09 
(-0.15, -0.03) 
BP > 99% 
Sexb 
0.36 
(-1.23, 1.96) 
BP = 67% 
-0.20 
(-1.18, 0.78) 
BP = 66% 
-0.47 
(-2.26, 1.34) 
BP = 70% 
0.73 
(-0.99, 2.44) 
BP = 63% 
MCSa 
-0.06 
(-0.13, 0.01) 
BP = 97% 
-0.10 
(-0.14, -0.06) 
BP > 99% 
-0.05 
(-0.13, 0.03) 
BP > 90% 
-0.17 
(-0.24, -0.09) 
BP > 99% 
PCSa 
-0.03 
(-0.13, 0.08) 
BP = 68% 
-0.08 
(-0.14, -0.02) 
BP > 99% 
0.05 
(-0.04, 0.15) 
BP > 86% 
-0.15 
(-0.27, -0.03) 
BP > 99% 
a Positive value indicates greater increase in MCS from treatment (Vs. Control) as covariate 
increases; b Positive value indicates greater increase in MCS from treatment (Vs. Control) for 
females Vs. males. 
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Figure 54 and Figure 55 show how effect modification can be used to define PCS/MCS zones 
in which each treatment is optimal. Broadly speaking, psychological therapy is optimal for 
participants with high PCS scores (low levels of disability) and moderate-to-high MCS scores 
(low levels of psychological distress). Passive physical therapy is optimal for participants with 
low PCS scores and high MCS scores, and sham therapy is optimal for participants with low 
PCS and MCS scores (high disability and high levels of psychological distress). If we disregard 
sham as a feasible recommendation, passive physical therapy becomes optimal for these 
participants (there are no participant profiles for which no intervention is optimal). To quantify 
the strength of evidence for these optimal zones, we calculated the probability that each 
treatment is optimal for a representative participant profile in each zone. The results (see Table 
52) show that, as with RMDQ, there is greater certainty around which treatments are sub-
optimal than around which treatments are optimal. However, the evidence for effect 
modification appears strongest on this outcome. It is of note that for some participant groups 
(those with high disability and high levels of psychological distress) it appears that sham 
treatment is highly likely to be the most effective option. 
 
Figure 54 MCS outcome; optimal l treatment as a function of MCS and PCS at baseline 
for men aged 50, with proportion of male participants whose MCS and PCS baseline 
scores fit into each zone (n = 2,296). 
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Figure 55 MCS outcome; optimal treatment as a function of MCS and PCS at baseline 
for women aged 50, with proportion of female participants whose MCS and PCS baseline 
scores fit into each zone (n = 3,278). 
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Table 52 Probability that any given treatment is optimal for a range of participant 
profiles. 
 Probability that treatment is optimal for this participant profile 
 Active 
Physical 
Passive 
Physical Psychological Sham 
Participant profile 1: 
Male, MCS 60 and PCS 
60 
6% <1% 91% <1% 
Participant profile 2: 
Male, MCS 70 and PCS 
20 
11% 65% 13% 10% 
Participant profile 3: 
Male, MCS 30 and PCS 
30 
<1% 31% <1% 68% 
Participant profile 4: 
Female, MCS 60 and 
PCS 60 
12% <1% 82% <1% 
Participant profile 5: 
Female, MCS 80 and 
PCS 20 
26% 32% 15% 11% 
Participant profile 6: 
Female, MCS 80 and 
PCS 20 
<1% 13% <1% 87% 
 
It is perhaps of note that for some patient groups (those with high disability and high levels of 
psychological distress) it appears that sham treatment is highly likely to be the most effective 
option. 
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CHAPTER 11 - DISCUSSION 
11.1 INTRODUCTION 
This work is grounded in the pressing need to improve the outcomes for people living with low 
back pain. The targeting of treatments of proven but modest average effectiveness at those 
likely to gain the greatest benefit holds promise. It is the considerable uncertainty over which 
patients are most likely to benefit from which treatment strategy that was the driver for this 
research. Improved matching of patients to individual treatments has the potential to improve 
the overall health gain from, and cost-effectiveness of, treatments for LBP. In particular, how 
individual patient factors including duration and severity of the back pain, and physical, social 
and psychological factors might affect both adherence and treatment response. There is much 
published work on predictors of poor outcome for people with low back pain; for example the 
psychosocial ‘yellow flags’155 or the StartBack tool156. None, of this work has, however, 
addressed how these risk factors affect response to treatment. Without explicitly addressing if 
a particular patient characteristic moderates treatment outcome, targeting treatments at those 
perceived to be at high risk may not be an appropriate choice.  During this programme of work 
we have explored in considerable detail, in two systematic reviews, what is already known 
about identifying subgroups of people with LBP.  This work has demonstrated that the existing 
work to identify sub-groups of patients with low back pain, within randomised controlled trials 
is generally of a poor methodological quality and even the high quality studies do not present 
evidence to support treatment choices at an individual patient level. Importantly, in this work 
we have moved beyond using data from single trials and use of single parameters to define sub-
groups. A large focus of this work has been very technical on how best to address the challenge 
of pooling very complex datasets and how best to define sub-groups using multiple parameters. 
To do this we made a series of methodological developments, including three novel methods 
for subgroup identification: two algorithmic approaches (recursive partitioning, and adaptive 
risk group refinement); and individual participant data indirect network meta-analysis. 
Within the limits of the data that were suitable for pooled analysis, we have  identified 
exploratory subgroups of people who might gain a greater benefit from different treatment 
approaches in a consistent manner. Interestingly, the groups that we identified as possibly 
gaining greater benefit from therapist-delivered interventions rather than usual care were 
typically the converse of expectations. So far as the evidence goes, it seems that younger people 
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with less psychological distress are likely to gain the greatest benefit from these treatments. 
Whilst the findings are not strong enough to support these as parameters to prioritise treatment, 
they do challenge conventional wisdom that people with psychological distress should be 
targeted for treatment.  
11.2 SUMMARY KEY FINDINGS 
11.2.1 SYSTEMATIC REVIEWS (CHAPTER 2) 
Notwithstanding the perceived importance of performing research to identify subgroups of 
people living with chronic low back there is a paucity of high quality research in this area. We 
have identified that nearly all papers reporting analyses of subgroup effects provide no more 
than exploratory evidence and that only one study reporting treatment moderation was 
adequately powered for this analysis. Whilst it is the identification of differential subgroup 
effects that is of interest we failed to identify any robust research that considered subgroups 
defined by multiple parameters. Rather, we found studies that tested the effect of single 
potential effect moderators. We have previously found that the available data do not support 
the use of clinical prediction rules in the management of LBP.93  
Age, employment status, education level, back pain status, narcotic use, treatment expectations, 
moderated treatment effect with p<0.05 in one or more study. The exploratory nature of nearly 
all of the comparisons, the inconsistent findings across the four included studies, and the large 
number of comparisons made means that these findings cannot, in themselves, be used to 
inform management. Notwithstanding the limitations of the existing research we were able to 
identify some potential moderators to include in our final analyses. The overall weakness of 
the underpinning data meant that we included potential moderators in our analyses that did not 
meet conventional criteria for statistical significance. By including moderators found to be 
significant at the 20% level our pool of potential moderators became: age, gender, employment 
status, education, back pain status, pain related disability, narcotic use, treatment expectations, 
quality of life and psychosocial status.  
11.2.2 ANCOVA ANALYSES (CHAPTER 6) 
Our ANCOVA analyses replicate the conventional approach to moderator identification in a 
pooled dataset. The main purpose of this analysis was to inform selection of potential 
moderators for our main analysis based on identifying variables significant at the 20% level. 
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As with our analyses we were restricted in these analyses by the pool of trials using a common 
set of baseline covariates and outcomes. In this analysis comparing all intervention groups to 
all control groups (non-active usual care plus sham for clinical outcomes or usual care for 
Health economic outcomes) we identified some moderators that reached conventional 
statistical significance for some outcomes. Summarising these findings these data suggest that 
those who are worse on a measure of physical function (FFbHR/SF-12/36 physical component 
score, PCS) have the most to gain from treatment on physical outcomes and those who are 
worse on the SF-12/36 mental component score (MCS) at baseline gain the most on this 
outcome measure. For the outcome of EQ-5D its baseline value did not moderate treatment 
response, but pain, physical function (SF-12/36 PCS) and anxiety that are arguably components 
of the EQ-5D did moderate response. The exception to the observation that it is severity at 
baseline that predicts response to treatment on that measure is that a less favourable baseline 
FFBHR score moderates outcome on SF-12/36 MCS. Anxiety but not catastrophising, coping 
strategies, and depression, moderated treatment response, at p<0.05 in the analyses for the 
outcome of EQ-5D where those with lower risk of anxiety had less treatment effect than those 
with higher risk of anxiety. This is the first meta-analysis to assess effect moderation in the 
treatment of LBP and hence gives a far more robust assessment than any previous work in this 
area. The numbers in our analyses mean that if there were true moderation effects in this 
comparison of all treatments against control that they should have been identified. 
Whilst these observations are of some interest the main purpose of this analyses was to select 
potential moderators significant at the 20% level to take forward for our main analyses. We 
were able to take forward FFbHR, RMDQ, SF-12/36 PCS and MCS, age, gender, pain, fear 
avoidance and coping as variable with a possible single in one or more analysis. 
11.2.3 RECURSIVE PARTITIONING (CHAPTER 7) 
We successfully adapted two recursive partitioning approaches to identify subgroups in an 
individual participant data meta-analysis. There are important distinctions in the way they 
work. The IPD-IT method is seeking to maximise the size of the interaction term when making 
splits whilst the IPD-SIDES method is seeking to detect groups with the largest treatment 
effects.141 The choice of approach in any future analyses using a recursive partitioning 
approach will depend on the primary outcome of interest. For our current purpose we prefer 
the IPD-SIDES approach as we think it is more likely to identify clinically useful subgroups 
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with large effect sizes. The IPD-IT approach may be more suitable for more exploratory 
analyses where maximising any moderation is the outcome of interest. We have presented both 
analyses here to explore how they perform on a real dataset. The IPD-SIDES approach appears 
to be more sensitive as it has successfully identified some subgroups within our data whilst the 
IPD-IT method did not (see Table 53, Table 55, Table 56, Table 57 and Chapter 7). Our overall 
analysis of all interventions vs control (usual care or sham control) provides evidence that the 
IPD-SIDES method functions well; we found candidate subgroups in a real data set as well as 
the simulation in which it was originally tested. For the choice of treatment vs. control (sham 
plus usual care) using the full dataset there are some clusters of characteristics with different 
treatment outcomes. For example, for the outcome FFbHR (range of the score is from 0 = great 
limitation to 100 = no limitation) the overall treatment effect of 8.93 (95% CI 7.81 to 10.05) 
increases to 13.17 (95% CI 10.56 to 15.77) in those with an FFbHR score ≤54.2 and aged ≤60 
or for the SF-12/36 Physical Component Score (range 0-100 best) the overall treatments effect 
increases from 3.48 (95% CI 3.01 to 3.96) to 4.89 (95% CI 3.96 to 5.82) in those with a SF-
12/36 physical component score ≤40.0 and an SF-12/36 mental component score >54.2. It is, 
however, the pairwise comparisons, with usual care control, that might be useable to inform 
clinical practice.  
11.2.3.1 Passive physical therapy 
For passive physical therapy we identified subgroups for the outcomes of FFbHR, plus SF-
12/36 – mental and physical component scores. The results for FFbHR, which represent just 
acupuncture trials, find a maximal effect of 16.67 (95% CI 13.16 to 20.18) when compared to 
an overall treatment effect of 9.95 (95% CI 8.80 to 11.11) in those aged ≤53 and with an FFbHR 
≤54.2. Thus acupuncture is likely to more effective in those with a worse baseline score and 
who are younger. This finding is probably of little clinical importance as none of the splits 
identified a group in whom the treatment was ineffective and only 17% of participants 
(571/3272) were in this group with the largest effect. For the SF-12/36 mental component score 
the maximal effect is seen in those with a low score on both physical and mental component 
score. In the group with an MCS≤ 54.3 and PCS≤43.9 the treatment effect increases from 2.96 
(95% CI 2.31 to 3.61) to 4.27 (95% CI 3.39 to 5.15). On this occasion 56% of participants 
(2,171/3,898) fall into this group. Again none of the splits identified a group where the 
treatment was not effective suggesting it would not be helpful in clinical practice. This could, 
in any event, only be plausibly clinically important if the outcome of interest was mental health.  
  278 
For the SF-12/36 physical component score IPD-SIDES found nine candidate models, 
including one with three splits; baseline physical and mental component scores and gender. 
The final split on gender did not, however, achieve conventional statistical significance at the 
5% level. Several candidate models were identified. All included severity on the physical 
component score as the first split with either age of mental component score as the second split. 
Treatment most effective in those with more severe problems and who were younger or had 
better mental health. There was little to choose between the added effect from each of the 
different models with two splits, and no split was found for which the intervention was 
ineffective. This makes it difficult to suggest a ‘best’ choice. It is however of note that 
increasing psychological distress appears to make it less likely that passive physical 
interventions will be effective. This does not support the notion that such treatments should be 
targeted at those with increased psychological distress.  
11.2.3.2 Active physical therapy 
We did not find any subgroups with an enhanced response to active physical therapy 
11.2.3.3 Psychological therapy 
There were fewer participants included in this analysis (n=928) than for passive physical 
treatments (n = up to 3898) reducing potential for finding subgroups. Nevertheless the IPD-
SIDES method did identify one split for the RMDQ outcome based on baseline severity as 
measured using the RMDQ (range 0-24, 0=best). This split might be of clinical relevance; the 
75% (231/928) of participants with an RMDQ of >4 gained an additional 1.07 points benefit 
taking the average treatment effect from 1.40 (95% CI 0.89 to 1.91) to 1.72 (95% CI 1.12 to 
2.31). Furthermore for the group with an RMDQ score of ≤4 the 95% confidence interval for 
the mean effect included zero (0.65 (95% CI -0.11 to 1.40)). This indicates that psychological 
treatments should be reserved for those with higher RMDQ scores. For the RMDQ, unlike the 
other outcome measures reported here, there is an established minimally importance change 
for an individual; 5.0 points.30 The size of the interaction can be interpreted as a small 
difference; i.e. 0.21 of the minimally important change.157 It is nevertheless comparable with 
the overall effect size at three months identified in the Back Skills Training (BeST) trial (1.1 
points on RMDQ 95% CI 0.38 to 1.71) that did not have a lower limit of the RMDQ for study 
entry.31 These data can reasonably be used to indicate that psychological treatments should be 
reserved those with an RMDQ of >4. Interpreting the importance of this observation needs to 
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include the important caveat that all of the analyses reported here are exploratory rather than 
confirmatory. It also fits with the general pattern that treatment tend to have greater effects in 
those with worse baseline scores on the outcome of interest 
11.2.3.4 Sham treatment  
Interpreting the findings for sham treatments, on this occasion sham acupuncture from two 
trials 102, 117 on the SF-12/36 mental component score is quite challenging. The results of the 
IPD-SIDES analysis appear to show that for those aged over 65 and for those with an SF-12/36 
PCS of greater than 42.0 that sham acupuncture is substantially less effective and that in rest 
of the population the effect size is enhanced. Whilst the point estimates indicate harm the 95% 
confidence intervals include zero and, at least for SF-12/36 the interaction effect is of 
borderline statistical significance (p=0.043). It may well be, for age, that we are observing the 
same phenomena seen for other interventions where older people, and those with fewer 
symptoms, are less likely to benefit. The option of a sham treatment is unlikely to be explicitly 
offered by the NHS. It could be argued that we do not need to consider this further. On the 
other hand any sham intervention includes the potentially very important therapist–patient 
interaction that is part of all of the interventions we have examined. The differential effects 
observed might be clinically important in that we have identified subgroups (those aged over 
65 and those with a better physical component score > 42.0) who might be harmed by the sham 
intervention. If this were a true observation it might lead one to question the benefit of offering 
some therapist delivered interventions to an older age group or to those with less disability as 
a consequence of potential adverse effects on their mental health. 
11.2.4 ADAPTIVE REFINEMENT BY DIRECTED PEELING IN IPD META-ANALYSIS (CHAPTER 
8) 
We have successfully extended an adaptive risk group refinement method for use for 
identifying subgroups of patient who may respond better to different treatments. In contrast to 
the recursive partitioning approaches adaptive risk group refinement produces multiple 
solutions representing different sized proportions of the population, allowing the user to decide 
at which point on any trajectory plot that the additional benefit for selecting subgroups would 
be clinically worthwhile. This is achieved by repeatedly searching within the dataset to identify 
successively smaller subgroups with larger effects. This approach does not produce the 
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monotonic changes in subgroup specification seen when a peeling approach Chapter 9 is used, 
but may give a better representation of effect for a pre-specified size of subgroup.  
We were limited, by lack of computational power, to just exploring the effect of four co-
variates; there is however, no statistical reason for restricting the covariates used to just four. 
In this restriction we were able to do a more extensive search by considering all possible 
combinations of subgroups thus interrogating the data more thoroughly. It can be seen how this 
approach can define subgroups in the example of the FFbHR outcome (three acupuncture trials) 
for all interventions vs. control (usual care and sham) (see Figure 21 and Table 27). Here a 
clear trajectory with average effect size increasing from 8.47 to 16.79 is seen. This is largely 
driven by baseline FFbHR. In contrast no such pattern is seen for the RMDQ outcomes Figure 
25 suggesting that there is not potential for subgroup identification for this group of studies. 
For the SF-12/36 mental and physical component score outcomes the high variability as 
subgroup size decreases suggest that it is not possible to define subgroups reliably for these 
outcomes. Thus for our interpretation of all intervention vs. control (non-active usual 
care/placebo) is that for the FFbHR outcome younger people with a worse FFbHR and worse 
PCS may gain more from treatment and that for the SF-12/36 MCS outcome that those who 
are younger and with a worse MCS are likely to gain the greatest benefit. Results from pairwise 
comparisons between different types of treatment and non-active usual care controls are 
considered in the following subsections. 
11.2.4.1 Passive physical therapy 
We found a similar pattern to the overall comparison, for the FFbHR result when passive 
physical (acupuncture) was compared to non-active usual care; i.e. it was more effective for 
those who were younger with a worse baseline score.  
We also found that for the outcome of SF-12/36 MCS that those who were younger with worse 
PCS and MCS gained a greater benefit.   
11.2.4.2 Active physical therapy 
We did not find any subgroups with an enhanced response to active physical therapy. In 
particular we did not find that baseline RMDQ consistently identified subgroups with a better 
treatment effect.  
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11.2.4.3 Psychological therapy 
We did not find any subgroups with an enhanced response to psychological therapy. 
11.2.4.4 Sham  
We were again able to identify a group who might do better with sham treatment. Its definition 
was again driven by age and baseline severity. Curiously, a worse baseline mental component 
score appears to predict who responds better to sham acupuncture but not who responds to true 
acupuncture. 
11.2.5 IDENTIFICATION OF COST-EFFECTIVE SUBGROUPS BY DIRECT PEELING (CHAPTER 
9) 
The application of the peeling algorithm was successful in identifying potentially interesting 
subgroups for the interventions vs control comparison. These subgroups comprised patients 
who were older with relatively worse physical functioning at baseline. The gain in treatment 
effect for the subgroup was small. Therefore, given the relatively low cost of the intervention 
treatment is likely to be cost effective for the whole patient group. The algorithm, however, 
was not successful in finding any convincing subgroup in the pairwise comparison of active 
and passive physical treatment. This may be due to lack of power, or simply that there is no 
subgroup to be found. 
The QALY has some key advantages over the other available clinical outcomes. It is a holistic 
measure of health related quality of life designed to encompass both physical and mental 
aspects of a patient’s health state. Constructed using EQ-5D responses over time, the QALY 
also takes account of a patient’s recovery profile, integrating short and long term treatment 
response into a single measure. The EQ-5D is scored using the UK social tariff, this is validated 
and standardised allowing direct comparison of the treatment response for different 
interventions and diseases. The QALY estimated using the EQ-5D tariff is the accepted 
measure used by NICE for assessing the cost-effectiveness of new treatments for approval in 
the NHS. The QALY did, however, raise some particular challenges for the analysis. The use 
of repeated measures to estimate the QALY restricted the size of the sample, as more 
observations were lost to missing data when compared to the point estimates used in the clinical 
analysis. This reduced the power of statistical analyses. For the QALY analyses the group who 
  282 
had sham treatment were excluded. Whilst of some interest to explore the effects of sham 
treatments for clinical outcomes these are not relevant to an economic analysis.  
The same approach was taken for moderator identification for the economic component of the 
analysis as for the clinical analyses. Three potential moderators (Age, PCS, RMDQ) of 
treatment response were identified for the economic analysis. However the relationship of the 
QALY with the moderators differed in some cases to that of the clinical outcome measures. It 
was only for the overall comparison of treatment vs. control that any potential subgroups were 
identified.  
For the short term clinical outcome of PCS, the age by treatment interaction was found to be 
negative and significant (p<0.2), suggesting that younger patients had a better treatment effect. 
For the outcome of FFbHR, the age treatment interaction was also negative but was just outside 
the significance threshold of p<0.2. For the other included clinical outcomes, age was not 
significant. When the QALY was used as the outcome measure, the age treatment interaction 
was significant at p<0.2 but the relationship was positive, indicating that older patients had a 
better treatment effect. The EQ-5D at short term follow up also exhibited a positive relationship 
with age, although this relationship was not significant. It may not be surprising that the 
relationship of the moderators with the different outcomes differed, as they measure different 
aspects of patient health. Furthermore, the QALY differs, by construction from the other 
outcome measures, as it is calculated as the area under the curve for a sequence of follow up 
points. However, it is also possible the results are susceptible to missing data bias. Patients 
with missing EQ-5D data at one or more follow up points were on average four years younger 
than patients with complete EQ-5D data (p<0.05). One could speculate that younger patients 
with better expected outcomes might have been excluded from our complete case analysis, as 
they failed to return follow up questionnaires. This could bias the treatment response down for 
younger patients. Four trials had short term EQ-5D data, comprising 1,774 patients (1271 
Intervention; 503 Control) for which there was complete data. Of the 1,774 patient, 1,467 
(1,093 Intervention, 374 Control) had complete data at all EQ-5D follow up points, necessary 
to calculate a QALY estimate. This equates to an additional 17% missing data for QALYs 
compared with short term outcomes. This might possibly explain the difference in direction of 
relationship between age and treatment response by outcome measure, as the short term 
measures were less prone to missing data than the QALY. 
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Overall our interpretation is that those who are older, with worse RMDQ and SF-12/36 physical 
component score are likely to gain a greater benefit on QALY outcomes from treatment. Doing 
this will not, however, improve overall QALY gain for the whole population, as those outside 
the subgroup are likely, on average, to benefit from treatment. Treating only the subgroup is 
very unlikely to be seen as cost-effective given the relatively low cost of treatment and the 
NICE threshold of £20,000 - £30,000 per QALY 
11.2.6 NETWORK META-ANALYSIS (CHAPTER 10) 
In a further methodological development we successfully adapted a network meta-analysis 
approach to identify effect moderators and produce a probability that a particular treatment 
choice is optimal for individuals with particular profiles. This approach presents the data in a 
very different format to our other approaches to subgroup identification. Analysing the trials 
as a single network of evidence allow us to detect subgroup effects with greater precision, and 
the use of Bayesian methods allows to quantify the strength of evidence for alternative 
modalities. This has allowed us to estimate effect sizes for groups with similar characteristics. 
See, for example, Table 44, that  shows that for a paradigmatic case (male, age 50, baseline 
RMDQ=10, baseline PCS and MCS both equal 40) active physical, passive physical and 
psychological treatments are all likely to be effective in reducing RMDQ compared with 
control; the credible intervals exclude zero. For sham treatment the point estimate is consistent 
with it being effective but the 95% credible interval includes zero. Consistent with the pre-
planned analyses baseline severity strongly predicts response to treatment across all 
interventions (slightly weaker for sham treatment). The effect of age, gender, plus the baseline 
SF-12/36 physical and mental component scores are weaker and are not consistent across 
modalities. It is this variability that allows tables of probability for a particular treatment choice 
being the optimum choice. For our paradigmatic case the probability that passive physical is 
optimal is 45% and that psychological is optimum is <1%. These sorts of outputs have the 
potential to inform clinical decision making. It should, however, be noted that this approach 
generates a ranking and that the differences in effect sizes from moderation of the primary 
outcome by baseline characteristics remains modest. For our paradigmatic case all treatment 
options (except sham) have evidence of effectiveness, the 95% credible interval all exclude 
zero. The additional benefit for passive physical treatment over psychological treatment, 
however, is only 0.72 (95% credible Interval -0.08 to 1.52) points on the RMDQ and the 95% 
credibility interval includes zero. Nevertheless, this approach does have the potential to provide 
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some information, tailored to the individual, which can be used to inform clinical decision 
making.  
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Table 53 Overview of results: Intervention versus control (usual care or sham) 
METHOD  
(section) 
OUTCOMEa 
physical health pain mental health quality of life 
FFbHR RMDQ PCS average pain MCS EQ-5D QALYe 
ANCOVA 
(6.6.3) 
positive 
moderator 
none found 
moderate 
catastrophizing2; 
positive fear 
avoidanceb 
none found 
painb; MCSb; 
moderate fear 
avoidanceb 
none found 
femaleb; RMDQc 
painc; moderate 
fear avoidancec 
ageb; RMDQb 
negative 
moderators 
ageb; FFbHRc; 
PCSc 
none found 
ageb; PCSc; 
MCS<50b 
PCSb; low 
anxietyb; positive 
copingb; 
FFbHRc; MCSc 
PCSc; MCSb; 
low/mod 
anxietyc 
PCSb 
recursive 
partitioning 
IPD-SIDES 
(7.5.1.2) 
subgroups 
younger with 
worse FFbHR 
none found 
1. better MCS 
& worse PCS 
2 female with 
worse PCS 
none found worse MCS none found none found 
directed 
searchd 
(8.4.1; 9.3) 
subgroups 
1. younger with 
worse FFbHR/ 
2. younger with 
worse PCS 
none found none found none found 
younger with 
worse MCS 
none found 
1 older with 
worse RMDQ 
2 older with 
worse PCS 
a all outcomes measured as change from baseline at short term follow up (2-3 months); except for QALY, which is the area-under-curve for EQ-5D over 12 months; b variables 
with p<0.2 and >0.05for interactions with treatment effect (FFbHR ANCOVA Age p=0.2018); c variables with p<0.05 for interactions with treatment effect; d directed searches 
to identify subgroups of decreasing size with better expected response to treatment, assuming monotonicity of moderator effects on outcomes. A full search algorithm was used 
for the short term outcomes (FFbHR, RMDQ, PCS, pain, MCS, EQ-5D); and a directed peeling search for QALYs; e sham interventions not included in QALY analyses 
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Table 54 Overview of results: active physical versus control (usual care) 
METHOD  
(section) 
OUTCOMEa 
physical health pain mental health quality of life 
FFbHR RMDQ PCS average pain MCS EQ-5D QALYd 
NWMA 
(10.3)b 
positive 
moderators 
Not conducted RMDQ; PCS none found Not conducted none found Not conducted Not conducted 
negative 
moderators 
Not conducted age PCS Not conducted MCS Not conducted Not conducted 
recursive 
partitioning 
IPD-SIDES 
(7.5.1.2) 
subgroups none found none found none found none found none found none found none found 
directed 
search c 
(8.4.1 & 9.3) 
subgroups none found none found none found none found none found none found none found 
a all outcomes measured as change from baseline at short term follow up (2-3 months); except for QALY, which is the area-under-curve for EQ-5D over 12 months; b variables 
with BP>0.8 for interactions with treatment effect; c directed searches to identify subgroups of decreasing size with better expected response to treatment, assuming 
monotonicity of moderator effects on outcomes. A full search algorithm was used for the short term outcomes (FFbHR, RMDQ, PCS, pain, MCS, EQ-5D); and a directed 
peeling search for QALYs; d sham interventions not included in QALY analyses1 
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Table 55 Overview of results: passive physical versus usual care control 
METHOD  
(section) 
OUTCOMEa 
physical health pain mental health quality of life 
FFbHR RMDQ PCS average pain MCS EQ-5D QALYd 
NWMA 
(10.3)b 
positive 
moderators 
Not conducted 
men;  
RMDQ; PCS 
women Not conducted none found Not conducted Not conducted 
negative 
moderators 
Not conducted none found PCS Not conducted age; PCS; MCS Not conducted Not conducted 
recursive 
partitioning 
IPD-SIDES 
(7.5.1.2) 
subgroups 
younger with 
worse FFbHR 
none found 
1 younger with 
worse PCS 
2 worse PCS but 
better MCS 
3. women with 
worse PCS and 
better MCS 
none found 
worse MCS and 
worse PCS 
none found none found 
directed 
search c 
(8.4.1 & 9.3) 
subgroups 
younger with 
worse FFbHR 
Not conducted none found Not conducted 
younger with 
worse PCS and 
Worse MCS 
Not conducted none found 
a all outcomes measured as change from baseline at short term follow up (2-3 months); except for QALY, which is the area-under-curve for EQ-5D over 12 months; b variables 
with BP>0.8 for interactions with treatment effect; c directed searches to identify subgroups of decreasing size with better expected response to treatment, assuming 
monotonicity of moderator effects on outcomes. A full search algorithm was used for the short term outcomes (FFbHR, RMDQ, PCS, pain, MCS, EQ-5D); and a directed 
peeling search for QALYs; d sham interventions not include in QALY analyses 
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Table 56 Overview of results: psychological versus usual care control 
METHOD  
(section) 
OUTCOMEa 
physical health pain mental health quality of life 
FFbHR RMDQ PCS average pain MCS EQ-5D QALYd 
NWMA 
(10.3)b 
positive 
moderators 
Not conducted 
RMDQ; PCS; 
MCS 
MCS Not conducted PCS Not conducted Not conducted 
negative 
moderators 
Not conducted age age Not conducted MCS Not conducted Not conducted 
recursive 
partitioning 
IPD-SIDES 
(7.5.1.2) 
subgroups none found worse RMDQ none found none found none found none found none found 
directed 
search c 
(8.4.1 & 9.3) 
subgroups Not conducted none found Not conducted Not conducted Not conducted Not conducted Not conducted 
a all outcomes measured as change from baseline at short term follow up (2-3 months); except for QALY, which is the area-under-curve for EQ-5D over 12 months; b variables 
with BP>0.8 for interactions with treatment effect; c directed searches to identify subgroups of decreasing size with better expected response to treatment, assuming 
monotonicity of moderator effects on outcomes. A full search algorithm was used for the short term outcomes (FFbHR, RMDQ, PCS, pain, MCS, EQ-5D); and a directed 
peeling search for QALYs; d sham interventions not include in QALY analyses 
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Table 57 Overview of results: sham versus control 
METHOD  
(section) 
OUTCOMEa 
physical health pain mental health quality of life 
FFbHR RMDQ PCS average pain MCS EQ-5D QALY 
NWMA 
(10.3)b 
 Not conducted 
men 
RMDQ 
women Not conducted none found Not conducted Not conducted 
negative 
moderator 
Not conducted none found MCS; PCS Not conducted age; PCS; MCS Not conducted Not conducted 
recursive 
partitioning 
IPD-SIDES 
(7.5.1.2) 
subgroups none found none found none found none found 
younger with 
worse PCS 
none found none found 
directed 
search c 
(8.4.1 & 9.3) 
subgroups 
Younger with 
either worse 
FFbHR or PCS 
Not conducted Not conducted Not conducted 
any age; worse 
PCS; worse 
MCS 
Not conducted Not conducted 
a all outcomes measured as change from baseline at short term follow up (2-3 months); except for QALY, which is the area-under-curve for EQ-5D over 12 months; b variables 
with BP>0.8 for interactions with treatment effect; c directed searches to identify subgroups of decreasing size with better expected response to treatment, assuming 
monotonicity of moderator effects on outcomes. A full search algorithm was used for the short term outcomes (FFbHR, RMDQ, PCS, pain, MCS, EQ-5D); and a directed 
peeling search for QALYs. 
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11.2.7 INTERPRETATION 
11.2.7.1 Clinical relevance 
In our overall analyses (all interventions vs. control) it appears that women, with more severe 
disability and lower levels of psychological distress are likely to gain the greatest benefit on 
back pain disability and the physical component score of the SF-12/36. For psychological 
outcomes, as measured by the SF-12/36 mental component score those with poorer baseline 
psychological health gained the greatest benefit. That those with a less favourable baseline 
score gain the greatest treatment benefit, on the same measure, may not be surprising as these 
are the individuals with the greatest potential for improvement. We have in all of our analyses 
presented here, and as outlined in our analysis plan, used absolute differences in outcome rather 
than percentage changes from baseline. In a post hoc analysis we re-ran our initial ANCOVA 
analyses with percentage change from baseline as the dependant variable [Data not shown]. 
The apparent significance of any moderator effects was substantially reduced; For example, 
the significance of any effect of any moderation of effect of baseline FFbHR on FFbHR as the 
outcome p-value changed from <0.0001 to 0.0703. This suggests that our finding that baseline 
severity predicts outcome on the same measure might depend on the scale of measurement used 
for the change. 
Our pre-specified approaches, recursive partitioning and ARDP, did produce identifiable 
subgroups whose parameter definitions were grounded in the data. The differences in effect 
sizes were, however, generally small and unlikely to be clinically meaningful. The effect sizes 
in the groups who did less well would still justify the use of these interventions. This overall 
picture is, however, potentially misleading as the choice is not typically between treatment vs. 
no treatment; rather it is how to select particular treatments for individuals.  
Our pre-specified analyses give some insights here. For passive physical treatments 
(acupuncture, manual therapy) those who are younger, with less psychological distress and 
worse disability were likely to gain the greatest benefit on disability. For psychological 
treatments those with more baseline disability were likely to gain a greater benefit on disability. 
In both of these cases the difference in effects sizes are unlikely to be clinically important. 
Defining what is clinically important is a challenge for LBP research researchers exploring 
treatment moderation. The authors of the published protocol for an IPD meta-analysis of 
studies of exercise treatment for LBP have set minimally clinically important difference for 
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moderation, where p-value is <0.05, to be 20 points on a 100 point scale for pain, ten points on 
a 100 point scale for disability, or ‘another magnitude deemed clinically important by 
experts’.158 Others have argued that, for exercise interventions for LBP that a worthwhile 
between group differences in pain may be as ten points.159 None of the subgroups identified by 
the IPD-SIDES or ARDP-MA method met these criteria.  
All of the subgroups identified in this work had quantitative effects where the direction of the 
treatment effect was in favour of the intervention arm in both subgroups. It is open to debate 
whether a differential subgroup effect that is smaller than a main treatment effect is worthwhile. 
Where the choice is between treatment, or no treatment, one might expect that to be clinically 
meaningful any moderator effect should larger than the main effect. Otherwise, as our data 
show, the overall net benefit from treatment may decrease as it is offered selectively. If the 
choice is between different treatments with similar main effect sizes, acquisition & opportunity 
costs, and risk profiles, then quite small moderation effects might increase over treatment 
effectiveness.  
Our health economic analysis, suggests that it is possible to identify groups, with better than 
average QALY gain from treatment. Nevertheless, even in the groups with a smaller QALY 
gain, the incremental cost per QALY gained is sufficiently low that it falls far below the NICE 
threshold of £20,000. Our analyses show that selecting subgroups of individual for treatment 
reduces the overall QALY gain. This means there is not a cost-effectiveness argument for 
excluding some groups from access to treatments.  
On the basis of these analyses we can be confident that the only potentially worthwhile 
screening tool to select treatments is baseline severity of the measure of interest; although even 
here those who are less severe will still gain a benefit and we have failed to find evidence that 
it would be worthwhile offering treatment to selected patients based on baseline severity. We 
have found that those with higher levels of psychological distress are less likely to benefit from 
some interventions. Nevertheless the size of the interaction effect means it is unlikely to serve 
as a discriminator for selecting treatment approaches as those with higher levels of distress may 
still benefit from treatment.  
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The importance of these findings is that there is no justification for using higher levels of 
psychological distress to target treatments. This runs contrary to received wisdom that 
psychosocial yellow flags could be used to select those for would benefit from treatment.  
A randomised controlled trial of stratified care based on patient’s prognosis using the StartBack 
tool, found it to be a very effective and cost-effective approach to managing with LBP.38 The 
study design, however, did not allow the effect of the stratification tool to be separated out 
from the effects of therapist selection and the additional benefits of the customised treatment 
packages provided after stratification. Thus, whilst a promising overall approach to targeting 
back pain treatments it does not help us to identify differential subgroup effects in this 
population. 
Currently, treatment choice between the types of interventions we have examined here is 
largely decided by the treating therapist in consultation with the patient. A shared informed 
decision making model in which patients are given more information on the evidence for 
different treatment options and physiotherapists are trained to implement shared informed 
decision making does not improve outcomes; indeed it may have an overall harmful effect.160 
An alternative approach of using the output from network meta-analysis to help 
physiotherapists and their patients choose treatment options could be tested empirically. 
11.2.7.2 Psychological distress as a treatment moderator. 
That increased psychological distress, as measured by the SF-12/36 MCS does not appear to 
increase treatment effect from either passive physical or psychological interventions is an 
important finding. There is a substantial body of literature suggesting that those with 
psychological distress should be prioritised for treatment of their LBP because their prognosis 
is worse.161-166 Our data suggest that, for the interventions assessed here, that those with higher 
levels of psychological distress are less likely to benefit These observations, are of course 
limited by the measures we were able to use as potential moderators and that other moderator 
variables, for example back beliefs or self-efficacy might have produced different findings. 
There is some, limited evidence (p<0.2) in our overall ANCOVA that catastrophising and fear 
avoidance might moderate treatment response for the RMDQ outcome where people with more 
positive attitude (low scores on catastrophizing or low scores on fear avoidance) had greater 
treatment effect than those with a more negative attitude. In our dataset, psychological distress 
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as measured by the MCS is positively correlated with other measures such as fear avoidance 
(Spearman correlation, r=0.064), depression (r=0.137), and anxiety (r=0.151) [data not 
presented]. This means that it is extremely unlikely that increased values in these scores would 
have an opposite effect to those we observed for the SF-12/36 MCS.  
Thus, taking all of these findings together, a policy that treatment with conventional therapist 
delivered interventions should be focussed on those with higher levels of psychological distress 
is not sustainable. What these data cannot tell us whether there is a differential effect from a 
much more intensive treatment programme based on levels of psychological distress at 
baseline. In the absence of any such evidence, or any reasonable prospect that direct 
randomised controlled trial data will become available, one might be able to infer from our 
findings for less intense interventions that such more-intense interventions might be best 
targeted at those with more severe disability (however defined). This would concur with that 
which is current practice (where such services are available) and current NICE guidance. 
11.2.8 METHODOLOGICAL DEVELOPMENT 
A substantial part of the programme grant was around the development of new approaches to 
identifying subgroups. From our review of literature on subgroups we concluded the existing 
methods have a number of problems including being severely underpowered, only able to 
provide exploratory or insufficient findings and have rather poor quality of reporting (see 
Chapter 2). Therefore there is a need to develop new approaches to subgroup identification in 
back pain research. 
We have developed three approaches to subgroup identification:  
1. Recursive partitioning (IPD-IT and IPD-SIDES method) (see Chapter 7) 
2. Adaptive risk group refinement (see Chapter 8 & 9) 
3. Individual participant data indirect network meta-analysis (see Chapter 10) 
 
These new methods challenge the current paradigm for subgroup identification in which single 
moderator variables are sought. Whilst such an approach provides a useful first step to 
exploring subgroups the outputs have not produced clinically useful data to inform treatment 
choices for LBP. The more comprehensive methods developed as part of this programme of 
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work use a multi-parametric approach to subgroup identification that give far greater flexibility 
and clinical application.  
The recursive partitioning and adaptive methods we developed for this work did not allow us 
to identify clinically relevant subgroups within this dataset. We think that this reflects both the 
limitations of the dataset and the likelihood that there are no distinct subgroups that might be 
identified in this manner. Nevertheless, the techniques performed well on the available data 
and the different techniques have typically generated consistent outputs. These are important 
methodological innovations that we anticipate that have potential across a wide range of 
clinical areas. Importantly they both use an approach that examines both the effect of variables 
and provide cut-points grounded in the data. In particular the adaptive methods allow the end 
user to judge for themselves the size of any differential subgroup effect (clinical or cost-
effectiveness) that would be worthwhile and identify the parameters that would define such a 
group. For our adaptive approaches we have here just presented point estimates without also 
ascribing statistical inference to them. This is for the sake of clarity of presentation. We have 
explored how to add statistical inference to these analyses. This is possible but uses an 
extremely large amount of computer time and generates little additional information. They are 
an additional approach that could be used in future analyses.  
The development of network meta-analysis to provide individualised advice on which 
treatment has the highest probability of being optimal for a particular patient profile is 
extremely exciting. Whilst no more than exploratory here, as it was not pre-specified in our 
analysis plan, there is potential for this approach to inform clinical decision making in this, and 
other fields. Analysing the trials as a single network of evidence, and also adopting a Bayesian 
approach to probability has provided us with what appears to be useful data to inform clinical 
decision making in a field that has previously been devoid of useful information. Where 
evidence is suggestive but not conclusive, Bayesian methods allow this to be quantified in a 
way that can be incorporated into decision-making by individual clinicians and patients.  
We have developed a large and complex dataset. This has presented substantial challenges (not 
fully appreciated at the start of the project) in terms of data management and coding. In contrast 
to some other areas where individual patient data meta-analysis is more common, for example 
cardiovascular disorders, there is no consistency in how baseline variables or outcomes are 
measured and there is the need for a core outcome set in this area. This has meant we have had 
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to do further methodological development in order to develop a new EAV approach to 
managing such datasets that is far more flexible and simple for non-specialist IT staff to adapt 
as needed. We think this approach is more robust and flexible than the approach of using an 
Access database used by others doing IPD meta-analysis of back pain trials.158 This is an 
important methodological development that we consider has utility beyond the scope of this 
project. 
Whilst not exactly a methodological development we have examined carefully how one might 
map between different back pain outcome measures. The important finding here that they are 
neither sufficiently correlated, nor sufficiently similar in their responsiveness, for data from 
trials using different outcomes to be pooled is an important finding. This may not be entirely 
surprising if one examines the time windows over which different measures are considering 
outcome and the exact content of the measures. We are aware the NIH taskforce on back pain 
research identified producing cross-walk values for these ‘legacy measures’ as priority.130 Our 
findings demonstrate that this exercise is not worth pursuing further. These findings also mean 
that existing meta-analyses of back interventions where results from different trials that have 
used different outcome measures have been pooled may not be robust. There are multiple 
examples in the literature of meta-analyses that have either used standardised mean differences 
of scaled measure to a 0-100 scale. We suggest that all of these reviews need to be interpreted 
with caution until such time as this issue has been addressed it their analyses. We have also 
succeeded in developing an approach to judging if different PROMS measuring the same 
domain can be pooled for meta-analysis that has applicability outside of field of back pain. 
It may well be that the lasting legacy and impact of the programme of work resides in the 
methodological developments needed to do the analyses rather than the outputs of the analyses. 
11.2.9 STRENGTHS 
This pooled dataset of randomised control trials of therapist delivered interventions for LBP is 
a valuable resource for academics and researchers in the field for the future. Such a large dataset 
provides the statistical power needed for subgroup analyses, something which is lacking in 
many previous studies. This means that negative findings can be taken as absence of effect 
rather than absence of evidence of effect. In our original proposal we estimated that we needed 
data on around 3,000 participants to do our analyses. That we have a pooled data set of 9,328 
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means that we have substantially more statistical power than anticipated. This means that even 
though for many analyses we were only able to use relatively small sub-sets of the data where 
the same outcomes had been used that we were still able to perform robust analyses. Whilst not 
being able to pool data from all trials reduces numbers in each analysis we are confident that 
in each analysis the same thing is being measured in each trial. This contributes substantially 
to the strength of our conclusions 
The whole of this programme of work hinges on the strength of the programming and coding 
of trials which have enabled the data to be pooled. The data we obtained came from varied and 
complex datasets using different coding structures. A large amount of work went into 
standardising the coding. The final database we have developed is probably over-engineered 
for the analyses we have conducted. In particular we have, wherever possible, included 
individual item data rather than scores for any outcome measures. In the end we were not able 
to use this fine resolution data for our subgroup analyses. Nevertheless we have created an 
excellent resource for future researchers to use in the future to explore other research questions. 
Nearly all of the contributing trialists have indicated that they may be prepared to make the 
data available for future analyses, we would therefore be keen to encourage back pain 
researchers to formally bid to access the data. Furthermore we would like to continue to add 
data to the repository to increase its future utility, therefore we would encourage academics in 
the field to approach us with datasets they would like us to include. It is likely that we would 
need to charge researchers to upload the data to cover the research and programming time. We 
would therefore encourage researchers to include costs of uploading their final data into this 
dataset in any future grant applications. 
The results obtained come from the application of two different frequentist approaches to 
subgroup identification; recursive partitioning and adaptive risk group refinement. Both 
approaches yield similar conclusions; that although it is possible to use multiple parameters to 
describe subgroups these are unlikely to be clinically important. Additionally the network 
meta-analysis has identified the same parameters as being important and with the same 
directionality (although noting here that for the QALY analysis it is older people that gain a 
greater benefit). Therefore as a strength we can be confident that our analyses are robust 
yielding the same overall outcome. 
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11.2.10 LIMITATIONS  
Our exploratory work on mapping between outcome measures which measure the same 
domain, to a common scale led us to conclude that it is not possible to do this and therefore we 
would be unable to pool outcomes measuring the same domain (see Chapter 5). For this reason, 
despite having a large dataset, for some comparisons we had rather fewer data. As the 
programme was originally developed we had anticipated using individual item data to help 
define subgroups. As we developed our methodology it became clear that we would not be able 
to use such a large number of items and obtain meaningful outcomes in a reasonable time 
frame; such analyses would be beyond capacity of our computing systems. Further, as the work 
developed, we selected moderators for our analyses grounded in existing data. There is a hazard 
we would falsely identify moderators as data from three of the fours studies that informed our 
choice of potential moderators were included in our analyses here. In the event the results were 
have not identified large subgroup effects and this need not be of great concern. We were only 
able to explore some of the domains identified in our literature review because in many cases 
only one study had measured that particular variable and there would be no added value from 
for running an analysis in the pooled dataset.  
The interventions used in the trials were trial specific. To enable grouping of interventions 
trials were broadly grouped into, active physical; passive physical; psychological; sham and 
control. 
Initially we grouped the sham and control together as a single control group. This was later 
separated out based on some exploratory analyses indicating a treatment effect for sham. The 
sham group is largely made up participants who received sham acupuncture. Some may argue 
that our approach to grouping these interventions is not conventional as every intervention is 
different, and therefore how can they be grouped and treated as being the same. From a practical 
perspective of managing the data and using it to do any meaningful analyses it was essential 
that the data were grouped in some manner. The approach we have taken was carefully 
considered by the research team including our lay members before the final groupings were 
decided.   
Therapist and group effects can also affect the analysis of trials of the types of interventions 
we are evaluating here. We did not have enough detail to include these in our pooled analyses. 
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From our experience of the BeST31 and BEAM34 trials where we know these were measured 
we have found therapist effects to be negligible and therefore unlikely to be a source of bias. 
All of these findings need to be interpreted with some caution. We have done many analyses 
meaning that some positive findings might have been observed by chance. Also several of the 
datasets we included in our analyses were also datasets that were used, in other studies, to 
identify our possible moderators; and were the same dataset we used for our ANCOVA 
analyses. This again increases the possibility that we might have found a spurious positive 
result. That, in our pairwise comparisons, and with these caveats we failed to identify any clear 
and consistent differential subgroup effects beyond those who have more problems at baseline 
have more to gain, and that with increased psychological distress, as measured by the SF-12/36 
Mental Component Score may gain less benefit, thus become a very strong finding.  
Our exploratory analytical approach to identifying subgroups who may do best with different 
treatment approaches using a Bayesian network meta-analysis has provided some promising 
results. In this analysis we have not identified subgroups in a conventional manner. Rather we 
have used all of the available data to assess the probability that for a group of patients with a 
similar profile that a particular treatment choice is the most likely to be effective. For some of 
our paradigmatic cases there are clear messages as to which treatment types may be more 
effective. In some cases sham treatment (typically sham acupuncture) appears to be the 
preferred choice. Since the NHS is unlikely to offer sham treatment as a patient choice some 
thought is needed on how to interpret these findings. Perhaps one would choose to offer verum 
acupuncture which many argue is inherently a sham treatment; being no more than a theatrical 
placebo.167 Even if it is truly a sham treatment it is one that many have belief in that could be 
offered rather than something no-one has belief in such a de-tuned ultrasound. Whilst of some 
academic interest to explore how sham treatment could appear to be the optimal treatment, 
even ahead of the active treatment for which it is the control, this is not of clinical relevance. 
If this approach to treatment selection was implemented clinically the option of sham treatment 
could be removed and the second choice approach recommended.  
11.3 MEANING OF THE RESULTS AND CLINICAL IMPLICATIONS  
The important clinical implication of the results is that there is very little clinical or cost-
effectiveness justification for using baseline characteristics we studied to define groups who 
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might benefit from different back pain treatment. Based on these data the hypothesis that low-
intensity therapist delivered interventions should be targeted at those with higher levels of 
psychological distress (as measured by SF-12/36 MCS), is not supported. It is possible that the 
results of the Bayesian analysis might allow us to give more information that might help 
improve treatment selection; this will need empirical testing before it can be recommended. 
Most importantly we have developed statistical methods for subgroups analysis that move 
beyond simply looking for interaction effects with single moderator variables. These 
approaches may have quite wide applicability. 
11.4 RECOMMENDATIONS FOR FUTURE RESEARCH 
We have made a number of suggestion for further research however these are not necessarily 
in order of priority.  
1. Making the dataset available to other researchers 
We are in the process of updating data sharing agreements to allow us to make our 
data available to other researchers 
2. Adding additional trial datasets to the repository 
We are aware of two other groups working on intervention specific individual patient 
data meta-analyses. We are working with them to develop a shared codebook for 
these trials.  A next step would be to develop a user friendly interface that would 
allow the original researchers to upload their data into the repository.  We are aware 
of moves to make trial data more freely available for secondary research.  Further 
development of this dataset will provide such a resource for the back pain research 
community. 
3. Application of these methods for the identification of subgroups in other clinical areas 
We will make our methods freely available to other researchers 
4. Re-analysis of existing meta-analyses of back pain treatments that have pooled 
different outcome measures 
As current Cochrane reviews are updated it would be possible to group any meta-
analyses according to outcome measure being reported. In the absence of 
heterogeneity in outcome according to outcome measure used it may be possible to 
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pool data to give an overall estimate with some caveats as to whether pooling in this 
manner is robust 
5. Further development of methods and application to the data we already have 
6. Explore the need for a core outcomes set for low back pain in light of existing 
developments in the area. 
11.5 CONCLUSIONS 
The lasting legacy of this work is likely to be the methodological developments need to do our 
analyses. We have; developed improved systems for storing large, complex datasets; developed 
methods for assessing comparability of outcome measures that have demonstrated different 
back pain outcome measures cannot be safely pooled for meta-analyses; we have developed 
three different approaches to the identification of differential subgroup effects that provide 
considerable added values compared to conventional analyses that simply test for interactions.  
Using frequentist approaches (recursive partitioning or adaptive approaches) has not allowed 
the identification of subgroups who might have worthwhile additional benefits from different 
treatment approaches beyond the potential benefits being greater in those with more disability 
at baseline. Importantly increased psychological distress, as measured using the SF-12/36 
mental component score may identify those less likely to benefit from treatment; the opposite 
of conventional wisdom which is that this group should be targeted for intervention.  
An approach based on Bayesian network meta-analysis offers a potential approach to deciding 
on optimal therapies. We would suggest that these methods are applied in other clinical areas 
where subgroup identification and targeting of treatment may be advantageous.  
Our findings do challenge conventional wisdom on who should be prioritised for back pain 
treatments; i.e. those with greater psychological distress.  We would not support such an 
approach until there is evidence to challenge our findings. 
Finally we have developed an important resource for back pain researchers wishing to do 
further analyses on data from multiple trials. 
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a clinical prediction rule for spinal manipulative therapy: a randomised controlled trial. 
European Spine Journal 2008;17:936-43. 
Testing a clinical prediction rule 
Jellema P, van der Windt DA, van der Horst HE, Twisk JW, Stalman WA, Bouter LM. 
Should treatment of (sub)acute low back pain be aimed at psychosocial prognostic factors? 
Cluster randomised clinical trial in general practice. BMJ 2005;331:84. 
Look at effect modification over 
time 
Jellema P, van der Roer N, van der Windt DA, van Tulder MW, van der Horst HE, 
Stalman WA et al. Low back pain in general practice: cost-effectiveness of a minimal 
psychosocial intervention versus usual care. European Spine Journal 2007;16:1812-21. 
Outcome in sub-group analyses not 
a clinical measure of low back pain 
(cost-effectiveness) 
  
 
Paper Reason for exclusion 
Kool JP, Oesch PR, Bachmann S, Knuesel O, Dierkes JG, Russo M et al. Increasing days 
at work using function-centered rehabilitation in nonacute nonspecific low back pain: a 
randomized controlled trial. Archives of Physical Medicine & Rehabilitation  2005;86:857-
64. 
Outcome in sub-group analyses not 
a clinical measure of low back pain 
(days worked over 3 months) 
Lamb SE, Lall R, Hansen Z, Castelnuovo E, Withers EJ, Nichols V et al. A multicentred 
randomised controlled trial of a primary care-based cognitive behavioural programme for 
low back pain. The Back Skills Training (BeST) trial. Health Technology Assessment 
(Winchester, England) /20;14:1-253. 
HTA report. Secondary sub-groups 
analyses paper published elsewhere 
and used instead (Underwood 
2011) 
Scheel IB, Hagen KB, Herrin J, Oxman AD. A randomized controlled trial of two 
strategies to implement active sick leave for patients with low back pain. Spine 
2002;27:561-6. 
Outcome in sub-group analyses not 
a clinical measure of low back pain 
(active sick leave) 
Skargren EI, Carlsson PG, Oberg BE. One-year follow-up comparison of the cost and 
effectiveness of chiropractic and physiotherapy as primary management for back pain. 
Sub-group analysis, recurrence, and additional health care utilization. Spine 1998;23:1875-
83. 
Looked at an addition disorder 
(neck pain) 
Skargren EI, Oberg BE, Carlsson PG, Gade M. Cost and effectiveness analysis of 
chiropractic and physiotherapy treatment for low back and neck pain. Six-month follow-
up. Spine 1997;22:2167-77. 
Looked at an addition disorder 
(neck pain) 
  
 
Paper Reason for exclusion 
Staal JB, Hlobil H, Koke AJ, Twisk JW, Smid T, van MW. Graded activity for workers 
with low back pain: who benefits most and how does it work? Arthritis & Rheumatism 
2008;59:642-9. 
Outcome in sub-group analyses not 
a clinical measure of low back pain 
(return to work) 
Steenstra IA, Knol DL, Bongers PM, Anema JR, van MW, de Vet HC. What works best 
for whom? An exploratory, sub-group analysis in a randomized, controlled trial on the 
effectiveness of a workplace intervention in low back pain patients on return to work. 
Spine 2009;34:1243-9. 
Outcome in sub-group analyses not 
a clinical measure of low back pain 
(return to work) 
Thomas KJ, MacPherson H, Ratcliffe J, Thorpe L, Brazier J, Campbell M et al. Longer 
term clinical and economic benefits of offering acupuncture care to patients with chronic 
low back pain. Health Technology Assessment (Winchester, England) /1/10;9:iii-iiv. 
HTA report. Secondary sub-groups 
analyses paper published elsewhere 
and used instead (Thomas 2006) 
Toda Y. Impact of waist/hip ratio on the therapeutic efficacy of lumbosacral corsets for 
chronic muscular low back pain. Journal of Orthopaedic Science 2002;7:644-9. 
Intervention not delivered by 
therapist (Corsets given to patients) 
van Poppel MN, Koes BW, van der Ploeg T, Smid T, Bouter LM. Lumbar supports and 
education for the prevention of low back pain in industry: a randomized controlled trial. 
JAMA 1998;279:1789-94. 
Intervention not delivered by 
therapist (Lumbar supports given 
to patients) 
Reproduced with permission from Lippincott, Williams & Wilkins publishers  
 
  
 
APPENDIX 2 – INVITATION LETTER 
  
  
 
 
Professor Martin Underwood 
 Warwick Medical School Clinical Trials Unit 
    University of Warwick 
  Coventry 
  CV4 7AL 
[INSERT ADDRESS] 
 
[INSERT DATE] 
 
Study Title: Improving outcomes from the treatment of back pain 
 
Dear [INSERT NAME] 
 
We have successfully obtained funding from the National Institute for Health Research for a 
programme grant on the management of low back pain.  One aspect of this is programme is to 
develop a pooled database of the original data from randomised controlled trials of therapist 
delivered interventions for low back pain.   
 
The overall aim of our programme grant is to improve the clinical and cost-effectiveness of 
low back pain treatment by providing patients, their clinical advisors, and health service 
purchasers with better information about which patients are most likely to benefit from which 
treatment choices.  
 
By developing this repository of original patient data we hope to conduct pooled secondary 
analyses. This will help us to determine which patient characteristics, if any, predict clinical 
response to different treatments for low back pain and/or predict the most cost-effective 
treatments for low back pain. 
 
We would be very grateful if you would consider sharing the data from your [INSERT 
STUDY] trial for this important study. If you have any questions or you are interested in 
sharing this data with us please could you email repository@warwick.ac.uk in the first instance.  
 
We look forward to hearing from you.  
 
Yours sincerely 
 
Martin Underwood 
Professor of Primary Care Research  
  
 
APPENDIX 3 – INFORMATION SHEET 
  
  
 
Low Back Pain Trial Repository Programme 
Information Sheet for Investigators 
Programme Summary and Investigator Involvement 
 
Warwick CTU has been funded by UK National Institute of Health Research to do individual patient 
data meta-analysis of data from trials of low back pain treatments.  We are inviting custodians of 
existing trial datasets to contribute data to this project.  There are two stages to this; the first stage 
is for our currently funded project to explore sub-groups in low back pain (LBP) and the second stage 
is to maintain a data repository of individual patient data from trials of therapist delivered 
intervention in low back pain as a resource for the back pain community.  The Chief investigator for 
this project is Martin Underwood. 
Stage 1: Improving outcomes from the treatment of back pain 
At a population level, we have useful data on the management of LBP. What is not clear is how we 
can use these data to maximise the treatment benefit for the individual patient i.e. which patients 
are most likely to benefit from which treatment choices. If we could predict which patients would be 
most likely to benefit from different treatments, overall effectiveness, and cost-effectiveness, of 
treatments for Low Back Pain would improve. Any randomised controlled trial (RCT) to directly 
address this problem would need to be very large. 
We have received funding from the NIHR to undertake an individual patient data meta-analysis to 
identify moderators of treatment effect. From this programme of research, we aim to produce 
evidence to help patients, their clinical advisors and health service purchasers to select the ‘right 
treatment for the right person at the right time’. We are interested in both clinical and cost-
effectiveness. 
We have obtained ethical approval for this project from both the University of Warwick’s Biological 
Research Ethics Committee and also a UK National Health Service research ethics committee flagged 
to assess applications to establish a research database.  We have of course considered ethical issues 
of secondary analysis of data carefully. We will only request and utilise anonymous data and will 
seek assurance from collaborators that nothing in the original consent process would preclude 
sharing anonymous data in this way. 
In this first stage, once we have sufficient data, we will explore how the complex relationship 
between demographic factors, patient history and patient characteristics can be used to predict the 
response to different treatments. We will; 
1. estimate within-trial indicators of clinical and economic outcomes at the individual patient 
level (e.g. health care costs and QALYs over the trial period), 
2. statistically analyse the RCT dataset to identify moderators that could contribute to a 
practical Clinical Prediction Rule that can be used to inform LBP management. 
We would like you to share data for this work.  Ideally we want to include individual item 
responses to outcome measures rather than summary values in order that we can ensure 
consistency in how summary scores are calculated. However, we would like to stress that you 
  
 
are under no obligation to send us any data you wouldn’t wish to share.  If you only have 
summary measures available we would still be delighted to have your data. We are particularly 
interested in any data that will inform our cost-effectiveness analyses. 
 
We would like you to share the following data with us: 
 Participant characteristics and baseline measurements  
 Assigned intervention(s) 
 Intervention(s) received 
 Recorded outcomes at each time point (during the intervention and follow-up) including 
o Values of individual items from all the questionnaires  
o Health economic/utility measurements (e.g. EQ5D or SF6D items) 
 Recorded use of health services and related expenditure for patients (during intervention 
and follow-up) 
 Anonymised data allowing us to measure any clustering by therapist or site 
If they are available and you are happy to share them with us then copies of the following documents: 
 The final protocol 
 Case report forms (CRF) 
 Coding manual for the CRF codes 
We are aware that these documents may not be available – for example we know of one large study 
that lost all its archived material in a flood.  Whatever you have available would be very helpful to 
the team. 
Upon receiving the dataset we will run a validity and quality check to ensure data integrity. A 
validity-quality report will be sent to you for comment and/or feedback. We aim to resolve any 
inconsistencies in the data before integrating the dataset with the rest of the dataset in the 
repository. Once the dataset has been integrated into the repository, the original dataset from you 
will be destroyed. 
We have established secure methods to transfer anonymous data sets and will send you full details 
when appropriate.  We are only too aware of how hard it was to collect these data in the first place; 
will handle them very carefully! 
At present we are asking for data sharing agreements for this study only.  We will produce a new 
data sharing agreement for stage two of the project. 
All research teams who contribute to the project will be acknowledged in any publications. Where 
possible, we will do this by including one member of each trial team as a named member of the 
collaborative group who have supported this programme; you may choose whom is acknowledged.  
This may be a different person for each set of trial data you share with us. This will ensure your 
contribution will be recognised by PubMed and citation tracking. We will give you the opportunity to 
comment on any papers that have used your data prior to submission.  You will not, however, be 
obliged to comment.  
Stage 2: Future use of the repository 
  
 
Once developed, we would like to maintain this pooled data set as a resource for the research 
community as we anticipate that there will be many future research questions to be asked from this 
data set. Therefore any shared data sets will need to be as complete as possible as we will only be 
able to put each study into the repository once; this is why we are asking for such a detailed dataset 
for stage one of the project. 
We will establish a governance structure including an independent steering committee to oversee 
fair access to the data by ourselves and others in the future. As a collaborator we would welcome 
any application to utilise this data (subject to steering committee approval).  I do not anticipate 
needing to charge for access to these data.  We will be seeking additional funding to maintain and 
add to the pooled dataset as a resource for the back pain research community.  
We will be looking for additional funding to continue supporting the database and adding further 
trial data sets in the future. 
We will ask for separate and additional consent from you to include your data in phase 2. If you do 
not wish any of your data to be used in any subsequent analyses, you will be able to specify this at 
this point. Please be assured that we will not use your data for any other analyses than those 
stipulated by you and those which have received approval from the steering committee. 
Thank you for taking the time to read this information and we hope that you will consider our 
request to share your data and contribute to this valuable programme. 
Repository Programme Team: 
Professor Martin Underwood (Chief Investigator) 
Professor of Primary Care Research 
University of Warwick 
Warwick Clinical Trials Unit 
Gibbet Hill Campus 
Coventry  
CV4 7AL 
Tel: 02476 574664 
Email: M.Underwood@warwick.ac.uk  or repository@warwick.ac.uk 
 
Professor Nigel Stallard, Professor of Medical Statistics, University of Warwick 
Professor Tim Friede, Professor of Biostatistics, University Medical Center Göttingen 
Professor Sallie Lamb, Professor of Rehabilitation, Warwick Clinical Trials Unit 
Dr Shilpa Patel, Research Fellow, University of Warwick 
Dr Joanne Lord, Reader Health Economics Research Group, Brunel University 
Dr David Ellard, Senior Research Fellow, University of Warwick  
  
  
 
APPENDIX 4 – SAMPLE DATA SHARING AGREEMENT 
  
  
 
Data Sharing Agreement 
Standard Template 
 
Research Project title: Improving outcomes from the treatment of back pain  
Reference: RP-PG-0608-10076 
 
1.0 - Organisations 
 
This Data Sharing Agreement is drawn up between: 
 
Professor Martin Underwood  
Warwick Clinical Trials Unit 
University of Warwick 
Gibbet Hill 
Coventry 
CV4 7AL  
 
And:  
 
[INSERT DETAILS] 
 
2.0 Period of agreement 
 
This agreement commences on [INSERT DATE] and will terminate on [INSERT DATE] 
unless extended by mutual agreement of both parties in writing, at which point an 
Amendment will be issued by University of Warwick to replace this document.   
 
3.0 Data required 
 
[INSERT INSTIUTION NAME] will supply all anonymous trial data from [INSERT 
TRIAL NAME]. Data required: 
 
 Individual patient data with descriptions of variable coding 
AND/OR 
 Scored variable databases with descriptions of variable coding 
 
We will require confirmation from the Chief Investigator that patients in the original trial 
have given informed consent.  
 
4.0 Permissions 
 
The data will come from completed randomised controlled trials. All data will be 
anonymous and no patient identifiable information will be shared.  
 
Approval to obtain data will be obtained from the University of Warwick’s Biological 
Research Ethics Committee and the Oxford ‘C’ NHS REC.  
  
 
5.0 Purpose for which the Data are to be used 
 
 
The data will be used to develop a repository of individual patient data on potential 
moderators, health outcomes, and health care resource use & costs, from RCTs 
testing therapist delivered interventions for low back pain. We will conduct statistical 
and health economic analyses on this pooled dataset.  
 
We will not reanalyse any trial data already published. 
 
Data access is restricted to those named in Table 1 of this agreement. Any changes 
will be notified to [INSERT INSITUTION NAME].  
 
 
Table 1 - Individuals who will have access to and use of the repository 
 
Permitted Users  Job title – Organisation they work for – Where 
they will access data 
Martin Underwood  Chief investigator based at Warwick CTU – Medical 
School, data will be accessed within the university 
only. 
Shilpa Patel  Study Manager based at Warwick CTU – Medical 
School, data will be accessed within the university 
only. 
Sallie Lamb 
 
 
Co-investigator based at Warwick CTU – Medical 
School, data will be accessed within the university 
only. 
Nigel Stallard Statistical lead based at Warwick CTU – Medical 
School, data will be accessed within the university 
only. 
Tim Friede Statistical advisor based at Göttingen University, 
data will be accessed within their institution. 
Statistician (Research Fellow)  
 
Statistics Research based at Warwick CTU – 
Medical School, data will be accessed within the 
university only. 
Joanne Lord Health Economist lead based at Brunel University, 
data will be accessed within their institution. 
Health Economist (Research 
Fellow)  
 
Health Economist Research Fellow based at Brunel 
University, data will be accessed within their 
institution. 
Dipesh Mistry PhD student based at Warwick CTU – Medical 
School, data will be accessed within the university 
only. 
Programming Team Programming team based at Warwick CTU – Medical 
School, data will be accessed within the university 
only. 
Claire Daffern Quality Assurance Manager at Warwick CTU – 
Medical School, data will be accessed within the 
university only. 
  
 
6.0 User Obligations 
The University of Warwick formally wishes to acknowledge its explicit commitment to 
maintaining the confidentiality, safety, security and integrity of all Data to which the 
organisation is privy and which may be held under its guardianship. 
 
The University of Warwick continues to legitimately enter into formal agreement and/or 
implicit undertaking with all its clients, staff, visitors, suppliers and others, in 
recognition of the fact that the data is held under the guardianship of University of 
Warwick which is pertinent to the individual client, staff member, visitor, supplier and/or 
other, will only be used for the explicit agreed purpose or purposes for which it has 
been provided, and that there will be no unlawful disclosure or loss of the same. 
 
Users of the data supplied are obliged to fully comply with The Data Protection Act 
1998, together with all other related and relevant legislation and Department of Health 
directives covering issues of Data sharing and including: 
 
 British (International) Standard ISO 27001; 
 The Caldicott Report 1997; 
 The Freedom of Information Act 2000; 
 Section 251 of the Health and Social Care Act 2006; 
 Confidentiality: NHS Code of Practice 2003; 
 NHS Records Management Code of Practice (Part 1, 2006 & Part 2, 2009); 
 The NHS Information Security Management Code of Practice 2007; 
 The Computer Misuse Act 1990; 
 The Electronic Communications Act 2000; 
 The Regulation of Investigatory Powers Act 2000; 
 The Copyright, Designs and Patents Act 1988; 
 The Re-Use of Public Sector Information Regulations 2005; 
 The Human Rights Act 1998 
 
 
7.0 Transfer of Data from [INSERT INSITUTION NAME] and the University of 
Warwick 
 
Anonymous data will be obtained from [INSERT INSITUTION NAME]. Data will be 
encrypted and sent to the University of Warwick by [INSERT INSITUTION NAME] via 
the University’s file transfer application.  
 
Once the data has been received, the original source will be moved to an encrypted 
drive.   A processed copy of the data will be imported into a secure database.  
 
Together with the encrypted data [INSERT INSITUTION NAME] will provide a detailed 
description of the variables.  
 
  
 
8.0 Storage of Data  
 
The originally data source will be temporarily stored on a file server directory that is 
only accessible to the chief investigator and study manager until it is moved to an AES 
256 encrypted volume.  Data will be processed and imported from the encrypted 
volume into a Microsoft 2005 SQL Server database hosted in the University of 
Warwick’s data centre. The data will be regularly replicated onto a failover server and 
routinely backed up to a Storage Area Network (SAN).    
 
 
9.0 Data Retention 
 
The intention is to keep the repository once it has been developed and make it 
available to other researchers. An independent steering committee will be 
convened to assess applications for the repository.  
 
If the repository is deemed to be no longer required, all data will be deleted from 
the servers.  Deletion of data is irreversible and involves the database being 
disconnected and all data and transaction files being destroyed using a secure 
deletion application.   
 
The WCTU may invoke the right to implement the research exemption clause of 
the data protection act in order to retain the data for future research activities.   
 
 
10.0 Agreement Signatures 
 
For and on behalf of: 
Warwick Clinical Trials Unit  
Signed: 
 
Print Name: Professor Martin Underwood 
Post/Title: Head of Division of Health 
Sciences, Warwick Medical School 
Date: 
 
For and on behalf of: 
[INSERT INSITUTION NAME]  
Signed: 
 
Print Name:  
Post/Title:  
Date:  
 
  
  
 
APPENDIX 5 – INSTRUCTION ON SECURE DATA TRANSFER 
  
  
 
Repository Programme 
Instructions for transferring datasets to the University of Warwick 
 
 Please ensure your datasets are anonymised. 
 Compress/encrypt your dataset using an open-source compression software programme 
(e.g. 7Zip) 
 Follow this link: 
https://files.warwick.ac.uk/repositorylbpdata/sendto 
 
 
 Please fill in the boxes as required: 
o Your name 
o Your email; and 
o Any message (e.g.: name of the trial, contact telephone number) 
 Click on the ‘Browse’ button 
 Choose the file to upload 
 Click on the ‘Upload and send file’ button 
A member of the Repository team will send an email confirming that the dataset have been 
uploaded successfully. We will also call you to obtain the password required to decrypt the file.  
 
Thank you. 
  
 
APPENDIX 6 – EXCLUDED STUDIES  
  
  
 
Paper Trial 
Number of 
participants 
Brinkhaus B, Witt CM, Jena S, Linde K, Streng A, Irnich D, et al. Interventions and physician characteristics in 
a randomized multicenter trial of acupuncture in patients with low-back pain. J Altern Complement Med 
2006;12(7):649-57. 
Brinkhaus 301 
Hancock MJ, Maher CG, Latimer J, Herbert RD, McAuley JH. Can rate of recovery be predicted in patients 
with acute low back pain? Development of a clinical prediction rule. Eur J Pain 2009;13(1):51-5. 
Hancock 240 
Hancock MJ, Maher CG, Latimer J, McLachlan AJ, Cooper CW, Day RO, et al. Assessment of diclofenac or 
spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a 
randomised controlled trial. Lancet 2007;370(9599):1638-43. 
Hancock 240 
Härkäpää K, Järvikoski A, Mellin G, Hurri H. A controlled study on the outcome of inpatient and outpatient 
treatment of low back pain. Part I. Pain, disability, compliance, and reported treatment benefits three months 
after treatment. Scand J Rehabil Med. 1989;21(2):81-9. 
Härkäpää 459 
Härkäpää K, Mellin G, Järvikoski A, Hurri H. A controlled study on the outcome of inpatient and outpatient 
treatment of low back pain. Part III. Long-term follow-up of pain, disability, and compliance. Scand J Rehabil 
Med. 1990;22(4):181-8. 
Härkäpää 476 
Hurwitz EL, Morgenstern H, Chiao C. Effects of Recreational Physical Activity and Back Exercises on Low 
Back Pain and Psychological Distress: Findings From the UCLA Low Back Pain Study. American Journal of 
Public Health 2005;95(10):817-1824. 
Hurwitz 681 
  
 
Paper Trial 
Number of 
participants 
Hurwitz EL, Morgenstern H, Harber P, Kominski GF, Belin TR, Yu F, et al. A randomized trial of medical care 
with and without physical therapy and chiropractic care with and without physical modalities for patients with 
low back pain: 6-month follow-up outcomes from the UCLA low back pain study. Spine 2002;27(20):2193-204. 
Hurwitz 681 
Hurwitz EL, Morgenstern H, Harber P, Kominski GF, Belin TR, Yu F, et al. The effectiveness of physical 
modalities among patients with low back pain randomized to chiropractic care: Findings from the UCLA low 
back pain study. Journal of Manipulative & Physiological Therapeutics 2002;25(1):10-20. 
Hurwitz 681 
Hurwitz EL, Morgenstern H, Kominski GF, Yu F, Chiang LM. A randomized trial of chiropractic and medical 
care for patients with low back pain: eighteen-month follow-up outcomes from the UCLA low back pain study. 
Spine (Phila Pa 1976) 2006;31(6):611-21; discussion 22. 
Hurwitz 681 
Koes BW, Bouter LM, van Mameren H, Essers AH, Verstegen GM, Hofhuizen DM, et al. Randomised clinical 
trial of manipulative therapy and physiotherapy for persistent back and neck complaints: results of one year 
follow up. Bmj 1992;304(6827):601-5. 
Koes 256 
Koes BW, Bouter LM, van Mameren H, Essers AH, Verstegen GM, Hofhuizen DM, et al. A blinded 
randomized clinical trial of manual therapy and physiotherapy for chronic back and neck complaints: physical 
outcome measures. J Manipulative Physiol Ther 1992;15(1):16-23. 
Koes 256 
  
 
Paper Trial 
Number of 
participants 
Koes BW, Bouter LM, van Mameren H, Essers AH, Verstegen GM, Hofhuizen DM, et al. The effectiveness of 
manual therapy, physiotherapy, and treatment by the general practitioner for nonspecific back and neck 
complaints. A randomized clinical trial. Spine 1992;17(1):28-35. 
Koes 256 
Kominski GF, Heslin KC, Morgenstern H, Hurwitz EL, Harber PI. Economic evaluation of four treatments for 
low-back pain: results from a randomized controlled trial. Medical care. 2005;43(5):428-35. 
Hurwitz 681 
Lamb SE, Lall R, Hansen Z, Castelnuovo E, Withers EJ, Nichols V, et al. A multicentred randomised controlled 
trial of a primary care-based cognitive behavioural programme for low back pain. The Back Skills Training 
(BeST) trial. Health Technol Assess 2010;14(41):1-253, iii-iv. 
BeST 701 
Mellin G, Hurri H, Harkapaa K, Jarvikoski A. A controlled study on the outcome of inpatient and outpatient 
treatment of low back pain. Part II. Effects on physical measurements three months after treatment. 
Scandinavian journal of rehabilitation medicine 1989;21(2):91-5. 
Härkäpää 459 
Myers SS, Phillips RS, Davis RB, Cherkin DC, Legedza A, Kaptchuk TJ, et al. Patient expectations as 
predictors of outcome in patients with acute low back pain. J Gen Intern Med 2008;23(2):148-53. 
Myers 444 
Sherman KJ, Cherkin DC, Ichikawa L, Avins AL, Barlow WE, Khalsa PS, et al. Characteristics of patients with 
chronic back pain who benefit from acupuncture. BMC Musculoskelet Disord 2009;10:114. 
Sherman 638 
  
 
Paper Trial 
Number of 
participants 
Skargren EI, Oberg BE. Predictive factors for 1-year outcome of low-back and neck pain in patients treated in 
primary care: comparison between the treatment strategies chiropractic and physiotherapy. Pain 1998;77(2):201-
7. 
Skargren 323 
Skargren EI, Oberg BE, Carlsson PG, Gade M. Cost and effectiveness analysis of chiropractic and 
physiotherapy treatment for low back and neck pain. Six-month follow-up. Spine 1997;22(18):2167-77. 
Skargren 323 
Smeets RJ, Maher CG, Nicholas MK, Refshauge KM, Herbert RD. Do psychological characteristics predict 
response to exercise and advice for subacute low back pain? Arthritis Rheum 2009;61(9):1202-9. 
Smeets 259 
Steenstra IA, Knol DL, Bongers PM, Anema JR, van Mechelen W, de Vet HC. What works best for whom? An 
exploratory, sub-group analysis in a randomized, controlled trial on the effectiveness of a workplace 
intervention in low back pain patients on return to work. Spine (Phila Pa 1976) 2009;34(12):1243-9. 
Steenstra 196 
Rivero-Arias O, Gray A, Frost H, Lamb SE, Stewart-Brown S. Cost-utility analysis of physiotherapy treatment 
compared with physiotherapy advice in low back pain. Spine (Phila Pa 1976) 2006;31(12):1381-7. 
Rivero-
Arias 
286 
Underwood MR, Morton V, Farrin A. Do baseline characteristics predict response to treatment for low back 
pain? Secondary analysis of the UK BEAM dataset [ISRCTN32683578]. Rheumatology (Oxford) 
2007;46(8):1297-302. 
BEAM 1,334 
  
 
Paper Trial 
Number of 
participants 
Whitehurst DG, Lewis M, Yao GL, Bryan S, Raftery JP, Mullis R, et al. A brief pain management program 
compared with physical therapy for low back pain: results from an economic analysis alongside a randomized 
clinical trial. Arthritis Rheum 2007;57(3):466-73. 
Whitehurst 402 
  
  
 
APPENDIX 7 – TRIALS UNAVAILABLE 
  
  
 
Full reference 
Number of 
participants 
Alaranta H, Rytokoski U, Rissanen A, Talo S, Ronnemaa T, Puukka P, et al. Intensive physical and psychosocial training program 
for patients with chronic low back pain. A controlled clinical trial. Spine 1994;19(12):1339-49. 
193 
Albaladejo C, Kovacs FM, Royuela A, del Pino R, Zamora J. The efficacy of a short education program and a short physiotherapy 
program for treating low back pain in primary care: a cluster randomized trial. Spine (Phila Pa 1976) 2010;35(5):483-96. 
348 
Anema JR, Steenstra IA, Bongers PM, de Vet HC, Knol DL, Loisel P, et al. Multidisciplinary rehabilitation for subacute low back 
pain: graded activity or workplace intervention or both? A randomized controlled trial. Spine (Phila Pa 1976) 2007;32(3):291-8; 
discussion 99-300. 
196 
Berwick DM, Budman S, Feldstein M. No clinical effect of back schools in an HMO. A randomized prospective trial. Spine 
1989;14(3):338-44. 
222 
Cherkin DC, Deyo RA, Battie M, Street J, Barlow W. A Comparison of Physical Therapy, Chiropractic Manipulation, and Provision 
of an Educational Booklet for the Treatment of Patients with Low Back Pain. The New England Journal of Medicine 
1998;339(15):1021-29. 
321 
Cherkin DC, Eisenberg D, Sherman KJ, Barlow W, Kaptchuk TJ, Street J, et al. Randomized trial comparing traditional Chinese 
medical acupuncture, therapeutic massage, and self-care education for chronic low back pain. Arch Intern Med 2001;161(8):1081-8. 
262 
Cherkin DC, Sherman KJ, Avins AL, Erro JH, Ichikawa L, Barlow WE, et al. A randomized trial comparing acupuncture, simulated 
acupuncture, and usual care for chronic low back pain. Arch Intern Med 2009;169(9):858-66. 
638 
  
 
Full reference 
Number of 
participants 
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1. Background 
1.1 Summary 
The aim of the Low Back Pain Repository is to develop a repository of individual patient data 
(IPD) from randomized controlled trials (RCT) testing therapist-delivered interventions for low 
back pain (LBP). Principal investigators (PI) whose trials satisfy the inclusion criteria (Table 
1.1) are approached to share their anonymized data with us. Datasets from them are then 
queried and validated before they are uploaded to the standardized repository database.  
 
The primary objective of this study is to determine which patient characteristics at baseline 
predict clinical response to different treatments and the most cost-effective treatments for low 
back pain. 
 
1.2 Design of the programme 
Development of the data repository 
The flow diagram of the development of the data repository is shown in Figure 1.1. 
 
Identification of treatment moderators 
A systematic review was performed to search for RCT of therapist delivered interventions for 
LBP that identified patient characteristics at baseline that might predict the response to 
treatments. Variables that were identified from this review are entered into the pool of potential 
moderators to inform the final analysis. 
 
1.3 Timing of analysis and reporting 
The timeline for the data collection, analysis and reporting is shown in Table 1.2. All the 
investigators who have consented to share their data uploaded their data to the secure shared 
space before 28 February 2013.  
Table 1.1 Inclusion and exclusion criteria  
Inclusion criteria Exclusion criteria 
Randomized controlled trials for non-specific low back 
pain 
Therapist delivered interventions trials (including 
psychological interventions and intensive 
rehabilitation programmes) 
Participants aged ≥ 18 
Non-randomized controlled trials (for example, 
observational, cohort, retrospective study) 
Pharmacotherapy trials 
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Abbreviations: RCT, randomized controlled trials; LBP, low back pain. 
Figure 1.1 Flow diagram of the development of the data repository 
2. Aims of the analysis 
The primary aim of the analysis is to identify a combination of patient characteristics at baseline 
to recommend a particular therapist delivered intervention to a subpopulation where it would 
be optimal to and are associated with the endpoints of interest, namely, disability (Section 4.1), 
pain (Section 4.2), psychological distress (Section 4.3), non-utility quality of life (Section 4.4), 
health utility (Section 4.5) and cost-effectiveness (Section 4.6).  
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Table 1.2 Timing of analysis and reporting 
 2013 2014 
 Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun 
1. Freeze collection of data                 
2. Query, validate and 
upload all data obtained 
to the Repository 
database 
                
3. Map the network 
diagram 
                
4. Develop statistical 
models for clinical 
analysis 
                
5. Develop the models for 
economic analysis 
                
6. Analyse the data with 
models developed in (4) 
and (5) 
                
7. Refine the predictor 
model 
                
8. Test and validate the 
refined predictor model 
                
9. Result report                 
10. Final report                 
11. Dissemination and 
publication 
                
 
3. Quality control 
3.1 Data query 
Data query is performed on all data uploaded to the secure shared space. Any inconsistency, for 
example, out-of-range values, inconsistent dates, is resolved before being uploaded to the standardized 
repository database.  
3.2 Extract, transform and load 
A technical guideline (Appendix A) gives a detailed procedure to transfer, query, map, report and load 
the shared trial data to the repository database. 
3.3 Verification of uploaded data to the repository database 
Once the original data have been uploaded to the repository database, the data are verified manually to 
ensure that the process of uploading did not compromise the data integrity. 
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4. Outcome variables 
This section describes the derivations of the scoring and scales for the measurements of the outcomes 
of interest. Clinical outcomes are classified broadly into physical disability (Section 4.1), pain (Section 
4.2), psychological distress (Section 4.3) and non-utility quality of life (Section 4.4). The health utility 
and cost-effectiveness outcomes are presented in Sections 4.5 and 4.6. 
As there is no single instrument that was used by all trials, the methodology in either selecting an 
instrument or scaling each instruments to one standard measurement will be discussed within each 
subsection; section 4.1.2 for physical disability, section 4.2.2 for pain and section 4.3.2 for 
psychological distress. 
4.1 Physical disability  
According to the definition from the World Report on Disability by World Health Organization (2011), 
disability refers to difficulties arising from any or all three of these conditions; impairments, activity 
limitations and participation restrictions. It is not merely a health problem but arises from the interaction 
between the health condition(s) and environmental and personal factors. 
4.1.1 Instruments 
Benefits of treatments 
Some RCTs might have a single standalone instrument that asked the participant to rate the benefit of 
the treatment they have received. It is usually presented as a numerical rating scale with “substantial 
benefit” on one end, “substantial harm” on the other end, and a “no benefit” in between. 
Chronic Pain Grade Scale 
The Chronic Pain Grade Scale (CPG) is an instrument to grade chronic pain status (Von Korff et al., 
1992). It has two dimensions, namely, disability and pain intensity scores. It used with different 
durations recall, and may refer to all pain or specifically to low back pain. The disability score is made 
up of three items: 
 In the past XX months/weeks, how much has (back) pain interfered with your daily activities 
rated on a 0-10 scale where 0 is 'no interference' and 10 is 'unable to carry on any activities'? 
 In the past XX months/weeks, how much has (back) pain changed your ability to take part in 
recreational, social and family activities where 0 is 'no change' and 10 is 'extreme change'? 
 In the past XX months/weeks, how much has (back) pain changed your ability to work 
(including housework) where 0 is 'no change' and 10 is 'extreme change'? 
 
The disability score is derived as followed,  
Disability score = mean(of the three items) × 10. 
The range of the score is from 0 to 100 where the higher score means more severe disability.  
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Hannover Functional Ability Questionnaire for Measuring Back Pain-Related Functional 
Limitations (Funktionsbeeintrachtigung durch Ruckenschmerzen) 
The Hannover Functional Ability Questionnaire for measuring back pain-related functional limitations 
(FFbHR) is a self-administered questionnaire developed to assess the functional limitations in daily 
living activities (Kohlmann and Raspe, 1996). There are 12 items and participants are instructed to tick 
if they could perform the activity (Yes, final score 2), could perform but with difficulty (Yes but with 
difficulty, final score 1) or not (No or with external help, final score 0). 
FFbHR score = (sum of all items)/24 × 100. 
The range of the score is from 0 (great limitation) to 100 (no limitation). 
 
Oswestry Disability Index 
The Oswestry low back pain Disability Questionnaire (ODI) is made up of 10 sections that are found 
to be most relevant to people suffering from low back pain (Fairbank et al., 1980). It aims to assess the 
limitations of various activities of daily living. The activities are pain intensity, person care, lifting, 
walking, sitting, standing, sleeping, sex life, social life and travelling. Each section is scored between 0 
and 5 (greatest disability) and the final score is 
ODI score = Total score from all sections/Total possible score × 100. 
For example, if all 10 sections were completed and the total score was 16, then ODI score was 
16/50×100=32. However, if one section was missing or not applicable and the total score was also 16 
then ODI score was 16/45×100=35.5. The range of the score is from 0 (no disability) to 100 (greatest 
disability). 
 
Pain Disability Index 
The Pain Disability Index (PDI) is a measurement of the degree to which pain interferes with 
functioning in family/home responsibilities, recreation, social activity, occupation, sexual behaviour, 
self-care, and life-support activities (Tait et al., 1990). Each item score ranges from 0 (no disability) to 
10 (worst disability).  
PDI score = sum of all seven items. 
The range of the score is from 0 (no disability) to 70 (worst disability). 
Patient Specific Functional Scale 
The Patient Specific Functional Scale (PSFS) is an instrument that requires participants to identify up 
to 5 important activities that they are unable to perform or have difficulty with because of their low 
back pain (Stratford et al., 1995). Participants are also asked to rate the level of difficulty, from 0 (unable 
to perform activity) to 10 (able to perform activity at preinjury level) associated with each activity. 
Participants are reminded of these activities at subsequent follow-ups and rate the level of difficulty. 
 
  
   
Statistical Analysis Plan for the Low Back Pain Repository 
 
Effective: 9 December 2103 Page 10 of 33 Version 1.0 
Roland-Morris Disability Questionnaire 
The Roland-Morris Disability Questionnaire (RMDQ) is a measurement for low back pain function in 
primary care trials (Roland and Morris, 1983). Participants are instructed to tick the statement that 
describes them on the day of completing the questionnaire. Item that is ticked is represented numerically 
by 1 and by 0, otherwise.  
RMDQ score = sum of all items that are ticked. 
The range of the score is from 0 (no disability) to 24 (severe disability). 
 
SF-12/SF-36 
The standard (4-week recall) and acute (1-week recall) of SF-12 (versions 1 and 2) and SF-36 (version 
1 and 2) are 12- and 36-item generic measurements of quality of life, respectively (Ware et al., 2002; 
and Ware et al., 2000). The 12 items in the SF-12 measure eight scales, namely, physical functioning, 
role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. 
The 36 items in the SF-36 measure the same eight scales and an additional scale, health transition. Each 
of the scale is transformed and standardized to compute physical (PCS) and mental (MCS) summary 
measures. The steps for scoring and standardized transformation are available in the manuals. The 
standardized and norm-based scales are necessary for direct interpretation. 
 
The PCS component is of interest as a measurement disability measurement. The range of the score is 
from 0 (substantial limitations) to 100 (no physical limitations). 
 
Troublesomeness 
This is a 6-point Likert item to ascertain the troublesomeness of LBP symptom. It is rated as “no pain 
experienced” (score of 1) to “extremely troublesome” (score of 6) (Parsons et al., 2006). 
 
4.1.2 Selection of instrument 
All the trials had used either FFbHR, RMDQ or Von Korff as their disability outcome. An exploratory 
research will be performed to map FFbHR, RMDQ and Von Korff into quality-adjusted life years 
(QALY) or health utility outcome. The analysis is then based on the QALY/utility outcome. 
In the event that it is not possible to map any of the instruments’ scores to one common outcome, trials 
will be grouped by common outcome and analyses for these trials will be based on that common 
outcome. 
4.2 Pain 
4.2.1 Instruments 
Chronic Pain Grade Scale 
The Chronic Pain Grade Scale (CPG) is an instrument to grade chronic pain status (Von Korff et al., 
1992). It has two dimensions, namely, disability and pain intensity scores. It used with different 
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durations recall, and may refer to all pain or specifically to low back pain. The pain intensity score is 
made up of three items: 
 How would you rate your (back) pain on a 0-10 scale at the present time, that is, right now, 
where 0 is 'no pain' and 10 is 'pain as bad as could be'? 
 In the past XX months/weeks, how intense/bad was your worst pain rated on a 0-10 scale where 
0 is 'no pain' and 10 is 'pain as bad as could be'? 
 In the past XX months/weeks, on the average, how intense/bad was your pain rated on a 0-10 
scale where 0 is 'no pain' and 10 is 'pain as bad as could be'? 
The pain intensity score is derived as followed,  
Pain score = mean(of the three items) × 10. 
The range of the score is from 0 to 100 where the higher score means more severe pain. Underwood et 
al. (1999) modified the CPG pain intensity scale to be more specific for low back pain. However, the 
scoring for pain intensity remains the same. 
 
McGill Pain Questionnaire (VAS) 
The long (Melzack, 1975) and short (Melzack, 1987) forms of the McGill Pain Questionnaire aim to 
quantify the sensory, affective and evaluative dimensions of pain experience and are commonly used 
in diagnosis. The short form also has a visual analogue scale (VAS) that anchors with “no pain” at the 
left pole and “worst possible pain” at the right pole. 
 
SF-12/SF-36 
As described in Section 4.1.1, the SF-12/36 is made up of eight scales, namely, physical functioning, 
role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. 
One of them, bodily pain, is of interest as a measurement for pain. The range of the score is from 0 
(very severe and extremely limiting pain) to 100 (no pain or limitations due to pain). 
Visual Analogue Scale 
Most RCTs might have a single standalone instrument that asked the participant to either rate or mark 
in an analogue scale that describes their average/worst pain at the present time or over the past XX 
months/weeks. The VAS is usually presented as a line that anchors with “no pain” at one end and “worst 
possible pain” at the other end. The line could be either horizontal or vertical.  
 
4.2.2 Selection of instrument 
There exist slight differences between average pain and worst pain. The recall period asked in each 
instrument and between trials may also differ slightly and this may have an impact in the analyses. 
Thus, analyses will be performed for the following pain outcomes: 
 Average pain today 
 Average pain over the past 1 week 
   
Statistical Analysis Plan for the Low Back Pain Repository 
 
Effective: 9 December 2103 Page 12 of 33 Version 1.0 
 Average pain over the past 1 month 
 Average pain over the past 3 months 
 Worst pain today   
 Worst pain over the past 1 week 
 Worst pain over the past 1 month 
 Worst pain over the past 3 months 
For all analyses, individual VAS will be the primary pain outcome. Where a numerical rating scale 
(range, 0 to 10) is used it will be scaled to an analogue scale that gives a range from 0 to 100. 
 
If VAS was not available from a trial, the following instruments will be used (in descending order): 
 The CPG pain intensity score is an average of the three possible questions that are usually asked 
in VAS. Thus, if scoring from individual items were available then the scoring of the individual 
item that is equivalent to the VAS item will be used and scaled to an analogue scale to give a 
range from 0 to 100. However, if only the CPG pain intensity score is available then the 
summary score will be used. 
 The bodily pain domain of SF-12/36. 
4.3 Psychological distress 
4.3.1 Instruments 
Beck Depression Inventory 
The Beck Depression Inventory (BDI) is an instrument used to assess the intensity of depression in 
psychiatrically diagnosed patients and also to detect depression in normal population (Beck et al., 1961 
and 1979). It is made up of 21 items (symptoms) and the intensity is rated from 0 (neutral) to 3 
(maximum severity). 
BDI score = sum of all 21 items. 
The range of the score is from 0 to 63 where the higher score means severe depression. The classification 
(for those diagnosed with affective disorder) (Beck et al., 1988): 
None or minimal depression < 10 
Mild to moderate depression 10 - 18 
Moderate to severe depression 19 - 29 
Severe depression 30 - 63 
Center for Epidemiological Studies Depression Scale 
The Center for Epidemiologic Studies Depression Scale (CES-D Scale) is an instrument to measure 
current level of depressive symptomatology in normal population (Radloff, 1977). There are 20 items 
in the list that the participant might have felt or behaved during the past week. There are four possible 
frequency of occurrence for each symptom (item), namely, less than 1 day, 1 to 2 days, 3 to 4 days and 
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5 to 7 days. The response is subsequently scored from 0 to 3 where a score of 0 represents less than 1 
day and a score of 3 represents the highest frequency. 
CES-D score = sum of all 20 items. 
The range of the score is from 0 to 60 where the higher score indicates more symptoms. A score of 16 
or higher is an indicator of high depressive symptoms (Radloff, 1977). 
Depression Anxiety Stress Scales 
The Depression Anxiety and Stress Scale (DASS) is an instrument that measure depression, anxiety 
and stress in diverse settings (Lovibond and Lovibond, 1995). The full version of DASS consists of 42 
items whereas the short-form version, DASS-21, consists of 21 items taken from the full version (Henry 
and Crawford, 2005).  Each item asks the participant how much the statement applies to them over the 
past week and is scored from 0 (did not apply at all) to 3 (very much or most of the time). 
DASS-42depression/anxiety/stress = sum of all the corresponding items. 
DASS-21depression/anxiety/stress = sum of all the corresponding items × 2. 
 
The range for each subscale is from 0 to 42 with higher score indicates severity. The classification: 
 Depression Anxiety Stress 
Normal 0 - 9 0 - 7 0 - 14 
Mild 10 - 13 8 - 9 15 - 18 
Moderate 14 - 20 10 - 14 19 - 25 
Severe 21 - 27 15 - 19 26 - 33 
Extremely severe ≥ 28 ≥ 20 ≥ 34 
 
 
Distress and Risk Assessment Method 
The Distress and Risk Assessment Method (DRAM) is constructed from Modified Somatic Perception 
Questionnaire (MSPQ) and Modified Zung Depression Index (MZDI) (Main et al., 1992). It identifies 
four types of patients, namely, normal (N), at risk (R), distressed-depressive (DD) and distressed-
somatic (DS). The cut-offs for classification: 
Type N MZDI < 17 
Type R 17 – 33 MZDI and MSPQ < 12 
Type DD MZDI > 33 
Type DS: 17 – 33 MZDI and MSPQ ≥ 12. 
EuroQol (Anxiety/Depression) 
The descriptive system of EQ-5D-3L consists of five dimensions (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) (EuroQol Group, 1990). Only the anxiety/depression 
dimension is of interest here. The dimension has three severity levels indicating no problem (level 1), 
moderate (level 2) and extreme (level 3) problems. 
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Hospital Anxiety and Depression Scale 
The hospital anxiety and depression scale (HADS) is an instrument to detect anxiety and depression 
(Snaith, 2003). Each dimension consists of seven items and each item is rated from 0 to 3. 
 Anxiety = sum(of items 1, 3, 5, 7, 9, 11, 13). 
 Depression = sum(of items 2, 4, 6, 8 ,10, 12, 14). 
Therefore, the possible score for anxiety is from 0 to 21, and similarly, for depression, 0 to 21. The 
classification: 
Normal 0 - 7 
Possible presence of respective state 8 - 10 
Presence of respective state ≥ 11 
Table 4.1 Dimensions of psychological distress and the instruments used to measure them. 
Dimensions Instruments 
Depression DASS-42/21depression, DRAM, EuroQol (Anxiety/Depression), HADSdepression, MZDI, MCS of 
SF-12/36 
Anxiety DASS-42/21anxiety, EuroQol (Anxiety/Depression), HADSanxiety, MCS of SF-12/36 
 
 
Modified Zung Depression Index 
The Modified Zung Depression Index (MZDI) is an instrument that could recognise depressive features 
and has been highly associated with participant’s level of disability (Main et al., 1992). It consists of 
23 items and participant is to rate how frequent they experience each of the statement recently. The 
scoring for each item ranges from 0 (less than 1 day per week) to 3 (5 to 7 days per week). The scoring 
for items 2, 6, 7, 12, 14, 16, 18, 20, 21 and 23 is reversed. 
MZDI score = sum of all items. 
The range of the score is from 0 to 69 where higher score indicates more depressed. 
 
SF-12/SF-36 
As described in Section 4.1.1. The MCS component is of interest as a psychological distress 
measurement. The range of the score is from 0 (substantial social and role disability due to emotional 
problems) to 100 (absence of psychological distress). 
 
4.3.2 Selection of instrument 
There are two dimensions of psychological distress that are of particular interest, namely, depression 
and anxiety. Table 4.1 shows the instruments that are used to measure these dimensions. Within each 
instrument there is usually a classification system that is widely used to classify patients into ordinal 
category, for example, with minimal, moderate, or severe level of anxiety/depression. Therefore, all the 
instruments will be mapped into a single ordinal categorical variable. The scores will be categorized by 
the 33.33rd and 66.67th percentile or by the instrument’s cut-off that discriminate the low and high risk 
from the moderate risk group. 
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4.4 Quality of life 
SF-12/SF-36 
As described in Section 4.1.1. Both the PCS and MCS components are considered in the quality of life 
measurement. The range of the score is from 0 (substantial limitations/frequent psychological distress) 
to 100 (no physical limitations/absence of psychological distress). 
4.5 Health utility 
4.5.1 Utility measures hierarchy (EQ-5D – SF-12/36) 
One of the challenges with the economic analysis is differing Quality of Life (QoL) instruments being 
used to estimate patient utility across the different trials. As the primary measure to estimate utility we 
will use the EQ-5D.  If the data from the EQ-5D were not collected, the SF-12/36 will be used and a 
mapping process applied to convert the SF-12/36 results to EQ-5D dimension scores and utility 
estimates. 
 EuroQol 
The EQ-5D-3L is a standardized measurement of health status for clinical and economic appraisal 
(Brooks, 1996; Dolan, 1997). It incorporates the description and valuation of health status into a single 
package with two components. One component is a standardized multi-dimensional descriptive system 
of general health. The second is a ready-to-use preference-based value set obtained from the general 
population. The descriptive system of EQ-5D-3L consists of five dimensions (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression), and each dimension has three severity levels 
indicating no problem (level 1), moderate (level 2) and extreme (level 3) problems. The patient’s health 
status can be described and defined by filling in the descriptive system. Once the health status has been 
identified, an attached preference-based value can be calculated from the value set, which will serve as 
the quality adjustment weight for calculating quality-adjusted life years (QALYs). The UK Social Tariff 
value set will be used to calculate the quality adjustments (utility). 
SF-12/SF-36 
As described in Section 4.1.1. Both the PCS and MCS components are considered in the quality of life 
measurement. The range of the score is from 0 (substantial limitations/frequent psychological distress) 
to 100 (no physical limitations/absence of psychological distress). 
 
4.5.2 Mapping SF-12/36 to EQ-5D 
Mapping is an approach to derive an estimate of health state utility for one survey from scores elicited 
using another survey. The EQ-5D will be the primary instrument used to estimate utility. For trials with 
no EQ-5D data, the SF-12/36 will be used and a mapping process applied to convert the SF-12/36 results 
to EQ-5D dimension scores and utility estimates. 
 
It is possible to use an algorithm (Sheffield) to convert the SF-12/36 into an SF-6D and assign utility 
values, however studies (Brazier and Roberts, 2004) have demonstrated these may not be directly 
comparable with those from the EQ-5D tariff. 
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There are several methods available to map the SF-12/36 to the EQ-5D. Firstly, a choice must be made 
to map the SF-12/36 to the EQ-5D index score, or to map to the EQ-5D individual dimensions.  The 
advantage of mapping to the dimension score is that the data used to define the mapping algorithm is 
not country specific, whereas the index score is based on the country specific tariffs and limits the 
generalizability of the algorithm. This will not be an issue, as we are only considering utility from a UK 
valuation perspective. The disadvantage of mapping to the individual dimensions is added complexity 
without necessarily increased predictive power (Rowen et al., 2009).  
 
Once we have decided whether to map to the index value or the dimension score, we have our dependant 
variable.  Second there is a choice as to how we estimate the relationship between the SF-12/36 (our 
explanatory variable) and the EQ-5D (dependant variable). The first choice is to use existing estimates 
generated from existing algorithms based on large national datasets. The alternative is to generate our 
own estimates of the relationship using the trials with SF-12/36 data and EQ-5D data. We would 
generate these estimates using an existing, validated econometric approach.  Literature has shown 
(Rowen et al., 2009) that heterogeneity across populations can lead to different mapping estimates being 
generated. This suggests applying existing estimates to our trial data may not be appropriate if the 
characteristics of our trial data differ from the original study. However, the differences in estimates may 
be small and outweighed by the added simplicity of the approach. 
 
In addition, for the benefits of generating new mapping estimates to be realised, those studies used to 
generate the new estimates (studies with both SF-12/36 & EQ-5D data) must be of a large sample which 
is homogenous with the studies the mapping is applied to (studies with only SF-12/36 data). If new 
estimates are generated to support the mapping process, there is the added complexity of suitable 
validation of the estimates and approach. This is required as advised by the NHS DSU TSD guidelines 
(Longworth and Rowen, 2013). With an existing algorithm and estimates, this validation should have 
already occurred. 
 
With each of the mapping approaches discussed there exists the risk of bias being introduced into the 
results. Rowen et al. (2009) found each of these methods would overestimate the Health State Utility 
for patients with worse health states. For this reason, which ever approach is used, validation against 
those trials with both SF-12/36 and EQ-5D data is paramount to minimize this risk of bias.  
 
In the first instance a simple approach will be applied using existing estimates and mapping algorithm 
to estimate the EQ-5D utility index for the trials with only SF-12/36 data. For validation purposes this 
will also be applied to trials with both SF-12/36 & EQ-5D. The accuracy of the estimates can then be 
compared directly. More complex mapping methods, as described, will be explored as necessary. 
 
4.5.3 Derivation of QALYs 
Quality adjusted life years (QALYs) are a standardized measure of a patient’s health status. The EQ-
5D is a method of estimating a patient’s utility level at a given point in time. In order to turn this into a 
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QALY it must be integrated over time. For example, an EQ-5D utility score of 1, held by a patient for 
a 6 month period would equate to a QALY of 0.5. In this way QALYs can be calculated as the area 
under the curve (AUC), where time is on the horizontal axis and utility is measured on the vertical axis. 
Where EQ-5D data is not directly available, the mapped EQ-5D scores will be used and an AUC will 
be generated from the mapped utility scores. The AUC will be calculated for each patient, providing a 
QALY score as measured over a 1 year time horizon. 
 
Under perfect conditions an exact continuous curve could be estimated for each patient, giving an 
unbiased estimate of their QALY score over 1 year.  In practice this is not feasible.  As an alternative, 
a discrete approximation method is used, called discrete or numerical integration. The AUC is divided 
up into a series of trapezoids from which the area is then calculated.  For a curve concave to the origin 
this has the effect of slightly underestimating the true area, for a convex function the area will be slightly 
overestimated. 
 
The more data points (in our case EQ-5D follow up points) the better the accuracy of the numerical 
estimation method. This does lead to a further issue. The trials within this study have different numbers 
of follow up points. This suggests that for those with more follow up points a more accurate (less biased) 
estimate of their QALYs will be achieved. In practice this is unlikely to cause a material difference. 
  
4.6 Cost-effectiveness 
4.6.1 Cost 
Cost of treatment is made up of the cost of the intervention and the cost of healthcare resource use 
following the intervention. Unit costs will be identified for all healthcare resource use items from 
English national sources (NHS reference costs, PSSRU). The trials included in this study have varying 
levels of detail on healthcare resource usage. For trials with recorded resource use data, total costs per 
patient will be generated by multiplying the amount of resource use by its associated unit cost and 
adding the cost of the intervention itself. Costs will be calculated over a 1 year time horizon.  Costs will 
be presented as a total cost per patient from an NHS perspective. 
Primary analysis will include trials with both health outcomes and resource use data from which a cost 
of treatment can be estimated.  Trials with extensive missing resource use data may also need to be 
excluded if the missing data cannot be imputed in a robust and stable way (see Section 8.3). 
 
For trials lacking resource use data, costs cannot be calculated directly. Where this is the case, costs 
will be estimated indirectly as a function of the health outcomes. Using data from trials with both 
resource use and health outcome a regression model will be estimated. The specification of the model 
will be dictated by the data.  A mixed effects model controlling for clustering by trial and intervention 
with costs as the dependant variable will be assumed. Health outcomes will be the main independent 
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variable, with demographics and baseline data included as covariates to control for heterogeneity across 
trial.  The purposes of the model will be to estimate the relationship between the health outcomes, other 
covariates (primarily demographic data) and the total cost of treatment.  If the model does not have 
suitable predictive power it will not be appropriate to include those trials without resource use in the 
full economic analysis.  
 
4.6.2 Net monetary benefit 
Using the methods described above, QALYs/effects (E) and costs (C) will be estimated for each patient 
over a 1 year time horizon. The cost effectiveness analysis will be formed of three parallel streams. 
Firstly, to maximize QALYs (irrespective of costs), secondly to minimize costs (irrespective of 
QALYs) and finally to maximize expected net monetary benefit (NMB). The expected NMB is 
calculated as a function of the QALYs, costs and the societal willingness to pay per QALY gained () 
as shown above.  In this way, the expected NMB accounts for both costs and QALYs simultaneously. 
The NMB will be calculated using a threshold willingness to pay of £30k per QALY gained, as per 
National Institute for Health and Clinical Excellence (NICE) guidelines. 
 
5. Moderator variables 
This section defines the explanatory variables that may potentially be treatment moderators. The 
moderators are made up of participant characteristics/demographics (Section 5.1), employment and 
work status (Section 5.2), and baseline clinical data (Sections 4.1, 4.2, 4.3, 4.4 and 5.3). 
 
5.1 Participant characteristics and demographic data 
Variables collected at baseline: 
 Age 
 Sex 
 Ethnicity 
 Education 
 BMI 
 Previous treatment(s) 
  
5.2 Employment and work status 
The employment and work status are collected at baseline. 
 
5.3 Baseline clinical data  
This section describes the derivations of the scoring and scales of the instruments used to measure 
clinical outcomes at baseline. The outcomes are classified broadly into disability (Section 4.1), pain 
(Section 4.2), psychological distress (Section 4.3), quality of life (Section 4.4), fear avoidance and 
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beliefs (Section 5.3.1), catastrophizing (Section 5.3.2), coping (Section 5.3.3), sensory and affective 
perception (Section 5.3.4) and benefits of treatment (Section 5.3.5). 
 
5.3.1 Fear avoidance and beliefs 
Acute Low Back Pain Screening Questionnaire 
The Acute Low Back Pain Screening Questionnaire (ALBPSQ) is a biopsychosocial screening 
instrument with 24 items (Linton and Hallden, 1998). Three items asked for year of birth (age), sex and 
nationality, and the other 21 are scored from 0 to 10 that contribute to the ALBPSQ score. 
ALBPSQ score = sum of all items. 
The total score ranges from 0 to 210. However, only the following three items are used to measure the 
fear-avoidance beliefs: 
 Physical activity makes my pain worse. 
 An increase in pain is an indication that I should stop what I am doing until the pain decreases. 
 I should not do my normal work with my present pain. 
The scores for these items will be summed up. 
 
Back Beliefs Questionnaire 
The Back Beliefs Questionnaire (BBQ) is an instrument that measures a participant’s beliefs about their 
LBP and the inevitable future as the consequence of LBP (Symonds et al., 1996). It consists of nine 
inevitability statements and five “distracting” statements. Participant is to rate each item with score 
from 1 (completely disagree) to 5 (completely agree). The BBQ scale is computed by reversing the 
scoring for items 1, 2, 3, 6, 8, 10, 12, 13, and 14 (the inevitability statements), and then, summing them 
up. The total score ranges from 9 to 45 with a higher score indicates a more positive attitudes and 
beliefs. 
 
Fear-Avoidance Beliefs Questionnaire 
The fear-avoidance beliefs questionnaire (FABQ) is an instrument to measure participant’s beliefs about 
how physical activity and work affect their low back pain (Waddell et al., 1993). The physical 
component consists of four 7-level items and the work component consists of seven 7-level items. The 
individual item score ranges from 0 (completely disagree) to 6 (completely agree). 
FABQphysical = sum(of items 2, 3, 4, and 5). 
FABQwork = sum(of items 6, 7, 9, 10, 11, 12 and 15). 
Thus, the total score for physical component ranges from 0 to 24 and for work component ranges from 
0 to 42. 
 
Tampa Scale for Kinesiophobia 
The original Tampa Scale for Kinesiophobia (TSK) developed by Miller, Kopri and Todd was 
unpublished but was later published with permission in Vlaeyen et al. (1995). It consists of 17 items 
and aims to measure the fear of movement or (re)injury. Each item is scored from 1 (strongly disagree) 
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to 4 (strongly agree). For the computation of the total score, scores for items 4, 8, 12, and 16 are 
reversed. 
TSK score = sum of all items. 
The total score ranges from 17 to 68 with higher score indicates higher degree of kinesiophobia. 
 
5.3.2 Catastrophizing 
Coping Strategies Questionnaire 
The Coping Strategy Questionnaire (CSQ) is a 48-item instrument that assesses the cognitive and 
behavioural pain coping strategies of participants with chronic LBP (Rosenstiel and Keefe, 1983). The 
48 items summarize into six different cognitive coping strategies, namely, diverting attention (DA), 
reinterpreting pain sensations (RS), coping self-statements (CSS), ignoring pain sensations (IS), praying 
and hoping (PH) and catastrophizing (CAT), and two behavioural coping strategies, namely, increasing 
behavioural activity (IBA) and increasing pain behaviours (IPB).  However, some subscales may have 
lower internal reliability and other shorter versions of the CSQ are sometimes used (see, for example, 
Harland and Georgieff, 2003).  
 
Regardless of the version, each item in the CSQ is scored on a 7-point Likert scale from 0 (never do 
that) to 6 (always do that). Items that correspond to each of the subscale are summed up. Generally, six 
items from the CSQ sum up each subscale. Hence, the range of score for each subscale is from 0 to 36. 
The higher score means a more frequently used strategy in coping chronic pain. 
 
Only the catatrophizing (CAT) dimension of the CSQ is used. 
 
Pain-Related Self Statement 
The Pain-Related Self Statement (PRSS) scale assesses participant’s cognitive coping with pain (Flor 
et al., 1993). It consists of two subscales; “catastrophizing” and “coping”. Each subscale is summarized 
by nine items. Participant is to rate on a 6-point Likert scale of how often the statement entered their 
mind when they experienced severe pain. The score ranges from 0 (almost never) to 5 (almost always). 
PRSS-catastrophizing = sum of even numbered items. 
PRSS-coping = sum of odd numbered items. 
The total score for both subscales ranges from 0 to 45 with the higher score indicates more positive self-
statements. 
 
5.3.3 Coping 
Coping Strategies Questionnaire 
See section 5.3.2. Only the coping subscale of the CSQ (CSS) is used. 
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Pain-Related Self Statement 
See section 5.3.2. Only the coping subscale of the PRSS (PRSS-coping) is used. 
 
Pain Self-Efficacy Questionnaire 
The Pain Self-Efficacy Questionnaire (PSEQ) is an instrument aims to measure the confidence of the 
participant in performing a particular behaviour or task despite of their pain (Nicholas, 2007). There are 
10 items in the questionnaire and each item is made up of seven levels, ranging from 0 (not at all 
confident) to 6 (completely confident). 
PSEQ score = sum of all items. 
The total score ranges from 0 to 60 where the higher score reflects stronger self-efficacy beliefs. 
 
5.3.4 Sensory and affective perception 
McGill Pain Questionnaire 
The long (Melzack, 1975) and short (Melzack, 1987) forms of the McGill Pain Questionnaire aim to 
quantify the sensory, affective and evaluative dimensions of pain experience and are commonly used 
in diagnosis. In the short form, there are 11 items associated with sensory dimension of pain experience 
and four items associated with affective dimension. Participant is to rate the intensity of each pain 
descriptor as “none” (score, 0), “mild” (score, 1), “moderate” (score, 2) or “severe” (score, 3). 
Sensory index = sum of all 11 items associated with sensory perception. 
Affective index = sum of all 4 items associated with affective perception. 
The range of sensory index is from 0 to 33 and the range of affective index is from 0 to 12 where higher 
score indicates severe intensity. 
 
 
Modified Somatic Perception Questionnaire 
The Modified Somatic Perception Questionnaire (MSPQ) is an instrument that measures somatic and 
autonomic perception for chronic back pain patients (Main, 1983). It consists of 13 symptoms (items) 
and participant is to rate the extent of how they have felt over the past week for each item. The scoring 
ranges from 0 (not at all) to 3 (extremely). 
MSPQ score = sum of all items. 
The range of the score is from 0 to 39 where higher score indicates more marked general somatic 
symptoms. 
 
 
Pain Experience Scale (Schmerzempfindungsskala) 
The Pain Experience Scale (SES) is an instrument with 24 items that measures sensory and affective 
characterization of pain (Geissner, 1995). It is usually used as a diagnostic tool and has been proven to 
be suitable in different psychological pain management approaches, physio-therapeutic prevention and 
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a multimodal treatment programme of a specialized pain clinic. Participant is asked to rate the 
appropriateness of each item, from fully appropriate (score, 4) to not appropriate (score, 1).  
Affective score = sum of 14 items associate with affective characterization of pain. 
Sensory score = sum of 10 items associate with sensory characterization of pain. 
 
The range of affective score is from 14 to 56 and the range of sensory score is from 10 to 40. The higher 
score indicates severe pain experienced. 
 
Table 6.1 Grouping of treatment arms. 
Parent group Subgroup Subtype 
Intervention 
Active physical Exercise 
 Graded activity 
Passive physical Acupuncture  
 Manual therapy 
 Individual physiotherapy 
Psychological Advice/education  
 Psychological (cognitive behavioural) 
Sham control 
 Sham acupuncture 
 Sham electrotherapy 
 Mock transcutaneous electrical nerve stimulation   (TENS) 
 Sham advice/education 
Control GP/usual care 
General practitioner (GP) 
Waiting list 
 
 
5.3.5 Selection of instrument 
All of the instruments will be mapped into a single ordinal categorical variable. The scores will 
be categorized by the 33.33rd and 66.67th percentile or by the instrument’s cut-off that 
discriminate the low and high risk from the moderate risk group. 
 
6. Treatment arms 
The therapist delivered interventions are broadly classified into intervention, sham control and 
control. The intervention grouping may be further classified into three broad categories, 
namely, active physical, passive physical and psychological (Table 6.1). 
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7. Follow-up time points 
Due to the design of individual trial’s protocol, the follow-up time points are inherently 
different between trials. The follow-up times are classified broadly into short-term, mid-term 
and long-term (Table 7.1). 
Table 7.1 Follow-up time points. 
Follow-up Definition 
Short-term Between baseline and anytime from 8 weeks to 3 months from randomization or start 
of first day of treatment. 
Mid-term Between baseline and 6 months from randomization or start of first day of treatment. 
Long-term Between baseline and 12 months from randomization or start of first day of treatment. 
 
 
8. Datasets 
8.1 Complete case analysis 
The main analysis is to confirm proof of concept and hence will be based on complete case analysis.  
 
8.2 Missing data 
Missing data may be due to non-responders/withdrawals or missing items. Missingness due to non-
responders or withdrawals will not be imputed. Missing items (at each follow-up time point) may be 
imputed and the method for imputation is as described in Section 8.3. 
 
8.3 Imputed dataset 
Instruments that have a standardize method to impute missing items will be followed. For example, 
imputation for items in SF-12 and SF-36 will be according to the algorithm detailed in the manual (Ware 
et al., 2000, 2002). 
 
For other instruments that do not provide any recommendation, multiple imputation (MI) will be used. 
The standard implementations of MI assume that data are missing at random (MAR) but it can also be 
implemented under the assumption of missing not at random (MNAR). Thus, MI will be used to handle 
missing items. Imputation will only be performed if the fraction of missing items for an instrument is 
less than 30 per cent (White et al., 2011) for that particular follow-up time point. The method(s) and 
model(s) used will be according to the recommendations given by Little and Rubin (2002) and White 
et al. (2011).  
 
Imputation will not be performed on summary/composite-level for clinical outcomes as it is impossible 
to infer whether the participant was a non-responder or had withdrawn from the trial.   However, for 
some of the economic variables used to estimate health utility and costs, it may be necessary to impute 
on a summary/composite-level. 
Missing data for economic health outcomes will fall into 3 categories:   
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1. Individual dimensions missing for an outcome at a specific time-point. 
2. Entire response for a health outcome missing from one or more time-points. 
3. Entire response missing from a specific time-point forward to the end of the trial, where it is 
unknown if this is non-response or censoring due to drop out or death. 
 
Category 1 is unlikely to be present, however if found will be dealt with via MI for that time-point alone 
and performed at the level of the individual dimension. For category 2, MI will be used to estimate the 
missing data-point as a summary/composite index score. A suitable regression equation will be 
specified for each trial and MI will be performed for each trial separately. Each of the variables to be 
imputed will be left-hand side dependent variables, estimated simultaneously to preserve covariance 
between them. Baseline index score, demographics and all other relevant covariates with complete data 
will be right-hand side independent variables. The model specification will be adjusted to find the best 
predictors and a model that leads to a stable convergent MI process.  Individuals with no baseline data 
are unlikely to occur, however if they occur those individuals may have to be excluded from the 
analysis. 
 
For individuals that fall into category 3, the process will be the same as for 2, however if a censored 
individual is known to have died this will be controlled for using a categorical dummy variable and they 
will be given a health utility value of 0 beyond the time of death. If the reason for censoring is not 
known for a particular trial/individual, the data will still be imputed. However, we will need to be 
mindful of the potential bias in the result. Due to the nature of the conditions being explored in these 
trials death is unlikely to have occurred over and above the national average rate, so should not be a 
concern for this process. 
 
Truncated regression techniques will be used to constrain imputation results between the accepted 
ranges, for example, EQ-5D index scores can only lie between -0.59 and 1.0. 
 
Costs as described in Section 4.6.1 will be calculated from the underlying resource use. The imputation 
of missing data will be performed as part of the same process as the missing health outcomes, with 
resource use items/costs being estimated simultaneously with the missing health outcomes data to 
preserve the underlying relationship (assuming correlation between healthcare resource use and health 
outcomes is present). 
 
Specifically for costs, if some resource use has been captured for an individual at a time-point, any 
blanks at that time-point will be considered 0 rather than missing.  Only resource items explicitly coded 
as missing in the original trial data, or where there is no resource use information for an entire time-
point will be treated as missing. Resource use will, therefore, be imputed at a composite/summary level 
for each time-point.  In this case total costs may be used as the dependent variable to be imputed.  As 
with health outcomes this will be conditional on being able to specify a suitable model that leads to a 
robust and stable MI solution. Censoring will be dealt with in the same manner as for health outcomes. 
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Sensitivity analysis will be performed to check the validity of the assumptions. 
 
9. Statistical Analysis 
9.1 Descriptive summary 
The baseline information for each RCT and treatment arm will be summarized. The continuous data 
will be summarized as mean, standard deviation, median and interquartile range. The categorical data 
will be summarized as the number of participants and percentage within each category. 
 
9.2 Meta-analysis 
A one step individual patient data meta-analysis will be performed to explore the efficacy between 
intervention against control (sham treatment and GP/usual care). Trials will be modelled as random 
effect (Riley et al., 2010). 
 
9.3 ANCOVA analysis 
An individual patient data or summary/composite meta-analysis will be performed to identify any 
covariates that predict outcomes. Continuous covariate will be analysed with analysis of covariance 
(ANCOVA) method with trials as the random effect. Categorical covariate will be analysed with logistic 
regression. Variables are statistically significant at a two-sided 0.05 level.  
 
9.4 Clinical and health economic prediction rule and identification of 
subpopulations 
The construct of a clinical and health economic prediction rule and the identification of a subpopulation 
that may benefit from different treatment modalities will be as detailed below. Only two treatment arms 
will be compared at each construction. For example, intervention arm against control arm, active 
physical arm against control arm, and others (see Table 6.1 for the grouping of treatment arms). Results 
from each construction will be collated and report together. 
 
Table 9.1 Moderators identified from literature review (Gurung et al. 2013). 
Age 
Sex 
Employment status 
Education 
Use of narcotic 
Back pain status (baseline RMDQ) 
Treatment expectations 
Quality of life 
Psychosocial status (baseline anxiety and/or depression) 
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Stage 1: Interaction with treatment 
All covariates that are potential moderators will be tested for interaction treatment effects. Linear 
models will be used to test the moderator-by-treatment interaction effects. In the event that the assumed 
linear relationships between the covariate and outcome are not appropriate then an alternative non-
linear functional forms will be explored, e.g. through fractional polynomials (Royston and Sauerbrei, 
2008). As model selection can lead to overoptimistic results, shrinkage methods will be applied to 
correct for such bias (Tibshirani, 1996). Covariate is declared as statistically significant at the 20% 
level. This will ensure that covariates that approach statistical significance will not be missed and not 
to overwhelm the pool of potential moderators for Stage 2. 
Stage 2: Construction of clinical/health economic prediction rule 
2.1 Modelling 
Treatment moderators identified in Stage 1 and those that have been identified in the systematic review 
(see Table 9.1; Gurung et al., 2013) will make up the list of covariates to be considered for the 
clinical/health economic prediction rules analysis.  
There is no standard method that can be readily applied to this IPD subgroup identification. As such, 
we will explore and adapt two methods that are commonly used in identifying subgroups of poor 
prognosis in cohort studies. The first method, the Adaptive Risk Group Refinement (LeBlanc et al., 
2005) that identifies subgroups by a greedy algorithm “peeling” of fractions of the total data in a series 
of steps. The second method is based on recursive partitioning that, as the name suggests, recursively 
partition the covariate space to identify subgroups of patients who most (or least) benefit from treatment 
(see, for example, Dusseldorp et al., 2010; Lipkovich et al., 2011; and Su et al., 2009). 
 
Issues such as the splitting of a continuous variable or grouping of a categorical variable into fewer 
levels/groups, multiplicity adjustment and internal validation (e.g. cross-validation) will be handled 
within each method.  
 
2.2 Minimum subgroup size 
In splitting the covariate into two or more parts, it may be possible that the sample size of a 
subpopulation for a treatment arm (Table 6.1) may be very small. Prediction rules based on a very small 
sample size may produce unreliable and very poor estimates. As there is no clear threshold as to what 
is considered as a reasonable size, two proportions, namely, 1/10 and 1/20, of the population will be 
explored. The reliability of the estimates for each minimum size will be reported. 
 
2.3 Formulation of economic prediction rule 
The primary objective function for the economic prediction rule will be maximizing the expected net 
monetary benefit (NMB) as NMB combines both cost and effects simultaneously. We will also run 
parallel streams of analysis to maximise the sum of QALYs and minimise the total costs independently. 
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 The NMB will be estimated for each patient and substituted for the clinical outcome indicator in the 
prediction rule algorithm. Within this algorithm, a regression approach will be used to estimate the 
mean difference in outcome between one intervention and some comparator, in a sequence of subgroups 
defined by specified moderators and of varying size. By substituting the NMB as the dependent variable 
within the prediction rule algorithm, we can estimate the Incremental Net Monetary Benefit (INMB) 
for the intervention (relative to the comparator), for each of the subgroups tested. The optimum 
subgroup will be that which maximises the sum of INMB for all of the individuals in the subgroup.   
 
Alternative regression specifications may be more robust to potential bias from endogeniety between 
costs and effects, skew in the distribution of costs (Nixon and Thompson, 2005), and ultimately lead to 
more efficient estimates than this simple NMB approach. This will be explored within the analysis. We 
will also investigate the possibility of using a two-equation model (Willan, et al. 2004) to estimate the 
two related dependent variables of cost and QALYs, and to control for factors that might confound 
the treatment effects and potential heterogeneity between trials. 
 
 
For a specific treatment j, the expected NMB per individual can be expressed as: 
E(𝑁𝑀𝐵𝑗|𝑃𝑗) = [⁡𝜆 × E(𝐸𝑗|𝑃𝑗) − ⁡E(𝐶𝑗|𝑃𝑗)] 
Two comparators, treatment A vs. B 
In the simple case, one treatment of interest (B) will be compared to a control of usual care (or best 
current practice) (A).  Let Pj denote the proportion of the total population P treated with intervention j 
(j = A, B), ranging from 0 to 1. The treatment options are considered exhaustive and mutually exclusive. 
Therefore, the subsets of the population given each treatment can be defined in terms of one another;   
PB = P − PA.  There will be a minimum sample size equal to 10% of P, denoted by P10%.   
 
Let us consider the peeling algorithm to maximize expected NMB across the total population P. The 
starting case is that the maximum number patients receive treatment B. Based on the moderators of 
interest, the peeling algorithm will iteratively reduce the sample receiving treatment B provided a higher 
expected NMB across the whole population (P) can be achieved. This process will continue until the 
expected NMB can no longer increase, or the minimum sample size of PB = P10% is reached. 
 
As the algorithm reduces the size of the subgroup (PB) for treatment B by 10%, the subgroup (PA) for 
treatment A will be increased in size by 10%. The 10% will be made up of patients with the same 
characteristics as those removed from B, defined by the treatment modifier criteria. By weighting the 
E(NMB) by Pj for each treatment a representative total E(NMB) across the total population is estimated. 
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The objective function being maximized can therefore be expressed as 
E(𝑁𝑀𝐵|𝑃) = (𝑃𝐴) × E(𝑁𝑀𝐵𝐴|𝑃𝐴) + (1 − 𝑃𝐴) × E(𝑁𝑀𝐵𝐵|𝑃𝐵), 
provided PA and PB satisfied these conditions; PA ≥ P10%, P − PA ≥ P10% and PB = (1 − PA). Note that 
both proportions, PA and PB change as a function of the moderators of interest. 
 
Three comparators A vs. B vs. C 
At the next level of complexity, three comparators are introduced; A (usual care), treatment B and 
treatment C.  The same constraints of mutual exclusivity and exhaustiveness apply, thus each patient in 
the population P must receive one and only of treatments A, B or C. In this case the process can be 
considered as a network, or series of sequential optimizations. 
 
Firstly, the optimal allocation of patients between treatment B and treatment A is assessed exactly as 
before. We are left with two subgroups of size PA and PB = (P − PA). In the second phase we must 
identify if anyone in the two subgroups PA and PB would yield a better result if they were moved to 
treatment C.  Here we define a new subgroup PC where 
𝑃𝐴 + 𝑃𝐵 + 𝑃𝐶 = 𝑃 = 1. 
 
We now have a series of three optimization problems.  
 
Optimization 1 
The first being identical to our two-treatment scenario but with treatment C included and explicitly 
constrained to a sample set of 0. Thus, the expected NMB is expressed as 
E(𝑁𝑀𝐵|𝑃) = [(𝑃𝐴) × E(𝑁𝑀𝐵𝐴|𝑃𝐴)] + [(𝑃𝐵) × E(𝑁𝑀𝐵𝐵|𝑃𝐵)] + [(𝑃𝐶) × E(𝑁𝑀𝐵𝐶|𝑃𝐶)], (1) 
where PA and PB satisfied these conditions; PA ≥ P10%, PB ≥ P10%, PC = 0, and PA + PB + PC = 1. 
 
At this point the optimal subgroup between PA and PB has been determined excluding treatment C.  This 
has determined the starting subgroups for the next round of optimization. 
𝑆𝑡𝑎𝑟𝑡𝑖𝑛𝑔⁡𝑠𝑎𝑚𝑝𝑙𝑒⁡𝑠𝑒𝑡⁡𝑜𝑓⁡𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡⁡𝐴 = 𝑃𝐴
1, 
𝑆𝑡𝑎𝑟𝑡𝑖𝑛𝑔⁡𝑠𝑎𝑚𝑝𝑙𝑒⁡𝑠𝑒𝑡⁡𝑜𝑓⁡𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡⁡𝐵 = ⁡𝑃𝐵
1. 
 
Optimization 2 
Now we will identify if anyone from subgroup PB should be moved to treatment C. In this case subgroup 
PA will be held constant at 𝑃𝐴
1. The expected NMB is as expressed as equation (1) but PA is fixed at 𝑃𝐴
1 
whilst PB and PC satisfied these conditions;  𝑃10% ≤ 𝑃𝐵 ≤ 𝑃𝐵
1 and PC ≥ P10%. 
 
The output of this optimization will determine the final optimal solution for treatment B, designated as 
the subset 𝑃𝐵
∗ where treatment B is preferred over treatment A and C. There will also be those allocated 
to treatment C where we know treatment C is preferred to A and B, these will be designated as 𝑃𝐶
1.  
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Optimization 3 
We will now conduct the same process for subgroup 𝑃𝐴
1, as identified in Optimization 1.  However, for 
treatment B subgroup 𝑃𝐵 will be held constant at 𝑃𝐵
∗ and subgroup 𝑃𝐶 will start at 𝑃𝐶
1. The expected 
NMB is as expressed as equation (1) but PB is fixed at 𝑃𝐵
∗ whilst PA and PC satisfied these conditions; 
𝑃10% ≤ 𝑃𝐴 ≤ 𝑃𝐴
1 and 𝑃𝐶 ≥ 𝑃𝐶
1. 
 
Table 10.1 Items to be included in the statistical and health economic reports. 
Section and topic Description 
Methods  
Statistical method The statistical methods used for analyses as described in Sections 9.1 to 9.3. 
The statistical models used for analyses as described in Section 9.4 with 
references and a detailed description of changes made on the cited models so 
that they can be used in this project specifically. 
The validation methodology 
Results (for each clinical and health economic outcomes described in Section 4) 
Trials (participants) The trials involved. 
Interventions The interventions involved. 
Outcomes The specific instruments that have been selected for analysis. 
Discussion  
Interpretation Interpretation of the results. 
Generalizability/overall 
evidence 
General interpretation and recommendation to the community based on the 
current evidence. 
 
 
The output of this final optimization will yield subgroups 𝑃𝐴
∗ and 𝑃𝐶
∗. From Optimization 2 we know 
𝑃𝐵
∗. By construction, 𝑃𝐴
∗ + 𝑃𝐵
∗ + 𝑃𝐶
∗ = 𝑃 = 1 always. 
 
As can be seen, as this process expands beyond three comparators, the number of optimization problems 
will increase as a function of the number of treatment options. However the approach will be the same. 
The order in which the alternative treatments are compared should not influence the result of the peeling 
algorithm.  However, for completeness the algorithm will be run on treatment comparisons in different 
orders to verify the result. 
 
The same process will be followed for the purpose of maximizing total QALYs and for costs, simply 
substituting these measures for NMB. 
 
10. Reporting of the Results 
The statistical and health economics reports will consist of the features shown in Table 10.1. 
The reports will also be supported by figures and tables as appropriate. 
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1. Introduction 
1.1. These guides are intended as a detailed procedure to the individuals working to transfer, 
query, map, report and/or upload the trial data submitted to the Low Back Pain Trial 
Repository. 
2. Create Trial Folders 
2.1. Create a physical folder for each trial. 
2.2. Create a folder in the encrypted drive for storage of dataset (e.g. “O:\Original”, where O: 
drive is the encrypted drive) and one in the shared drive for storage of all other trial related 
electronic files in “M:\WMS\CTU\Rehabilitation Trials\Repository”. 
2.3. For ease of identification, the name of folders in the encrypted and shared drives should be 
the same. 
3. Transferring Data from Shared Space to Encrypted Drive 
3.1. Follow the instructions detailed in “Instructions for moving data from shared space to 
Repository.docx” in “M:\WMS\CTU\Rehabilitation Trials\Repository\3. DOCUMENTS TO 
SEND\File Transfer – Researchers”. 
4. Querying and Reporting Data 
4.1. Open the encrypted drive. The original data is found in the folder “Original”. In order for not 
editing and changing the original data accidentally during data query, create and copy a 
duplicate of the data and saved it in the folder “Temporary” which is located in the same 
drive. 
4.2. All querying will be performed on this duplicate data set. 
4.3. The data query can be performed with the following statistical programs: 
a. Stata 
b. SPSS 
c. SAS 
4.4. Each and every syntax use for the query should be recorded and saved in a folder named 
“Syntax” in the trial’s folder (see Section 2.2), e.g. the query of data set from the trial BeST is 
saved in “M:\WMS\CTU\Rehabilitation Trials\Repository\Statistics and Health 
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Economics\BeST\Syntax”. The output from the query should also be saved in the same 
“Syntax” folder. 
4.5. Any inconsistency, e.g. out-of-range values, inconsistent dates, etc, has to be recorded and 
dated. The actions taken to resolve these inconsistencies have to be recorded and dated, too. 
A query file template (“Data query.xlsx”) is in “M:\WMS\CTU\Rehabilitation 
Trials\Repository\Statistics and Health Economics\Templates”. 
4.6. Any email communication regarding the data set should be printed and kept in the trial’s 
physical folder. 
4.7. The demographic and clinical outcomes at each time point have to be summarized. Any issues 
arising from the data query should be included in the appendix of that summary report. This 
summary will be sent to the trial custodian (template “Template - Data Quality Report.docx” 
in “M:\WMS\CTU\Rehabilitation Trials\Repository\Statistics and Health 
Economics\Templates”). 
4.8. The summary will be sent off with a cover letter. The template of the cover letter is in the 
same folder and the name of the file is “Template - Letter for Data Quality Report.docx”. 
4.9. The cover letter requires wet-ink signature from the Repository Principal Investigator 
(Professor Martin Underwood). A copy of the summary report and cover letter has to be 
saved in the individual trial’s folder (physical and electronic versions). 
5. XML Mapping 
5.1. The mapping instructions are written in the XML language and the program for it is 
<oXygen/>. 
5.2. The XML file should be saved in “M:\WMS\CTU\Rehabilitation Trials\Repository\Statistics 
and Health Economics\XML mapping” and the name of the file should be clear and 
informative on which trial it is for. 
6. Uploading Data to Repository 
6.1. Before the original data is uploaded to the Repository, it has to be saved as a comma 
separated value (CSV) file. The CSV file is to be saved in the folder “Processed” in the 
encrypted drive. 
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6.2. In some instances the original data set have to be manipulated before saving it in the CSV 
format. Some examples of the possibility and circumstances: 
a. A few data files were submitted to the Repository and so they need to be merged into a 
single file as the uploader requires one single data file for each trial. 
b. Two or more variables have to be merged into one variable. 
c. One variable has to be split into two or more variables. 
6.3. The syntax used in the manipulation have to be recorded and saved as detailed in Section 4 
before saving the modified file into a CSV file for uploading.  
6.4. The syntax to merge data files: 
SPSS syntax (example): 
GET file="O:\Temporary\Trial01\Example01.sav" . 
SORT CASES by ID . 
DATASET NAME Base1 . 
GET file=" O:\Temporary\Trial01\Example02.sav" . 
SORT CASES by ID . 
DATASET NAME Month3 . 
GET file=" O:\Temporary\Trial01\Example03.sav" . 
SORT CASES by ID . 
DATASET NAME Month12 . 
MATCH FILES 
        / FILE = "Base1" 
        / FILE = "Month3" 
        / FILE = "Month12" 
        / BY ID . 
EXECUTE . 
 
6.5. The syntax to merge two or more variables into one variable: 
SPSS syntax (example): 
See section 6.6 
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o  
o Stata syntax (example): 
o  
* There are two dates of interview: "var1" and "var2" and they are  
mutually exclusive 
* Combine these two into one variable "interview" 
GENERATE interview = . 
REPLACE interview = var1 
REPLACE interview = var2 if var1 == . 
o FORMAT interview %td 
o  
 
6.6. The syntax to split one variable into two or more variables: 
SPSS syntax (example): 
* The original date of assessment was in a string format thus,  
* need to extract the dates, months and years (that is, split  
* the original variable into three variables before merging them 
* into one . 
* Define the variables . 
STRING assess_dd assess_mm assess_yy (A2) . 
* Extract the first two characters and assign it as date . 
COMPUTE assess_dd = CHAR.SUBSTR(string_assess,1,2) . 
* Extract the 3rd and 4th characters and assign them as month . 
COMPUTE assess_mm = CHAR.SUBSTR(string_assess,3,2) . 
* Extract the last two characters and assign them as year . 
COMPUTE assess_yy = CHAR.SUBSTR(string_assess,5,2) . 
EXECUTE . 
STRING assess_dttemp (A8) . 
COMPUTE assess_dttemp = CONCAT(rtrim(assess_dd),"-", 
rtrim(assess_mm),"-", 
rtrim(assess_yy)) . 
EXECUTE . 
COMPUTE assess_date = number(assess_dttemp, date) . 
FORMATS assess_date (date11) . 
 
   
Project Specific Guide for the Low Back Pain Repository Analysis 
Plan for the Low Back Pain Repository Transfer, Query, Map,  
 
7 of 21 
Effective: 9 December 2013 Version 1.0 
 
6.7. Note that there may be some string variables in the original data set and they may contain 
commas. In order for the Repository uploader not to confuse that the comma in a string 
variable is not meant to separate the data, these commas have to be replaced with semi-
colons before saving it as a CSV file. 
6.8. The syntax for replacing commas: 
SPSS syntax (example): 
DO REPEAT var = var1 var2 var3 . 
IF (char.index(var,",") GE 1)  var = REPLACE(var,",",";") . 
END REPEAT . 
EXECUTE . 
where var1 var2 and var3 are the short names of the string variables. 
 
Stata syntax (example): 
FOREACH CHVAR OF var1 var2 var3 { 
REPLACE `CHVAR' = SUBINSTR(`CHVAR', ",", ";", .)  
} 
where the notation (`) before CHVAR is the grave accent and not a single 
quotation ('). 
 
6.9. There may be in some occasions where the carriage return, vertical tab, new line or new 
page/form has been accidentally entered in these string variables. As such, these extra spaces 
have to be replaced as well. The syntax: 
 
Stata syntax (example): 
* "new line" (ASCII dec 10) 
FOREACH CHVAR OF var1 var2 var3 { 
REPLACE `CHVAR' = SUBINSTR(`CHVAR', "`=char(10)'", ";", .)  
} 
* "vertical tab" (ASCII dec 11) 
FOREACH CHVAR OF var1 var2 var3 { 
REPLACE `CHVAR' = SUBINSTR(`CHVAR', "`=char(11)'", ";", .)  
} 
* "form feed/new page" (ASCII dec 13) 
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FOREACH CHVAR OF var1 var2 var3 { 
REPLACE `CHVAR' = SUBINSTR(`CHVAR', "`=char(12)'", ";", .)  
} 
* "carriage return" (ASCII dec 13) 
FOREACH CHVAR OF var1 var2 var3 { 
REPLACE `CHVAR' = SUBINSTR(`CHVAR', "`=char(13)'", ";", .)  
} 
 
6.10. The Repository uploader requires that the patient’s identification number to be 
named as “ID” (non-case sensitive) so the variable has to be renamed if it is not already 
defined as “ID”. The syntax for renaming and saving the original file as a CSV file: 
SPSS syntax (example): 
SAVE TRANSLATE outfile = 'O:\Processed\LisetPengel\FullDat.csv' 
/ TYPE = CSV 
/ FIELDNAMES  
/ MISSING = RECODE 
/ CELLS = values 
/ RENAME = (Envelope_number=ID) . 
 
Stata syntax (example): 
RENAME PTID ID 
OUTSHEET USING “O:\Processed\BeST\BeST.csv”, COMMA NOLABEL QUOTE 
REPLACE 
 
6.11. Finally, to upload the trial data to the Repository: 
a. Open the “LBP Repository ETL” program.  
b. Select the CSV file and the corresponding XML file. 
c. Click “Connect”. 
d. Select server “Palmer”, and enter the username and password assigned by the 
programming team (Mr Ade Willis). 
e. Under the field “LBP trial selection”, select the name of the trial. 
f. Choose either a specific “Class” of data to be uploaded or check “Select all Classes”. 
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g. Click “Start”. 
A screenshot of the ETL program is in Appendix A. 
 
7. Verification of Uploaded Data 
7.1. Once the original data have been uploaded, it is crucial to verify that the data transformation 
and mapping (see Section 5) are done as requested and the process of uploading does not 
compromise the data integrity. 
7.2. To set up the ODBC connection for the first time, follow the instructions provided by the 
programming team. 
7.3. To access the uploaded data with SAS, an example of the macro syntax is in a file named 
“MacroConnectOLEDB.sas” which is in “M:\WMS\CTU\Rehabilitation 
Trials\Repository\Statistics and Health Economics\Data query”. 
7.4. To access the Repository data with SPSS: 
a. Open the SPSS program. 
b. Click “File”, “Open Database” and select “New Query…” 
c. Select “lbpRepository” or “lbpRepository2” from the ODBC Data Sources panel. 
d. Click “Next”. 
e. Enter the “Login ID” and “Password” assigned by the programming team (Mr Ade Willis). 
f. Click “OK”. 
g. De-select "Tables" and select "Views". 
h. Double-click the class that you wish to view, for example, to view TREATMENTS double-
click "stats.TREATMENTS" and then “Next”. 
i. To restrict the data that is retrieved, select the variable to be restricted in the 
"Expression 1" box, select the relation in the "Relation" box, and enter the value to be 
restricted to in the "Expression 2" box. Then click “Finish”. 
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o Example 1:  
o  
o To select only subjects from the Kennedy trial, the values to be entered in 
“Expression 1”, “Relation” and “Expression 2” are: 
o  
O  O EXPRESSION 1 O RELATION O EXPRESSION 2 O  
o  o prms_TrialName o = o 'Kennedy' o  
o  
o Note that the string value (e.g. Kennedy) is enclosed in single quote. 
o  
Example 2: 
o To select only subjects over 50 years old, the values to be entered in “Expression 
1”, “Relation” and “Expression 2” are: 
o  
 O EXPRESSION 1 O RELATION O EXPRESSION 2  
 o Age o > o 50  
 
 
 Step-by-step screenshots are shown in Appendix B. 
 
7.5. To access the Repository data with STATA: 
a. Open the STATA program 
b. Increase memory size by typing in “set memory 1000m” in the command box 
c. Click “Enter” 
d. To get the data  from the ODBC Data sources panel type “odbc lo, exec("SELECT * 
FROM stats.HEALL;") dsn("lbpRepository2" or “lbpRepository”) p(password) 
u(username) low clear” in the command box 
e. Click “Enter” 
              Step-by-step screenshots are shown in Appendix C 
   
Project Specific Guide for the Low Back Pain Repository Analysis 
Plan for the Low Back Pain Repository Transfer, Query, Map,  
 
11 of 21 
Effective: 9 December 2013 Version 1.0 
 
 
7.6. Data from a few participants for each Class and time points (baseline and any follow-up) 
should be chosen for the data verification. 
7.7. Syntax used to verify data should be saved in the individual trial’s folder called “Mapping” 
and saved as “Verification Syntax”. 
7.8. Any inconsistency should be dealt with immediately to ensure data are mapped correctly. 
7.9. Once all the checks have been done and the mappings are correct, the data can be 
transferred from the server “Palmer” to the “live” server, that is, “Bauer”. Email the 
programming team (Mr Ade Willis) to transfer the data from “Palmer” to “Bauer”.  
 
8. Adding or Editing Classes and Attributes 
8.1. It is possible to add new classes, and both ETL program and the XML schema rules have to be 
updated with the new classes. 
8.2. The XML schema rules file is “ImportRules.xsd” and this is in “M:\WMS\CTU\Rehabilitation 
Trials\Repository\Statistics and Health Economics”. The new class(es) is(are) inserted under 
the heading <xs:restriction base="xs:string"> which is under <xs:simpleType 
name="typeClass"> 
8.3. In order to update the ETL program, open the “LBP Repository ETL” program, select a dummy 
CSV file and a dummy XML file (available in the folder “M:\WMS\CTU\Rehabilitation 
Trials\Repository\Statistics and Health Economics\Examples and Dummy”). Follow steps (c) 
and (d) in Section 6.8 then select “Class Manager”. 
8.4. To add a new class, point to “Classes”, right click, select “Add Class” and proceed. 
8.5. To delete an existing class, point to the class, right click and select “Delete Class”. 
8.6. To add a new attribute (variable) into an existing class, point to that class, right click, select 
“Add Attribute” and proceed. 
8.7. To edit an existing attribute, select that attribute and proceed. 
8.8. To delete an existing attribute, point to the attribute, right lick and select “Delete Attribute”. 
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8.9. After all changes have been made, click “Refresh Stat Views”. Email the programming team 
(Mr Ade Willis) of all the changes that have been made so that they can subsequently update 
the “Bauer” database. 
9. Data Analysis 
9.1. As the process of acquiring dataset is a fluid and continuing process, any statistical and health 
economic analyses to be done will be on data that have been acquired up to a cut-off time. 
Therefore, the statistician needs to inform the programming team (by email) to replicate the 
“live” database which is then saved in a server called “Buchanan”. 
9.2. Analyses are then based on the replicated dataset. 
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A. Screenshot of the ETL Program 
 
 
Figure A.1 The screenshot of the ETL program. 
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B. Screenshots of SPSS 
 
Figure B.1 Screenshot of steps (a) – (b) to access Repository data with SPSS as given in 
Section 7.4. 
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Figure B.2 Screenshot of steps (c) – (d) to access Repository data with SPSS as given in 
Section 7.4. 
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Figure B.3 Screenshot of steps (e) – (f) to access Repository data with SPSS as given in 
Section 7.4. 
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Figure B.4 Screenshot of steps (g) – (h) to access Repository data with SPSS as given in 
Section 7.4. 
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Figure B.5 Screenshot of step (i) to access Repository data with SPSS as given in Section 
7.4. 
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C. Screenshots of STATA 
 
Figure C.1 Screenshots of step (a) – (c) to access Repository data with STATA given in 
Section 7.5. 
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Figure C.2 Screenshots of step (d) – (e) to access Repository data with STATA given in 
Section 7.5. 
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Figure C.3 Screenshot of Repository data in STATA . 
 
 
